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ABSTRACT 
22q11DS is the most common microdeletion syndrome in humans, causing a range of 
phenotypes associated with abnormal pharyngeal development. TBX1 is considered the 
major genetic determinant of the syndrome. Deletion of Tbx1 in animal models 
phenocopies the patient manifestations. In an effort to understand the pathways involved in 
these processes, potential Tbx1 effectors previously determined by microarray screens were 
studied. 
Smad7 is an inhibitor of the TGF-/BMP pathways and to date several TGF-/BMP 
signalling genes have been described in heart development. In this thesis Smad7 was found 
expressed in pharyngeal and cardiovascular structures during mouse embryogenesis while a 
gene-trap mouse model displayed a partially penetrant 22q11DS-like phenotype. 
Furthermore, Tbx1 and Smad7 were found to interact synergistically towards arch artery 
morphogenesis. 
Hes1 is a transcriptional repressor, part of the Notch signalling pathway, which 
produces craniofacial and cardiovascular anomalies when deactivated. Expression analysis 
undertaken demonstrated that Hes1 overlaps with Tbx1 in the embryonic pharynx and it is 
diminished in Tbx1
-/-
 embryos. A conditional mutagenesis approach revealed non cell 
autonomous actions for Hes1 in the ectoderm affecting great vessel and eye development, 
while Hes1 was required in both the ectodermal and neural crest lineages for thymus 
morphogenesis. 
Slit2 is a secreted protein that regulates axonal guidance, migration, outgrowth and 
branching. Recent evidence suggests a possible mechanism by which Tbx1 may regulate 
neural crest patterning through the Slit/Robo pathway. Slit1 and Slit2 were here shown to 
share expression domains with Tbx1 in the embryonic pharynx. Nevertheless, neither the 
Slit2 nor the Slit1;Slit2 mutation produced a 22q11DS-like phenotype while double 
mutation for Tbx1;Slit2 did not enhance the Tbx1 haploinsufficient phenotype.  
Altogether, this thesis provides data clarifying a subset of Tbx1 mechanisms 
important for cardiovascular development and identifies Smad7 as a Tbx1 regulated gene 
involved in great vessel morphogenesis. 
Abbreviations - 6 
Irinna Papangeli 
ABBREVIATIONS 
 
22q11DS, chromosome 22q11 deletion syndrome  
AAo, ascending aorta  
ALK, activin receptor-like kinase 
AMH, anti-mullerian hormone  
ANF, atrial natriuretic factor  
AP, aorticopulmonary 
A/S, antisense  
ASD, atrial septal defect 
AV, atrioventricular  
AVC, atrioventricular canal  
AVCD, atrioventricular canal defect 
AVJ, atrioventricular junction  
AVSD, atrioventricular septal defect  
BAC, bacterial artificial chromosome 
bHLH, basic helix-loop-helix  
BMP, bone morphogenetic protein 
BSA, bovine serum albumin  
CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy 
CAFS, conotruncal anomaly face syndrome 
CAMs cell adhesion molecules  
Cas-L, Crk-associated substrate lymphocyte type  
CAT, common arterial trunk  
CHD, congenital heart disease  
ChIP, chromatin immunoprecipitation  
ChIP-Seq, ChIP with massively parallel sequencing  
CIAP, calf intestinal alkaline phosphatase 
CNS, central nervous system  
CoA, coronary artery  
COET, conditional over-expression of Tbx1 
co-Smad, common mediator Smad 
Abbreviations - 7 
Irinna Papangeli 
C-terminal, carboxyl-terminal 
DA, ductus arteriosus 
Dao, dorsal aorta  
Dcc, deleted in colon cancer 
del22q11, deletion of chromosome 22q11.2 
DesAo, descending aorta 
DMP, dorsal mesenchymal protrusion  
DNA, deoxyribonucleic acid 
DORV, double outlet right ventricle 
E, day of embryonic development 
ECE1, endothelin converting enzyme  
ECM, extracellular matrix  
EGF, epidermal growth factor 
EGFR, epidermal growth factor receptor  
EMSA, electromobility sift assay  
EMT, epithelial-mesenchymal transition  
En2, engrailed 2  
ES, embryonic stem  
EtOH, ethanol 
FACS, fluorescence activated cell sorting 
FDR, false discovery rate 
FGF, fibroblast growth factor  
FHF, first heart field  
FN, fibronectin   
GDF, growth and differentiation factor 
GDNF, glial cell line-derived neurotrophic factor 
HDAC, histone deacetylase 
HES, hairy and enhancer of split  
HEY, Hes-related transcription factor  
HOS, Holt-Oram Syndrome  
HUVEC, human umbilical vain endothelial cell  
IAA, interrupted aortic arch  
IAA-A, interrupted aortic arch type A 
Abbreviations - 8 
Irinna Papangeli 
IAA-B, interrupted aortic arch type B  
IAA-C, interrupted aortic arch type C 
IF, immunofluorescence 
IG, immunoglobulin  
IP, intraperitoneal  
IRES, internal ribosomal entry site  
ISA, intersegmental artery 
I-Smad, inhibitory Smad 
L, left 
LAP, latency-associated peptide  
LCC, left common carotid  
LCR, low copy repeat  
LSCA, left subclavian artery  
LTBP, latent TGF--binding protein 
LV, left ventricle  
m, milli 
M, molar 
MAML, mastermind-like  
Mb, mega base 
MEF, mouse embryonic fibroblast 
MeOH, methanol 
MES, midline epithelial seam  
MH, mad-homology 
MME, medial edge epithelia  
MMP, matrix metalloproteinase protein 
mRNA, messenger RNA 
n, nano 
Neo, neomycin 
NICD, intracellular domain of Notch  
NLS, nuclear localisation signal  
NP, non patent  
NRG, neuregulin 
NTD, neural tube defect 
Abbreviations - 9 
Irinna Papangeli 
N-terminal, amino-terminal 
O/N, overnight  
OCT, optimal cutting temperature double 
OG, oral gavage 
PAA, pharyngeal arch artery 
PAC, P1 artificial chromosome  
PBS, phosphate buffered saline 
PCR, polymerase chain reaction  
PDGF, platelet-derived growth factor 
PFO, patent foramen ovale  
PLB, passive lysis buffer  
PT, pulmonary trunk 
PTA, persistent truncus arteriosus  
r, rhombomeric segment 
R, right  
RA, retinoic acid  
RAA, right-sided aortic arch  
RALDH2, retinaldehyde dehydrogenase 2  
RBP-J, recombination signal binding protein for immunoglobulin kappa J region 
RCC, right common carotid  
RNA, ribonucleic acid 
Robo, roundabout  
RSCA, right subclavian artery 
R-Smad, receptor activated smad 
RT, reverse transcription  
RV, right ventricle  
S, sense 
SA, splice acceptor 
SAP, shrimp alkaline phosphatase  
SARA, smad anchor for receptor activation  
SDS, sodium dodecyl sulphate   
SEMA3C, semaphorin 3C  
SHF, second heart field  
Abbreviations - 10 
Irinna Papangeli 
SHH, Sonic Hedgehog  
SIK, salt-inducible kinase  
SMC, smooth muscle cells  
SMURF, smad ubiquitination regulatory factor 
SNP, small nuclear polymorphism  
SRF, serum response factor  
TACE, tumor necrosis factor-!-converting enzyme  
TAE, tris-acetate-EDTA 
TBE, transcription binding element 
TDR, typically deleted region  
TE, Tris Base/HCl-EDTA  
TESPA, 3-aminopropyl-triethoxysilane  
TGA, transposition of the great arteries  
TGF-, transforming growth factor -  
Th-P, thin patent  
Tm, melting temperature 
TOF, tetralogy of Fallot  
UTR, untranslated region 
UV, ultra violet 
VEGF, vascular endothelial growth factor  
VSD, ventricular septal defect  
VSM, vascular smooth muscle 
WB, western blotting 
WT, wild type  
YAP, yes-associated protein  
µ, micro 
Abbreviations - 11 
Irinna Papangeli 
GLOSSARY TERMS 
 
Type I transmembrane receptors 
Single pass transmembrane proteins, that have their C-terminus in the cytoplasm and 
their N-terminus oriented towards the lumen or extracellular space. 
Type II transmembrane receptors 
Single-pass transmembrane proteins that have their C-terminus on the cell surface and 
their N-terminus in the cytoplasm.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE OF CONTENTS
Table of Contents - 13 
Irinna Papangeli 
Acknowledgements ...................................................................................................... 4 
ABSTRACT................................................................................................................. 5 
ABBREVIATIONS...................................................................................................... 6 
GLOSSARY TERMS................................................................................................. 11 
TABLE OF CONTENTS............................................................................................ 12 
LIST OF FIGURES.................................................................................................... 22 
LIST OF TABLES ..................................................................................................... 25 
I. INTRODUCTION................................................................................................... 28 
1. DiGeorge syndrome............................................................................................ 29 
2. The pharyngeal apparatus, derivative affected structures and embryology........... 31 
2.1. The embryonic system ................................................................................. 31 
2.2. Patterning roles of the different cell populations........................................... 32 
2.2.1. The epithelia.......................................................................................... 32 
2.2.2. The mesoderm....................................................................................... 33 
2.2.3. The neural crest ..................................................................................... 34 
3. The neural crest in detail..................................................................................... 35 
3.1. Distinct phases of cranial neural crest migration........................................... 36 
3.2. Cranial neural crest migratory streams ......................................................... 36 
3.3. Cardiac neural crest...................................................................................... 38 
3.4. Neural crest gene regulation......................................................................... 39 
3.4.1. Induction............................................................................................... 39 
3.4.2. Cardiac neural crest migration............................................................... 39 
3.4.3. Differentiation....................................................................................... 41 
4. Pharyngeal arch arteries...................................................................................... 42 
4.1. Formation and remodelling .......................................................................... 42 
4.2. Mechanisms of remodelling ......................................................................... 44 
4.3. Types of great vessel defects and embryological origin ................................ 46 
5. Endocrine glands - pharyngeal pouch derivatives................................................ 57 
6. Palate - pharyngeal arch derivative...................................................................... 59 
7. The heart............................................................................................................. 62 
7.1. Heart and outflow tract formation................................................................. 62 
7.2. Heart and outflow tract septation and remodelling........................................ 64 
7.2.1. Heart ..................................................................................................... 64 
Table of Contents - 14 
Irinna Papangeli 
7.2.2. Outflow tract ......................................................................................... 67 
7.3. Heart fields and signalling factors ................................................................ 69 
7.3.1. Induction............................................................................................... 69 
7.3.2. Induction of FHF and SHF lineages....................................................... 70 
7.3.3. Remodelling.......................................................................................... 71 
7.4. Types of heart defects .................................................................................. 71 
7.5. Types of outflow tract defects (conotruncal malformations) ......................... 73 
7.6. Mechanisms and models of great vessel and outflow tract defects ................ 75 
7.6.1. Mechanisms .......................................................................................... 75 
7.6.2. Animal models ...................................................................................... 76 
8. Mouse models of DiGeorge syndrome and candidate genes ................................ 80 
9. TBX1 .................................................................................................................. 81 
9.1. General ........................................................................................................ 81 
9.2. Tbx1 mouse models and expression pattern .................................................. 81 
9.3. Tbx1 is required in different tissues, dosages and time-points....................... 85 
9.4. Tbx1 interactors and modifiers of 22q11DS.................................................. 94 
9.5. TBX1 human mutations ................................................................................ 97 
10. Research project outline - Tbx1 targets and pathways...................................... 100 
II. MATERIALS AND METHODS.......................................................................... 103 
1. Mouse strains, breeding, genotyping................................................................. 104 
1.1. Mouse strains ............................................................................................. 104 
1.2. Breeding .................................................................................................... 106 
1.3. Tamoxifen administration .......................................................................... 106 
1.4. Genotyping ................................................................................................ 106 
2. DNA extraction ................................................................................................ 107 
2.1. Lysis Buffer extraction............................................................................... 107 
2.2. Phenol-Chloroform extraction.................................................................... 107 
3. Polymerase Chain Reaction .............................................................................. 107 
3.1. Primer design............................................................................................. 107 
3.2. PCR conditions .......................................................................................... 107 
4. Gel electrophoresis ........................................................................................... 108 
5. Sequencing ....................................................................................................... 108 
6. RNA extraction................................................................................................. 109 
Table of Contents - 15 
Irinna Papangeli 
6.1. Trizol (Invitrogen) ..................................................................................... 109 
6.2. RNAeasy (Qiagen)..................................................................................... 109 
7. Reverse transcription (RT)................................................................................ 109 
8. Quantitative real time PCR ............................................................................... 109 
9. Protein extraction.............................................................................................. 110 
9.1. Embryo collection...................................................................................... 110 
9.2. Protein quantification - Bradford................................................................ 110 
9.3. Western Blotting ........................................................................................ 111 
9.3.1. Protein denaturation ............................................................................ 111 
9.3.2. SDS - Polyacrylamide gel electrophoresis (PAGE).............................. 111 
9.3.3. Western Blotting ................................................................................. 111 
9.3.4. Immunodetection................................................................................. 111 
9.3.5. Membrane stripping ............................................................................ 112 
10. Whole mount in situ hybridisation .................................................................. 112 
10.1. Ribophore labeling and purification.......................................................... 112 
10.1.1. Plasmid linearisation ......................................................................... 112 
10.1.2. Labelling........................................................................................... 113 
10.1.3. Purification........................................................................................ 113 
10.2. Embryo collection.................................................................................... 113 
10.3. Embryo pretreatment................................................................................ 113 
10.4. Embryo hybridisation............................................................................... 114 
10.5. Post hybridisation washes, blocking and antibody incubation ................... 114 
10.6. Post antibody washes ............................................................................... 115 
10.7. Colour development................................................................................. 115 
10.8. Viewing/Imaging ..................................................................................... 115 
11. Embryo powder .............................................................................................. 115 
12. X-gal staining ................................................................................................. 116 
13. Intracardiac ink injection................................................................................. 116 
14. Embedding and sectioning .............................................................................. 116 
14.1. Paraffin embedding.................................................................................. 116 
14.2. OCT embedding....................................................................................... 117 
15. Immunohistochemistry.................................................................................... 117 
16. Viewing/Imaging ............................................................................................ 117 
Table of Contents - 16 
Irinna Papangeli 
17. Cloning........................................................................................................... 118 
17.1. Plasmid mini-midi-maxi preps.................................................................. 118 
17.2. Digests ..................................................................................................... 118 
17.3. Gel extraction........................................................................................... 118 
17.4. TA cloning............................................................................................... 118 
17.5. Ligation ................................................................................................... 118 
17.6. De-phosphorylation of plasmids............................................................... 119 
17.7. Transformation......................................................................................... 119 
18. Mammalian cell culture .................................................................................. 119 
19. Cell transfections ............................................................................................ 119 
20. Luciferase assay.............................................................................................. 120 
20.1. --galactosidase Luciferase Assay ............................................................. 120 
20.2. Dual Luciferase Assay ............................................................................. 120 
21. Bone and cartilage staining ............................................................................. 120 
22. Bioinformatics ................................................................................................ 121 
23. Statistics ......................................................................................................... 121 
24. Gel band quantification................................................................................... 121 
III.  SMAD7 ............................................................................................................. 122 
1. Introduction – Literature review........................................................................ 123 
1.1. TGF- pathway ........................................................................................... 123 
1.1.1. Biological functions ............................................................................ 123 
1.1.2. Protein interactions.............................................................................. 123 
1.1.3. Smad proteins...................................................................................... 127 
1.1.4. Cross-talk with other pathways............................................................ 129 
1.1.5. Smad7 interactors/regulators ............................................................... 129 
1.2. TGF!/BMP/Smad gene mutations .............................................................. 130 
1.2.1. TGF! mutants ..................................................................................... 130 
1.2.2. BMP mutants....................................................................................... 131 
1.2.3. Smad mutants ...................................................................................... 132 
2. Project overview............................................................................................... 135 
3. Results.............................................................................................................. 136 
3.1. Smad7 in Tbx1 mutant embryos.................................................................. 136 
3.2. Tbx1 binding onto the Smad7 promoter...................................................... 138 
Table of Contents - 17 
Irinna Papangeli 
3.3. Smad7 gene-trap validation ........................................................................ 141 
3.4. Smad7 in the mouse embryo....................................................................... 145 
3.5. The Smad7 mutant phenotype .................................................................... 148 
3.5.1. 22q11DS-like spectrum of defects ....................................................... 148 
3.5.2. Great vessel and arch artery phenotype................................................ 150 
3.5.3. Neural crest migration......................................................................... 155 
3.5.4. Shear stress related factors................................................................... 155 
3.5.5. TGF-/BMP pathway ........................................................................... 157 
3.6. Tbx1;Smad7 mutant phenotype................................................................... 158 
3.6.1. 22q11DS-like spectrum of defects ....................................................... 158 
3.6.2. Great vessel and arch artery phenotype - genetic interaction ................ 159 
3.6.3. Shear stress related factors................................................................... 164 
3.7. Smad7 gene-trap time-dependent excision.................................................. 164 
4. Discussion - Future directions........................................................................... 173 
4.1. Smad7 as a Tbx1 target .............................................................................. 173 
4.2. Direct or indirect target?............................................................................. 173 
4.3. Smad7 is expressed in heart and pharyngeal structures during development 175 
4.4. Smad7 mutation produces aspects of the 22q11DS-like phenotype ............. 176 
4.4.1. The  Smad7 mutant great vessel and arch artery phenotype in detail .... 178 
4.4.2. Smad7 mutants display aberrant expression of Klf2, a shear stress related 
factor ............................................................................................................ 178 
4.4.3. Smad7 mutants appear to have unaffected neural crest patterning........ 179 
4.5. TGF-/BMP pathway inhibition by Smad7.................................................. 180 
4.6. Double heterozygosity for Tbx1 and Smad7 induces thymic and cardiovascular 
anomalies.......................................................................................................... 181 
4.6.1. The great vessel and arch artery phenotype in detail ............................ 181 
4.6.2. Tbx1 genetically interacts with other genes towards fourth arch artery 
development ................................................................................................. 182 
4.6.2.1. Defining “genetic interaction” ...................................................... 182 
4.6.2.2. Pooling data from the literature..................................................... 183 
4.6.2.3. Description and interpretation of the fourth arch artery phenotype in 
Tbx1 heterozygotes ................................................................................... 184 
Table of Contents - 18 
Irinna Papangeli 
4.6.2.4. Reviewed gene interactions with Tbx1 in pharyngeal arch artery 
morphogenesis .......................................................................................... 185 
4.6.3. Tbx1 is involved in pathways affecting pharyngeal arch artery remodelling
..................................................................................................................... 193 
4.6.3.1 Tbx1, Wnt signalling and arch artery remodelling.......................... 193 
4.6.3.2. Tbx1, retinoic acid signalling and arch artery remodelling............. 195 
4.6.4. Concluding remarks on Tbx1-Smad7 interaction in pharyngeal arch artery 
morphogenesis .............................................................................................. 197 
4.7. Smad7 gene-trap time-dependent rescue..................................................... 198 
4.8. Conclusion and future directions ................................................................ 200 
IV. HES1.................................................................................................................. 202 
1. Introduction – Literature review........................................................................ 203 
1.1. Notch pathway........................................................................................... 203 
1.1.1. Biological functions ............................................................................ 203 
1.1.2. Notch pathway genes........................................................................... 203 
1.1.3. Notch target genes............................................................................... 205 
1.1.3.1. Hes1 protein, interactors and biological functions......................... 205 
1.1.4. Notch pathway in cardiovascular development .................................... 207 
1.2. Notch gene mutations................................................................................. 208 
1.2.1. Notch pathway gene mutations............................................................ 208 
1.2.2. Notch target gene mutations ................................................................ 209 
2. Project overview............................................................................................... 212 
3. Results.............................................................................................................. 213 
3.1. Hes1 in the mouse embryo ......................................................................... 213 
3.2. Tissue-specific contributions of Hes1......................................................... 215 
3.2.1. Hes1 in the neural crest ....................................................................... 215 
3.2.1.1. Hes1 may have a minor role in the neural crest towards arch artery 
morphogenesis .......................................................................................... 215 
3.2.1.2. Hes1 is required in the neural crest for thymus development......... 217 
3.2.1.3. Hes1 may have a minor role in the neural crest towards secondary 
palate and ventricular septum development ............................................... 218 
3.2.1.3. Hes1 is not required in the neural crest for eye development......... 219 
3.2.2. Hes1 in the ectoderm........................................................................... 219 
Table of Contents - 19 
Irinna Papangeli 
3.2.2.1. Hes1 is required in the neural crest and ectoderm towards arch artery 
morphogenesis .......................................................................................... 219 
3.2.2.2. Hes1 is required in the neural crest and ectoderm for thymic 
development.............................................................................................. 221 
3.2.2.3. Hes1 may have a minor role in the neural crest and ectoderm during 
secondary palate and ventricular septum development............................... 223 
3.2.2.4. Hes1 is required in the neural crest and ectoderm for eye development
................................................................................................................. 223 
3.2.3. Hes1 in the anterior heart field............................................................. 224 
3.2.3.1. Hes1 is not required in the anterior heart field for arch artery 
morphogenesis .......................................................................................... 225 
3.2.3.2. Hes1 is not required in the anterior heart field for thymus, palate or 
eye development ....................................................................................... 226 
3.2.4. Hes1 in the endoderm.......................................................................... 228 
3.3. Hes1 in the neural crest lineage.................................................................. 230 
3.3.1. Hes1 in neural crest cell patterning...................................................... 230 
3.3.2. Hes1 in post migratory neural crest...................................................... 231 
3.4. Hes1 and the Notch pathway during pharyngeal development .................... 232 
3.5. Hes1 and the FGF pathway during pharyngeal development ...................... 234 
4. Discussion - Future directions........................................................................... 236 
4.1. Hes1 is expressed in overlapping domains with Tbx1 during early 
embryogenesis .................................................................................................. 236 
4.2. Tissue-specific contributions of Hes1 to the null phenotype ....................... 237 
4.2.1. Cardiovascular development................................................................ 237 
4.2.2. Thymus development .......................................................................... 240 
4.2.3. Eye development................................................................................. 240 
4.2.4. Neural tube closure.............................................................................. 242 
4.3. Genetic background considerations ............................................................ 242 
4.4. Hes1 in the neural crest lineage.................................................................. 243 
4.5. Hes1 and Notch pathway genes during pharyngeal development ................ 244 
4.6. Hes1 and the FGF pathway ........................................................................ 245 
4.7. Conclusion and future directions ................................................................ 245 
V. SLIT2 .................................................................................................................. 247 
Table of Contents - 20 
Irinna Papangeli 
1. Introduction – Literature review........................................................................ 248 
1.1. The Slit/Robo pathway............................................................................... 248 
1.1.1. Biological functions ............................................................................ 248 
1.1.2. Protein interactions.............................................................................. 248 
1.1.2.1. Slit2 .............................................................................................. 249 
1.2. Slit/Robo gene mutations ........................................................................... 249 
2. Project overview............................................................................................... 250 
3. Results.............................................................................................................. 251 
3.1. Slit1 and Slit2 in the mouse embryo............................................................ 251 
3.1.1. Expression domains............................................................................. 251 
3.1.2. Slit2 mutant phenotype ........................................................................ 252 
3.1.3. Slit1;Slit2 mutant phenotype
1
............................................................... 252 
3.2. Tbx1-Slit2 genetic interaction..................................................................... 253 
3.2.1. Tbx1 and Slit2 double heterozygosity .................................................. 254 
3.2.2. Tbx1 heterozygosity on a Slit2 null background................................... 255 
4. Discussion - Future directions........................................................................... 258 
4.1. Slit1 and Slit2 share expression domains with Tbx1 .................................... 258 
4.2. Slit2 or Slit1;Slit2 deficiency does not induce cardiovascular defects.......... 258 
4.3. Slit2 or Slit1;Slit2 deficiency does not induce thymic defects...................... 259 
4.4. Tbx1 and Slit2 probably do not genetically interact..................................... 259 
4.5. Conclusion and future directions ................................................................ 260 
VI. CONCLUSIONS AND SUMMARY.................................................................. 262 
1. Conclusions ...................................................................................................... 263 
1.1. General overview: “From disease to gene and back” .................................. 263 
1.2. Dealing with Tbx1 targets and complex interactions................................... 264 
1.2.1. Microarray screens, outcomes and limitations...................................... 265 
1.2.2. Characterisation of mutant phenotypes - an invaluable tool for linking 
genes to developmental processes ................................................................. 266 
1.2.3. Conditional deletion - a tool for dissecting tissue and/or time-specific gene 
requirements ................................................................................................. 266 
1.2.4. Genetic interaction - a tool for dissecting genetic pathways ................. 267 
1.2.5. Bioinformatics - probably a weak tool in establishing direct interactions
..................................................................................................................... 268 
Table of Contents - 21 
Irinna Papangeli 
2. Thesis summary................................................................................................ 270 
PUBLICATIONS/CONTRIBUTIONS..................................................................... 271 
BIBLIOGRAPHY .................................................................................................... 274 
APPENDIX I............................................................................................................ 306 
Stock solutions and Antibodies ............................................................................. 307 
1. Stock Solutions ............................................................................................. 307 
2. Antibodies .................................................................................................... 308 
APPENDIX II .......................................................................................................... 309 
Primer Sequences and Cycling conditions............................................................. 310 
1. Genotyping primer sequences ....................................................................... 310 
2. Quantitative real time PCR primer sequences................................................ 311 
3. Smad7 luciferase construct primer sequences................................................ 311 
4. Cycling conditions ........................................................................................ 312 
APPENDIX III ......................................................................................................... 313 
Plasmid constructs ................................................................................................ 314 
1. Whole mount in situ hybridisation probe plasmids ........................................ 314 
2. Expression and luciferase constructs ............................................................. 315 
Lists - 22 
Irinna Papangeli 
LIST OF FIGURES 
 
I. INTRODUCTION 
Figure 1. 1. The mammalian pharyngeal apparatus.. ................................................... 32 
Figure 1. 2. Segmental organisation of the hindbrain and distinct pathways of cranial 
neural crest cell migration................................................................................... 37 
Figure 1. 3. Normal pharyngeal arch artery remodelling in the mouse......................... 44 
Figure 1. 4. Embryological origin of the double aortic arch......................................... 47 
Figure 1. 5. Embryological origin of the RAA. ........................................................... 49 
Figure 1. 6. Embryological origin of the left-sided arch with abnormal branching....... 52 
Figure 1. 7. Embryological origin of the cervical aortic arch....................................... 53 
Figure 1. 8. Embryological origin of the IAA.............................................................. 55 
Figure 1. 9. The mouse facial primordia...................................................................... 60 
Figure 1. 10. Stages of heart development................................................................... 64 
Figure 1. 11. Cardiac septation. .................................................................................. 66 
Figure 1. 12. Conotruncal septation. ........................................................................... 68 
Figure 1. 13. Cardiac alignment defects. ..................................................................... 72 
Figure 1. 14. Cardiac septation defects........................................................................ 73 
Figure 1. 15. Outflow tract defects.............................................................................. 74 
III. SMAD7 
Figure 3. 1. Simplified schematic representation of the TGF-/BMP pathways. ......... 127 
Figure 3. 2. Smad protein structure. .......................................................................... 128 
Figure 3. 3. Tbx1 and Smad7 mRNA expression detected by in situ hybridisation at 
E9.5. ................................................................................................................. 137 
Figure 3. 4. Conserved TBEs on the Smad7 gene and upstream/downstream regulatory 
regions among human, mouse rat and dog genomes.. ........................................ 139 
Figure 3. 5. Smad7 promoter activation by TBX1. .................................................... 141 
Figure 3. 6. Smad7 gene-trap model characterisation. ............................................... 143 
Figure 3. 7. Smad7 expression during embryogenesis. .............................................. 145 
Figure 3. 8. Smad7 expression in pharyngeal and cardiac structures.......................... 147 
Figure 3. 9. 22q11DS-like spectrum of defects in Smad7 gene-trap embryos............. 149 
Figure 3. 10. Arch artery and great vessel defects in Smad7 gene-trap embryos. ....... 153 
Lists - 23 
Irinna Papangeli 
Figure 3. 11. Arch artery defects observed in Smad7 gene-trap embryos at E11.5 and 
E15.5-E18.5...................................................................................................... 154 
Figure 3. 12. Neural crest patterning in Smad7 gene-trap embryos at E10.5. ............. 155 
Figure 3. 13. Klf2 expression levels in Smad7 gene-trap embryos. ............................ 156 
Figure 3. 14. pSmad2/3 and pSmad1/5/8 levels in Smad7 gene-trap embryos............ 157 
Figure 3. 15. Arch artery and great vessel defects in Tbx1;Smad7 double heterozygous 
embryos. ........................................................................................................... 161 
Figure 3. 16. Arch artery defects observed in Tbx1;Smad7 double heterozygous embryos 
at E11.0 and E15.5............................................................................................ 162 
Figure 3. 17. Proportional representation of the fourth arch artery phenotype scored at 
E11.0 and E15.5 in Tbx1 heterozygous and Tbx1;Smad7 double heterozygous 
embryos. ........................................................................................................... 163 
Figure 3. 18. Klf2 expression levels in Tbx1 heterozygous and Tbx1;Smad7 double 
heterozygous embryos. ..................................................................................... 164 
Figure 3. 19. Smad7 expression levels in Tbx1 or Smad7 heterozygous and Tbx1;Smad7 
double heterozygous embryos. .......................................................................... 167 
Figure 3. 20. Smad7 gene-trap vector recombination efficiency in Smad7
GT/GT
;CaggsCre 
embryos under different protocols of tamoxifen administration......................... 168 
Figure 3. 21. Smad7 gene-trap vector recombination efficiency in 
Smad7
+/GT
;Tbx1
+/lacZ
;CaggsCre embryos under different protocols of tamoxifen 
administration. .................................................................................................. 169 
Figure 3. 22. Reporter expression indicating recombination efficiency in 
Smad
GT/GT
;CaggsCre embryos. ......................................................................... 170 
Figure 3. 23. Genomic amplification of the gene-trap and recombined gene-trap vector 
in different genotypes. ...................................................................................... 172 
Figure 3. 24. Schematic representation of the presumptive requirement for Tbx1 and 
Smad7 during vessel development..................................................................... 187 
Figure 3. 25. Schematic representation of the presumptive modes of interaction between 
Tbx1 and Smad7 during development................................................................ 198 
IV. HES1 
Figure 4. 1. Simplified schematic representation of Notch signalling in two adjacent 
cells. ................................................................................................................. 204 
Lists - 24 
Irinna Papangeli 
Figure 4. 2. Tbx1 and Hes1 expression detected by immunofluorescence at E8.5 and in 
situ hybridisation at E9.5................................................................................... 214 
Figure 4. 3. Wnt1Cre conditional deletion................................................................. 218 
Figure 4. 4. Ap2"Cre conditional deletion................................................................. 222 
Figure 4. 5. Craniofacial defects in the Ap2"Cre conditional embryos at E15.5......... 223 
Figure 4. 6. Eye defects in the Ap2"Cre conditional embryos at E15.5...................... 224 
Figure 4. 7. Mef2cCre conditional deletion. .............................................................. 227 
Figure 4. 8. Foxa2mcm system induction at E9.5. ..................................................... 229 
Figure 4. 9. Sox17-2A-iCre system induction at E9.5. ............................................... 229 
Figure 4. 10. Neural crest patterning in Hes1 mutant embryos at E10.5..................... 231 
Figure 4. 11. Neural crest patterning in Hes1 mutant embryos at E9.5....................... 231 
Figure 4. 12. Neural crest patterning in Hes1 mutant embryos at E10.5..................... 232 
Figure 4. 13. Pharyngeal expression of Notch genes in Hes1 mutant embryos at E9.5.
......................................................................................................................... 233 
Figure 4. 14. Expression of FGF genes in Hes1 mutant embryos at E8.5 and E9.5. ... 234 
V. SLIT2 
Figure 5. 1. Tbx1, Slit1 and Slit2 mRNA expression detected by in situ hybridisation at 
E9.5. ................................................................................................................. 251 
Figure 5. 2. Great vessel, palate and intracardiac defects observed in the Tbx1;Slit2 
double heterozygous embryos at E15.5. ............................................................ 255 
Figure 5. 3. Thymic and great vessel defects observed in the Tbx1;Slit2 double mutant 
embryos at E15.5. ............................................................................................. 256 
 
Lists - 25 
Irinna Papangeli 
LIST OF TABLES 
 
I. INTRODUCTION 
Table 1. 1. Genetic mutations of Tbx1 in mouse models.............................................. 85 
Table 1. 2. The Tbx1 time-dependent phenotype. ........................................................ 89 
Table 1. 3. The Tbx1 dosage-dependent phenotype.. ................................................... 91 
II. MATERIALS AND METHODS 
Table 2. 1. Embryo stage and incubation times in 10µg/ml Proteinase K in PBT for 
whole mount in situ hybridisation. .................................................................... 114 
III. SMAD7 
Table 3. 1. TGF- superfamily signalling factors in human........................................ 126 
Table 3. 2. Smad7 gene-trap validation by quantitative real time PCR....................... 144 
Table 3. 3. Frequency of P10 genotypes observed from Smad7
+/GT
 (x) Smad7
+/GT
 
matings.. ........................................................................................................... 144 
Table 3. 4. Smad7 expression in pharyngeal and cardiac structures. .......................... 146 
Table 3. 5. Thymic and great vessel defects observed in the Smad7 gene-trap embryos at 
E15.5-E18.5...................................................................................................... 149 
Table 3. 6. Arch artery defects observed in the Smad7 gene-trap embryos at E15.5-
E18.5. ............................................................................................................... 150 
Table 3. 7. Arch artery defects observed in the Smad7 gene-trap embryos at E10.5... 151 
Table 3. 8. Arch artery defects observed in the Smad7 gene-trap embryos at E11.5... 151 
Table 3. 9. Arch artery defects observed in the Smad7 gene-trap embryos at E10.5-
E11.5. ............................................................................................................... 152 
Table 3. 10. Thymic and great vessel defects observed in the Tbx1;Smad7 double 
heterozygous embryos at E15.5-E18.5.. ............................................................ 159 
Table 3. 11. Arch artery defects observed in the Tbx1;Smad7 double heterozygous 
embryos at E15.5. ............................................................................................. 159 
Table 3. 12. Arch artery defects observed in the Tbx1;Smad7 double heterozygous 
embryos at E11.0. ............................................................................................. 162 
Table 3. 13. Tamoxifen administration and CaggsCre-dependent recombination 
efficiency of the Smad7 gene-trap vector........................................................... 166 
Lists - 26 
Irinna Papangeli 
Table 3. 14. Arch artery defects observed in embryos with double mutations for Tbx1 
and other genes, at early or late developmental stages in the different studies.
............................................................................. Error! Bookmark not defined. 
IV. HES1 
Table 4. 1. Arch artery defects observed in Hes1 embryos at E10.5. ......................... 210 
Table 4. 2. Thymic cardiovascular and palate defects observed in Hes1 embryos at 
E14.5-E15.5...................................................................................................... 211 
Table 4. 3. Arch artery defects observed in the Wnt1Cre conditional embryos at E10.5.
......................................................................................................................... 216 
Table 4. 4. Thymic, great vessel and eye defects observed in the Wnt1Cre conditional 
embryos at E15.5. ............................................................................................. 216 
Table 4. 5. Arch artery defects observed in the Ap2"Cre conditional embryos at E10.5..
......................................................................................................................... 220 
Table 4. 6. Thymic, great vessel and eye defects observed in the Ap2"Cre conditional 
embryos at E15.5. ............................................................................................. 221 
Table 4. 7. Arch artery defects observed in the Mef2cCre conditional embryos at E10.5.
......................................................................................................................... 225 
Table 4. 8. Thymic, great vessel and eye defects observed in the Mef2cCre conditional 
embryos at E15.5-E19.5.................................................................................... 226 
Table 4. 9. Summary of the Hes1 conditional deletion phenotypes............................ 237 
V. SLIT2 
Table 5. 1. Thymic, great vessel and intracardiac defects observed in the Slit2 embryos 
at E15.5-E18.5. ................................................................................................. 252 
Table 5. 2. Great vessel defects observed in the Slit1;Slit2 double mutant embryos at 
E14.5.. .............................................................................................................. 253 
Table 5. 3. Thymic and great vessel defects observed in the Slit1;Slit2 double mutant 
embryos at E18.5. ............................................................................................. 253 
Table 5. 4. Thymic cardiovascular and palate defects observed in the Tbx1;Slit2 double 
heterozygous embryos at E15.5......................................................................... 254 
Table 5. 5. Thymic and great vessel defects observed in the Tbx1;Slit2 double mutant 
embryos at E15.5. ............................................................................................. 256 
APPENDIX I 
Lists - 27 
Irinna Papangeli 
Table AI. 1. Stock solutions...................................................................................... 308 
Table AI. 2. Antibodies. ........................................................................................... 308 
APPENDIX II 
Table AII. 1. Genotyping PCR primer sequences...................................................... 310 
Table AII. 2. Quantitative real time PCR primer sequences....................................... 311 
Table AII. 3. Smad7 luciferase construct PCR primer sequences. ............................. 311 
Table AII. 4. PCR cycling conditions........................................................................ 312 
APPENDIX III 
Table AIII. 1. Whole mount in situ hybridisation probe plasmids.............................. 314 
Table AIII. 2. Expression and luciferase constructs................................................... 315 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I. INTRODUCTION
Introduction - 29 
Irinna Papangeli 
1. DiGeorge syndrome 
DiGeorge is the most common microdeletion syndrome in humans, with an 
incidence of 1 in 4000-5000 live births (Emanuel, 2008; Wurdak et al., 2006; Yagi et 
al., 2003). Historically it was described separately as velocardiofacial syndrome 
(Shprintzen syndrome), conotruncal anomaly face syndrome (CAFS or Takao 
syndrome) and Sedlackova syndrome, however, in recent years all have been grouped 
under chromosome 22q11 deletion syndrome (22q11DS) (Epstein, 2001; Momma, 
2010; Paylor and Lindsay, 2006; Saitta et al., 2004; Schwinger et al., 2010).  
The clinical phenotype is very heterogeneous and includes congenital heart 
defects (approximately 70% of all cases), craniofacial dysmorphism and thymic and 
parathyroid aplasia/ hypoplasia (Shprintzen, 2008; Wurdak et al., 2006). Behavioural, 
learning and psychiatric complications have also been reported (Shprintzen, 2008; 
Wurdak et al., 2006). All these manifestations can be grouped in three categories: (1) 
the pharyngeal phenotype, representing abnormalities in the development of the 
pharyngeal apparatus, (2) the neurobehavioral phenotype, concerning learning and 
psychiatric disabilities and (3) a heterogeneous group of clinical symptoms, including 
kidney, non-craniofacial skeletal and vascular defects (Baldini, 2004). The majority of 
patients exhibit features of at least two of the three categories of phenotypes (Baldini, 
2004). The cardiovascular phenotype of the 22q11DS includes both conotruncal and 
aortic arch defects, namely tetralogy of Fallot (TOF) (~30%), interrupted aortic arch 
type B (IAA-B) (~15%), ventricular septal defect (VSD) (~15%), common arterial trunk 
(CAT) (~10%) or others (~5%) (Yamagishi, 2002). Hemizygous deletion of 
chromosome 22q11.2 is the second most common genetic cause of congenital heart 
disease (CHD) and is present in approximately 60% of the patients with IAA-B, 35% of 
the patients with CAT and 15% of the patients with TOF (or 55% of the patients with 
TOF combined with pulmonary atresia and major aortopulmonary collateral arteries) 
(Yamagishi, 2002). 
In over 85% of the cases the disease is caused by a 3 Mb hemizygous deletion of 
chromosome 22q11.2 (del22q11) (Emanuel, 2008; Wurdak et al., 2006; Yamagishi and 
Srivastava, 2003). This 3 Mb typically deleted region (TDR) that encompasses 
approximately 40 genes, is flanked by low copy repeat (LCR) sites near or at the break 
points of del22q11 (Aggarwal and Morrow, 2008; Baldini, 2004; Paylor and Lindsay, 
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2006; Yamagishi and Srivastava, 2003). The sequence identity shared by these LCRs 
predisposes the respective regions to non-allelic homologous recombination, resulting 
in aberrant interchromosomal exchange and subsequent deletion (Baldini, 2004; 
Emanuel, 2008; Saitta et al., 2004). The remaining 7-8% of patients carry recurrent 1.5-
2 Mb nested deletions, however there are cases of smaller atypical deletions, all of 
which have phenotypic manifestations consistent with the diagnosis of 22q11DS 
(Emanuel, 2008; Gong et al., 2001; Paylor and Lindsay, 2006; Scambler, 2010; Yagi et 
al., 2003). Correlations between the genotype and the phenotype of the syndrome are 
unlikely as there is no difference in the severity of the phenotype among the various 
deletions (Aggarwal and Morrow, 2008; Saitta et al., 2004). Even patients that share the 
same sized deletion exhibit significant clinical variability (Aggarwal and Morrow, 
2008). Most of the deletions occur de novo, with 10% or less being inherited from an 
affected parent (Saitta et al., 2004). In a proportion of patients that do not carry the 
typical deletion there have been found point mutations in TBX1, a gene localising within 
the TDR (Paylor et al., 2006; Stoller and Epstein, 2005a; Torres-Juan et al., 2007; Yagi 
et al., 2003; Zweier et al., 2007).  
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2. The pharyngeal apparatus, derivative affected structures and 
embryology 
2.1. The embryonic system  
A large proportion of the phenotypes observed in 22q11DS patients are associated 
with incorrect patterning of the pharyngeal apparatus (Wurdak et al., 2006), a 
vertebrate-specific, transient structure that forms in the lateral side of the embryo 
(Graham, 2008; Grevellec and Tucker, 2010). It is constituted of five bilaterally 
symmetrical arches, formed successively in an anterior to posterior direction (Graham, 
2008; Grevellec and Tucker, 2010; Wurdak et al., 2006). In mouse this occurs between 
the 8
th
 and 11
th
 day of embryonic development (E8.0-E11.0) while in humans it 
develops between the 2
nd
 and 7
th
 week of gestation (Wurdak et al., 2006). The arches 
are numbered from 1 to 6, omitting number 5 by convention (Wurdak et al., 2006). 
Within the pharyngeal arches five sets of arteries are initially formed (Wurdak et al., 
2006). These undergo extensive remodelling throughout development to become the 
mature left-sided aortic arch (Gittenberger-de Groot et al., 2006; Kameda, 2009; 
Kellenberger, 2010; Molin et al., 2002; Snider et al., 2007). 
Different cell types are recruited to form the apparatus, deriving from all the 
embryonic layers. Ectodermal and endodermal cells populate the external and internal 
surfaces respectively, while mesenchyme colonises the intermediate region (Figure 1.1) 
(Graham, 2003; Grevellec and Tucker, 2010). The boundaries of each arch are defined 
by the regions of contact of the ectoderm and the endoderm between the arches 
(Graham, 2003; Grevellec and Tucker, 2010). This is apparent externally as ectodermal 
clefts and internally as endodermal pouches (Graham, 2003; Grevellec and Tucker, 
2010). Neural crest cells populate each arch and mesodermal cells are confined to the 
core of the mesenchyme surrounding each arch artery (Graham, 2003; Graham, 2008). 
The different cell populations produce distinct structures. The ectoderm generates the 
epidermal lining of the arches and the sensory neurons of the epibranchial ganglia 
(Graham, 2001; Graham, 2003; Graham, 2008; Grevellec and Tucker, 2010). The 
endoderm forms the epithelium of the pharynx, the taste buds and endocrine glands 
(Graham, 2001; Graham, 2003; Graham, 2008; Grevellec and Tucker, 2010). The neural 
crest develops into skeletal and connective tissues and part of the neurosensory ganglia 
of the head while the core mesoderm is responsible for the head and neck musculature, 
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skeletal elements and the endothelial lining of the arch arteries (Graham, 2001; Graham, 
2003; Graham, 2008; Grevellec and Tucker, 2010). 
Each pair of arches is populated by the same cell types and generates the same 
basic components; nevertheless, each pair also has an individual identity (Graham, 
2001; Graham, 2003). The first arch shapes the jaw, the second forms the hyoid 
apparatus and the more caudal arches are incorporated into the throat (Graham, 2001; 
Graham, 2003). The caudal pouches are also regionalised and give rise to the thyroid, 
parathyroid and thymus glands (Graham, 2008; Grevellec and Tucker, 2010; Jerome 
and Papaioannou, 2001).  
 
Figure 1. 1. The mammalian pharyngeal apparatus. Lateral and frontal views of the 
pharyngeal system consisting of a series of arches, which are covered by an ectodermal 
layer externally and an endodermal lining internally. Each arch surrounds an arch artery 
and is populated by mesoderm and neural crest cells.  
2.2. Patterning roles of the different cell populations 
2.2.1. The epithelia 
Pharyngeal patterning requires reciprocal signalling between the constituent 
tissues, primarily between the pharyngeal epithelia, the ectoderm and the endoderm 
(Graham, 2003). The endoderm appears to drive pharyngeal segmentation (Graham, 
2008). The endodermal pouches physically separate the branchial arches and by 
defining the anterior and posterior boundaries of each arch they provide distinct 
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identities for each (Graham, 2008; Grevellec and Tucker, 2010). Also, by being a 
segmentally organised tissue, the endoderm provides the necessary positional cues for 
the mesoderm and the invading neural crest of the arches (Graham, 2008). The pouches 
are first evident at the sites of contact between the endoderm and ectoderm of the 
pharyngeal apparatus (Graham, 2008; Grevellec and Tucker, 2010). Cells within the 
pouch endoderm have an organised network of actin cables required for pouch 
morphogenesis (Quinlan et al., 2004), so that throughout this process the endodermal 
tissue as a whole will expand in all directions while the pouches will mainly expand 
along the dorsoventral axis (Graham, 2008). Fibroblast growth factor (FGF) signalling 
is particularly important for pouch formation (Graham, 2008). The pharyngeal 
endoderm is required for the patterning of arch components, such as the epibranchial 
placodes, focal thickenings of the ectoderm that give rise to the epibranchial ganglia 
(Graham, 2008; Trainor and Krumlauf, 2001). In zebrafish and amphibia it has been 
shown that the chondrogenenic fate of the neural crest is promoted by the pharyngeal 
endoderm (Graham, 2008; Trainor and Krumlauf, 2001). The endoderm is also involved 
in the induction of neural crest-derived skeletal elements (Graham, 2008). The surface 
ectoderm, apart from its involvement in pharyngeal segmentation though clefting 
(Graham, 2008; Grevellec and Tucker, 2010), regulates the patterning of the neural crest 
of the first arch and consequently plays a key role in odontogenesis (Trainor and 
Krumlauf, 2001). Additionally, through Fgf8, which is expressed in the anterior 
ectoderm of the first arch, it determines the rostrocaudal polarity of the arch (Trainor 
and Krumlauf, 2001). 
2.2.2. The mesoderm  
It has been shown that the mesoderm provides maintenance signals for the neural 
crest cells of the second branchial arch, by permitting but not initiating Hox gene 
expression, thus regulating the identity of these cells (Trainor and Krumlauf, 2000). The 
cranial mesoderm, being primarily myogenic, is tightly linked to neural crest skeletal 
and connective tissue patterning (Trainor and Krumlauf, 2001). Maintaining an anterior-
posterior register between the primordial tissues may be an important step in subsequent 
craniofacial morphogenesis (Trainor and Krumlauf, 2001). 
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2.2.3. The neural crest 
The neural crest is not involved in pharyngeal metamerism (Graham, 2008). 
However, the gene expression pattern of each subpopulation of crest cells defines their 
response to endodermal cues and the generation of different derivatives (Graham, 
2008). The neural crest cells are important for the final patterning of the arch arteries, 
although not required for the initial formation (Hutson and Kirby, 2007; Kameda, 
2009). Neural crest cells migrate into the arches, surround the endothelial tubes that 
originally constitute the arch arteries and differentiate into the smooth muscle tunics of 
the future great arteries (Hutson and Kirby, 2007; Scholl and Kirby, 2009). 
Developmental anomalies that result in inability of the neural crest cells to colonise 
their final targets cause a large number of birth defects (Kulesa and Gammill, 2010; 
Tucker, 2004). 
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3. The neural crest in detail  
The neural crest is a pluripotent, transient, migratory cell population originating 
from the dorsal aspect of the neural tube, at the junction between the neuroepithelium 
and the surface ectoderm, commonly known as the neural plate border (Aman and 
Piotrowski, 2010; Kalcheim and Burstyn-Cohen, 2005; Kulesa et al., 2004; Lallier et 
al., 1992; Sauka-Spengler and Bronner-Fraser, 2008; Tucker, 2004). Cues from the 
surrounding non-neural ectoderm and mesoderm induce the neural crest cells to undergo 
epithelial-mesenchymal transition (EMT), exit the neural tube and migrate extensively 
in a rostro-caudal progression throughout the body of the embryo (Aman and 
Piotrowski, 2010; Kalcheim and Burstyn-Cohen, 2005; Kulesa et al., 2004; Sauka-
Spengler and Bronner-Fraser, 2008; Tucker, 2004). In mouse, migration commences at 
the five-somite stage (E8.25) (Kulesa et al., 2004). The neural crest cells differentiate at 
their sites of colonisation and eventually develop into several different cell types, tissues 
and organs (Aman and Piotrowski, 2010; Snider et al., 2007; Tucker, 2004). Along the 
neural axis four main subcategories of neural crest are identified: cranial, vagal, trunk 
and sacral (Jones and Trainor, 2005; Lallier et al., 1992), while the cranial crest includes 
a subpopulation known as the cardiac neural crest (Snarr et al., 2008; Snider et al., 
2007). Each population has different migratory pathways and generates different sets of 
derivatives (Jones and Trainor, 2005; Lallier et al., 1992). The cranial neural crest cells, 
originating from pre-somitic levels, follow a cranial route through the mesenchyme and 
produce skeletal elements of the face, cranial parasympathetic and sensory ganglia 
(Jones and Trainor, 2005; Lallier et al., 1992), whilst contributing to the tunica media of 
the great arteries, the aorticopulmonary (AP) septum and the semilunar valves (Jones 
and Trainor, 2005; Nakamura et al., 2006; Snider et al., 2007). The vagal population, 
originating from the level of somites 1-7, migrates into the gut and populates the 
majority of the enteric ganglia, whilst trunk neural crest cells, originating from the level 
of somites 8-28, move between the somites and underneath the ectoderm and ultimately 
give rise to sensory and sympathetic ganglia, adrenal chromaffin cells and melanocytes 
(Jones and Trainor, 2005; Lallier et al., 1992). Last, the sacral neural crest population 
that originates below the level of somite 28, produces enteric ganglia and some 
parasympathetic and sensory ganglion cells (Jones and Trainor, 2005; Lallier et al., 
1992).  
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3.1. Distinct phases of cranial neural crest migration 
There are at least three phases of cranial neural crest cell migration. During the 
first phase the cells acquire the ability to migrate directionally, which involves cell 
contact and microenvironment interactions, followed by cell surface changes that 
promote migration (Kulesa et al., 2010; Kulesa and Gammill, 2010). In the second 
phase the neural crest cells move along the dorsolateral pathway towards the branchial 
arches, whilst remaining in loosely connected streams (Kulesa et al., 2010; Kulesa and 
Gammill, 2010). The cells proliferate at different rates and establish different 
trajectories, depending on the stream they follow, their position within the stream and 
their neighboring cells (Kulesa et al., 2010; Kulesa and Gammill, 2010). In the last 
phase the neural crest cells invade the branchial arches, a phase followed by repression 
of the cells’ migratory ability upon arrival at the target site (Kulesa et al., 2010; Kulesa 
and Gammill, 2010). The different phases are regulated by a number of signalling cues 
with regard to targeted invasion, survival, proliferation and differentiation, with factors 
like Sonic hedgehog (SHH), Transforming growth factor - (TGF-), Semaphorins/ 
Neuropilins and Slits/Robos (Kulesa et al., 2010). 
3.2. Cranial neural crest migratory streams 
The cranial neural crest cells migrate in three distinct, segregated streams, 
depending on the cranio-caudal origin of the migrating cells (Kulesa et al., 2004; Kulesa 
et al., 2010). The vertebrate hindbrain is segmented into seven rhombomeric segments 
(r) and provides a structural framework for the description of the cranial crest migratory 
streams (Kulesa et al., 2010; Trainor and Krumlauf, 2000). Neural crest cells from the 
first two rhombomeres (r1 and r2) migrate in a ventrolateral direction and along with 
midbrain-derived neural crest cells invade the first branchial arch (Kulesa et al., 2004). 
The second branchial arch is mainly populated by cells deriving from r4 (Kulesa et al., 
2004). R3 produces fewer neural crest cells compared to r1 and r2, which migrate 
anteriorly following the r2 stream and posteriorly following the r4 stream (Kulesa et al., 
2004; Trainor and Krumlauf, 2000). Similarly to r3, neural crest cells from r5 lack the 
ability to migrate laterally and move anteriorly and posteriorly, merging with the even-
numbered streams from r4 and r6 (Kulesa et al., 2004; Trainor and Krumlauf, 2000). In 
comparison, more neural crest cells delaminate from r5 than r3, but still significantly 
less than from r4 (Kulesa et al., 2004). Neural crest cells migrating from r5 and r6 
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populate the third branchial arch while the fourth arch is populated by r7-derived and a 
minor r6-derived population of neural crest cells (Kulesa et al., 2004) (Figure 1.2). The 
neural crest free zones adjacent to r3 and r5 can be explained (prevailing theories) by 
limited neural crest cell production, increased apoptosis or compromised movement of 
the neural crest cells originating from the respective rhombomeres (Kulesa et al., 2010). 
Hox genes have a segment-restricted pattern of expression, suggestive of their role in 
patterning of the rhombomere identity and subsequently the vertebrate head (Trainor 
and Krumlauf, 2000; Trainor and Krumlauf, 2001). 
 
Figure 1. 2. Segmental organisation of the hindbrain and distinct pathways of 
cranial neural crest cell migration. The hindbrain is divided into seven rhombomeres 
(r1-7). The first arch is populated by neural crest cells originating from r1-2 and a minor 
r3-derived population. The second arch is invaded by neural crest cells originating from 
r4 and a small population from r3 and r5. The third arch is populated by r6 and a few r5-
derived neural crest cells. PA, pharyngeal arch; ov, otic vesicle; r, rhombomere. 
Modified from Trainor and Krumlauf, 2001. 
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3.3. Cardiac neural crest 
The cardiac neural crest is a subpopulation of the cranial neural crest that arises at 
the level between the otic placode and the fourth somite (Snarr et al., 2008; Snider et al., 
2007). As it has common properties of both the cranial and trunk crest, it is thought to 
be a transitional region between the two (Hutson and Kirby, 2007; Scholl and Kirby, 
2009). Similar to the more cranial crest it can give rise to ectomesenchyme while it 
cannot regenerate, which is a trunk crest property (Hutson and Kirby, 2007; Scholl and 
Kirby, 2009). The cardiac neural crest cells migrate through the caudal pharyngeal 
arches (arches 3, 4 and 6), where they form the vascular smooth muscle (VSM) cell 
lining of the arch arteries (Hutson and Kirby, 2007; Scholl and Kirby, 2009), into the 
outflow tract cushions and promote septation of the single great vessel of the primitive 
heart into the aorta and pulmonary arteries (Epstein et al., 2000; Scholl and Kirby, 2009; 
Snider et al., 2007; Stoller and Epstein, 2005b). After AP septation, the outflow tract 
cushions undergo remodelling and form the semilunar valve leaflets (Nakamura et al., 
2006; Restivo et al., 2006). Cell lineage tracing experiments in the mouse have shown 
that the neural crest cells populate the ascending aorta, the right brachiocephalic artery, 
the left carotid artery, the ductus arteriosus, the pulmonary tract, the semilunar valves 
(Nakamura et al., 2006), generate all of the parasympathetic innervation of the heart 
(Hutson and Kirby, 2007) and are associated with the maturation of the proximal 
cardiac conduction system (Nakamura et al., 2006). The role of cardiac neural crest in 
normal patterning of the great arteries, cardiac outflow tract septation and myocardial 
function is supported by studies in avian models where ablation of the pre-migratory 
cardiac neural crest disrupts proper myocardial function and produces malformations of 
the outflow tract and the great vessels (Hutson and Kirby, 2007; Schafer et al., 2003). In 
the recent years, numerous models of heart disease have been described in the mouse, 
many of which recapitulate all or aspects of the neural crest ablation phenotype in the 
chick (Hutson and Kirby, 2007; Scholl and Kirby, 2009). In these models outflow tract 
and aortic arch artery abnormalities are commonly associated with cardiac neural crest 
defects, while impaired development and function of the myocardium have also been 
linked (Gittenberger-de Groot et al., 2006; Hutson and Kirby, 2007; Scholl and Kirby, 
2009; Stoller and Epstein, 2005b). 
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3.4. Neural crest gene regulation  
3.4.1. Induction  
The events that govern initial specification and induction of the neural crest at the 
neural plate border are numerous and complex. A number of secreted signals is required 
from the surrounding epidermis, neural plate and underlying mesoderm involving 
factors like Wnts, Bone morphogenetic proteins (BMPs), FGFs and Retinoic acid (RA) 
signalling (Jones and Trainor, 2005; Kalcheim and Burstyn-Cohen, 2005; Kuriyama and 
Mayor, 2008; Scholl and Kirby, 2009). Prospective neural plate border cells then 
express neural plate border specifier genes (Kalcheim and Burstyn-Cohen, 2005). 
Notch/Delta signalling in the zebrafish neural plate border represses pro-neural gene 
expression, acting as a regulator of neural crest cell production (Kalcheim and Burstyn-
Cohen, 2005). Eventually neural crest survival or neural crest specifier genes are 
expressed, signifying neural crest cell specification (Kuriyama and Mayor, 2008; 
Sauka-Spengler and Bronner-Fraser, 2008). Among others, these include Snail (Snail 
and Slug) family genes, Sox9/10, FoxD3 and Ap2" (Kalcheim and Burstyn-Cohen, 
2005; Sauka-Spengler and Bronner-Fraser, 2008; Scholl and Kirby, 2009). 
Subsequently, the neural crest cells express a third group of genes, the neural crest 
effector genes (or migration/differentiation genes) (Kuriyama and Mayor, 2008; Sauka-
Spengler and Bronner-Fraser, 2008), proliferate, undergo EMT and proceed to 
delamination (Kuriyama and Mayor, 2008; Sauka-Spengler and Bronner-Fraser, 2008; 
Scholl and Kirby, 2009). EMT is accompanied by changes in neural crest cell Cadherin, 
Connexin and Matrix Metalloproteinase (MMPs, required for extracellular matrix 
digestion) expression patterns (Kuriyama and Mayor, 2008; Sauka-Spengler and 
Bronner-Fraser, 2008; Scholl and Kirby, 2009). The cardiac neural crest, as a 
subpopulation of the cranial neural crest, follows this initial sequence of inductive 
events but also possesses unique properties.  
3.4.2. Cardiac neural crest migration 
The definitive migration patterns and stereotypic destinations of the cardiac neural 
crest are tightly regulated. Depending on the cranio-caudal origin, the cranial neural 
crest cells express specific sets of Hox genes, nonetheless, they exhibit plasticity in this 
expression pattern, suggesting that environmental cues are important for establishing 
their regional identity (Trainor and Krumlauf, 2000). Ephrin and Eph-receptor genes are 
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also expressed in individual combinations by the neural crest and mesoderm of different 
arches, which restricts the intermingling of neural crest cells between different 
migratory streams (Kuriyama and Mayor, 2008; Scholl and Kirby, 2009). Permissive 
and restricted areas of migration determine these segmentally restricted streams 
(Christiansen et al., 2000; Kuriyama and Mayor, 2008). Extracellular matrix (ECM) 
proteins provide permissive signals, while Gdnf (glial cell line-derived neurotrophic 
factor) and Dcc (Deleted in Colon Cancer) are considered as possible attractants 
(Kuriyama and Mayor, 2008). However, no sound evidence exists in support of a 
definitive chemoattractant assisting neural crest migration (Kuriyama and Mayor, 
2008). The Slit/Robo families of molecules were until recently thought to be involved 
only in trunk crest migration, acting in a ligand-receptor fashion as repellents of 
migrating neural crest, inhibiting the migration on the dorsal pathway (Kuriyama and 
Mayor, 2008). Calmont et al., showed that Robo1-positive cardiac neural crest streams 
are detected as early as E9.0 in the mouse, while the ligand Slit2 is expressed in the 
pharyngeal surface ectoderm at E8.75 and robustly in the pharyngeal endoderm by E9.5 
(Calmont et al., 2009). Both genes appeared downregulated or misspatterned in a mouse 
model displaying cardiac neural crest migration defects, further supporting a role for 
Slit/Robo signalling in cardiac crest migration (Calmont et al., 2009).  
Migrating neural crest cells do not only receive signals, but actively interact with 
their surrounding tissues during their journey and at the target sites (Scholl and Kirby, 
2009). Cardiac crest cells modulate Fgf8 signalling in the pharyngeal epithelia (Hutson 
et al., 2009). Signalling in the caudal pharynx is important as it affects the splanchnic 
mesoderm, including progenitor cells that eventually populate the outflow tract 
(Kuriyama and Mayor, 2008; Scholl and Kirby, 2009). Cardiac neural crest ablation in 
avian models results in secondary failure in migration of second heart field (SHF)-
derived myocardial progenitors into the outflow tract (Waldo et al., 2005). The cells 
undergo proliferation instead of initiating the process of migration to invade the outflow 
tract (Waldo et al., 2005). Semaphorin 3C (Sema3C), expressed by the outflow tract 
myocardium, and its receptor, Plexin A2, expressed by the cardiac crest cells, guide the 
final cardiac crest migration into the outflow tract (Kuriyama and Mayor, 2008; Scholl 
and Kirby, 2009). Other morphogens, like SHH signalling, shown to modulate 
responsiveness of enteric neural crest cells to Gdnf, and members of the BMP, FGF and 
RA signalling pathways shown through knock-out studies to affect proper cardiac 
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neural crest migration, are likely candidates in modulating this process (Jones and 
Trainor, 2005). 
3.4.3. Differentiation 
Upon arrival at their target sites, the neural crest cells respond to local signalling 
and differentiate in situ (Sauka-Spengler and Bronner-Fraser, 2008). The multipotency 
of the crest cells and the regulatory factors underlying it have been extensively studied. 
The Notch/Delta pathway favours glial over neuronal neural crest fates (Christiansen et 
al., 2000; Kalcheim and Burstyn-Cohen, 2005) in contrast with BMP signalling that 
promotes neurogenesis (Le Douarin and Dupin, 2003). Neural crest cells can give rise to 
autonomic or sensory neuronal types, a process controlled at least in part by 
Neurogenins (Christiansen et al., 2000). Endothelin signalling is involved in melanocyte 
and posterior enteric nerve plexus development (Le Douarin and Dupin, 2003). Other 
factors, like Sox10 inhibit neural crest lineage commitment, thus maintaining the 
multipotency of the tissue (Kim et al., 2003). Apart from generating distinct derivatives, 
the neural crest acts on pharyngeal arch artery support (Hutson and Kirby, 2007; Scholl 
and Kirby, 2009) and subsequent re-patterning (Kameda, 2009; Snider et al., 2007) 
Endothelin, Platelet-Derived Growth Factor (PDGF) and TGF! are considered 
mediators of these processes in the neural crest, studied in several animal models 
(Scholl and Kirby, 2009).  
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4. Pharyngeal arch arteries  
4.1. Formation and remodelling  
During normal cardiovascular development, five pairs of pharyngeal arch arteries 
connect the truncus arteriosus and the aortic sac at the distal end of the cardiac outflow 
with the paired dorsal aortae (DAo) (Gittenberger-de Groot et al., 2006; Kameda, 2009; 
Yanagisawa et al., 1998). Over the course of development this transient, symmetrical 
configuration remodels into the mature, unilateral, left-sided arterial system 
(Gittenberger-de Groot et al., 2006; Kameda, 2009; Kellenberger, 2010; Molin et al., 
2002; Snider et al., 2007; Yanagisawa et al., 1998). After the initial construction of the 
endothelial network through vasculogenesis and angiogenesis, arteriogenesis takes place 
by differentiation of neural crest cells into a VSM layer, that provides support and 
stabilisation to the arch arteries (Gittenberger-de Groot et al., 2006). The remodelling 
process that follows involves programmed asymmetrical expansion, regression, 
persistence and change of relative position of the different vascular segments 
(Gittenberger-de Groot et al., 2006; Kameda, 2009; Yanagisawa et al., 1998). This 
extensive reconfiguration process occurs at around E11.5 in the mouse and by E13.5 it 
is completed for all branchial arch arteries and major vessels (Hiruma et al., 2002; 
Yanagisawa et al., 1998). Regression of the first two cranial sets of arch arteries occurs 
by E11.0 (Hiruma et al., 2002) and at E11.5 the remaining symmetrical pairs of arch 
arteries (pairs 3, 4 and 6) connect the two DAo with the ventrally located aortic sac, 
while the right sixth arch artery becomes slender commencing from its proximal part 
(Hiruma et al., 2002; Yanagisawa et al., 1998). The aortic sac begins to septate from its 
proximal part (Hiruma et al., 2002). At E12.0 the narrowing of the right sixth arch 
artery is followed by the narrowing of the left carotid duct (DAo segment connecting 
the third and fourth arch arteries, . segment in Figure 1.3.A) (Yanagisawa et al., 1998). 
At E12.5 the aortic sac is separated into an ascending aorta and pulmonary trunk 
(Yanagisawa et al., 1998). The third arch arteries run parallel to the fourth pair, while 
they are being elongated in a cranial direction (Hiruma et al., 2002; Yanagisawa et al., 
1998). Both carotid ducts are slender or completely absent (Hiruma et al., 2002; 
Yanagisawa et al., 1998). The caudal part of the right DAo (! segment in Figure 1.3.A) 
becomes thinner (Hiruma et al., 2002). By this stage the right sixth arch artery has 
completely regressed (Yanagisawa et al., 1998). At E13.0 the ascending aortic arch and 
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the proximal part of the brachiocephalic trunk (aortic sac-derived) continue to develop 
rostrally (Yanagisawa et al., 1998). The left fourth arch artery is enlarged and forms the 
arch of the aorta while the connection of the right DAo (! segment in Figure 1.3.A) to 
the abdominal DAo is very narrow (Yanagisawa et al., 1998). At E13.5 the third arch 
arteries are formed into the left and right common carotid arteries (LCC and RCC) and 
the right DAo is completely absent (Hiruma et al., 2002; Yanagisawa et al., 1998).  
The regression process, that maintains the same pattern in all vascular segments 
programmed to regress, begins with a progressive decline in lumen diameter and a 
reduction in vessel wall thickness (Molin et al., 2002). This results in the formation of a 
characteristic smooth muscle strand, followed by the interruption of the vascular 
segment at its midpoint and finally the disappearance of the proximal and distal ends 
(Molin et al., 2002). Arteries of the same pair do not necessarily share a common 
remodelling program. For example the right fourth arch artery reduces in size before it 
becomes part of the right subclavian artery (RSCA) while the left fourth arch artery 
retains its size since it forms a segment of the mature aortic arch (Yanagisawa et al., 
1998). The same stands for the sixth pair of arch arteries, whereby the right arch artery 
regresses completely while the left counterpart becomes the ductus arteriosus and 
supports circulation during the embryonic period (Yanagisawa et al., 1998).  
Ultimately the first and second arch arteries become vasculature of the head 
(Hiruma et al., 2002; Kellenberger, 2010; Yanagisawa et al., 1998). The third pair forms 
the common carotid arteries, whilst the fourth arch arteries contribute to the distal part 
of the aortic arch (left arch artery) and the brachiocephalic artery and a proximal part of 
the RSCA (right arch artery) (Hiruma et al., 2002; Kellenberger, 2010; Yanagisawa et 
al., 1998). The right sixth arch artery regresses completely and the left sixth forms the 
ductus arteriosus (Hiruma et al., 2002; Kameda, 2009; Kellenberger, 2010; Yanagisawa 
et al., 1998) and the proximal parts of the pulmonary arteries (Kameda, 2009; 
Kellenberger, 2010). The seventh intersegmental arteries (ISA), caudal branches of the 
DAo, remodel into parts of the subclavian arteries (Kameda, 2009; Kellenberger, 2010). 
The aortic sac becomes part of the ascending aorta, proximal aortic arch and 
brachiocephalic artery (Kellenberger, 2010). By the end of the remodelling process an 
arch that lies to the left of the trachea, arches over the mainstream bronchus and 
continues as the DAo to the left of the spine is generated (Kellenberger, 2010). The first 
arterial branch passes to the right as the brachiocephalic artery, giving rise to the RCC 
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and RSCA arteries, followed in succession by the LCC and the left subclavian arteries 
(LSCA) (Kellenberger, 2010). The ductus arteriosus is positioned on the left and 
connects the proximal left pulmonary artery with the distal aortic arch (Figure1.3.D) 
(Kellenberger, 2010). 
 
Figure 1. 3. Normal pharyngeal arch artery remodelling in the mouse. Remodelling 
commences at E11.5 with a symmetrical arterial system of paired aortic arches III, IV 
and VI, DAo segments !, -, and . and seventh ISAs (A). By E12.5, the aortic sac 
(AoSac) has remodelled into a separate ascending aorta (AAo) and pulmonary trunk 
(PT) (B). After E14.0 the coronary arteries (CoA) connect to the AAo (C). By E15.5 the 
process has completed with the first arterial branch passing to the right as the 
brachiocephalic artery, which gives rise to the RCC and RSCA arteries, followed in 
succession by the LCC and LSCA. The ductus arteriosus is on the left connecting the 
proximal left pulmonary artery with the distal aortic arch (D). AAo, ascending aorta; 
CoA, coronary artery; DA, ductus arteriosus; DesAo, descending aorta; III, IV and VI, 
third, fourth and sixth aortic arches; PA, pulmonary artery; PT, pulmonary trunk; 
RCC/LCC, right/left common carotid artery; RSCA/LSCA, right/left subclavian artery; 
R7th ISA/L7th ISA, right/left seventh intersegmental artery. Modified from Molin et 
al., 2002. 
4.2. Mechanisms of remodelling 
The remodelling process of the pharyngeal arteries into their final arrangement 
and morphology, resulting in the mature great vessel configuration, is controlled by 
reciprocal signalling between the mesoderm-derived endothelial and neural crest-
derived VSM lining of the arteries, as well as the surrounding mesenchyme and 
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endoderm of the arches (Snider et al., 2007). Interestingly, the fourth pair of arch 
arteries has a distinct vascular morphology (Molin et al., 2004). The smooth muscle 
cells (SMC) of the vessel walls have very low smooth muscle !-actin expression, 
prominent expression of neurofilament protein and the neural marker NCAM-1, while 
they present with an abundance of Smad2-positive nuclei (Molin et al., 2004). In Tgf!2
-
/-
 mutants with fourth arch artery hypoplasia, atresia or aortic arch interruption, both 
markers appear miss-expressed while no Smad2-positive nuclei are detected (Molin et 
al., 2004). This characteristic pattern was not observed in the carotid ducts, third or 
sixth pairs of arch arteries nor in normally forming fourth arch arteries in Tgf!2
-/-
 
mutants (Molin et al., 2004).  
Aside from morphogenetic factors, the remodelling of the respective vascular 
segments is thought to be additionally regulated by blood flow haemodynamics 
(Gittenberger-de Groot et al., 2006; Molin et al., 2002; Yashiro et al., 2007). The 
significance of blood flow in cardiovascular development has been shown by means of 
mechanical obstruction of arterial or venus vessels or of heart segments (Hogers et al., 
1997; Hogers et al., 1999). Such experiments produce several cardiac malformations 
like double outlet right ventricle (DORV), VSDs and arch artery defects in avian 
models (Hogers et al., 1997; Hogers et al., 1999). In the mouse model, regression of the 
right sixth arch artery appears to be controlled initially by mechanical and 
haemodynamic forces, which subsequently induce apoptotic cues (Yashiro et al., 2007). 
Yashiro et al., demonstrated that the outflow tract movement between E11.5-E12.5, 
which occurs because of the rotation of the arterial pole, shifts the entry point of the 
right sixth arch artery towards the left, adjacent to the DAo (Yashiro et al., 2007). By 
ligating the left sixth arch artery, the authors induced abnormal regression of the vessel 
with concomitant persistence of its right counterpart, contrary to normal development 
(Yashiro et al., 2007). An in vitro experimental and computational study of normal and 
abnormal fetal aortic arch haemodynamics has shown differences in the blood flow 
between the normal and the disease settings (Pekkan et al., 2008). Moreover, flow 
modeling of the chicken embryonic pharyngeal system showed that spatial shear stress 
and velocity distributions change between stage 18 (arch arteries 2, 3 and 4 are present) 
and stage 24 (arch arteries 3, 4 and 6 are present) (Wang et al., 2009). The results 
correlate well with the shift of the three-pair arch artery configuration from an anterior 
to a posterior position and the increased cardiac output between the stages (Wang et al., 
2009). 
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Selective apoptosis is also an important factor in the regression process (Molin et 
al., 2002). Apoptotic cells are initially preferentially seen in the mesenchyme 
surrounding the vascular segments that are programmed to regress (Molin et al., 2002). 
Eventually these cells grow in number and expand towards initially and later into the 
outer border of the smooth muscle tissue (Molin et al., 2002). A non-lumenised strip of 
SMCs is the last remainder of the vessel before complete regression (Molin et al., 
2002). 
The individual pairs of pharyngeal arches display distinct gene expression 
patterns, which may play a role in the remodelling process. Hox(a-d)4 are exclusively 
expressed in the fourth pair of arches, while Hoxb5 is detected in the sixth pair (Molin 
et al., 2002). Hoxa3 is required for the morphogenesis of the third arch and pouch, while 
homozygous mutation of the gene results in, among others, anomalies of the carotid 
arch artery system due to compromised proliferation of the neural crest cells within the 
arch (Kameda, 2009). Similar misspatterning of the cellular component of each arch, in 
particular of the neural crest population that is responsible for the VSM layer of each 
arch artery, may result in several remodelling defects (Kameda, 2009; Molin et al., 
2002). Other morphogenetic factors may be equally important. Blocking SHH in quail 
embryos results in abnormal formation of the arch arteries, shown by failure of vessel 
lumenisation and abnormal subsequent remodelling (Kolesova et al., 2008). TGF- 
enhances the expression of SMC-specific proteins that are essential for vessel wall 
structure (Kumar and Owens, 2003). Consistent with that, Tgf!2 homozygous mutants 
exhibit great vessel defects as a result of abnormal regression of the fourth arch (Molin 
et al., 2002). Nevertheless, the precise mechanisms underlying the patterning of the 
great vessels remain elusive.  
4.3. Types of great vessel defects and embryological origin 
Abnormal formation and/or remodelling of the branchial arch arteries can cause a 
number of congenital anomalies of the aortic arch and the great vessels, commonly seen 
in cardiovascular disease (Bialowas et al., 2000; Davies and Guest, 2003; Dillman et al., 
2008; Kellenberger, 2010; Kutsche and Van Mierop, 1984; McElhinney et al., 1999; 
Mishra, 2009; Morishima et al., 2003; Van Mierop and Kutsche, 1984; Van Praagh et 
al., 1971; Yang et al., 2008). Such aberrations can occur as isolated lesions, without 
serious clinical symptoms, or can correlate with defects in heart development and 
cyanotic lesions (Bialowas et al., 2000; Kellenberger, 2010). There are at least four 
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distinct categories of anatomic arch anomalies that deviate from the normal left-sided 
configuration (Kellenberger, 2010). 
1. Double aortic arch  
A double aortic arch is observed when the caudal part of the right DAo fails to 
follow the normal regression process and instead persists, leading in the formation of a 
vascular ring (Davies and Guest, 2003; Kellenberger, 2010). Most commonly, the DAo 
is located on the left side of the spine so the right arch runs behind the esophagus and 
the left arch in front of the trachea (Kellenberger, 2010). Usually the right arch is higher 
and wider than the left (Davies and Guest, 2003; Kellenberger, 2010). The common 
carotid and subclavian arteries arise independently from the respective aortic arches 
while the ductus arteriosus may be present on either or both sides connecting the 
pulmonary arteries with the distal arches (Figure 1.4) (Kellenberger, 2010). A double 
aortic arch is usually an isolated anomaly that does not associate with cardiac 
abnormalities (Kellenberger, 2010).  
 
Figure 1. 4. Embryological origin of the double aortic arch. Persistence of the caudal 
part of the right DAo gives rise to a vascular ring. DAo, dorsal aorta; III, IV and VI, 
third, fourth and sixth aortic arches; RCC/LCC, right/left common carotid artery; 
RSCA/LSCA, right/left subclavian artery; R7th ISA/L7th ISA, right/left seventh 
intersegmental artery. Drawn after Van Mierop and Kutsche, 1984. 
2. Right-sided aortic arch (RAA) 
An RAA occurs when abnormal regression or failure of the left fourth arch artery 
to form is compensated by the enlargement of the right counterpart with concomitant 
persistence of the right DAo (Morishima et al., 2003). The entire right dorsal arch 
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persists resulting in a configuration where the mature arch lies on the right side of the 
trachea before descending on either the right or the left side of the spine (Bialowas et 
al., 2000; Davies and Guest, 2003; Kellenberger, 2010). Almost invariably this 
configuration is associated with cyanotic congenital heart lesions, most commonly TOF, 
pulmonary atresia with VSD or CAT (Bialowas et al., 2000; Kellenberger, 2010; 
McElhinney et al., 1999). There are two subcategories, RAA with mirror image 
branching (Figure 1.5.A, B) or RAA with abnormal branching  (Figure 1.5.C, D) 
(Bialowas et al., 2000; Davies and Guest, 2003). In the first instance the arch has three 
branches, the left brachiocephalic trunk, which is the most proximal branch of the arch, 
the RCC and then the RSCA in succession (Davies and Guest, 2003; Kellenberger, 
2010; McElhinney et al., 1999). The ductus arteriosus is often left-sided and connects 
the left brachiocephalic artery and the left pulmonary artery (Figure 1.5.A) 
(Kellenberger, 2010; McElhinney et al., 1999). If the ductus is right-sided and courses 
from the underside of the descending arch to the right pulmonary artery it forms a true 
mirror image arch (Figure 1.5.B) (Kellenberger, 2010; McElhinney et al., 1999). In the 
second instance, concurrent with the persistence of the right DAo is the complete 
regression of the left fourth branchial artery, thus producing an RAA that has four 
branches, beginning with the LCC proximal to the arch and followed in succession by 
the RCC, the RSCA and finally an aberrant LSCA (A-LSCA), that originates from the 
DAo and passes to the left, behind the oesophagus (Figure 1.5.C) (Davies and Guest, 
2003; Kellenberger, 2010; McElhinney et al., 1999). If the ductus is left-sided a 
complete vascular ring is formed (Figure 1.5.D) (McElhinney et al., 1999). This 
configuration is less frequently associated with an intracardiac defect, but when it is, 
TOF is the most common lesion (McElhinney et al., 1999).  
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Figure 1. 5. Embryological origin of the RAA. Abnormal regression of the left fourth 
arch artery, enlargement of the right fourth arch artery and persistence of the right DAo 
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lead to a right-sided configuration (A-D). RAA with mirror image branching describes a 
right arch that has three branches, the left brachiocephalic trunk, the RCC and the 
RSCA in succession (A-B). If the ductus arteriosus is left-sided it connects the left 
brachiocephalic artery and the left pulmonary artery (A), while if it is right-sided it 
courses from the underside of the descending arch to the right pulmonary artery and 
forms a true mirror image arch (B). RAA with abnormal branching occurs after 
complete regression of the left fourth arch artery, which results in a right arch that has 
four branches, the LCC, the RCC, the RSCA and an A-LSCA that originates from the 
DAo and passes to the left, behind the oesophagus (C). If the ductus is left-sided a 
complete vascular ring is formed (D). DAo, dorsal aorta; III, IV and VI, third, fourth 
and sixth aortic arches; RCC/LCC, right/left common carotid artery; RSCA/LSCA, 
right/left subclavian artery; R7th ISA/L7th ISA, right/left seventh intersegmental artery. 
Drawn after Van Mierop and Kutsche, 1984. 
3. Left-sided aortic arch, abnormal branching or interruptions 
The normal aortic arch descends to the left; however, branching aberrations or 
missing segments produce abnormal anatomies (Bialowas et al., 2000; Davies and 
Guest, 2003; Kellenberger, 2010; Kutsche and Van Mierop, 1984).  
Abnormal branching 
A commonly affected vessel is the RSCA that forms aberrantly (A-RSCA) when 
the right fourth branchial artery is absent or involutes before the regression of the right 
DAo (Davies and Guest, 2003; Kutsche and Van Mierop, 1984; Morishima et al., 2003). 
Three different anatomies can arise (Kutsche and Van Mierop, 1984). If the caudal part 
of the right DAo persists it forms an A-RSCA with the right seventh ISA (Figure 1.6.A) 
(Davies and Guest, 2003; Kutsche and Van Mierop, 1984; Reardon et al., 1984). The A-
RSCA originates from the DAo or a diverticulum and crosses to the right behind the 
oesophagus, constituting an incomplete vascular ring (retro-oesophageal RSCA) 
(Davies and Guest, 2003; Kellenberger, 2010; Morishima et al., 2003). If this is 
combined with the disappearance of the right third arch artery then the right 
brachiocephalic trunk leaves the aortic arch as the last branch and runs beyond the 
oesophagus (Bialowas et al., 2000). In rare cases where a right-sided ductus arteriosus is 
present connecting the right pulmonary artery and the right subclavian artery, the A-
RSCA may originate from a retro-oesophageal diverticulum, forming a complete 
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vascular ring with the right-sided ductus connection (Kellenberger, 2010). In the second 
case, an A-RSCA can originate from the right pulmonary artery (Kutsche and Van 
Mierop, 1984). The dorsal segment of the right sixth arch artery persists and forms the 
A-RSCA with a segment of the right DAo and the right seventh ISA (Figure 1.6.B) 
(Kutsche and Van Mierop, 1984). The right sixth arch artery in this instance 
compensates for the absent fourth (Kutsche and Van Mierop, 1984). Alternatively, after 
regression of the right fourth arch artery an A-RSCA can arise from the persistence of 
the right carotid duct that remains connected to the brachiocephalic branch, thus giving 
rise to a cervically located RSCA (cervical RSCA) (Figure 1.6.C) (Kutsche and Van 
Mierop, 1984). 
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Figure 1. 6. Embryological origin of the left-sided arch with abnormal branching. 
Abnormal regression of the right fourth arch artery results in aberrant origin of the 
RSCA (A-C). If the caudal part of the right DAo persists it forms a retro-oesophageal 
RSCA with the right seventh ISA (A). If the dorsal segment of the right sixth arch 
artery persists it forms an A-RSCA with a segment of the right DAo and the right 
seventh ISA (B). If the right carotid duct persists it remains connected to the 
brachiocephalic trunk and gives rise to a cervically located A-RSCA (C). DAo, dorsal 
aorta; III, IV and VI, third, fourth and sixth aortic arches; RCC/LCC, right/left common 
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carotid artery; RSCA/LSCA, right/left subclavian artery; R7th ISA/L7th ISA, right/left 
seventh intersegmental artery. Drawn after Van Mierop and Kutsche, 1984. 
Cervical aortic arch 
In the case of a cervical aortic arch the apex of the arch extends beyond the 
sternum and into the neck (Davies and Guest, 2003; Kellenberger, 2010). The 
embryological basis of this anomaly is controversial, however, it is thought to be a 
result of abnormal formation or regression of the fourth branchial artery in combination 
with enlargement of the third arch artery and persistence of the respective carotid duct 
(Figure 1.7) (Morishima et al., 2003). This configuration provides an alternative route 
for the arch, via the carotid duct, raising it higher than normal (Morishima et al., 2003). 
It is another example of compensation for the abnormal formation or regression of the 
fourth arch artery (Morishima et al., 2003). More often it appears on the right side 
(cervical RAA) where the definitive arch is formed by the right third arch and right 
DAo (Davies and Guest, 2003; Kellenberger, 2010). The branches are variable, but the 
common carotid arteries and the RSCA often arise independently from the arch (Davies 
and Guest, 2003; Kellenberger, 2010). 
 
Figure 1. 7. Embryological origin of the cervical aortic arch. Abnormal regression of 
the fourth arch artery, enlargement of the third arch artery and persistence of the 
respective carotid duct lead to the formation of a cervically located aortic arch. DAo, 
dorsal aorta; III, IV and VI, third, fourth and sixth aortic arches; RCC/LCC, right/left 
common carotid artery; RSCA/LSCA, right/left subclavian artery; R7th ISA/L7th ISA, 
right/left seventh intersegmental artery. Drawn after Van Mierop and Kutsche, 1984. 
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4. Interruptions 
An interrupted aortic arch (IAA) describes the luminal discontinuity or the 
presence of a fibrous strand between the ascending and descending aorta (Dillman et al., 
2008; Mishra, 2009; Reardon et al., 1984; Van Mierop and Kutsche, 1984; Yang et al., 
2008). Based on the site of the interruption the lesion is classified as three types 
(Dillman et al., 2008; Kellenberger, 2010; Mishra, 2009; Reardon et al., 1984; Van 
Mierop and Kutsche, 1984; Yang et al., 2008). Type A describes an interruption of the 
aortic arch distal to the left subclavian artery, in type B the defect is found between the 
LCC and left subclavian arteries and in type C the discontinuity exists between the 
brachiocephalic and the LCC arteries (Dillman et al., 2008; Kellenberger, 2010; Mishra, 
2009; Reardon et al., 1984; Van Mierop and Kutsche, 1984; Yang et al., 2008). Each 
affected segment of the aortic arch has a different embryological origin, the junction of 
the fourth and sixth arches, the left fourth branchial arch and the aortic sac, respectively 
(Yang et al., 2008). Coarctation of the aorta, a partial involution of the left dorsal aortic 
arch (Davies and Guest, 2003), between the LSCA and the ductus arteriosus, is 
considered responsible for the pathogenesis of IAA-A (Figure 1.8.A) (Van Mierop and 
Kutsche, 1984). Abnormal formation or regression of the left fourth arch artery results 
in IAA-B (Figure 1.8.B) (Dillman et al., 2008; Kutsche and Van Mierop, 1984; Reardon 
et al., 1984; Van Mierop and Kutsche, 1984). The last type, IAA-C, is suggested to 
result after involution of the left limb of the aortic sac and its derivatives, the ventral 
portions of the left third and left fourth arches, with concomitant persistence of the left 
carotid duct (Figure 1.8.C) (Reardon et al., 1984; Van Praagh et al., 1971). All 
interruptions can coexist with an A-RSCA (Kellenberger, 2010; Kutsche and Van 
Mierop, 1984; Reardon et al., 1984; Van Mierop and Kutsche, 1984; Yang et al., 2008) 
and although a rare condition, 50-80% of all IAA cases are linked to 22q11DS, 
commonly in conjunction with an RAA (Dillman et al., 2008; Kellenberger, 2010; 
Mishra, 2009; Yang et al., 2008). Often patients also exhibit VSD, CAT and/or 
transposition of the great arteries (TGA) in association with an interruption (Dillman et 
al., 2008; Kellenberger, 2010; Mishra, 2009; Yang et al., 2008).  
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Figure 1. 8. Embryological origin of the IAA. An IAA-A can occur after an aortic 
coarctation between the LSCA and the ductus arteriosus (A), an IAA-B can result after 
abnormal formation or regression of the left fourth arch artery  (B) while an IAA-C can 
arise after involution of the left limb of the aortic sac and the ventral segments of the 
left third and left fourth arches, with concomitant persistence of the left carotid duct (C). 
DAo, dorsal aorta; III, IV and VI, third, fourth and sixth aortic arches; RCC/LCC, 
right/left common carotid artery; RSCA/LSCA, right/left subclavian artery; R7th 
ISA/L7th ISA, right/left seventh intersegmental artery. Drawn after Van Mierop and 
Kutsche, 1984. 
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Other vascular malformations exist, like defects in the pulmonary vascular system 
(Davies and Guest, 2003), which will not be discussed in this thesis. 
In some cases, like RAA or the cervical arch discussed above, failure of a vascular 
segment, in these cases the fourth arch arteries, results in compensatory arterial 
rearrangements, so that the end configuration is compatible with postnatal life. These 
rearrangements do not always occur and the underlying mechanisms of this plasticity 
are not known. The genetic background, haemodynamic forces, the type and time of 
occurrence of the primary defect, as well as stochastic events are all possible 
interplaying factors (Morishima et al., 2003).  
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5. Endocrine glands - pharyngeal pouch derivatives 
The thymus, thyroid, parathyroid, and ultimobranchial bodies, endocrine glands 
that derive from the third and fourth pharyngeal pouches (Graham, 2008; Grevellec and 
Tucker, 2010; Jerome and Papaioannou, 2001; Manley and Capecchi, 1998), develop in 
parallel and subsequently migrate to their final destinations (Manley and Capecchi, 
1998). For the purposes of this thesis, only the thymus gland will be further discussed. 
The vertebrate thymus is a complex epithelial organ that forms in the caudal-
ventral region of the third pouch and is responsible for the production of mature T-cells 
that are released in the systemic circulation (Manley, 2000). Thymic organogenesis 
requires reciprocal interactions between adjacent tissues of all three embryonic germ 
layers (Hollander et al., 2006; Manley, 2000). Initiating signals at E9.5 induce cells 
from the endoderm of the third pharyngeal pouch to proliferate, undergo EMT and 
delaminate from the inner layer of the foregut into the neural crest-derived underlying 
mesenchyme (Boehm, 2008; Manley, 2000). Although the thymic epithelium itself is of 
endodermal origin (Gordon et al., 2004), the surrounding neural crest-derived 
connective tissues affect its development (Gill et al., 2003; Manley, 2000; Muller et al., 
2008) and give rise to the perivascular mesenchyme of the adult organ (Muller et al., 
2008). Pre-migratory neural crest ablation experiments result in thymus dysplasia or 
aplasia (Gill et al., 2003; Grevellec and Tucker, 2010; Manley, 2000). Between E11.5-
E12.0 primarily proliferative events take place so that the common thymus/parathyroid 
primordia increase significantly in size, while the thymus starts to expand caudally 
(Grevellec and Tucker, 2010). By then the thymic primordia express markers that 
promote endothelial cell differentiation, a process essential for the specification of the 
organ and the subsequent colonisation by thymocyte progenitor cells (Boehm, 2008; 
Gill et al., 2003; Grevellec and Tucker, 2010; Hollander et al., 2006; Manley, 2000). 
From E12.5 to E13.5 these bilateral primordia separate from the endoderm of the 
pharynx and move caudally, ventrally and medially, towards the anterior thoracic cavity 
(Grevellec and Tucker, 2010; Hollander et al., 2006). At the same time lymphoid 
precursors migrate into the thymic epithelium, where they become committed to the T-
cell lineage (Gill et al., 2003; Hollander et al., 2006). At E15.5 each primordium still 
descends caudally and medially before reaching its final position above the heart and 
joining its symmetric thymic lobe (Grevellec and Tucker, 2010).  
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Defective thymic development may reflect abnormalities in either the 
specification of the endodermal cells of the third pouch, mainly controlled by the 
expression of Foxn1 and upstream factors (Boehm, 2008), or the formation of the third 
pouch itself. In Hoxa3 and Eya1 mutants there is loss of third pouch identity and 
subsequent loss of the gland primordia (Grevellec and Tucker, 2010). Tbx1 and Pax9 
mutants present with thymic hypo/aplasia as a result of arrested development of the 
thymic primordium (Boehm, 2008; Grevellec and Tucker, 2010; Hollander et al., 2006). 
Pbx1 and Six1 genes also have a reported role in pharyngeal pouch formation (Boehm, 
2008). Wnt and BMP signalling are postulated to initiate or maintain Foxn1 expression 
in the thymic epithelium, respectively (Boehm, 2008). In addition to Pax and Hox 
factors, FGFs appear to be required for pharyngeal gland relocation, and indeed Fgf10 
and Fgf7 are expressed in the mouse thymus during organ migration to the midline 
(Grevellec and Tucker, 2010). SHH signalling is involved in controlling the size of the 
thymic field, while the overall size of the gland is probably regulated by p63 and FGF 
signalling (Boehm, 2008). 
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6. Palate - pharyngeal arch derivative 
Facial clefting, a common characteristic of the 22q11DS phenotype (Shprintzen, 
2008; Wurdak et al., 2006), has three main categories: isolated cleft lip and/or alveolus, 
isolated cleft palate and combined cleft lip, alveolus and palate (Meng et al., 2009). The 
clefts can be complete or incomplete and unilateral or bilateral (Meng et al., 2009). 
Developmentally, the five facial primordia that give rise to the maxillo-mandibular 
complex are two pairs of mandibular and maxillary prominences and the frontonasal 
prominence (Figure 1.9) (Jugessur et al., 2009). These prominences consist of epithelial 
outgrowths of mesoderm and neural crest cells deriving from the midbrain and 
hindbrain (Jugessur et al., 2009). Mandibular clefts are extremely rare, possibly 
indicating that the early fusion of the mandibular prominences is very robust (Jugessur 
et al., 2009). The generation of the maxilla, primary and secondary palate however, 
requires a more complex sequence of fusion events (Jugessur et al., 2009).  
 The maxillary prominence is a first pharyngeal arch derivative and gives rise to 
the zygomatic complex, the lateral maxilla and the secondary palate (Jugessur et al., 
2009). The latter forms as an outgrowth of the maxillary prominence (Gritli-Linde, 
2007; Jugessur et al., 2009). The frontonasal prominence extends caudally and gives 
rise to the midfacial structures including the medial part of the nose, the philtrum, the 
intermaxillary segment and the primary palate (Jugessur et al., 2009). Fusion of the left 
and right maxillary prominences with the intermaxillary segment results in the 
continuous upper jaw that includes the primary palate (Gritli-Linde, 2007; Jugessur et 
al., 2009). The secondary palate is formed from the palatal shelves that initially grow 
vertically from the maxillary prominence but eventually elevate and oppose each other 
as the tongue flattens and the overall oral volume increases (Gritli-Linde, 2007; 
Jugessur et al., 2009; Meng et al., 2009). The subsequent contact and fusion of the 
shelves results in the formation of the secondary palate (Gritli-Linde, 2007; Jugessur et 
al., 2009; Meng et al., 2009). The primary and secondary palates must also fuse at their 
contacting sites, a process that requires interplay between different transcription factors, 
growth factors and signalling molecules (Gritli-Linde, 2007; Jugessur et al., 2009; 
Meng et al., 2009). Facial clefts can result from abnormal progression of either of these 
processes, although the most frequent mechanisms are deficient mesenchymal cell 
proliferation or failure of epithelial fusion (Nie et al., 2006).  
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Figure 1. 9. The mouse facial primordia. The facial prominences surround the 
stomodeal opening. Fusion of the lip will take place at the intersection of the tissues in 
the grey box. fnm, frontonasal mass; fnp, frontonasal prominence; lnp, lateral nasal 
prominence; mnp, medial nasal prominence; md, mandibular prominence; mxp, 
maxillary prominence. Modified from Szabo-Rogers et al., 2010. 
The development of the secondary palate requires complex interactions among 
epithelial cells, mesenchymal cells and the ECM in an ordered sequence (Meng et al., 
2009). It is a multi-step process that includes palatal shelf growth, elevation, medial 
elongation, fusion and the disappearance of the midline epithelial seam (MES) (Nie et 
al., 2006; Okano et al., 2006). In mouse, the palatal primordia first appear between 
E11.5-E12.5 at the lateral edges of the maxillary process (Gritli-Linde, 2007; Meng et 
al., 2009; Okano et al., 2006). The shelves extend vertically along the sides of the 
tongue and elongate by E14.5 (Gritli-Linde, 2007; Meng et al., 2009; Okano et al., 
2006). The opposing edges of the palatal shelves contact each other and adhere by the 
glycoprotein coat and desmosomal junctions of the medial edge epithelia (MME) (Meng 
et al., 2009; Okano et al., 2006). During this fusion process the MME form the MES 
(Gritli-Linde, 2007; Meng et al., 2009; Okano et al., 2006). Although the mechanism of 
disappearance of the epithelia in the MES is unclear, apoptosis, migration towards the 
periphery of the midline and EMT have been suggested (Gritli-Linde, 2007; Meng et 
al., 2009; Okano et al., 2006). The MES has disappeared by E16.0 when the palatal 
fusion is completed and then ossification takes place to form the hard palate (Gritli-
Linde, 2007; Meng et al., 2009). The posterior end of the palate remains unossified and 
constitutes the soft palate (Gritli-Linde, 2007; Meng et al., 2009). 
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The mechanisms that regulate palate development have been extensively studied 
and most studies revolve around the TGF- family. TGF- factors, including BMPs and 
Activins, are involved in proliferation, apoptosis, ECM synthesis and deposition, cell 
migration, EMT and degradation of basement membranes, all processes that occur 
during palatogenesis (Meng et al., 2009). Different factors have been shown responsible 
for different processes, for example, Tgf!3 is required for palatal shelf fusion whilst 
Tgf!1, Tgf!2 and the BMPs play a role in mesenchymal proliferation (Meng et al., 
2009). Individual transcription factors like Msx1, Lhx8, Shox2 and Osr2 are expressed 
in the developing palatal shelves and are indispensable for palatogenesis, acting on 
tissue patterning, growth or differentiation (Gritli-Linde, 2007). Other factors that have 
a role in palate development are the epidermal growth factor receptor (Egfr), FGFs and 
Pdgfc as well as the SHH and Wnt pathways (Gritli-Linde, 2007; Jugessur et al., 2009; 
Meng et al., 2009). Cell adhesion molecules, like integrins, cadherins, nectins and 
desmosomal components, and ECM components such as collagens, glycoproteins and 
proteoglycans are also important (Gritli-Linde, 2007; Meng et al., 2009). 
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7. The heart  
7.1. Heart and outflow tract formation 
The vertebrate heart originates mainly from mesodermal cell populations 
(Dunwoodie, 2007; Moorman et al., 2003; Perez-Pomares et al., 2009; Snarr et al., 
2008; Wagner and Siddiqui, 2007a). During gastrulation, cardiac precursors lying in the 
rostral half of the primitive streak in an anterior-posterior sequence migrate laterally 
towards the anterior part of the embryo to form two bilateral heart-forming regions 
(anterior lateral plate mesoderm) (Nakajima, 2010; Snarr et al., 2008; Wagner and 
Siddiqui, 2007a). Cells from this pre-cardiac mesoderm undergo differentiation into 
endocardial and myocardial lineages, which combined are known as the first heart field 
(FHF) (Snarr et al., 2008). The bilateral heart fields converge medially to form a 
crescent shaped domain (E7.0) (Perez-Pomares et al., 2009; Snarr et al., 2008; Wagner 
and Siddiqui, 2007a). This is followed by fusion of the paired primordia at the 
embryonic midline and establishment of the primitive heart tube (E8.0) (Nakajima, 
2010; Perez-Pomares et al., 2009; Snarr et al., 2008; Wagner and Siddiqui, 2007a). At 
the same time the heartbeat is initiated and the blood streams through the tube in a 
caudal (venous inflow) to cranial (arterial outflow) direction (Dunwoodie, 2007). The 
linear heart tube consists of an outer myocardial layer, an intermediate layer of acellular 
matrix, the cardiac jelly, and an inner endocardial layer (Dunwoodie, 2007; Snarr et al., 
2008; Wagner and Siddiqui, 2007b). Developmentally the primitive tube develops into 
the left ventricle (LV), part of the atrioventricular (AV) region and the atria (Nakajima, 
2010; Perez-Pomares et al., 2009) and has a small cellular contribution to the right 
ventricle (RV) (Nakajima, 2010). The growth of the tube is facilitated by both 
myocardial cell proliferation and cell addition processes (Dunwoodie, 2007; Nakajima, 
2010). Cells are recruited into the outflow tract from two distinct cell populations, the 
cardiac neural crest (Dunwoodie, 2007; Kaartinen et al., 2004; Kirby, 2002; Nakajima, 
2010; Perez-Pomares et al., 2009; Snider et al., 2007) and the SHF, a second 
cardiogenic domain that provides myocardial progenitors (Dunwoodie, 2007; Kirby, 
2002; Moorman et al., 2003; Nakajima, 2010; Perez-Pomares et al., 2009; Snider et al., 
2007; Wagner and Siddiqui, 2007a). During the looping stage of the heart tube the 
outflow region shifts to the right, followed by dorsal-anterior relocation of the inflow 
complex such that the inflow and outflow complexes converge (Dunwoodie, 2007). 
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Differential growth in the anterior-posterior and dorsoventral axes of the heart tube 
create inner and outer curvatures, while the cardiac chambers are starting to form, 
indicated by the development of trabeculae, a sponge-like layer of myocytes (by E13.5) 
(Wagner and Siddiqui, 2007b). Furthermore, the cardiac jelly that was initially 
uniformly distributed in the heart tube, condenses locally in the atrioventricular junction 
(AVJ) and the outflow tract, producing swellings known as endocardial cushion 
primordia (Snarr et al., 2008). At the end of the looping stage the primitive heart 
undergoes remodelling, including the formation of the interventricular septum that will 
divide the ventricles, and the cardiac conduction system (Dunwoodie, 2007). The 
chamber walls thicken and form the “compact layer” by increasing the proliferation rate 
of the outer ventricular walls (Dunwoodie, 2007). The endocardial cushion primordia 
are colonised by different populations of mesenchymal cells (Wagner and Siddiqui, 
2007b) and eventually form the scaffold for the AP septum in the outflow tract region 
and the aortic and pulmonary valves (Dunwoodie, 2007). In the atrioventricular canal 
(AVC, the boundary between the atrial and ventricular regions) the endocardial 
cushions develop into the tricuspid and mitral valves (Dunwoodie, 2007). The principal 
stages of cardiac development are summarised in Figure 1.10. 
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Figure 1. 10. Stages of heart development. The bilateral heart fields (A) converge at 
the midline and form the cardiac crescent (B) and subsequently the linear heart tube (C). 
The tube elongates and undergoes a rightward looping (D). Further remodelling 
includes AVC formation that forms a boundary between the presumptive atrial and 
ventricular regions of the heart (E), endocardial cushion formation, which will act as the 
precursors of the four major heart valves (F), chamber trabeculation (G), chamber 
septation and remodelling of the outflow tract into the aorta and the pulmonary artery 
(H). Finally, an organ with four distinct chambers is produced (I). AV, atrioventricular. 
Modified from High and Epstein, 2008. 
7.2. Heart and outflow tract septation and remodelling  
7.2.1. Heart 
The septation process of the heart tube into the four-chambered mature 
configuration occurs at three levels, the atrium, the ventricle and the arterial pole 
(Gittenberger-de Groot et al., 2005), although the latter is described separately in this 
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thesis. Following the looping stage of the heart, endocardial cells in the outflow tract 
and AV segments undergo EMT and populate the cardiac jelly, producing the 
endocardial cushions (Nakajima, 2010). Atrioventricular septation is facilitated by the 
AV cushions at the AVJ (Anderson et al., 2003b; Snarr et al., 2008). Initially two major 
cushions (superior and inferior) arise, followed by a pair of lateral cushions (Snarr et al., 
2008). Fusion of the superior and inferior cushions, with contribution from the outflow 
tract cushions, promotes closure of the primary interventricular septum (Gittenberger-de 
Groot et al., 2005). The cushions are also adjoined to the muscular ventricular septum, 
which forms between the growing apical regions of the right and left ventricles 
(Anderson et al., 2003b). In that respect, the membranous part of the interventricular 
septum is formed from the proximal parts of the outflow tract cushions that fuse with 
the already completed AV component (Figure 1.11.A) (Anderson et al., 2003b; 
Gittenberger-de Groot et al., 2005). The primary atrial septum is considered to form 
from different components in addition to the AV cushions (Snarr et al., 2008; Webb et 
al., 1999). The muscular primary atrial septum (septum primum), also known as the 
mesenchymal cap, develops on the dorso-cranial wall of the primary atrium, elongates, 
descends into the atrial cavity and fuses with the superior endocardial cushion, thus 
separating the left from the right atrium (Figure 1.11.B) (Anderson et al., 2003b; Snarr 
et al., 2008; Webb et al., 1999). A more caudally located, second mesenchymal mass, 
the dorsal mesenchymal protrusion (DMP) that was originally described as the spina 
vestibuli, arises at the venous pole of the heart, grows into the atrium and fuses with the 
inferior endocardial
 
cushion (Anderson et al., 2003b; Snarr et al., 2008). A muscular 
infolding of the atrial wall into the right
 
of the primary atrial septum, the septum 
secundum, also contributes to the closure
 
of the ostium secundum (secondary atrial 
foramen) (Kirby, 2002; Webb et al., 1999). Essentially, it is the fusion of several 
different mesenchymal components that leads to the closure of the primary atrial 
foramen (Anderson et al., 2003b). By the end of the septation process the superior 
cushion forms the aortic leaflet of the mitral valve and the inferior cushion forms the 
septal leaflet of the tricuspid valve, while the DMP mesenchyme forms the myocardial 
base of the primary atrial septum (Snarr et al., 2008). 
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Figure 1. 11. Cardiac septation. Four chamber view of the embryonic heart before 
septation (A). The outflow tract is deviated rightward to visualise the AVC. The 
developing embryonic atria (RA, LA) and ventricles (RV, LV) have formed as 
“balloons” on the outer curvature of the heart tube while their interconnecting structures 
retain a tubular shape. Transverse section through the AVC and outflow tract indicate 
the position of the endocardial cushions. Sagittal section through the primary atrial 
septum (PAS), AVC, and the LV (following the dashed line in A) shows the relation 
between the AV cushions and the atrial spine (B). 1, inferior AV cushion; 2, superior 
AV cushion; 3,4, outflow tract cushions; AVC, atrioventricular canal; AS, atrial spine 
with spur (5) on the leading edge of the PAS; 6, body of atrium; 7, interventricular 
septation; PAS, primary atrial septum; OFT, outflow tract; R/LA, right/ left atrium; 
R/LV, right/left ventricle (Lamers and Moorman, 2002). 
Reciprocal interaction between the overlaying myocardium and the endocardium 
promotes the EMT process required for the formation of the AV cushions (Nakajima, 
2010; Wagner and Siddiqui, 2007b). TGF-/BMP factors are crucial for the induction of 
the EMT process (Kirby, 2002; Nakajima, 2010). In the chick TGF-2 mediates 
endothelial cell-cell separation while TGF-3 promotes morphological cell changes 
required for the migration into the ECM (Kirby, 2002). Hyalouronic acid (Ha) synthase 
2 (Has2)/ErbB2, ErbB3/Ras (Jiao et al., 2003), Vascular endothelial growth factor 
(VEGF), Wnt and Notch pathways are also involved in the formation of the AV 
cushions (Wagner and Siddiqui, 2007b). VEGF appears to inhibit EMT and thus 
cushion formation and is found upregulated in the AVC after initiation of cushion 
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formation, probably limiting the cells undergoing EMT (Kirby, 2002). BMP2 and Tbx2 
are required for AVC development by specifying the boundary between the canal and 
the chamber myocardium (Niessen and Karsan, 2008).  
7.2.2. Outflow tract 
During the course of development the cardiac outflow tract, the single outflow 
vessel located on the arterial pole of the primitive heart tube, remodels into separate 
aortic and pulmonary arteries (Restivo, 2006). The outflow tract, also known as the 
conotruncus, consists of two myocardial regions, the conus on the proximal (connection 
with the ventricles) and the truncus on the distal (connection with the aortic sac) side 
(Lamers and Moorman, 2002; Restivo et al., 2006) which give rise to different 
structures of the definitive heart (Restivo et al., 2006). Septation of the truncus 
arteriosus divides the common outflow orifice into the arterial valve orifices, whereas 
septation and rotational remodelling of the conus produces the subpulmonary 
infundibulum (a muscular tube supporting the leaflets of the pulmonary valve, 
(Anderson, 2000)) (Restivo et al., 2006). Both segments contain a pair of cushions 
(conal and truncal) (Gittenberger-de Groot et al., 2005; Restivo et al., 2006; Snarr et al., 
2008) that in a proximal to distal direction follow a rightward spiraling course (Lamers 
and Moorman, 2002). The septation process is mediated by the truncal and conal 
endocardial cushions (Restivo et al., 2006). Initially the opposing cushions fuse across 
the lumen of the outflow tract in a distal to proximal direction (Gittenberger-de Groot et 
al., 2005; Webb et al., 2003). The truncal septum that forms divides the outflow tract 
into the aortic and pulmonary outlet components (Webb et al., 2003) so that the aortic 
channel connects to the third and fourth and the pulmonary channel to the sixth arch 
arteries (Figure 1.12) (Lamers and Moorman, 2002). Apart form the AP septum, the 
truncal cushions also contribute to the formation of the semilunar valves (Snarr et al., 
2008). These cushions are originally heavily populated by neural crest-derived cells 
(Snarr et al., 2008). The same sequence of events takes place in the proximal part of the 
outflow tract (Webb et al., 2003), where a septum separating the outlets of the left and 
right ventricles is formed after fusion of the conal cushions (Snarr et al., 2008). 
Endocardial cells compose the proximal part of the conal septum while the distal part is 
predominantely of neural crest origin, including a minor SHF-derived population (Snarr 
et al., 2008). Remodelling of the conal cushions ultimately forms the leaflets and 
supporting sinusal walls of the aortic and pulmonary valves (Webb et al., 2003). The 
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spiral path of the endocardial cushions within the outflow tract results, after septation, 
in the positioning of the root of the ascending aorta caudal to that of the pulmonary 
trunk, while the fourth pair of arch arteries remains cranial to the sixth pair (Webb et al., 
2003). 
 
Figure 1. 12. Conotruncal septation. The division of the outflow tract by the 
aorticopulmonary septum (APS) begins in the aortic sac between the fourth (systemic) 
and sixth (pulmonary) aortic arch arteries to form the base of the aorta (Ao) and 
pulmonary trunk (PT), which proceeds into the truncus and conus. Ao, aorta; APS, 
aorticopulmonary septum; PT, pulmonary trunk (Kirby, 2002). 
The outflow tract remodelling process requires complex interactions between the 
myocardium, endocardium and neural crest cells (Bajolle et al., 2006). Signals from the 
overlaying myocardium induce endocardial cells to undergo EMT and form the 
conotruncal cushions (Bajolle et al., 2006). Neural crest cells are required in normal 
heart septation as they invade the ECM of the cushions and participate in AP septation 
(Bajolle et al., 2006). Cardiac neural crest ablation in the chick produces outflow tract 
defects including TOF, CAT, DORV (Bajolle et al., 2006). TGF-, BMP and RA 
signalling factors play an important role in EMT and the subsequent morphological cell 
changes that will allow cell migration into the underlying ECM, while VEGF appears to 
have inhibitory roles in the EMT process (Kirby, 2002). 
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7.3. Heart fields and signalling factors 
7.3.1. Induction 
The cardiac fate of pre-cardiac mesoderm is determined very early in 
embryogenesis by interplay of positive and negative regulatory signals between the 
surrounding tissues and the pre-cardiac mesoderm (Dunwoodie, 2007). The lateral 
mesoderm interacts with the anterior endoderm and non-neural ectoderm that promote 
cardiac specification, while the axial tissues and the neural plate repress the formation 
of heart tissue in the head mesoderm (Dunwoodie, 2007). SHH, BMP, FGF and Wnt-
JNK (non canonical) signalling are positive cues towards a cardiogenic fate, while Wnt-
--catenin (canonical) signalling and Wnt ligands like Wnt-1 and Wnt-3a, anti-BMPs, 
Chordin, Noggin and Serrate are repressing it (Dunwoodie, 2007; Wagner and Siddiqui, 
2007a). The negative signals are possibly required to restrict the cardiogenic induction 
to a specific population of mesodermal cells (Wagner and Siddiqui, 2007a). The FHF, 
initially defined as a “region of mesoderm that gives rise to differentiated 
cardiomyocytes”, describes a population of myocardial and endocardial progenitors that 
derive from pre-cardiac mesodermal cells and give rise to the future LV, the atria, the 
sinus venosus and have a small contribution to the future RV (Dunwoodie, 2007; 
Nakajima, 2010). The SHF is a population of undifferentiated myocardial progenitor 
cells (Dunwoodie, 2007; Nakajima, 2010; Perez-Pomares et al., 2009; Rochais et al., 
2009a), located medially and caudally to the cardiac crescent (Dunwoodie, 2007; 
Nakajima, 2010). These cells contribute to the outflow tract, RV and parts of the LV 
and inflow region (Dunwoodie, 2007). Although there was initial debate concerning the 
term used to describe this cell population, a consensus has now been met in regarding 
the anterior or secondary heart field as a subpopulation of the SHF (Perez-Pomares et 
al., 2009). The anterior or secondary heart field was identified with the use of cell 
labelling and genetic markers including Fgf10 and enhancer elements of Mef2c 
(Dunwoodie, 2007). The SHF cells possess distinct molecular and spatio-temporal 
properties, like elevated proliferation and differentiation delay as compared to FHF cells 
and are distinguished by the expression of Isl1, Tbx1 Fgf8 and Fgf10 genes (although 
FHF cells transiently express certain SHF genes like Isl1 and Fgf8) (Rochais et al., 
2009a). Mommersteg et al. recently provided evidence that the splanchnic mesoderm 
divides into subpopulations corresponding to the heart fields from E7.5 progressively, 
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indicating that before that stage the cardiac progenitors constitute a common population 
(Mommersteeg et al., 2010).  
7.3.2. Induction of FHF and SHF lineages 
Most cardiac induction studies fail to discriminate between the induction of the 
different heart fields, and although similar inductive processes are involved, there are 
characteristic differences (Dunwoodie, 2007). Indeed, FGF signalling, along with 
TGF--like factors (Dunwoodie, 2007; Kirby, 2002; Perez-Pomares et al., 2009; Wagner 
and Siddiqui, 2007a) and SHH signalling are required by both heart fields for 
subsequent expression of Nkx2.5 and Mef2c (Dunwoodie, 2007). Tbx5 however is 
specifically restricted in the FHF, and interacts with Nkx2.5 and Gata4 to stimulate 
chamber-specific genes later in development (Dunwoodie, 2007). Hand1 and Hand2 are 
amongst the earliest cardiac transcription factors identified, restricted in the FHF and 
SHF respectively (Dunwoodie, 2007). Tbx20 is expressed in the FHF at the cardiac 
crescent stage while at the linear heart tube stage an extension of its expression is 
observed into the SHF (Dunwoodie, 2007). Isl1 is the gene that defined the SHF and is 
expressed from the cardiac crescent stage to at least E9.75, while it is switched off as 
cells enter the heart tube (Dunwoodie, 2007). Foxh1, which is restricted in the SHF but 
not in its derivatives (Dunwoodie, 2007), is hypothesised to regulate Fgf8 and Fgf10-
related induction of Isl1 and Tbx1-positive progenitors into activating myocardial 
factors including Gata4 and Mef2c (Perez-Pomares et al., 2009). In terms of 
transcriptional regulation, Nkx, GATA, Mef2c, T-box and Hand family genes are 
amongst the most important ones, all characteristic of a myogenic cell program (Kirby, 
2002; Perez-Pomares et al., 2009; Wagner and Siddiqui, 2007a). Cardiomyogenesis is 
inhibited by Notch signalling by promotion of non-muscle pericardial cell fates (High 
and Epstein, 2008). While cells from the SHF are being added into the linear heart tube, 
SHH, FGF and canonical Wnt signalling regulate the survival, proliferation and 
migration of these myocardial progenitors (Rochais et al., 2009a). BMP signalling is 
suggested to downregulate Isl1 expression in the SHF-derived cells that have entered 
the outflow tract, thus promoting cell differentiation instead of expansion (Rochais et 
al., 2009a).  
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7.3.3. Remodelling 
As development proceeds, RA signalling is required for the cranio-caudal polarity 
of the heart tube (Kirby, 2002). The myocardial identity for subsequent chamber 
formation is determined at various stages during heart development (Kirby, 2002). The 
rightward looping of the heart tube is important for chamber formation and is governed 
by asymmetric gene expression patterns established early in development through 
embryonic laterality (Wagner and Siddiqui, 2007a). The ventricles are initially specified 
along the anterior-posterior axis but acquire distinct identities after the looping stage 
and their left-right juxtaposition (Wagner and Siddiqui, 2007a). Conversely, left and 
right atria formation is a result of differences in left and right progenitor pools of lateral 
plate mesoderm (Wagner and Siddiqui, 2007a). The heart is partitioned into chamber 
and non-chamber myocardium, which is crucial for further heart remodelling 
(Dunwoodie, 2007). Transcription factors involved in chamber specification are Hand1, 
Cited1, Irx1/Irx3/Irx5, members of the T-box family, the vasoactive hormone atrial 
natriuretic factor (ANF, encoded by the Nppa gene), conduction proteins of the 
connexin family, and the muscle-specific cytoskeletal protein Chisel (encoded by the 
Smpx gene) (Dunwoodie, 2007). Subsequent ventricular trabeculation is implemented 
through RA, neuregulin/ErBb and Bmp10 signalling (Wagner and Siddiqui, 2007b). 
Notch signalling is suggested to act in the endocardium as an upstream regulator of both 
the latter pathways, in terms of proliferation and differentiation of trabecular myocytes 
(High and Epstein, 2008). Furthermore, studies have shown that Hey genes, which are 
Notch targets, are involved in the AVC formation while Notch1 and RBP-J take part in 
the EMT that precedes endocardial cushion formation (High and Epstein, 2008). 
7.4. Types of heart defects 
As cardiac remodelling progresses, the AP (truncal), outflow (conal), AV, 
interventricular and primary atrial septa align and fuse with each other, thus producing 
the four-chambered mature organ (Nakajima, 2010). Aberrations in either of the 
processes can result in various types of cardiac malformations (Nakajima, 2010). 
1. Alignment defects  
This category includes the malformations of the inflow or outflow of the heart, 
resulting from aberrant alignment or the atria with the ventricles or aberrant alignment 
of the aorta and pulmonary trunk with the right and left ventricles (Kirby, 2002). Inflow 
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malalignment results in defects like double inlet left ventricle and straddling tricuspid 
valve, while malalignment of the outflow is always associated with a dextroposed aorta, 
whereby the aorta overrides and receives blood from the right ventricle (Kirby, 2002). 
Dextroposed aorta occurs in DORV and TOF (Kirby, 2002). 
In DORV both the great arteries arise from the RV (Figure 1.13.B) (Johnson, 
2010) and there is loss of fibrous continuity between the AV and semilunar valves 
(Johnson, 2010; Kirby, 2002). The only outlet from the LV is through a VSD ( Johnson, 
2010; Kirby, 2002). Depending on the type of VSD present a DORV can be subaortic, 
subpulmonic, doubly committed, or remote (Johnson, 2010). The great arteries may be 
normally related, side-by-side, or malposed (Johnson, 2010). 
Tetralogy of Fallot is the concomitant existence of interventricular 
communication (VSD), obstruction of the right ventricular outflow tract, overriding 
aorta and secondary hypertrophy of the RV (Figure 1.13.C) (Bailliard and Anderson, 
2009; Carotti et al., 2008). Pulmonary atresia with VSD (or TOF with pulmonary atresia 
or PA-VSD) constitutes the extreme spectrum of a TOF where the blood to the 
pulmonary arteries flows through the patent arterial duct or through multiple 
aortopulmonary collateral arteries (Bailliard and Anderson, 2009; Carotti et al., 2008; 
Johnson, 2010). 
 
Figure 1. 13. Cardiac alignment defects. Normal alignment of the pulmonary artery 
(PA) with the RV and the ascending aorta (AAo) with the LV (A). In a DORV both the 
PA and AAo originate from the RV (B). In TOF, apart from VSD (not shown here) 
there is obstruction of the right ventricular outflow tract, overriding aorta and secondary 
hypertrophy of the RV (C). AAo, ascending aorta; DORV, double outlet right ventricle; 
PA, pulmonary artery; R/LV, right/left ventricle; TOF, tetralogy of Fallot; VSD, 
ventricular septal defect. Modified from Nakajima, 2010. 
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2. Septation defects 
Atrioventricular canal defects (AVCD) cover a spectrum of abnormalities, from 
the partial form with defects in the lower part of the primary arterial septum to the 
complete form in which absence of the AV septum results in a single common AVC 
(Jiao et al., 2003). VSDs are openings in the ventricular septum classified
 
according to 
their location as membranous or muscular (Figure 1.14.A) (Minette and Sahn, 2006). 
The muscular septum can be further divided
 
into inlet, trabecular, and infundibular 
components (Minette and Sahn, 2006). Atrial septal defects (ASD) describe similar 
malformations in the primary atrial foramen (Figure 1.14.B) (Hein et al., 2005). A 
patent foramen ovale (PFO) is a defect in the septum secundum itself, or non-adherence 
of the septum primun and secundum (Hein et al., 2005). Last, in an atrioventricular 
septal defect (AVSD), where the atrial septum fails to meet the ventricular septum, there 
is a common AVJ instead of the figure-of-eight normal configuration (Adachi et al., 
2008).  
 
Figure 1. 14. Cardiac septation defects. In a VSD there is interventricular 
communication resulting from abnormal ventricular septation (A), while in an ASD 
there is similarly communication between the atria, caused by malformations in the 
primary atrial foramen (B). ASD, atrial septal defect; VSD, ventricular septal defect. 
7.5. Types of outflow tract defects (conotruncal malformations) 
During normal conotruncal development, the outflow tract elongates and rotates 
to a final position with the pulmonary trunk arising from the right ventricle being 
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positioned on the left ventral side of the left ventricle-originating aorta (Nakajima, 
2010). Aberrations in the correct development, for example by compromised addition of 
neural crest cells (Jia et al., 2007; Nie et al., 2008) or myocardial progenitors from the 
SHF (Xu et al., 2004), and/or remodelling of the conotruncus can cause a range of 
congenital malformations (Carotti et al., 2008; Johnson, 2010; Nakajima, 2010; Restivo 
et al., 2006). 
1. Common arterial trunk 
CAT describes a malformation in which a single outlet from the heart, the 
common arterial trunk, often dilated, supplies the systemic, coronary and pulmonary 
circulations (Figure 1.15.B) (Carotti et al., 2008; Johnson, 2010; Restivo et al., 2006). 
The single truncal valve that forms is usually abnormal, with two to five cusps with 
different degree of stenosis and/or regurgitation (Johnson, 2010). The defect occurs due 
to incorrect development and lack of fusion of the truncal cushions that fail to produce a 
truncal septum (Restivo, 2006). The pulmonary arteries originate together or 
independently from the truncal root (Johnson, 2010). 
2. Transposition of the great arteries 
TGA describes a defect in which the RV is connected to the right ventrally 
malpositioned aorta and the LV is connected to the left dorsal pulmonary trunk (Figure 
1.15.C) (Nakajima, 2010). It is thought to be caused by shortening and reduced rotation 
of the outflow tract, straight conotruncal septation and ventriculo-arterial 
misconnections (Nakajima, 2010).  
 
Figure 1. 15. Outflow tract defects. Normal alignment of the pulmonary artery (PA) 
with the RV and the ascending aorta (AAo) with the LV (A). In CAT there is a single 
great vessel arising from the heart (B), while in TGA the RV is connected to the right 
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ventrally malpositioned aorta and the LV is connected to the left dorsal pulmonary trunk 
(C). AAo, ascending aorta; CAT, common arterial trunk; PA, pulmonary artery; R/LV, 
right/left ventricle; TGA, transposition of the great arteries. Modified from Nakajima, 
2010. 
7.6. Mechanisms and models of great vessel and outflow tract defects 
7.6.1. Mechanisms 
The great vessel and outflow tract defects described earlier can be a result of 
abnormal formation and/or remodelling of the primitive structures. A considerable 
number of underlying causes has been suggested for these events, although there are 
still mechanisms that remain unclear. Cardiac neural crest cells provide the 
mesenchymal support and subsequent VSM layer to the pharyngeal arch arteries 
(Hutson and Kirby, 2007; Scholl and Kirby, 2009), while also contributing to the AP 
septum (Epstein et al., 2000; Nakamura et al., 2006). Aberrations in crest migration, 
proliferation or in situ differentiation, described in several animal models below, result 
in such cardiovascular defects. Moreover, single gene mutations, like the Tbx1 
mutation, that directly affects the formation of the fourth arch arteries (Lindsay et al., 
2001) and the SHF myocardial contribution to the outflow tract (Xu et al., 2004), or the 
Tgf!2 mutation, that affects the remodelling of the fourth arch arteries (Molin et al., 
2002), lead to a range of great vessel and outflow tract defects. Other factors like blood 
flow haemodynamics are likely to play a role too. Studies have shown that the 
hydrodynamic conditions in the developing outflow tract favour laminar blood flow 
from the RV through the left ductus arteriosus and into the left DAo, leading to 
predominance of a left-sided configuration (McElhinney et al., 1999). If the pulmonary 
outflow is decreased in the developing heart, then the right-to-left ductal flow is lost or 
at least decreased, thereby abolishing the flow-related impetus for persistence of the left 
ductus and dorsal aorta (McElhinney et al., 1999). This may allow for a more stochastic 
distribution of right and left arch predominance (McElhinney et al., 1999). Although 
this theory has not been proven, empirical evidence are lesions with right ventricular 
outflow obstruction (TOF, pulmonary atresia, and CAT) which are frequently 
accompanied by an RAA (McElhinney et al., 1999). The combination of multiple 
factors is more likely responsible for the congenital anomalies of the aortic arch. In 
recent years a vast array of mouse models presenting with great vessel and outflow tract 
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defects have been used towards understanding all these mechanisms. In most cases 
perturbation of a pathway results in a combination of outflow tract and great vessel 
malformations, although the formation and remodelling of these structures depend on 
distinct and independent processes. Interestingly, most of the mutants described with 
aberrant remodelling of the vessels involve elements of the TGF- pathway. 
7.6.2. Animal models 
Endothelin (ETA, ECE-1) mutants form their pharyngeal arch arteries in 
anatomically correct positions and at the expected time, while these are populated by 
neural crest cells and form the VSM layer (Yanagisawa et al., 1998). At term however 
mutants present with multiple great vessel and outflow tract defects including IAA-B, 
DORV and persistent truncus arteriosus (PTA) (Yanagisawa et al., 1998). The authors 
discuss possible incorrect differentiation and proliferation of the post-migratory crest in 
the absence of endothelin signalling, although these were not further tested 
(Yanagisawa et al., 1998). The same was observed in the PdgfR"/! neural crest 
conditional mutants, which exhibited retro-oesophageal A-RSCA and PTA phenotypes 
with 100% penetrance at term (Richarte et al., 2007). Neural crest migration into the 
arches and subsequent differentiation into VSM were normal (Richarte et al., 2007). 
Fewer cells were scored migrating through the conotruncal region and into the heart, 
while the neural crest cell proliferation and apoptosis rates were normal (Richarte et al., 
2007). Reduced cellularity was considered the primary cause of the defects, and it may 
indeed be for the PTA and VSD phenotypes, but it does not directly explain the A-
RSCA, since all arch arteries were normally populated with crest cells that efficiently 
differentiated into VSM (Richarte et al., 2007). 
In T!RII neural crest conditional mutants (at term phenotypes include PTA, VSD 
and IAA-B with complete penetrance) the pharyngeal arch artery formation, neural crest 
migration into the arches and the conotruncal region, and VSM support of the arch 
arteries occurred normally (Choudhary et al., 2006). The neural crest proliferation and 
apoptosis rates in the AP septum were also normal (Choudhary et al., 2006). The 
authors rationalised that the neural crest cells that migrated had lost their ability to 
signal to the surrounding tissues, due to lack of the receptor (T-RII), leading to an arrest 
of development of the respective structures (Choudhary et al., 2006). The only 
perturbation found was inappropriate apoptosis of cells surrounding the right fourth 
arch artery, but this may be secondary to signalling disturbances (Choudhary et al., 
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2006). Similarly, null mutants for the latent TGF! binding protein 1 (Ltbp1, which 
belongs to a family of large extracellular glycoproteins) had unaffected neural crest 
migration, correct invasion of the outflow tract and normal proliferation and apoptosis 
rates of the post migratory neural crest cells (Todorovic et al., 2007). The absence of an 
AP septum, leading to PTA, VSD and ASD at term, was attributed to a functional defect 
of post migratory neural crest while the enhanced apoptosis observed in the VSM cells 
surrounding the fourth arch artery explained the development of IAA-B (Todorovic et 
al., 2007). It did not however provide a genetic mechanism for it. From a cellular 
marker point of view, the neural crest cells in the null animals did not express Plexin A2 
or FoxC1, two cardiac neural crest markers, although the VSM layer appeared normal in 
the arch arteries (Todorovic et al., 2007). In the septating outflow tract, decreased TGF- 
signalling was detected but no further associations were made (Todorovic et al., 2007). 
Bmp4 is suggested to be required for the recruitment or differentiation of SMCs in 
both the arch arteries and the outflow tract (Liu et al., 2004). Conditional mutants for 
Bmp4 in the branchial arch mesenchyme and outflow tract myocardium (Nkx2.5Cre) 
exhibit among others IAA-B, VSD and PTA (Liu et al., 2004). In the mutants cellular 
apoptosis in the endoderm in the proximity of the outflow was modestly upregulated, 
while cell proliferation was severely reduced in the outflow tract cushions (Liu et al., 
2004). Additionally, the pharyngeal arch arteries were well formed but the VSM 
component was comprised of fewer cells, in comparison to wild types, while fewer 
SMCs were also found invading the outflow tract at the same stage (Liu et al., 2004). 
Conditional deletion of the gene in the cardiomyocyte lineage induced AV septation 
defects, although the endocardial cushion formation was normal, suggesting Bmp4 plays 
a role in the septation process after the formation of the cushions (Jiao et al., 2003). 
Other members of the BMP pathway like Alk6 or Alk2, when conditionally ablated in 
the neural crest produce outflow tract septation defects, frequently leading to PTA. In 
Alk6 conditional mutants, the crest cells migrated normally into the arches and some 
into the outflow tract, and although great vessel morphogenesis was unaffected, the 
outflow septum failed to form (Stottmann et al., 2004). The authors suggested that Alk6 
is required in the neural crest for successful colonisation of the outflow tract, while it is 
also probably involved in regulatory signalling to the surrounding tissues (Stottmann et 
al., 2004). Alk2 conditional mutants presented with bilateral third or sixth arch artery 
regression and failure to complete AP septation, although an initial septum was formed 
(Kaartinen et al., 2004). PTA was scored with complete penetrance, while hyperplastic 
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RV and pharyngeal arch artery defects were also observed (Kaartinen et al., 2004). 
Although neural crest cells populated the pharyngeal arches normally, differentiation 
into VSM was proven defective around the third and sixth arch arteries (Kaartinen et al., 
2004). The neural crest cell outflow tract invasion was also defective, so the authors 
concluded that Alk2 might be essential for migration and/or maintenance of the neural 
crest cells in the outflow tract (Kaartinen et al., 2004). A different theory suggests that a 
minimum population may be required in the arches before allowing further migration of 
cells into the outflow tract (Scholl and Kirby, 2009). This would mean that Alk2 has 
primarily a pharyngeal role and secondary to that regulates neural crest invasion of the 
outflow tract (Scholl and Kirby, 2009).  
Another similar example is the conditional ablation of Smad4 in the neural crest, 
which affects outflow tract septation and causes delay in pharyngeal arch artery 
remodelling (Nie et al., 2008). While neural crest migration occurred normally towards 
the arches in these mutants, large clumps of dying cells were observed, so the neural 
crest contribution to the outflow tract was dramatically reduced (Nie et al., 2008).  
Null mutation of the Crkl locus produced a 22q11DS-like phenotype including 
IAA, cervical RSCA, DORV, overriding aorta and VSD (Guris et al., 2001). There was 
no notable abnormality in the development of the arch arteries at E11.5, while neural 
crest migration was normal in the Crkl
-/-
 embryos between E9.5-E10.5 (Guris et al., 
2001). The authors did not elaborate on the causes of abnormal arch artery remodelling. 
Conditional deletion of !-catenin in the pharyngeal mesenchyme from E10.5 
onwards induced pharyngeal arch artery remodelling defects by inhibiting normal 
regression of the carotid ducts between E11.5-E13.5 (Huh and Ornitz, 2010). This was 
associated with a range of great vessel defects, including A-RSCA, increased spacing 
between the right brachiocephalic and LCC arteries and lower positioning of the LSCA 
on the DAo, compared to wild type controls (Huh and Ornitz, 2010). Neural crest 
patterning did not appear disturbed in these mutants, and the causative mechanism was 
reasoned to be lack of apoptosis in the pharyngeal mesenchyme surrounding the carotid 
ducts (Huh and Ornitz, 2010). As with the Crkl mutation (Guris et al., 2001), the !-
catenin conditional mutants recapitulated the 22q11DS-like phenotype, while the Wnt-
--catenin signalling was also shown required to repress Tbx1 and FGF signalling in the 
pharyngeal apparatus (Huh and Ornitz, 2010). 
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In conclusion, although many mouse models have been described so far with 
defects in great vessel and outflow tract remodelling, very few provide links to 
individual processes, like selective apoptosis (Molin et al., 2002), failed differentiation 
of post migratory crest (Liu et al., 2004) or reduced cellularisation of various structures 
(Kaartinen et al., 2004; Richarte et al., 2007). For the majority of the models the 
underlying causes are unknown, and even in the few, the individual processes are 
usually not sufficient to explain the complete phenotype. It is now clear that 
remodelling of the outflow tract and great vessels requires the combination of multiple, 
tightly regulated mechanisms, involving different sets of genes and pathways. The 
neural crest cells are important not only for the support of the primitive arch arteries, 
through the VSM lining, but probably also for the future persistence or regression of 
each vascular segment, while cellular contribution to the AP septum is more 
straightforward in outflow tract development. The importance of the other embryonic 
tissues should not be understated either, since the mesoderm provides the endothelial 
layer of the arch arteries and the myocardial component of the heart and outflow tract, 
whereas the ectoderm is a distant regulator of several developmental process via 
molecular signalling.  
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8. Mouse models of DiGeorge syndrome and candidate genes  
The common 3 Mb deletion carried by the majority of the 22q11DS patients 
harbors over 35 genes (Momma, 2010) and, although in different genomic organisation, 
they are conserved and localise in a relatively compact genomic region of the mouse 
chromosome 16 (Baldini, 2002). This is with the exception of CLTCL and the LCRs, 
that do not appear to be conserved in the mouse (Baldini, 2002). With the use of mouse 
chromosome engineering technologies several of the 22q11DS phenotypes have been 
successfully modeled in the mouse and there are now both single-gene and multi-gene 
deletions for most of the genes within del22q11 (Baldini, 2002; Lindsay, 2001; Paylor 
and Lindsay, 2006). The first hemizygous deletion, generated by Lindsay et al., was 
named Df1 and encompassed mouse homologues of 18 out of the 24 genes that are 
deleted in patients carrying the 1.5 Mb deletion (Lindsay et al., 1999). Heterozygous 
mice (Df1/+) exhibited aortic arch defects (Lindsay et al., 1999) while the homozygotes 
displayed early embryonic lethality (Lindsay et al., 2001). The aortic arch phenotype 
was rescued in mice that carried the Df1 deletion on one chromosome 16 and a 
reciprocal duplication on the other, which essentially restored normal gene dosage 
(Lindsay et al., 1999). Deletions of the proximal or distal region of the TDR did not 
produce a 22q11DS phenotype (Kimber et al., 1999; Lindsay et al., 2001; Puech et al., 
2000). Merscher et al. generated mice carrying a hemizygous deletion spanning from 
Idd to Hira genes, named Lgdel/+ (Merscher et al., 2001). This deletion contained the 
Df1 region and another 5 genes, and the mice displayed aortic arch anomalies similar to 
the Df1/+ mice, with additional parathyroid aplasia (Merscher et al., 2001). In an effort 
to localise the haploinsufficient gene, independently two groups, Lindsay et al. and 
Merscher et al. used chromosomal engineering and transgenic complementation and 
both concluded that the critical gene responsible for the aortic arch phenotype seen in 
Df1/+ and Lgdel/+ mice was Tbx1 (Lindsay et al., 2001; Merscher et al., 2001). 
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9. TBX1 
9.1. General 
TBX1 localises within chromosome 22q11.2 and is an important regulator of 
pharyngeal development in mammals (Arnold et al., 2006; Baldini, 2002; Lindsay et al., 
2001; Merscher et al., 2001; Zhang et al., 2005). It is a member of the T-box family of 
genes, coding for transcription factors characterised by a highly conserved DNA 
binding domain, the T-box (Naiche et al., 2005; Plageman and Yutzey, 2005). Five 
distinct T-box gene subfamilies have been reported in mammals that include at least 17 
different genes (Naiche et al., 2005). Some of these genes have been associated with 
human genetic disorders, such as TBX5 with Holt-Oram Syndrome (HOS) and TBX3 
with Ulnar mammary syndrome (Hoogaars et al., 2007; Naiche et al., 2005; Plageman 
and Yutzey, 2005), while TBX1 is considered to be the main determinant of 22q11DS 
(Paylor et al., 2006; Stoller and Epstein, 2005a; Torres-Juan et al., 2007; Yagi et al., 
2003; Zweier et al., 2007).  
Binding site selection experiments have identified a palindromic sequence that 
has the highest affinity for Brachyury, the first T-Box protein identified in Drosophila 
(Conlon et al., 2001; Wilson and Conlon, 2002). Brachyury binds to the sequence as a 
dimer, with each monomer binding half of the sequence or T-half site (Conlon et al., 
2001; Wilson and Conlon, 2002). All the T-box proteins that have been examined so 
far, including the human TBX1A (Sinha et al., 2000), can bind to the site as monomers 
or dimers, while some bind sequences containing two or more T-half sites, arranged in 
various orientations (Sinha et al., 2000; Wilson and Conlon, 2002).  
9.2. Tbx1 mouse models and expression pattern 
Aside from the deletions of chromosome 16 that include Tbx1, there are several 
mouse mutants carrying Tbx1 mutations (Table 1.1) (Arnold et al., 2006; Jerome and 
Papaioannou, 2001; Lindsay et al., 2001; Merscher et al., 2001; Xu et al., 2004; Zhang 
et al., 2005; Zhang et al., 2006). The typical knock-out displays hypoplasia and 
defective segmentation the pharynx with complete loss of the caudal pharyngeal arch 
arteries (3rd, 4th and 6th pairs) (Lindsay et al., 2001), PTA, complete aplasia of the 
thymus and parathyroid glands, microtia and craniofacial malformations (Jerome and 
Papaioannou, 2001). Death occurs at birth due to cardiovascular insufficiency (Jerome 
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and Papaioannou, 2001). Tbx1
+/-
 animals are indistinguishable to the Df1/+ and Lgdel/+ 
models, exhibiting fourth arch artery hypo/aplasia with complete penetrance, which 
produces a 10% incidence of neonatal lethality (Jerome and Papaioannou, 2001; 
Lindsay et al., 2001). A smaller percentage (30-50%) of the heterozygous embryos 
display fourth arch artery-derived defects at term, including IAA-B, A-RSCA and RAA 
(Jerome and Papaioannou, 2001; Lindsay et al., 2001; Zhang et al., 2005). Tbx1 is 
expressed from as early as E7.5 in the head and splanchnic mesoderm, located dorsally 
to the cardiac crescent (Chapman et al., 1996; Huynh et al., 2007). Half a day later, at 
E8, it is expressed in the pharyngeal epithelia and mesoderm (Huynh et al., 2007; Vitelli 
et al., 2002a) as well as the head mesenchyme, while by E9 surface ectoderm expression 
is observed at the level of the presumptive caudal arches (Huynh et al., 2007). At E9.5 
Tbx1 is found in the head mesenchyme, pharyngeal ectoderm, endoderm (Chapman et 
al., 1996; Huynh et al., 2007; Lindsay et al., 2001), core and splanchnic mesoderm 
including the SHF (Huynh et al., 2007). However, at no given developmental stage is 
Tbx1 ever expressed in the neural crest-derived mesenchyme (Chapman et al., 1996; 
Huynh et al., 2007; Lindsay et al., 2001; Merscher et al., 2001; Vitelli et al., 2002a). 
Later on in development Tbx1 expression is detected in several cardiac tissues including 
the RV, atria, conal region, ascending aorta and pulmonary trunk (Huynh et al., 2007). 
In non cardiac tissues, Tbx1 is found in the tongue, otic vesicle (Chapman et al., 1996), 
sclerotome, lung buds, regions of the surface ectoderm that correspond approximately to 
the nuchal region and part of the face, follicles and vibrissae, tooth buds and muscle 
segments of the limbs (Huynh et al., 2007). 
Other animal models - xenopus, fish 
Both the sequence and the expression of Tbx1 are well conserved throughout 
species, so models of the syndrome have also been developed in organisms other than 
the mouse (Scambler, 2010). In zebrafish, the vgo mutation, generated in a large scale 
mutagenesis screen, represents a null allele of the tbx1 gene (Piotrowski et al., 2003). 
The vgo/vgo fish display lack of segmentation of the posterior pharyngeal arches, small 
otic vesicles and neural crest-derived craniofacial abnormalities (Piotrowski et al., 
2003). The mutants exhibit aortic arch and thymic defects closely phenocopying 
22q11DS (Piotrowski et al., 2003). Nonetheless, in zebrafish the mutation is recessive 
and the heterozygotes are normal, in contrast with the human and mouse deletions, 
which are haploinsufficient (Piotrowski et al., 2003). Tbx1 knock-down in zebrafish 
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through a morpholino approach induced otic vesicle, thymus, posterior pharyngeal arch, 
arch artery and pharyngeal cartilage abnormalities (Zhang et al., 2010). Heart looping 
disturbances, associated with reduced heart rate were also observed (Zhang et al., 2010). 
Similar to the mouse model, the neural crest cells that populate the arches of the 
morphant fish were greatly reduced (Zhang et al., 2010).  
In Xenopus embryos, repression of XTbx1 produced a range of dosage-sensitive 
abnormalities during embryogenesis (Ataliotis et al., 2005). The defects included 
severely hypoplastic pharyngeal apparatus, abnormally looped heart, pericardial edema 
and disorganised or absent head cartilage structures (Ataliotis et al., 2005). Co-
expression of the repressor with XTbx1 mRNA could improve the severity of the 
phenotypes, although not completely rescue them (Ataliotis et al., 2005). 
Name Synonyms Category Mutation Reference 
Tbx1
tm1Pa 
targeted mutation 
1, Virginia 
Papaioannou 
 targeted 
(Knock-out) 
Insertion, intragenic deletion. 
A loxP-flanked neomycin selection 
cassette replaced most of the coding 
region of the gene. 
Jerome et al., 2001 
Tbx1
tm1Rak 
targeted mutation 
1, Raju 
Kucherlapati 
Tbx1
- 
targeted 
(Knock-out) 
Insertion, intragenic deletion. 
A hygromycin resistance cassette was 
inserted into exons 1 and 2. 
Merscher et al., 2001 
Tbx1
tm1Bld 
targeted mutation 
1, Antonio Baldini 
Tbx1
-
, 
Tbx1
lacZ 
targeted 
(Reporter) 
Insertion.  
An IRES-lacZ reporter gene followed by 
a loxP-flanked neomycin resistance 
cassette was inserted into exon 5, 
resulting in a functionally null allele. 
Lindsay et al., 2001 
Tbx1
tm1Dsr 
targeted mutation 
1, Deepak 
Srivastava 
Tbx1
neo 
targeted 
(Floxed/Frt) 
Insertion. 
A hypomorphic allele created by the 
insertion of an FRT-flanked neomycin 
resistance gene into intron 3, and loxP 
sites flanking exons 4-8. 
Hu et al., 2004 
Tbx1
tm1.1Dsr 
targeted mutation 
1.1, Deepak 
Srivastava 
Tbx1
null 
targeted 
(Knock-out) 
Intragenic deletion. 
The FRT-flanked neomycin cassette and 
exons 4-8 were removed by Cre-
mediated excision in Tbx1
tm1Dsr 
mice. 
Hu et al., 2004 
Tbx1
tm2Bld 
targeted mutation 
2, Antonio Baldini 
Tbx1
neo 
targeted 
(Floxed/Frt) 
Insertion.  
A hypomorphic allele created by the 
insertion of a floxed PGK-neo cassette 
and a third loxP site such that cre-
mediated recombination may excise exon 
5 and/or the neo cassette.  
Xu et al., 2004 
Tbx1
tm3Bld 
targeted mutation 
3, Antonio Baldini 
Tbx1
flox 
targeted 
(Floxed/Frt) 
Insertion. 
Exon 5 was flanked by loxP sites by cre-
mediated recombination of Tbx1
tm2Bld
 in 
ES cells that removed the neomycin 
cassette. 
Xu et al., 2004 
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Tbx1
tm4(cre/Esr1)Bld 
targeted mutation 
4, Antonio Baldini 
Tbx1
mcm 
targeted 
(Knock-in) 
Insertion. 
An IRES and a MerCreMer fusion gene 
were inserted into exon 5 via homologous 
recombination, resulting in tamoxifen 
inducible cre expression under the control 
of the endogenous Tbx1 promoter. 
Xu et al., 2004 
Tg
(Tbx1-Cre)1Joe
 
transgene insertion 
1, Jonathan A 
Epstein 
Tbx1
-Cre
 transgenic 
(Cre/Flp) 
Insertion.  
Cre recombinase gene was adjoined to 
mouse Tbx1 promoter sequence that 
extended 16 kb from the start codon and 
included the proximal promoter and three 
conserved enhancer regions.  
Brown et al., 2004 
Tbx1
tm1(Fgf8)Vite 
targeted mutation 
1, Francesca Vitelli 
Tbx1
Fgf8 
targeted 
(Knock-in) 
Insertion. 
A 0.8 kb Fgf8 cDNA encoding isoform 
8b was inserted into exon 5. 
Vitelli et al., 2006 
Tbx1
tm1Bern 
targeted mutation 
1, Bernice E 
Morrow 
Tbx1
hygro 
targeted 
(Floxed/Frt) 
Insertion.  
A hygromycin resistance cassette flanked 
by loxP sites was inserted between exons 
3 and 4 along with a single loxP site 
between exons 1 and 2.  
Arnold et al., 2006 
Tbx1
tm1.1Brn 
targeted mutation 
1.1, Bernice E 
Morrow 
Tbx1
flox 
targeted 
(Floxed/Frt) 
Insertion. 
Exons 2 and 3 were flanked with loxP 
sites by cre-mediated recombination that 
removed the hygromycin cassette of 
Tbx1
hygro 
mice.  
Arnold et al., 2006 
Tbx1
tm1.2Brn 
targeted mutation 
1.2, Bernice E 
Morrow 
Tbx1
- 
targeted 
(Knock-out) 
Intragenic deletion. 
Exons 2 and 3 were removed by cre-
mediated excision in Tbx1
flox 
mice. 
Arnold et al., 2006 
Tbx1
tm5Bld 
targeted mutation 
5, Antonio Baldini 
Tbx1
neo2 
targeted 
(Knock-out) 
Insertion. 
A hypomorphic allele that can revert to a 
functional allele upon cre recombination, 
created by insertion of a floxed neomycin 
cassette into intron 5. 
Zhang et al., 2006 
Tbx1
tm6(cre)Bld 
targeted mutation 
6, Antonio Baldini 
Tbx1Cre
 
targeted 
(Knock-in) 
Insertion. 
An IRES-Cre cassette was inserted into 
exon 5. Author states that this is a null 
allele. 
Huynh et al., 2007 
Tg
(COET)1Bld
 
transgene insertion 
1, Antonio Baldini 
Tbx1
-COET
 transgenic 
(Cre/Flp) 
Insertion.  
A chicken --actin promoter drives the 
expression of a loxP-flanked neomycin 
resistance cassette and triple 
polyadenylation signal, followed by a 
mouse Tbx1 cDNA.  
Vitelli et al., 2009 
Tbx1
m1Jlk 
spontaneous 
mutation 1, John 
Klingensmith 
Tbx1
GtoT 
spontaneous  Single point mutation.  
A G to T transversion in the boundary 
region between exon 2 and intron 2 at the 
5th base into intron 2. This mutation 
results in splicing irregularities including 
exon skipping and intron retention. 
Choi et al., 2009 
Chromosome 16 deletions and human BAC transgene that incorporates Tbx1 
 Del(16Es2el-
Ufd1l)217Bld 
deletion, Chr 16, 
Antonio Baldini 
del(16) 
(Es2-Ufd1l), 
Del217Bld, 
Df1 
targeted 
(Knock-out) 
Intergenic deletion. 
Deletion on chromosome 16, including 
19 genes, spanning from Es2el to Ufd1l 
Lindsay et al., 2001 
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 Del(16Dgcr2-
Hira)1Rak 
deletion 1, Chr 16, 
Raju Kucherlapati 
Del1Rak, 
Lgdel 
targeted 
(other) 
Intergenic deletion. 
Deletion on chromosome 16, including 
24 genes, spanning from Idd to Hira 
Merscher et al., 2001 
Tg
(GNB1L, TBX1, 
GP1BB, SEPT5)23Rak
 
transgene insertion 
23, Raju 
Kucherlapati 
316.23, 
BAC316.23, 
Tg316 
transgenic Insertion. Merscher et al., 2001 
Tbx1 localises on chromosome 16, comprises of 9 exons and the initiator is in exon 2. 
Information is collated at: http://www.informatics.jax.org/searches/allele_report.cgi?_Marker_key=13762 
Table 1. 1. Genetic mutations of Tbx1 in mouse models. 
9.3. Tbx1 is required in different tissues, dosages and time-points 
Tbx1 in mice is important in early heart and pharyngeal development (Jerome and 
Papaioannou, 2001; Lindsay et al., 2001; Merscher et al., 2001) in a tissue-specific 
(Arnold et al., 2006; Xu et al., 2004; Zhang et al., 2005; Zhang et al., 2006), time (Xu et 
al., 2005) and dosage (Vitelli et al., 2009; Zhang and Baldini, 2008) dependent fashion. 
A multitude of studies have been undertaken in order to establish the different roles of 
the gene in these developmental processes. 
Tissue-specific roles  
Hemizygous deletion of Tbx1 in the mesoderm, with the use of the Mesp1 or 
Nkx2.5 Cre drivers (Tbx1
Fl/+
;Mesp1Cre or Tbx1
Fl/+
;Nkx2.5Cre), did not produce the 
fourth arch artery phenotype seen in the Tbx1
+/-
 animals, concluding that the 
mesodermal expression of Tbx1 is unrelated to fourth arch artery development (Zhang 
et al., 2005). Hemizygous deletion of Tbx1 in the mesoderm on an already heterozygous 
background (Tbx1
Fl/-
;Mesp1Cre or Tbx1
Fl/-
;Nkx2.5Cre) recapitulated most of the null 
phenotype, with the exception of no evidence of palatal defects and the aortic arch 
phenotype being milder (Xu et al., 2004; Zhang et al., 2006). Nevertheless, consistently 
with the single allele conditional deletion experiments, reactivation of the gene in the 
mesoderm was sufficient to completely rescue the severe outflow tract phenotype, 
together with the second, third, and sixth arch artery phenotype and the external ear 
hypoplasia, but not the thymic hypoplasia or the fourth arch artery defects (Zhang et al., 
2006).  
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Epithelial hemizygous excision of Tbx1 using a more general Cre driver initially 
(Foxg1Cre, shown by reporter expression to induce recombination in the pharyngeal 
epithelia as well as the pharyngeal mesoderm) and a more specific one later 
(TgFgf15Cre or TgFgf15HspCre, shown by reporter expression to induce 
recombination in the pharyngeal epithelia) was sufficient to cause fourth arch artery 
defects, although with reduced penetrance (Zhang et al., 2005). The authors rationalised 
that the reduced penetrance was a result of the time of activation of the Cre drivers 
(approximately E9), or, at least in part, due to the different genetic backgrounds 
between this and previous studies (Zhang et al., 2005). A second study used the same 
Cre driver (Foxg1Cre) to hemizygously delete Tbx1 in the endoderm on a heterozygous 
background, but in this case all mice were maintained on the same genetic background 
(Arnold et al., 2006). The tissue-specific inactivation was tested by in situ hybridisation, 
which proved intact Tbx1 expression and absent Cre expression in the mesoderm 
(Arnold et al., 2006), although there was no mention regarding the ectodermal domain. 
All conditional null embryos recapitulated the null phenotype in full and it was 
concluded that Tbx1 is required in the pharyngeal endoderm for the patterning of the 
apparatus, and secondary to that it affects the development of the derivative structures 
(Arnold et al., 2006). The authors suggested that lack of segmentation indirectly affects 
outflow tract development by compromising neural crest migration into the AP septum 
and SHF cell addition to the elongating outflow tract, recognising however the existence 
of cell-autonomous roles of the mesodermal Tbx1 in outflow tract development (Arnold 
et al., 2006). 
The early, haploinsufficient role of Tbx1 in fourth arch artery development has 
been proven pivotal in the subsequent development of the cardiovascular phenotype 
(Jerome and Papaioannou, 2001; Lindsay et al., 2001; Merscher et al., 2001). In an 
effort to clarify the tissue-specific requirements of the gene in the development of the 
fourth arch artery, fate mapping experiments were undertaken, showing that Tbx1-
expressing cells contribute to the endothelial lining of the fourth arch artery, but not to 
the VSM layer, which is of neural crest origin (Zhang et al., 2005). However, 
conditional deletion of Tbx1 in endothelial precursors (Tie2Cre or Mesp1Cre) did not 
reproduce the Tbx1
+/-
 haploinsufficiency phenotype (Zhang et al., 2005). This suggests 
that Tbx1 may have earlier roles (before the endothelial progenitor stage) in fourth arch 
artery development or that other tissue-specific Tbx1 actions are involved. Deleting 
Tbx1 in the endothelial cell lineage using the Tie2Cre promoter affected the 
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lymphangiogenesis of E18.5 embryos, while TBX1 regulated the transcription of growth 
factors and angiogenic markers in human umbilical vain endothelial cells (HUVECs) in 
vitro (Chen et al., 2010). 
The fourth arch artery defect has complete penetrance in both Df1, and Tbx1 
heterozygous lines and is attributed to failure of growth, rather than formation of the 
vessel (Lindsay and Baldini, 2001; Vitelli et al., 2002a). One reason the fourth arch 
artery collapses in these mutants is considered the deficiency the Df1 and Lgdel 
heterozygous animals present in neural crest cell differentiation into VSM of the fourth 
and sixth arch arteries (Kochilas et al., 2002; Lindsay and Baldini, 2001). Defects have 
also been seen in the neural crest cell migratory pathways of Tbx1 homozygotes 
(Moraes et al., 2005; Vitelli et al., 2002a), which until recently was believed to be 
secondary to the absence of pouches and normal signalling in the pharyngeal region 
(Arnold et al., 2006; Vitelli et al., 2002a). Similar defects have not been observed in 
Df1/+ (Lindsay and Baldini, 2001) or Lgdel/+ (Kochilas et al., 2002) animals, however, 
the cardiac neural crest cell migration pattern was recently shown to be compromised in 
Tbx1 heterozygous and Tbx1 hypomorphic embryos that have no pharyngeal 
segmentation defects (Calmont et al., 2009). The progressive reduction in Tbx1 mRNA 
levels correlated well with increased penetrance of fourth arch artery defects and with 
increased incidence of cardiac neural crest cell defects in the hypomorph mutants 
(Calmont et al., 2009). This showed that Tbx1 has non-cell autonomous roles in neural 
crest cell migration and that additional to defective in situ differentiation, migration is 
also associated with fourth arch artery defects (Calmont et al., 2009). Moreover, the 
same study provided evidence linking the ectodermal expression of Tbx1, via Gbx2, to 
fourth arch artery development (Calmont et al., 2009).  
To conclude, epithelial Tbx1 expression in the pharynx is suggested to regulate 
segmentation of the apparatus, and secondary to that thymus, parathyroid, 
cardiovascular and craniofacial morphogenesis (Arnold et al., 2006; Zhang et al., 2005) 
while mesodermal expression is required mainly for outflow tract development, but also 
contributes to arch artery, craniofacial and glandular formation (Zhang et al., 2006). The 
ectodermal expression of Tbx1 is directly associated with the development of the fourth 
arch artery (Calmont et al., 2009) whereas endothelial Tbx1 is involved in 
lymphangiogenesis (Chen et al., 2010). 
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Time-dependent roles 
Xu et al. used a tamoxifen inducible CaggsCre driver to produce a time course of 
Tbx1 inactivation and assess the time-dependent requirements of the gene in the 
development of the different structures and organs (Xu et al., 2005). The genomic Tbx1 
locus was completely recombined by 24 hrs after drug injection, thus causing 
ubiquitous deletion (Xu et al., 2005). In summary, tamoxifen injection at E7.5 (full 
excision by E8.5) recapitulated the germ line homozygous mutant phenotype, although 
not with complete penetrance, at E8.5 (full excision by E9.5) produced outflow tract 
and thymic defects along with cleft palate, at E9.5 or E10.5 (full excision by E10.5 or 
E11.5) thymic and palate defects and at E11.5 (full excision by E12.5) only palate 
defects (Table 1.2) (Xu et al., 2005). Also, with induction at E7.5 the embryos lacked 
the caudal pharyngeal arches (arches 3, 4 and 6) while with induction at E8.5 the 
embryos lacked arches 4 and 6 (Xu et al., 2005). A defect in proliferation of the 
endodermal cells in these mutants was further shown (Xu et al., 2005). In the same 
respect, a tamoxifen inducible allele that drives Cre expression under the control of the 
Tbx1 gene was used to map the fate of Tbx1-expressing cells at different time-points 
(Xu et al., 2005). Following induction at E7.5, among other tissues, the pharyngeal 
ectoderm and the endothelium of the fourth arch arteries were labelled, which was not 
observed after induction at E8.5 or E9.5 (Xu et al., 2005). Induction at E8.5 however, 
revealed a strong contribution of labeled cells to the outflow tract, which was very weak 
with induction at E9.5 (Xu et al., 2005). The authors concluded that Tbx1 is important 
for expansion of the endodermal tissue during the formation of the 3rd pouch (between 
E9.0-9.5) that directly affects pharyngeal segmentation (Xu et al., 2005). Moreover, 
they postulated that the fourth arch artery haploinsufficiency phenotype is due to an 
early requirement for Tbx1, that precedes the morphological appearance of the arteries, 
at E9.5 (Xu et al., 2005). It was also suggested that the crucial time point Tbx1 is 
required at for the development of the outflow tract was between E8.5 and E9.5, 
through an outflow tract-specific subpopulation of cardiomyocyte precursors (Xu et al., 
2005). Thymus development was controlled by Tbx1 in the same interval and there was 
a strong contribution of labeled cells to the thymic primordia after induction at E8.5 (Xu 
et al., 2005). However, there was an additional, although limited, contribution of labeled 
cells to the thymus, after induction at E9.5 and E10.5, indicating different mechanisms 
for formation and morphogenesis (Xu et al., 2005).  
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tamoxifen 
phenotype 
E7.5 E8.5 E9.5 E10.5 E11.6 
aortic arch 
(haploinsufficiency) 
abnormal 
(44%) 
normal normal normal normal 
external ears hypoplastic normal normal normal normal 
outflow tract PTA PTA normal normal normal 
thymus absent absent small small normal 
secondary palate cleft cleft cleft cleft cleft 
(45%) 
Table 1. 2. The Tbx1 time-dependent phenotype. Phenotypes scored in E18.5 
conditional homozygous (Tbx1
Fl/-
;CaggsCre) or heterozygous (Tbx1
Fl/+
;CaggsCre, 
aortic arch defects only) embryos after in utero exposure to tamoxifen at the stages 
indicated. The penetrance of the defects was complete, unless indicated otherwise. PTA, 
persistent truncus arteriosus (Xu et al., 2005). 
Dosage-dependent roles 
Zhang et al. generated a series of mouse mutants with near-continuous variation 
of the Tbx1 mRNA dosage by combining different Tbx1 alleles (Zhang and Baldini, 
2008). The levels of Tbx1 mRNA were measured by quantitative real time PCR (Zhang 
and Baldini, 2008). They showed that the levels gradually decreased from wild type 
(100%) to null (Tbx1
-/-
, 0%) embryos, with the intermediate levels being Tbx1
+/Neo2
 
(70.5%), Tbx1
+/Neo
 (53.3%), Tbx1
+/-
 (49.9%), Tbx1
Neo2/Neo2 
(34%) and Tbx1
Neo/Neo
 (4.1%) 
(Zhang and Baldini, 2008). They also included Dp1/Dp1 embryos (179%), that carry a 
chromosomal duplication encompassing Tbx1 (Zhang and Baldini, 2008). The 
phenotypic analysis demonstrated that Tbx1
Neo/Neo
 embryos were nearly identical to 
Tbx1
-/-
 embryos with the exception of normal palatogenesis and a milder outflow tract 
alignment phenotype in some embryos (Zhang and Baldini, 2008). All heterozygous 
mutants had high viability in contrast with all the homozygous and double heterozygous 
mutants (except for Dp1/Dp1), which had a 100% incidence of neonatal lethality 
(Zhang and Baldini, 2008). Tbx1
+/Neo2
, Tbx1
+/Neo
 and Tbx1
+/-
 had hypoplastic thymus 
and aortic arch artery abnormalities of fourth arch origin (Zhang and Baldini, 2008). 
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The penetrance of the defects was variable and increased with reduced Tbx1 dosage 
(Zhang and Baldini, 2008). In Tbx1
Neo2/Neo2 
the thymic hypoplasia was more severe, and 
the aortic arch artery defects had complete penetrance (Zhang and Baldini, 2008). 
Further reduction of Tbx1 dosage in the Tbx1
Neo/Neo
 embryos caused outflow tract 
defects additionally to the thymus and aortic arch artery defects (Zhang and Baldini, 
2008). Pharyngeal patterning defects were also associated with Tbx1 mRNA levels 
(Zhang and Baldini, 2008). At E10.5 Tbx1
Neo2/Neo2
 embryos had hypoplastic fourth 
pharyngeal arches and absent fourth arch arteries, while Tbx1
Neo2/-
 embryos had a 
pharyngeal segmentation phenotype similar to that of Tbx1
-/-
 embryos, although in some 
cases one of the two sixth arch arteries was present and there were rudimentary fourth 
pouches (Zhang and Baldini, 2008). The Tbx1
Neo/Neo
 pharyngeal phenotype was 
indistinguishable to the Tbx1
-/-
 phenotype (Zhang and Baldini, 2008). The authors 
concluded that there is a linear correlation between aortic arch artery defects and Tbx1 
mRNA levels within the range of 75-25% mRNA levels, while for the outflow tract 
defects the range is much narrower (Zhang and Baldini, 2008). Moreover, it was noted 
that there was very limited variability, with regard to the type of outflow tract defects 
seen, in animals with the same genotype, with the exception of the Tbx1
Neo2/Neo
 that 
included the entire range of defects scored, as well as individuals with normal outflow 
tract (Zhang and Baldini, 2008). This suggests that phenotypic variability is also 
associated with the mRNA dosage (Zhang and Baldini, 2008). The results of this study 
are summarised in Table 1.3. 
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Tbx1 
genotype 
Tbx1 dosage* lethality AoA thymus outflow 
tract (s) 
outflow 
tract (a) 
cleft 
palate 
Neo2/+ 70.5% low x m. hypo    
Neo/+ 53.3% low x m. hypo    
+/- 49.9% low x m. hypo    
Neo2/Neo2 34% complete x s. hypo    
Neo2/Neo 18.5% complete x aplasia x   
Neo2/- 15.4% complete x aplasia x x  
Neo/Neo 4.1% complete x aplasia x x  
-/- 0.2% complete x aplasia x x x 
Table 1. 3. The Tbx1 dosage-dependent phenotype. Tbx1 mRNA levels in the 
different genotypes measured by quantitative real time PCR and the phenotypic 
characteristics of each mutation. AoA, aortic arch; s, septation defect; a, alignment 
defect; m. hypo, mild hypoplasia; s. hypo, severe hypoplasia; x, indicates the presence 
of a defect. * relative to the wild type levels (Zhang and Baldini, 2008). 
Similar to the Dp1 line that was used by Zhang et al. as a Tbx1 over-expression 
construct (Zhang and Baldini, 2008), another transgenic model was generated that 
expresses Tbx1 cDNA upon Cre recombination (Vitelli et al., 2009). Vitelli et al. used 
this line (COET, conditional over-expression of Tbx1) to rescue the Tbx1 heterozygous 
phenotype by employing the Tbx1
+/Cre
 line (Vitelli et al., 2009). This model has an 
IRES-Cre cassette inserted in exon 5, in the same respect as the Tbx1
tm1Bld
 mutation, so 
it is essentially a null allele (Vitelli et al., 2009). By quantitative real time PCR it was 
shown that the COET allele is comparable to the level of expression of two wild type 
alleles (Vitelli et al., 2009). Nonetheless, the COET;Tbx1
+/Cre
 animals died perinatally, 
while 95% of term embryos exhibited aortic arch and intracardiac defects and 79% 
exhibited thymic defects (Vitelli et al., 2009). Interestingly, the COET allele seemed to 
rescue the early fourth arch artery phenotype (33%, n=12, in COET;Tbx1
+/Cre
 as 
opposed to 80%, n=5, in Tbx1
+/Cre
 embryos) (Vitelli et al., 2009), although this result 
was not statistically significant. Next, the authors examined the COET;Tbx1
-/Cre
 
mutation, and showed that in this setting Tbx1 levels were comparable to wild type at 
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E10.5, whereas the Tbx1 expression pattern was somewhat expanded, compared to wild 
type (Vitelli et al., 2009). It was rationalised that the COET allele is irreversibly 
activated after Cre recombination, thus Tbx1 remains active and functions in tissues it is 
normally shut down (Vitelli et al., 2009). For this reason the COET allele did not rescue 
the haploinsufficient Tbx1
+/Cre
 phenotype, although it was sufficient to rescue most 
aspects of the Tbx1 loss of function phenotype, with the exception of the fourth arch and 
associated artery which remained hypoplastic in the rescued embryos (Vitelli et al., 
2009). Overall, early stage pharyngeal patterning as well as outflow tract septation, ear 
and palate defects were ameliorated or rescued in the COET;Tbx1
-/Cre
 mutants (Vitelli et 
al., 2009). The fact that the COET allele could rescue most of the Tbx1 loss of function 
(Tbx1
-/Cre
) phenotypes but only some of the Tbx1 haploinsufficiency (Tbx1
+/Cre
) 
phenotypes led the authors to conclude that some organs are sensitive not only to the 
Tbx1 dosage but also to dysregulation of the expression of the gene, and that the 
COET;Tbx1
+/Cre
 was essentially a gain of function mutation (Vitelli et al., 2009). 
Fourth arch phenotype penetrance and genetic rescue  
Over the last ten years there has been extensive study of Tbx1 and its roles in 
cardiovascular development. Different groups have generated a multitude of Tbx1 
alleles (Table 1.1) and have described the same general phenotypic characteristics for 
all. However, the penetrance of each phenotype varies greatly, especially considering 
the fourth arch artery defect. Such differences may be due to the different genetic 
backgrounds used or they could reflect small sample sizes, nevertheless it remains an 
issue that should be accounted for. The Df1 mutation in heterozygosity results in 100% 
penetrance of fourth arch artery defects at E10.5 (Lindsay et al., 2001), while the 
penetrance of the same defect in Tbx1
+/tm1Bld
 embryos has been reported as complete 
(100%, n=14, Lindsay et al., 2001) or incomplete (93%, n=14, Vitelli et al., 2002b and 
46%, n=11, Calmont et al., 2009) by three different studies. Similarly 45% of 
Tbx1
+/tm1Pa
 embryos show a fourth arch artery defect on an inbred background, which is 
reduced to 19% on a mixed background (Jerome and Papaioannou, 2001).  
Linsday et al. first described the phenomenon of genetic rescue of the fourth arch 
artery phenotype of the Df1 mutants (Lindsay and Baldini, 2001). This line in 
heterozygosity exhibits complete penetrance of fourth arch artery defects at E10.5, 
which is however reduced to 65.5% in E11.5 embryos and to 32% in term embryos 
(Lindsay and Baldini, 2001). The same stands for the Tbx1
tm1Bld
 mutation that has 
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complete penetrance of fourth arch defects in heterozygosity at E10.5 (Lindsay et al., 
2001), which is reduced to 26-38% in term embryos (Calmont et al., 2009; Vitelli et al., 
2002b Vitelli et al., 2006; Zhang and Baldini, 2008). Furthermore, although the Lgdel/+ 
embryos were not examined at the early stage, given that they carry a deletion that 
includes the Df1 region, the penetrance of the E10.5 fourth arch artery defects is 
expected to be high, nonetheless, defects were scored in 46% of term embryos 
(Merscher et al., 2001). Similarly the penetrance of the defect in term Tbx1
+/tm1Rak
 
embryos is 50% (Merscher et al., 2001), in term Tbx1
+/tm1Dsr
 embryos is 22% (Hu et al., 
2004), in term Tbx1
+/tm3Bld
;CaggsCre embryos is 44% (tamoxifen injection at E7.5) (Xu 
et al., 2005) and in term Tbx1
+/tm1(Fgf8)Vite
 embryos is 75% (Vitelli et al., 2006). The 
genetic recovery of the fourth arch artery defects has also been associated with the 
genetic background (Taddei et al., 2001). Taddei et al. demonstrated that in term 
129SvEv Df1/+ embryos the incidence of the defect was 16.1%, while the same 
mutation on a mixed background produced an approximately 32% penetrant phenotype 
(Taddei et al., 2001). C57BL/6J Df1/+ embryos had a much higher penetrance, of 50% 
(Taddei et al., 2001). Differences were not observed with regard to the types of defects 
seen in the different strains (Taddei et al., 2001). Of particular note is the finding that 
irrespective of the different genetic background, the fourth arch artery defect presented 
with complete penetrance in all groups of E10.5 Df1/+ embryos (Taddei et al., 2001). 
The authors concluded that the phenotypic variability of the 22q11DS-like phenotype of 
the Df1 mutation is genetically controlled and postulated that there are genetic modifiers 
unrelated to allelic variation at the haploid locus but more likely located elsewhere in 
the genome (Taddei et al., 2001). 
The genetic background of a mouse strain refers to the genetic make-up of the 
strain that involves all alleles in all loci, apart from the mutated gene of interest (JAX®, 
2006). Different genetic modifiers can affect the phenotype expressivity, penetrance and 
dominance of each gene (Nadeau, 2001). Since each strain has unique background 
alleles, a mixed background can influence the phenotype of a mutation, transgene, or 
other genetic insert (JAX®, 2006). This explains why normal development and 
physiology may vary significantly among inbred strains (JAX®, 2006). In light of the 
above studies, certain general considerations should be regarded when the
 
effects of the 
genetic background are being discussed. There
 
is no ideal genetic background for
 
every 
class of phenotypes (Montagutelli, 2000). Nonetheless, the phenotypic differences
 
seen 
in different backgrounds can assist the generation of mouse models that resemble 
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aspects
 
of human diseases more closely (Montagutelli, 2000). Genetic heterogeneity 
exists in most human genetic diseases and the human phenotypes can present great 
ranges, while mouse mutants in an inbred background exhibit more homogeneous 
phenotypes (Montagutelli, 2000). These can be compared with
 
only a subset of human 
patients (Montagutelli, 2000). By assessing the mutation
 
on a different genetic 
background the range of phenotypes can widen (Montagutelli, 2000). In summary, a 
mutation should be considered to induce a phenotype in a specific
 
genomic context 
(Montagutelli, 2000). Consequently, great caution is needed when comparing data 
between different experiments and studies, as the background genetic modifiers can 
play an important role in the resulting phenotype. 
9.4. Tbx1 interactors and modifiers of 22q11DS 
As discussed previously, the vast majority of 22q11DS patients carry an identical 
3 Mb deletion (Emanuel, 2008; Wurdak et al., 2006; Yamagishi and Srivastava, 2003). 
They present however with considerable phenotypic variability, with phenotypes 
ranging from life threatening heart defects to developmental delay and mild craniofacial 
abnormalities (Shprintzen, 2008; Vitelli and Baldini, 2003; Wurdak et al., 2006; 
Yamagishi and Srivastava, 2003). Genetic background modifiers affect the penetrance 
of the cardiovascular phenotype in a del22q11 mouse model, suggesting that a complex 
network of interactions is taking place from the genotype towards the end phenotype 
(Taddei et al., 2001). Initial studies focused around genes that affect the development 
and morphogenesis of pharyngeal arch and pouch derivatives and are co-expressed with 
Tbx1. Fgf8, retinaldehyde dehydrogenase 2 (Raldh2) and Vegf are three of the several 
genes that have been studied in this respect (Scambler, 2010; Taddei et al., 2001; Vitelli 
and Baldini, 2003).  
Fgf8 is strongly expressed in the pharyngeal clefts and pouches and the ectoderm 
of the first pharyngeal arch (Vitelli and Baldini, 2003). Hypomorphic mutants exhibit 
cardiovascular defects similar to the Tbx1 mutation phenotype, including fourth arch 
related aortic arch, outflow tract septation, alignment and rotation defects (Vitelli and 
Baldini, 2003). In addition, pharyngeal segmentation of the caudal arches appears 
compromised (arches 3, 4 and 6) and Fgf8 mRNA is completely lost in the pharyngeal 
endoderm of Tbx1
-/-
 mutants (Vitelli and Baldini, 2003). Double heterozygous animals 
present with higher incidence of aortic arch and thymic defects, supporting a genetic 
interaction between the two genes, placing Tbx1 upstream of Fgf8 in the endoderm 
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(Vitelli and Baldini, 2003). However, Fgf8 expression off a Tbx1 promoter is not 
sufficient to rescue the fourth arch artery phenotype seen in Tbx1
+/-
 embryos (Vitelli et 
al., 2006). The same allele, which is effectively a Tbx1 null allele, was used in 
combination with Tbx1
Neo2
 that expresses minimal levels of Tbx1 (Vitelli et al., 2010). 
Tbx1
Neo2/Fgf8
 animals presented with an improved outflow tract phenotype, including 
PTA, DORV and TGA, as compared to the Tbx1
Neo2/-
 embryos that displayed 95% 
penetrance of PTA (Vitelli et al., 2010). It was further shown that Tbx1
-/-
 mouse 
embryonic fibroblasts (MEFs) did not respond normally to Fgf8, which was improved 
in Tbx1
Neo2/-
 MEFs (Vitelli et al., 2010). The authors concluded that reduced Fgf8 
expression in Tbx1 null embryos contributes to the outflow tract septation phenotype 
and that Tbx1 is required for tissue-specific response to Fgf8 (Vitelli et al., 2010). 
RA and its receptors play a crucial role in pharyngeal development, while a 
hypomorph mutant for Raldh2 (converts retinaldehyde to RA) displays aortic arch 
anomalies, as well as outflow tract septation, thymic and parathyroid malformations 
(Vermot et al., 2003). Raldh2 was found greatly upregulated in the pharyngeal region of 
Tbx1 null embryos, due to a cranial expansion of the expression domain (Ryckebusch et 
al., 2010), although after E8.5 this is attributed at least in part to pharyngeal hypoplasia 
(Ivins et al., 2005). Evidence from in vivo systems as well as proteomic analyses 
support a mutually repressive regulatory interaction between RA signalling and Tbx1 
(Caterino et al., 2009; Guris et al., 2001; Ivins et al., 2005; Roberts et al., 2005; 
Ryckebusch et al., 2010). 
Vegf is required for vasculogenesis and angiogenesis, while mice lacking one of 
the isoforms exhibit aortic arch, craniofacial, and glandular defects, as well as reduced 
vascular densities of the affected organs (Stalmans et al., 2003). Tbx1 appears reduced 
in the Vegf mutants and morpholino knock-down experiments in zebrafish support a 
genetic interaction between the two genes (Stalmans et al., 2003). Small nuclear 
polymorphism (SNP) variants of VEGF have been found more frequent in 22q11DS 
patients with cardiovascular defects than in normal controls (Stalmans et al., 2003). 
TBX1 is also shown to regulate VEGFR3 expression by binding onto a conserved 
transcription binding element (TBE) found in the regulatory region of VEGFR3, a result 
validated by chromatin immunoprecipitation (ChIP) analysis (Chen et al., 2010).  
Homozygous deletion of Crkl recapitulates the 22q11DS phenotype displaying 
craniofacial, arch artery, outflow tract, thymic and parathyroid defects, although the 
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heterozygous deletion does not produce a phenotype (Guris et al., 2001). Crkl was one 
of the four genes included in the P1 artificial chromosome (PAC) that was used to 
genetically rescue the Df1 22q11DS-like phenotype (Lindsay et al., 2001). As with 
previous studies, the genetic interaction between Crkl and Tbx1 was studied through 
double mutagenesis, which showed increased frequency and severity in the aortic arch, 
thymic and parathyroid defects, as compared to Tbx1
+/-
 mice (Guris et al., 2006). The 
defects were at least in part a result of aberrant development of caudal pharyngeal arch 
formation as well as abnormal regional patterning of the apparatus, maybe a result of 
locally aberrant RA signalling (Guris et al., 2006). 
The pathway seems very complex, since Fgf8 and Crkl genetically interact too 
towards the formation and possibly subsequent remodelling of the fourth arch and the 
outflow tract (Moon et al., 2006). Double heterozygotes as well as Fgf8
+/-
;Crkl
-/-
 
embryos present with increased penetrance and severity of cardiovascular defects 
(Moon et al., 2006). The pharyngeal epithelia, neural crest and SMC populations 
located near or migrating into the arches showed a marked increase in apoptosis (Moon 
et al., 2006). Additionally, FGF receptors bound directly to the SH2 domain of Crkl in 
vitro (Moon et al., 2006). Taken together, these results suggest that Fgf8, Crkl and Tbx1 
may operate in common pathways during cardiovascular and pharyngeal development. 
Huh et al., recently demonstrated that the Wnt---catenin signalling is a repressor 
of Tbx1 and the Tbx1-related FGF downstream signalling in the pharyngeal apparatus of 
mouse embryos (Huh and Ornitz, 2010). Moreover, conditional inactivation of !-
catenin in the pharyngeal mesenchyme induced a range of 22q11DS-like phenotypes, 
including craniofacial, cardiovascular, ear, thymic and parathyroid defects, while 
diminishing the Fgf8 dosage in these mutants could partially rescue the arch artery 
remodelling phenotype (Huh and Ornitz, 2010).  
More recent studies have employed microarray hybridisations and mouse models 
in order to establish Tbx1-associated genes. As mentioned earlier, Gbx2 interacts with 
Tbx1 in the surface ectoderm, regulating fourth arch artery morphogenesis (Calmont et 
al., 2009). Null mutation of Gbx2 produces a cardiovascular phenotype reminiscent of 
the Tbx1 heterozygous and null phenotype (Calmont et al., 2009). Hes1, a Notch 
regulated repressor gene, is also suggested as a potential Tbx1 interactor (van Bueren et 
al., 2010). During early embryogenesis Hes1 shares expression domains with Tbx1 
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while the Hes1 null phenotype is reminiscent of the Tbx1 heterozygous and null 
phenotypes with incomplete penetrance (van Bueren et al., 2010). 
Regulatory elements of the Tbx1 gene have also been characterised. One such 
enhancer includes a conserved Fox-binding site and can drive expression of a reporter 
gene in the pharyngeal endoderm and head mesenchyme in transgenic experiments, 
while Foxc1, Foxc2 and Foxa2 can bind to it (Vitelli and Baldini, 2003). SHH 
signalling regulates Foxa2 and Foxc2 and it is important for aortic arch and outflow 
tract development (Vitelli and Baldini, 2003). While Tbx1 is reduced in Shh mutants, 
the pharyngeal phenotype of these animals is less severe than in Tbx1 mutants, 
suggesting either that loss of Shh only partially diminishes Tbx1 expression or that other 
regulatory mechanisms might be important for expression of Tbx1 (Vitelli and Baldini, 
2003).  
Tbx1 has been shown to bind serum response factor (Srf), a master regulator of 
muscle differentiation, and negatively regulate its protein levels but not Srf mRNA, 
indicating regulation is not occurring at the transcriptional level (Chen et al., 2009). 
Affinity purification experiments have also identified Smad1 as a potential Tbx1 
interactor, which was validated by co-immunoprecipitation assays (Fulcoli et al., 2009). 
This protein interaction interfered with the Smad1-Smad4 complex and inhibited the 
activation of a Smad-responsive reporter gene (Fulcoli et al., 2009).  
It is now evident that multiple genes, through different pathways, act as genetic 
modifiers of the phenotype of del22q11, some studied more extensively than others. 
Understanding which mechanisms underlie the resulting set of phenotypes is of great 
importance. Nevertheless, caution is needed when interpreting the results of such 
studies, since a more severe phenotype observed in double mutants may be a result of 
additive effects, due to interfering of independent and parallel pathways that are 
required in normal development.  
9.5. TBX1 human mutations 
Further evidence supporting the role of TBX1 as a major genetic determinant in 
the etiology of 22q11DS are mutations of the gene, reported in human patients that do 
not carry the common chromosome 22q11.2 deletion. Yagi et al. first reported two 
missense (F148Y, G310S) and one frameshift (1223delC) mutations in TBX1 in a study 
of 13 patients without del22q11 (Yagi et al., 2003). The frameshift mutation led to a 
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premature stop codon and the truncated TBX1 protein lacked the C-terminal domain 
including the nuclear localisation signal (NLS) and a putative transactivation domain 
(Yagi et al., 2003). In vitro experiments by Stoller et al. subsequently showed that the 
truncated protein localised predominantly to the cytoplasm, in contrast with the wild 
type form found exclusively in the nucleus (Stoller and Epstein, 2005a). Additionally, 
even after forced nuclear localisation with fusion of the mutated construct with the 
SV40 NLS, the mutant protein failed to promote transcriptional activation (Stoller and 
Epstein, 2005a). The other two mutations had no effect on the protein (Stoller and 
Epstein, 2005a). All the patients in this study had the typical facies of CAFS, while the 
patient carrying the 1223delC mutation displayed TOF, RAA and hypoplastic thymus 
(Yagi et al., 2003). More recently, Paylor et al., in a screen for genes implicated in the 
neurobehavioural manifestations of 22q11DS identified Tbx1 and Gnb1l as potential 
factors (Paylor et al., 2006). Sequencing of those genes in a small cohort of patients 
with 22q11DS-like phenotype but without the typical 22q11.2 deletion, revealed in all 
three family members a frameshift mutation in TBX1 (1320-1342del23bp) that disrupts 
the central domain of a highly conserved NLS (Paylor et al., 2006). Further in vitro 
experiments demonstrated that the mutant protein could in fact translocate to the 
nucleus like the wild type form, but it could not activate the reporter construct (Paylor et 
al., 2006). Therefore, the authors concluded that the 1320-1342del23bp is a null 
mutation causing TBX1 haploinsufficiency in the carriers (Paylor et al., 2006). Zweier et 
al., examined 10 patients exhibiting the 22q11DS phenotype but without carrying any 
typical or atypical 22q11.2 deletions (Zweier et al., 2007). A heterozygous missense 
mutation (H194Q) in TBX1 was identified in one of the patients that did not however 
exhibit cardiac defects (Zweier et al., 2007). The mutation was located within the T-box 
domain and in vitro assays demonstrated that it induces overactivation of the reporter 
(Zweier et al., 2007). The previously described F148Y and G310S missense mutations 
(Yagi et al., 2003) were tested too, and showed a statistically significant increase in 
activation as well (Zweier et al., 2007). In vitro assays suggested that there was no 
increase in the expression levels between the mutant and wild type proteins, implying a 
gain of function effect of the mutations (Zweier et al., 2007). Modelling of the mutant 
proteins revealed that both the F148Y and H194Q are expected to increase the protein 
stability by additional hydrogen bonds (Zweier et al., 2007). Torres-Juan et al. screened 
38 patients that have some of the features of 22q11DS and do not carry any typical or 
atypical deletions or duplications of chromosome 22q11.2 (Torres-Juan et al., 2007). 
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Apart from previously described polymorphisms, two novel rare variants of the TBX1 
gene were reported in heterozygosity (L411P, /39C 0 T) (Torres-Juan et al., 2007). 
The L411P change was located nine nucleotides downstream of the 1223delC 
frameshift mutation but it was not situated within the identified NLS (Torres-Juan et al., 
2007). The second variant was a /39C 0 T nucleotide change in the second exon of the 
gene, within the 5‘UTR (Torres-Juan et al., 2007). Computer modelling of the 
/39C 0 T variant predicted decreased stability of the secondary structure of the mRNA 
at the 5‘UTR and differential folding (Torres-Juan et al., 2007). Subsequent in vitro 
translation experiments showed increase of protein reporter levels, indicating that the 
mutation may increase the endogenous TBX1 levels (Torres-Juan et al., 2007). The 
patient that carried the L411P mutation among other defects had TOF (Torres-Juan et 
al., 2007). The /39C 0 T variant was found in two brothers also exhibiting TOF 
(Torres-Juan et al., 2007). The healthy mother carried the familial mutation. (Torres-
Juan et al., 2007). To date, no TBX1 mutations have been associated with non-
syndromic congenital heart defects (Scambler, 2010) and there is no evidence 
suggesting that variants of the remaining TBX1 copy of 22q11DS patients affect the 
phenotypic variability (Rauch et al., 2004). 
All in all, two frameshift mutations, affecting the NLS of the protein (Paylor et 
al., 2006; Stoller and Epstein, 2005a; Yagi et al., 2003), three missense mutations, 
possibly attributing gain of function properties (Yagi et al., 2003; Zweier et al., 2007), 
and a rare variant that increases the translational efficiency of the gene (Torres-Juan et 
al., 2007) suggest that haploinsufficiency of TBX1 may cause 22q11DS. 
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10. Research project outline - Tbx1 targets and pathways 
TBX1 has proven to be an important regulator in the development of several 
embryonic structures (Arnold et al., 2006; Lindsay et al., 2001; Merscher et al., 2001; 
Xu et al., 2004; Zhang et al., 2005), and is now considered the major determinant of 
22q11DS (Paylor et al., 2006; Stoller and Epstein, 2005a; Torres-Juan et al., 2007; Yagi 
et al., 2003; Zweier et al., 2007). Extensive research in mouse models has illuminated 
the distinct tissue-specific and time and dosage-dependent requirements for Tbx1 in 
heart and pharyngeal development, the main structures affected in 22q11DS (Arnold et 
al., 2006; Vitelli et al., 2009; Xu et al., 2005; Xu et al., 2004; Zhang and Baldini, 2008; 
Zhang et al., 2005; Zhang et al., 2006). However, although it has been the focus of 
research for over ten years, since it was mapped within del22q11 (Chieffo et al., 1997), 
the genetic pathways and downstream effectors are only partially characterised. 
Microarray experiments performed by us and others have established a list of potential 
Tbx1 target genes (Ivins et al., 2005; Liao et al., 2008; van Bueren et al., 2010). A large 
number of those genes have been validated by means of real time quantitative PCR 
and/or whole mount in situ hybridisation (Ivins et al., 2005; Liao et al., 2008; van 
Bueren et al., 2010). We recently undertook a refined approach towards identifying 
Tbx1 targets by comparing the genetic profiles of Tbx1-expressing cells from 
heterozygous (Tbx1
+/lacZ
) and null (Df1/Tbx1
lacZ
) embryos on microarray chips, using 
Fluorescence activated cell sorting (FACS)-Gal to isolate the cells (van Bueren et al., 
2010). On the basis of their expression profiles, association with known pathways and 
involvement in pharyngeal and/or heart development, Smad7, Hes1 and Slit2 were 
selected for further analysis, in the context of 22q11DS. The aim of this project was to 
characterise putative Tbx1 downstream effectors and to link the pathways with the 
pathogenesis of the different 22q11DS phenotypes.  
Smad7 is an inhibitor of the TGF- pathway, shown to be expressed in cardiac 
tissues throughout mouse embryonic development (Liu et al., 2007; Luukko et al., 2001; 
Zwijsen et al., 2000). The TGF- signalling is involved in heart development and has 
been studied primarily through knock-out models targeting genes of the pathway. Most 
are embryonic lethal and induce a range of cardiovascular phenotypes such as great 
vessel, valve and outflow tract defects, as well as cardiac hypertrophy and fibrosis 
(Person et al., 2005). Interestingly, Smad6, the only other inhibitory Smad, has a 
reported role in heart development and has a restricted expression pattern in the 
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cardiovasculature (Galvin et al., 2000). The standard Smad6 knock-out exhibits cardiac 
valve hyperplasia and outflow tract septation defects (Galvin et al., 2000). Recently, a 
cardiovascular phenotype was also reported for the Smad7 mutant mice, including VSD 
and outflow tract defects (Chen et al., 2009). During this project, a Smad7 gene-trap 
model was used to study the knock-out phenotype in the context of 22q11DS. The 
complexity of biological systems has lately turned the focus of research from individual 
genes to the interactions between genes (Wang et al., 2010). Examining such functional 
relationships can be a useful tool in understanding the basic principles of the underlying 
genetic networks (Hartman et al., 2001; Wong et al., 2004). Genetic interactions are 
involved in many complex phenotypes and are the defining basis of multigenic genetic 
human disease (Wong et al., 2004). As part of this thesis the possible genetic interaction 
between Tbx1 and Smad7 was assessed, while further analysis involved efforts 
dissecting the genetic pathway Tbx1 acts in, via Smad7, to regulate pharyngeal arch 
artery remodelling. 
Hes1 is an effector of the Notch pathway and presented a good candidate, since 
other Notch target genes have a reported role in cardiovascular development (High and 
Epstein, 2008; Niessen and Karsan, 2008). Notch signalling is involved in many steps 
of cardiac development, namely cardiomyocyte differentiation, AVC and valve 
development, ventricular trabeculation and outflow tract remodelling (Niessen and 
Karsan, 2008). Animal models modulating the Notch pathway functions exhibit a range 
of cardiac defects such as VSD, ASD, TOF, cardiomyopathy, pulmonary artery 
stenosis, valve defects, abnormal heart looping and trabeculation defects (High and 
Epstein, 2008). We have shown that Hes1 null mutants present with a range of defects 
including cardiovascular malformations (van Bueren et al., 2010). The tissue-specific 
requirements, however, for Hes1 are not known. To that end conditional mutagenesis 
was employed, while the expression of Notch and FGF effectors was studied in the 
respective mutants, to elucidate the pathway through which Hes1 acts towards great 
vessel morphogenesis. 
Last, Slit2 is a secreted protein that binds to its receptor and regulates axon 
guidance and migration as well as outgrowth and branching (Andrews et al., 2008). 
Slit/Robo signalling is required for trunk neural crest migration in the chicken embryo 
(De Bellard et al., 2003; Jia et al., 2005). Several studies have discussed the neural crest 
migration defects in Tbx1 null embryos (Baldini, 2002; Kelly et al., 2004; Moraes et al., 
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2005; Vitelli et al., 2002a), but none has suggested a possible mechanism so far, apart 
from attributing it to the pharyngeal malformation defect (Arnold et al., 2006; Vitelli et 
al., 2002a). We recently showed that the cardiac neural crest migration pattern is altered 
in Tbx1 heterozygous and hypomorph embryos too, while Slit2 and Tbx1 share common 
domains of expression during early embryogenesis (Calmont et al., 2009). Slit2 was 
downregulated in Tbx1 homozygous mutants (Calmont et al., 2009). For the purposes of 
this project, the phenotype of the Slit2 and Slit1;Slit2 null mutations, as well as the 
potential genetic interaction between Slit2 and Tbx1 in the development of structures 
affected in 22q11DS were assessed. 
  
 
 
 
 
 
 
 
 
 
 
II. MATERIALS AND METHODS
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All reagents were of AnalaR grade and supplied by Sigma Aldrich or BDH unless 
otherwise stated.  Solutions were made using milliQ H2O and autoclaved where 
appropriate. All stock solutions used are detailed in APPENDIX I.  
1. Mouse strains, breeding, genotyping 
1.1. Mouse strains 
Tbx1
+/lacZ
 mice were obtained from Antonio Baldini, Baylor College of Medicine, 
Houston, Texas, USA. They contain a non-functional Tbx1 allele, which was generated 
by inserting an Internal Ribosomal Entry Site (IRES)-!-galactosidase reporter gene 
followed by a loxP-flanked neomycin resistance cassette into exon 5 (Lindsay et al., 
2001). The mice were maintained on a C57BL/6J background. 
Tbx1
+/mcm
 mice were obtained from Antonio Baldini, Baylor College of Medicine, 
Houston, Texas, USA. They contain a non-functional Tbx1 allele which was generated 
by insertion of a targeting cassette containing an IRES followed by the mER;Cre;mER 
encoding sequence into exon 5 via homologous recombination, resulting in tamoxifen 
inducible Cre expression under the control of the endogenous Tbx1 promoter (Xu et al., 
2004). The mice were maintained on a C57BL/6J background. 
Tbx1
+/Neo2
 mice were obtained from Antonio Baldini, Baylor College of Medicine, 
Houston, Texas, USA. They contain a hypomorphic Tbx1 allele that can revert to a 
functional allele upon Cre recombination and were generated by insertion of a floxed 
neomycin resistance cassette into intron 5 (Zhang et al., 2006). The mice were 
maintained on a C57BL/6J background. 
Smad7 gene-trap mice were obtained from BayGenomics, University of California, San 
Francisco, USA. The pGT0Lxf vector is integrated within intron 3 of Smad7 and 
consists of the first intron of the Engrailed 2 (En2) gene followed in succession by the 
mouse En2 exon 2 splice acceptor, the !-galactosidase gene and the SV40 
polyadenylation site. The splice acceptor is flanked by two lox sites 
(http://baygenomics.ucsf.edu/). The mice were maintained on a C57BL/6J background. 
Hes1
+/-
 mice were obtained from Francois Guillemot, National Institute for Medical 
Research, London, UK. The Hes1 mouse was generated by replacing the first three 
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exons of the gene with a PGK-neomycin resistance cassette (Ishibashi et al., 1995). The 
mice were maintained on an MF1 or C57BL/6J background. 
Hes1
Fl
 mice were obtained from Ryoichiro Kageyama, Institute for Virus Research, 
Kyoto University, Kyoto, Japan. They were generated by insertion of a targeting 
cassette containing loxP sites flanking the last three exons of the gene (Imayoshi et al., 
2008). The mice were maintained on a C57BL/6J background.  
Wnt1Cre mice were obtained from Andrew Copp, Neural Development Unit, Institute 
of Child Health, University College London, London, UK. They were generated by 
insertion of a cassette containing the Cre recombinase coding sequence between the 
Wnt1 promoter and the Wnt1 enhancer (Danielian et al., 1998). The mice were 
maintained on a C57BL/6J background. 
Ap2"Cre mice were obtained from Anne Moon, University of Utah School of Medicine, 
Salt Lake City, Utah, USA. They were generated by insertion of an IRES-Cre cassette 
in the 3’ untranslated region (UTR) of the Ap2! locus (Macatee et al., 2003). The mice 
were maintained on a C57BL/6J background. 
Mef2c-AHF-Cre mice were obtained from Brian Black, University of California, San 
Francisco, California, USA. They were generated by cloning the Mef2c anterior heart 
field promoter and enhancer into a Cre recombinase expression plasmid also containing 
the SV40 splice acceptor and polyadenylation sequence (Verzi et al., 2005). The mice 
were maintained on a C57BL/6J background. 
Foxa2mcm mice were obtained from Anne Moon, University of Utah, Salt Lake City, 
Utah, USA. They were generated by insertion of a targeting cassette containing an IRES 
followed by the mER;Cre;mER encoding sequence into the Foxa2 locus (Park et al., 
2008). The mice were maintained on a C57BL/6J background. 
Sox17-2A-iCre mice were obtained from Heiko Lickert, Helmholtz Zentrum Munchen, 
Institute of Stem Cell Research, Neuherberg, Germany. They were generated by 
replacing the Sox17 translational stop codon in exon 5 by a T2A (Thosea asigna virus, 
TaV) self-cleaving peptide followed by the improved Cre (iCre) for the efficient and 
equimolar translation of Sox17 and iCre (Engert et al., 2009). Sox17 and iCre are 
posttranslationally cleaved by a 2A-mediated ribosome-skipping mechanism (Engert et 
al., 2009). The mice were maintained on a C57BL/6J background. 
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Slit2
+/-
 mice were obtained from Marc Tessier-Lavigne, Departments of Anatomy and 
of Biochemistry and Biophysics, Howard Hughes Medical Institute, University of 
California, Berkeley, California, USA. The mice were generated by replacing the first 
two exons with a PGK-neomycin resistance cassette that includes a tauGFP fusion 
protein (Plump et al., 2002). They were maintained on a C57BL/6J background. 
ROSA26 reporter mice were obtained from Philippe Soriano, Department of 
Developmental and Regenerative Biology, Mount Sinai School of Medicine, New York 
University, New York, USA. The mice were generated by insertion of a targeting vector 
that includes a splice acceptor, a loxP-flanked PGK-neomycin resistance cassette 
followed by a !-galactosidase reporter gene and a polyadenylation sequence (Soriano, 
1999). They were maintained on a C57BL/6J background. 
CD1 mice were used as wild type controls for expression profile analysis. 
1.2. Breeding 
Embryos were collected from timed matings. At midday, females with a copulation plug 
were considered to be at embryonic day 0.5. Pregnant females were killed by cervical 
dislocation and the uterus was placed in Phosphate Buffered Saline (PBS) for further 
dissection. 
1.3. Tamoxifen administration 
Pregnant females were treated with tamoxifen (T5648 or H6278, Sigma Aldrich) at 
different time points of embryonic development, by intraperitoneal (IP) injection or oral 
gavage (OG). It was prepared by dilution to 100mg/ml in 100% EtOH at 37 °C and then 
1:10 in autoclaved peanut or sesame oil. 
1.4. Genotyping 
Genotyping of mice and embryos was carried out by polymerase chain reaction (PCR) 
analysis of yolk sac or tail tip genomic DNA. An aliquot of each sample was checked 
by agarose gel electrophoresis. The primer sequences and cycling conditions used are 
detailed in APPENDIX II. 
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2. DNA extraction 
2.1. Lysis Buffer extraction 
DNA extraction from yolk sacs (embryo genotyping) or tail tip biopsies (pup or adult 
mouse genotyping) by incubation in Tail Lysis Buffer and 100µg/ml Proteinase K 
(Roche, UK) at 55 
°
C, overnight (O/N). The enzyme was heat inactivated at 95-100 °C 
for 5 minutes. The DNA was precipitated in an equal volume of isopropanol, washed in 
70% ice-cold ethanol (EtOH), air dried and resuspended in Tris Base/HCl-EDTA (TE), 
pH 8. 
2.2. Phenol-Chloroform extraction 
DNA purification from enzymatic reactions was performed as follows. Dilution in 
DEPC H2O and equal volume of phenol (pH 8) and chloroform (49:1 CHCL3:IAA), 
centrifugation at 12,000 x g for 20 minutes, collection of the aqueous phase, dilution in 
equal volume of chloroform, centrifugation at 12,000 x g for 15 minutes and collection 
of the aqueous phase, precipitation on ice in 1/10 volume RNAase-free 3M sodium 
acetate (pH 5.2) and 2.5 volumes of ice-cold RNAase-free 100% EtOH for 30 minutes, 
followed by centrifugation for 20 minutes, washing of the pellet in ice-cold RNAase-
free 70% EtOH, air-drying and resuspending in DEPC H2O. 
3. Polymerase Chain Reaction 
3.1. Primer design 
Primers were designed manually or by using the Primer3 program 
(http://primer3.sourceforge.net/) and obtained from Sigma Aldrich or Operon. Forward and 
reverse PCR primers were designed with 50-60% GC content, at a 20-30 bp 
oligonucleotide length, with absence of repeat sequences and with similar melting 
temperatures (Tm). 
3.2. PCR conditions 
The reactions were carried out in sterile, distilled H2O in a final volume of 251l in PCR 
tubes as follows: 
20-50ng genomic DNA 
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1X NB buffer 
2001M each dNTP 
1.5mM MgCl2 
0.81M forward and reverse primer 
1u Taq Polymerase (Bioline) 
For amplification of large DNA fragments, Expand Long Template PCR System 
(Roche, UK) was used according to the supplier’s instructions.  
For amplification of DNA fragments that would be used for cloning reactions, Expand 
High Fidelity
Plus
 PCR System (Roche, UK) was used according to the supplier’s 
instructions, to reduce the chance of mutations being introduced in the amplified 
products. 
4. Gel electrophoresis 
DNA was separated on a 1-2% agarose gel containing 0.5µg/ml ethidium bromide in 1X 
TAE.  An appropriate 100 bp or 1 kb DNA ladder (Invitrogen) was also loaded. 
Samples were run in a 1/6 volume of loading buffer and gels were electrophoresed at 
50-150V until the fragments had separated sufficiently.  DNA was visualised by UV 
illumination. 
5. Sequencing 
Cycle sequencing reactions were performed with BigDye Terminator v3.1 (Applied 
Biosystems) and run on the MegaBACE (Amersham Biosciences), which uses the 
dideoxynucleotide chain termination method for sequencing. Sequencing reactions were 
carried out in 20 1l reaction volumes as follows: 3 1l miniprep plasmid DNA or PCR 
product, 5 pmol forward or reverse primer and sterile H2O were heated to 95 °C for 5 
minutes then 2 1l dilution buffer and 1 1l BigDye premix were added. The sequencing 
program used consisted of a denaturation step at 95 °C for 5 minutes followed by 36 
cycles at 95 °C for 20 seconds, 50 °C for 10 seconds and 60 °C for 3 minutes.   
Samples were sequenced by an in house sequencing facility. Files from the MegaBACE 
were downloaded in ABD format and analysed using the Sequencher v4.2 program. 
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6. RNA extraction  
6.1. Trizol (Invitrogen) 
RNA was extracted from cells using Trizol reagent (Invitrogen).  The cells were scraped 
off the well surface using a cell scraper and were homogenised by passing the sample 
through a pipette tip several times. Whole embryos were collected in cold PBS, 
transferred immediately in Trizol and homogenised by passing the sample through a 
syringe needle several times. The sample was left at room temperature for 5 minutes to 
allow complete dissociation of nucleoprotein complexes. Chloroform was added at one 
fifth of the initial Trizol volume to each sample and shaken by hand. The samples were 
then left for 3 minutes at room temperature before centrifuged at 12,000 x g for 15 
minutes at 4 °C to separate the aqueous, RNA-containing phase from the organic phase. 
The aqueous phase was collected into a new tube and isopropanol was added at half the 
original Trizol volume. The samples were incubated for 10 minutes at room temperature 
and were then centrifuged at 12,000 x g for 10 minutes at 4 °C to pellet the RNA. The 
pellet was washed with 75% ethanol at the original Trizol volume and centrifuged again 
at 7,500 x g for 5 minutes. Finally, the RNA pellet was air dried, resuspended in 
RNAase-free H2O and incubated at 55-60 °C to help dissolve the pellet. 
6.2. RNAeasy (Qiagen) 
Whole embryos were collected in buffer RLT, homogenised by passing the sample 
through a syringe needle several times and processed according to the supplier’s 
instructions. 
7. Reverse transcription (RT)  
cDNA was synthesised using 1µg total RNA with Superscript reverse transcriptase II 
(Invitrogen), according to the supplier’s instructions. The samples were kept at -20 °C. 
8. Quantitative real time PCR 
Quantitative real time PCR primers were designed to span one or more exons. Some 
primer sequences were obtained from Primerbank 
(http://pga.mgh.harvard.edu/primerbank/index.html), a public database of PCR primers 
specifically designed for use in quantitative real time PCR (Wang and Seed, 2003). 
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Primers were synthesised by Sigma Aldrich or Operon. All the oligonucleotides and 
cycling conditions used are detailed in APPENDIX II. 
The reactions were carried out in MicroAmp
TM
 (Applied Biosystems) optical plates and 
adhesive covers. SYBR green PCR master mix (Qiagen) was used, according to the 
supplier’s instructions. All reactions were performed in triplicate on an ABI Fast Real 
Time PCR system 7900 HT (Applied Biosystems). Product specificity was determined 
by analysing the dissociation curves. These curves highlight the melting temperature of 
the double-stranded product and the presence of primer dimers. Expression values were 
determined as previously reported, from the data collected from the SDS2.2.1 software 
(Bookout and Mangelsdorf, 2003). Expression values for each gene were normalised to 
Gapdh expression. Relative changes in gene expression were calculated by comparing 
the normalised expression values in the control samples with the normalised expression 
values in the other samples. The values are reported as the mean fold change relative to 
the controls, which were designated the value of one. 
9. Protein extraction 
9.1. Embryo collection 
Embryos for protein extraction were collected in cold PBS, transferred immediately into 
RIPA buffer, homogenised by passing the sample through a syringe needle several 
times and incubated for 1.5 hours at 4 °C rocking. Protease (Complete, Roche, UK) or 
phosphatase (PhosSTOP, Roche, UK) inhibitors were added to the buffer and the 
samples were centrifuged at maximum speed for 10 minutes, the supernatant was 
collected and stored at -80 °C. 
9.2. Protein quantification - Bradford 
Protein samples were quantified using the Bradford method, by creating a standard 
curve. The following Bovine serum albumin (BSA) (Biorad) dilutions were prepared. 
One µl of each protein sample was diluted in 800µl distilled H2O. 
Sample BSA H2O Final BSA concentration 
1 0µl 800µl 0µg/ml 
2 10µl 790µl 1.5µg/ml 
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3 20µl 780µl 3µg/ml 
4 40µl 760µl 6µg/ml 
5 80µl 720µl 12µg/ml 
6 120µl 680µl 18µg/ml 
In each tube 200µl of Bradford solution (Biorad) was added, the samples were 
incubated for 5 minutes at room temperature and an absorbance reading at 595nm was 
taken for each. 
9.3. Western Blotting 
9.3.1. Protein denaturation 
The protein samples were mixed with 6X in laemmli buffer containing 10% 2-
mercaptoethanol, denatured by incubation for 10 minutes at 100 °C, cooled on ice, 
centrifuged and used for electrophoresis. 
9.3.2. SDS - Polyacrylamide gel electrophoresis (PAGE) 
The gels were prepared with a 10-15% acrylamide resolving gel (ProtoGel acrylamide 
mix, National Diagnostics, 0.375M Tris pH 8.8, 0.1% SDS, 0.1% APS, 1% TEMED, in 
distilled H2O) and a 10% acrylamide stacking gel (ProtoGel acrylamide mix, National 
Diagnostics, 0.13M Tris pH 6.8, 0.1% SDS, 0.1% APS, 1% TEMED, in distilled H2O). 
A colour protein ladder (Precision Plus Protein
TM
 Kaleidoscope
TM
, Biorad) was also 
loaded. The denatured protein samples were electrophoresed in 1X Running buffer at 
100-150V at room temperature until the ladder bands had separated sufficiently.  
9.3.3. Western Blotting 
The electrophoresed proteins were transferred onto an Immuno-Blot
TM
 PVDF 
membrane (Biorad) by wet transfer for 2 hours at 150mA at 4 °C in 1X Transfer buffer. 
The PDVF membrane was equilibrated in 100% MeOH for 10 minutes prior to use. 
9.3.4. Immunodetection 
The membrane was rinsed once in 1X TBS and blocked for 1-2 hours at room 
temperature in blocking buffer (5% non-fat milk in 1X TBS/0.05%Tween or 5% BSA 
in 1X TBS/0.1%Tween for phosphorylated proteins), rocking. The membrane was 
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washed briefly in 1X TBS/0.05%Tween and incubated with the primary antibody 
diluted in blocking buffer O/N at 4 °C, rocking. The next day the membrane was 
washed four times in 1X TBS/0.5%Tween for 10 minutes at room temperature, rocking 
and incubated with the appropriate 1/2,500 HPR-linked secondary antibody, diluted in 
blocking buffer for 1 hour at room temperature, rocking, followed by four washes in 1X 
TBS/0.5%Tween for 10 minutes at room temperature, rocking. The signal was detected 
using the ECL Western Blotting detection Reagents (GE Healthcare), performed 
according to the supplier’s instructions, followed by overlaying an X-Ray film on the 
membrane and film developing. All antibodies used are detailed in APPENDIX I. 
9.3.5. Membrane stripping 
The membrane was stripped for 30 minutes at room temperature, rocking, in Restore
TM 
PLUS Western Blot Stripping Buffer (Thermo Scientific), and was used for further 
immunodetection. 
10. Whole mount in situ hybridisation  
The digoxygenin-labeled RNA probes were created in the laboratory by IMAGE clones 
obtained from Geneservice Limited (UK) or imaGenes (Germany), except for Smad7 
(Christine Mummery), Hes1 (Francois Guillemot), Tbx1 (Albert Basson), Fgf8 (Gail 
Martin), Fgf10 (Albert Basson), Etv4, Slit1 (Marc Tessier-Lavigne) and Slit2 (David 
Ornitz) that were kindly offered by other groups. 
All the plasmids acquired from Geneservice Limited (UK) and were used for RNA 
probe transcription were verified through sequencing using BigDye!"Terminator v3.1 
Cycle Sequencing Kit (Applied Biosystems, USA). All the plasmids acquired from 
imaGenes (Germany) were provided EST sequence verified. 
10.1. Ribophore labeling and purification 
10.1.1. Plasmid linearisation 
Five µg of plasmid DNA was linearised with an appropriate enzyme to create a 5’ 
overhang. The enzymes and RNA polymerases used for each vector are detailed in 
APPENDIXIII. The linear DNA was purified by phenol-chloroform extraction. 
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10.1.2. Labelling 
The in vitro transcription reaction was performed by combining the following: 4µl 5X 
transcription buffer (Promega), 2µl 0.1M DTT, 2µl DIG-labeled NTPs, 10.5µl (1µg) 
linearised plasmid, 0.5µl Ribonuclease inhibitor (40u/µl) and 2µl SP6, T7 or T3 RNA 
polymerase (10u/µl) (Promega). The mixture was incubated at 37 °C for 2 hours (or 40 
°C for SP6). 1µl of the probe was electrophoresed on a 1% agarose gel to check 
synthesis. An RNA band of approximately 10-fold greater intensity than the plasmid 
band indicated that approximately 10µg of probe had been synthesised.  
10.1.3. Purification 
The RNA probe was purified by dilution of the reaction in DEPC H2O and precipitation 
on ice by adding 1/10 volume of RNAase-free 3M sodium acetate (pH 5.2) and 2.5 
volumes of ice-cold RNAase-free 100% EtOH for 1.5 hours. This was followed by 
centrifugation for 15-20 minutes at 12,000 x g. The pellet was washed in ice-cold 
RNAase-free 70% EtOH, centrifuged for 10 minutes at 12,000 x g and finally 
resuspended in DEPC H2O. 
10.2. Embryo collection 
Embryos for whole mount in situ hybridisation were collected in cold PBS, fixed in 4% 
paraformaldehyde in PBS O/N, dehydrated in a gradient series of methanol 
(MeOH)/PBT (PBS, 0.1% Tween-20) and kept in 100% MeOH at -20 
°
C. 
10.3. Embryo pretreatment 
The embryos were rehydrated in a gradient series of methanol/PBT for 5 minutes and 
two washes in PBT for 5 minutes. The embryos were then bleached by incubating for 1 
hour in fresh 6% H2O2 (1/5) in PBT. This was followed by three washes in PBT for 5 
minutes and incubation in 10µg/ml Proteinase K (Roche, UK) in PBT for 4-15 minutes 
depending on the embryo stage (Table 2.1). The embryos were washed three times in 
PBT for 5 minutes and refixed for 20 minutes in 4% paraformaldehyde/0.2% 
glutaraldehyde in PBT. They were then washed twice in PBT for 5 minutes, once in 1:1 
mixture of PBT/Hybridisation solution for 10 minutes and once in Hybridisation 
solution for 10 minutes. The embryos were subsequently incubated, rocking, at 70 °C 
for over two hours. 
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embryo age 
(embryonic day) 
duration of incubation 
(minutes) 
6.5 4 
7.5 4-5 
8.5 6 
9.5 7 
10.5 8-10 
11.5 12 
12.5 15 
Table 2. 1. Embryo stage and incubation times in 10µg/ml Proteinase K in PBT for 
whole mount in situ hybridisation. 
10.4. Embryo hybridisation 
The embryos were incubated in 0.3mg/ml DIG-labeled RNA in Hybridisation solution 
at 70 °C, O/N.  
10.5. Post hybridisation washes, blocking and antibody incubation 
The embryos were washed once in Hybridisation solution for 5 minutes at 70 °C and 
twice in Solution I for 30 minutes at 70 °C, rocking. This was followed by one wash in 
Solution I and three washes in Solution II for 30 minutes at 65 °C, rocking. The 
embryos were cooled down to room temperature in the final solution and washed three 
times in MAB for 5 minutes at room temperature, rocking. The embryos were then 
blocked in MAB/2% BBR/10% heat inactivated sheep serum (GIBCO, Invitrogen) for 
60-90 minutes at room temperature, rocking. The Anti-Digoxigenin-AP Fab fragments 
(Roche, UK) antibody was pre-absorbed while embryos were blocking (3mg embryo 
powder was weighed in an eppendorf tube with 0.5ml MAB/2% BBR, which was 
incubated at 70 °C for 30 minutes, rocking. This was vortexed thoroughly, cooled on 
ice, 5µl heat inactivated sheep serum and 1µl of antibody was added, and the mix was 
incubated for 60-90 minutes at 4 °C, rocking. This was centrifuged at maximum speed 
for 10 minutes and the supernatant was collected. The embryos were incubated in 
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1/2,000 pre-absorbed antibody (the 0.5ml supernatant collected was diluted in 1.5ml 
MAB/2% BBR/1% heat inactivated sheep serum) O/N at 4 °C, rocking. 
10.6. Post antibody washes 
The antibody solution was removed and the embryos were washed three times in MAB 
for 5 minutes at room temperature, rocking, followed by at least five washes in MAB 
for 60-90 minutes at room temperature, rocking, while the last wash was performed O/N 
at 4 °C, rocking.  
10.7. Colour development 
The embryos were washed three times in NTMT for 10 minutes at room temperature, 
rocking and then incubated in BM Purple staining solution in the dark, at room 
temperature, rocking, for as long as each probe required for developing to the desired 
extent. The colour reaction was stopped rinsing the embryos in 2mM EDTA/PBT. The 
embryos were then postfixed in 4% paraformaldehyde in PBS for 1 hour at room 
temperature or O/N at 4 °C, rocking. The embryos were washed twice in PBS for 10 
minutes at room temperature, rocking and stored in PBS at 4 °C. 
10.8. Viewing/Imaging 
The imaging was conducted by a Zeiss SteREOLumar.V12 stereomicroscope equipped 
with AxioCam HRc digital camera and AxioVis40 v4.41.0 digital imaging software. 
The images were processed with Adobe Photoshop CS. 
11. Embryo powder 
Embryos at E13.5-E15.5 (approx. 5 litters) were collected in cold PBS, and the heads 
were removed. The embryos were homogenised in 3ml ice-cold PBS, using a glass 
tissue homogeniser. Four volumes of ice-cold acetone were added (12ml), the 
homogenate was mixed vigorously and left on ice for 30 minutes, while mixed every 5-
10 minutes. The homogenate was centrifuged at 10,000 rpm for 10 minutes at 4 °C, the 
pellet was resuspended in ice-cold acetone by vigorous mixing and left on ice for 10 
minutes. This was centrifuged at 10,000 rpm for 10 minutes at 4 °C, the pellet was 
transferred to a clean filter paper and was spread and dispersed repeatedly with a 
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spatula. It was let to air dry O/N at room temperature and the next day it was collected 
in an eppendorf tube and stored at 4 °C. 
12. X-gal staining  
Embryos were collected in cold MgCl2/PBS, fixed in 1% paraformaldehyde/0.2% 
glutaraldehyde in 2mM MgCl2/PBS for 20-30 minutes at room temperature, washed 
three times in 2mM MgCl2/PBS for 5 minutes at room temperature and used 
immediately for X-gal staining. The embryos were then incubated in X-gal buffer 
containing 1mg/ml X-gal (Promega) at 37 °C until the staining developed to the desired 
extent. The embryos were rinsed in PBS and fixed O/N in 4% paraformaldehyde in 
PBS. 
13. Intracardiac ink injection 
Embryos were collected in cold PBS, fixed in 4% paraformaldehyde in PBS O/N at 4 
°C, washed three times in PBS and stored in PBS at 4 °C. Indian Ink (Pelikan) was 
injected into the outflow tract or aorta of embryos using a microinjection needle to 
visualise the pharyngeal arch arteries or great vessels of the heart. 
14. Embedding and sectioning 
14.1. Paraffin embedding 
The embryos were dehydrated in 1:1 PBS/EtOH, followed by a gradient series of EtOH 
washes (70%-100%), at room temperature for at least 30 minutes. This was followed by 
two washes in Histoclear (National Diagnostics, UK) at room temperature for 30 
minutes, one wash in a 1:1 Histoclear/ Paraffin solution at 60 °C for 20 minutes and 
three washes in paraffin at 60 °C for 30-60 minutes. The embryos were placed in the 
appropriate molds and left to set at least O/N before sectioning. 
The embedded embryos were sectioned at 5-10µm thickness in coronal, transverse or 
parasagittal planes. The sections were flattened on water at 42 °C, set on TESPA coated 
slides (2% 3-aminopropyl-triethoxysilane in acetone) and air dried O/N. Rehydration of 
the sections was performed through incubation at 60 °C for 10 minutes two washes in 
Histoclear for 10 minutes, followed by a gradient series of EtOH washes (100%-30%) 
and two washes in distilled H2O, for 2 minutes, at room temperature. Counterstaining 
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was performed in hematoxylin (Raymond A Lamb, UK) for 3 minutes followed by 
eosin (Raymond A. Lamb, UK) for 1 minute. The sections were air-dried O/N and 
mounted with DPX mountant (Merck, UK).  
14.2. OCT embedding 
Embryos were collected in cold PBS, fixed in 4% paraformaldehyde for 2-3 hours at 4 
°C, rinsed in PBS once and left to equilibrate in 30% sucrose in PBS O/N at 4 °C. They 
were then transferred in 1:1 sucrose/Optimal Cutting Temperature double (OCT) and 
frozen in 100% OCT on dry ice.  OCT-embedded embryos were sectioned in coronal, 
transverse or parasagittal planes. Sections were cut at 101m, collected onto Superfrost+ 
glass slides, allowed to dry and stored at -80 °C. 
15. Immunohistochemistry 
Slides were allowed to reach room temperature and were rinsed once in PBS to remove 
OCT before being permeabilised with 0.5% Triton X-100/PBS for 5 minutes at room 
temperature. They were rinsed twice in PBS, allowed to dry to enable use of Immedge 
pen to draw around the sections and were then blocked for 1 hour in blocking buffer 
(1% BSA, 10% serum). The slides were subsequently incubated with the primary 
antibody diluted in blocking buffer, O/N at 4 
0
C. The next day the slides were washed 
three times in 0.1% Triton X-100/PBS and rinsed twice in PBS. They were then 
incubated with the secondary antibody diluted in blocking buffer 1/500 for 1 hour at 
room temperature and washed three times in PBS for 5 minutes. DAPI (1/25,000 in 
PBS) was added onto the slides for 20 seconds to visualise the nuclei and the slides 
were washed three times in PBS for 5 minutes before mounting with CitiFluor
TM
 
(Citifluor Ltd). All antibodies used are detailed in APPENDIX I. 
16. Viewing/Imaging 
Imaging for counterstained sections was conducted by a Zeiss Axiophot 2 microscope, 
equipped with a Kontron Prog/Res/3012 digital camera, using Adobe Photoshop 6 as 
the image importing software. The images were subsequently processed with Adobe 
Photoshop CS. For sections processed for immunofluorescence a Zeiss Imager Z.1 
microscope equipped with AxioCam MRm digital camera and AxioVis40 v4.7.1 digital 
imaging software was used. The images were processed with Adobe Photoshop CS. 
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17. Cloning 
17.1. Plasmid mini-midi-maxi preps 
IMAGE clone plasmid DNA and Bacterial artificial chromosomes (BACs) were 
received as stab cultures (Geneservice Limited, UK or imaGenes, Germany). On arrival, 
bacteria were streaked out onto LB plates containing the appropriate antibiotic and left 
to grow O/N at 37 °C. A culture of LB broth containing the appropriate antibiotic was 
inoculated with one colony and incubated O/N at 37 °C, shaking. 20% glycerol stocks 
were prepared and stored at -80°C. Purified plasmid DNA was isolated using Qiagen 
plasmid purification kits (Qiagen) according to the supplier’s instructions. Plasmid 
DNA was eluted in either distilled H2O or EB buffer.   
17.2. Digests 
Digests of plasmid DNA were carried out in a total volume of 50µl using 1-5µg plasmid 
DNA, 5µl 10X enzyme buffer, 0.5µl 100X BSA, 1-2u of enzyme in distilled H2O. The 
plasmids were digested at the appropriate temperature for optimal enzyme activity for 2 
hours and then electrophoresed on an agarose gel for analysis. 
17.3. Gel extraction 
Gel extraction was carried out to isolate and purify DNA fragments from agarose gels. 
The QIAquick gel extraction kit (Qiagen) was used following the manufacturer’s 
instructions and DNA was eluted in 30µl distilled H2O. 
17.4. TA cloning 
Purified PCR products were cloned directly into plasmids using TOPO XL PCR 
Cloning Kit (Invitrogen, UK) or pGEM-T Easy Vector System (Promega, UK), 
according to manufacturer’s instructions.  
17.5. Ligation 
For each ligation of a linear plasmid vector and a corresponding DNA fragment three 
different insert/vector molar ratios (3:1, 1:1, 1:3) as well as a vector only control were 
used. The quantity (ng) of the insert was calculated each time by the formula 
(Promega):  
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                  ng vector x size (kb) of insert 
                  ############  x insert/vector molar ratio = ng of insert 
                               size (kb) of vector 
Essentially, 100ng plasmid vector, ng of insert accordingly, 1µl 10X ligation buffer 
(Promega), 1µl T4 DNA ligase (Promega) and distilled H2O to a total volume of 10µl 
were mixed together. The ligation reaction was incubated O/N at 16 °C, according to 
the supplier’s instruction. 
17.6. De-phosphorylation of plasmids 
The TKGL2 plasmids were de-phosphorylated to remove the phosphate groups from the 
5’-ends to prevent self-ligation of the vector. Shrimp alkaline phosphatase (SAP) (USB) 
was used following the supplier’s instructions. The firefly luciferase vector TKGL2 was 
obtained from the Anita Rauch (Institute of Human Genetics, Schwabachanglage, 
Germany). It was digested at 37ºC overnight using Acc65I simultaneously with calf 
intestinal alkaline phosphatase (CIAP) in the Acc65I buffer to prevent self ligation. 
17.7. Transformation 
Transformation of plasmid, BAC DNA or ligation product into JM109 competent cells 
(Promega) by thawing the cells on ice, adding the DNA into the cells and incubating for 
20 minutes on ice, performing a heat shock for 45 seconds in a 42 ºC water bath and 
growing in 1ml LB broth for 1 hour at 37ºC, shaking. Finally, 200µl was plated on an 
LB agar plate with the appropriate antibiotic and incubated O/N at 37 ºC. 
18. Mammalian cell culture 
Jeg3 cells were obtained from Anita Rauch, (Institute of Human Genetics, 
Schwabachanlage, Erlangen, Germany). They were cultured in RPMI 1640 + Glutamax 
medium (GIBCO, Invitrogen) supplemented with 10% fetal bovine serum (FBS) and 
1% penicillin/streptomycin (GIBCO, Invitrogen). Cells were maintained at 37 °C, 5% 
CO2 in a humidified chamber.   
19. Cell transfections  
Lipofectamine 2000 (Invitrogen) was used for cell transfections, according to the 
supplier’s instructions. 
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20. Luciferase assay 
Transfected cells were lysed 24 hours post transfection and the luciferase activity was 
measured. 
20.1. !-galactosidase Luciferase Assay 
The cells were washed in PBS and lysed in 200µl 1X Reporter Lysis Buffer (Promega) 
for 15 minutes at room temperature. The cells were then scraped using the end of a 
pipette tip and the lysate was transferred to eppendorf tubes. The tubes were centrifuged 
at maximum speed for 2 minutes and the supernatant was collected. 
For the luciferase reading, 20µl of each lysate was transferred to a round bottom tube 
and 100µl of luciferase buffer (Promega) was added to each tube individually and 
immediately before taking a reading using the TD-20/20 Luminometer (Turner Designs, 
USA) set at a 3 second delay followed by a 15 second reading. For --galactosidase 
activity measurement, 75µl of each cell lysate was added to 75µl of 1X Reporter Lysis 
Buffer and 150µl --galactosidase assay buffer (0.2M Na phosphate, 2mM MgCl2, 0.1M 
2-mercaptoethanol, 1.5mg/mL ortho-Nitrophenyl---galactoside). A blank tube was also 
prepared. The tubes were vortexed and incubated at 37 ºC until a yellow colour 
developed. The reaction was stopped with 500µl 2M Na2CO3 and the tubes were 
centrifuged for 2 minutes. An absorbance reading at 420nm was taken using the 
Nanodrop ND-1000. 
20.2. Dual Luciferase Assay 
This assay was performed using the Dual Luciferase Assay Kit (Promega). The cells 
were washed in PBS and lysed using 250µl 1X Passive Lysis Buffer (PLB) for 15 
minutes. The PLB does not require cell scraping afterwards. 20µl of each lysate was 
transferred to round bottom tubes and the luciferase assay and normalisation was 
performed according to the manufacturer’s protocol. Essentially, two readings are 
obtained – one for firefly luciferase activity and the other for renilla luciferase activity 
(for normalisation). 
21. Bone and cartilage staining 
Embryos were collected in cold PBS and processed immediately for bone and cartilage 
staining. This was performed by fixing the embryonic heads in 95% EtOH for 3 days 
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and then placing them in acetone for at least two days, at room temperature. The heads 
were stained for at least 3 days in fresh bone and cartilage staining solution at 37 ºC. 
The heads were washed in distilled H2O and cleaned in 1% KOH for several days, until 
the skeleton was visible through the tissue. Then they were cleaned through 20%, 50% 
and 80% glycerol 1:1 with KOH and stored in 100% glycerol. 
22. Bioinformatics 
Genome sequences were acquired from the UCSC Genome Bioinformatics Site 
(http://genome.cse.ucsc.edu/). The sequences were aligned using the Multiple sequence 
local alignment and visualisation tool (MULAN, http://mulan.dcode.org/). The user 
defined consensus sequence search for the T-half site was performed using the 
TCACAM sequence, whereby M = A or C. 
23. Statistics 
Chi square, Fisher’s exact test (one tailed), t-test (two tailed) or Mann-Whitney U test 
were used for statistical analysis of the data collected in this thesis. The significance 
level was set at p<0.05. The Mann-Whitney U test, which uses a system of rankings and 
assigned values, was performed by hand. 
24. Gel band quantification 
ImageJ was use to quantify western blot and agarose gel electrophoresed samples. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
III.  SMAD7
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1. Introduction – Literature review 
1.1. TGF! pathway 
1.1.1. Biological functions 
TGF- family cytokines have many and diverse roles in embryonic development, 
being involved in processes like embryonic asymmetry, stem cell self renewal and 
differentiation, growth, cell proliferation and differentiation, ECM remodelling, 
immune response, organogenesis and wound healing (Guo and Wang, 2009; Javelaud 
and Mauviel, 2004; Moustakas and Heldin, 2009; Park, 2005; Yan et al., 2009). 
Aberrations in the TGF- signalling are often linked to human disease, including cancer, 
tissue fibrosis and autoimmune disorders (Guo and Wang, 2009; Javelaud and Mauviel, 
2004; Kamiya et al., 2010; Moustakas and Heldin, 2009; Park, 2005; Yan et al., 2009). 
1.1.2. Protein interactions 
The TGF- superfamily is divided into two subfamilies, the TGF-
-/activin/nodal/myostatin/inhibin consisting group and the BMP/anti-mullerian 
hormone (AMH) and growth and differentiation factors (GDFs) group (Moustakas and 
Heldin, 2009; Yan et al., 2009). All TGF- ligands are synthesised as precursor proteins, 
with a longer N-terminal pro-peptide, known as the latency-associated peptide (LAP), 
followed by a shorter C-terminal mature polypeptide (Javelaud and Mauviel, 2004; 
Moustakas and Heldin, 2009). Proteases cleave the TGF- LAP from the mature peptide, 
which however remain in association, with the LAP enveloping the smaller mature 
peptide within its core (Javelaud and Mauviel, 2004; Moustakas and Heldin, 2009). 
ECM components, the latent TGF--binding proteins (LTBPs), associate with this 
complex and regulate the secretion and storage of TGF- (Javelaud and Mauviel, 2004; 
Moustakas and Heldin, 2009; Yan et al., 2009). Several of the TGF- family members 
have this TGF- LAP ability of maintaining the ligand in an inactive state, but not all 
(Moustakas and Heldin, 2009). Most tissues are abundant in latent TGF-, although 
activation of minimal amounts of it are enough to generate maximal cellular response 
(Bujak and Frangogiannis, 2007). The TGF- ligands transduce their signal through 
serine/threonine kinase transmembrane type I and type II receptors and their 
downstream effectors, the Smads (Moustakas and Heldin, 2009; Ross and Hill, 2008). 
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Five type II and seven type I receptors of the TGF- superfamily have been identified in 
mammals and each TGF-/BMP pathway ligand binds to a characteristic combination of 
type I and type II receptors (Table 3.1) (Ikushima and Miyazono, 2010; Moustakas and 
Heldin, 2009; Ross and Hill, 2008; ten Dijke and Hill, 2004). The receptors form 
hetero-tetrameric complexes in the presence of the dimeric ligand (Ikushima and 
Miyazono, 2010; Moustakas and Heldin, 2009). Upon activation, TGF- ligands bind to 
type II receptors and the complex activates the type I receptors, also known as activin 
receptor-like kinases (ALKs), by phosphorylation in the juxtamembrare region 
(Javelaud and Mauviel, 2004; Ikushima and Miyazono, 2010; Moustakas and Heldin, 
2009; Ross and Hill, 2008; ten Dijke and Hill, 2004; Wrana, 2000). This leads to 
subsequent downstream signals through activation of the receptor activated Smads (R-
Smads, Smad1, Smad2, Smad3, Smad5 and Smad8) that form complexes with the 
common mediator Smad4 (co-Smad), translocate to the nucleus and together with other 
transcription factors, regulate gene expression (Bujak and Frangogiannis, 2007; 
Javelaud and Mauviel, 2004; Ikushima and Miyazono, 2010; Moustakas and Heldin, 
2009; Park, 2005; ten Dijke and Hill, 2004; Wrana, 2000). The TGF-/nodal/activin 
pathways signal via Smad2 and Smad3, while the BMP/GDF pathways via Smad1, 
Smad5 and Smad8 (Figure 3.1) (Moustakas and Heldin, 2009; Yan et al., 2009). In the 
case of Smad2/3 the interaction between the type I receptor and the R-Smads is 
facilitated by the membrane-bound scaffold protein Smad anchor for receptor activation 
(SARA) and the adaptor molecule Dab2 (Ross and Hill, 2008). Although the pathway is 
otherwise very conserved, in endothelial cells TGF- ligands can induce phosphorylation 
of Smad1, Smad5 and Smad8 through a receptor complex that contains the tissue-
specific Alk1 type I receptor (Ross and Hill, 2008). Inhibitory Smads (I-Smads, Smad6-
7) are negative regulators of the TGF-/BMP signalling and are induced by TGF-, BMP 
or activin signals through activated R-Smad complexes, thus establishing a negative 
feedback loop (Park, 2005; Yan et al., 2009). Smad7 is a general antagonist of both the 
TGF- and BMP pathways, whereas Smad6 preferentially inhibits the latter (Moustakas 
and Heldin, 2009; Park, 2005; Ross and Hill, 2008; Yan et al., 2009). Both I-Smads act 
by stably binding to type I receptors, competitively preventing R-Smad binding and 
phosphorylation (Park, 2005; Ross and Hill, 2008; ten Dijke and Hill, 2004; Yan et al., 
2009). Subsequently the I-Smads recruit phosphatases and E3-ubiquitin ligases, known 
as Smad ubiquitination regulatory factors (Smurfs, Smurf1 and Smurf2), to the 
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activated type I receptor leading to proteasomal degradation of the receptor and 
termination of the signalling (Ross and Hill, 2008; ten Dijke and Hill, 2004; Yan et al., 
2009). During this process Smad7 itself is degraded (Yan et al., 2009). I-Smads can 
additionally inhibit co-activator recruitment by the R-Smads, interfere with the 
formation of the R-Smad/co-Smad complexes, (Moustakas and Heldin, 2009; Park, 
2005; Ross and Hill, 2008), or bind to and disrupt Smad-DNA complexes in the 
nucleus, thereby inhibiting their transcriptional activity (Moustakas and Heldin, 2009; 
Ross and Hill, 2008; Yan et al., 2009). Smad7 also negatively regulates the pathway by 
promoting dephosphorylation and hence deactivation of TGF- type I receptors through 
recruitment of a complex of GADD34 and the catalytic subunit of protein phosphatase 1 
(Shi et al., 2004).  
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PATHWAY TFG- BMP GDF Activin AMH 
Ligand TFG-1 BMP2,4 GDF5,6,7 Inhibin -A AMH 
 TFG-2 BMP5,6,7 GDF9b Inhibin -B  
 TFG-3 BMP8A,8B GDF10,11 Nodal  
  BMP9,10 GDF15   
   GDF1,3   
   GDF8   
   GDF9   
RII T-RII BMPRII BMPRII ActRIIA AMHRII 
  ActRIIA, 
ActRIIB 
ActRIIA, 
ActRIIB 
ActRIIB  
RI T-RI 
(ALK5) 
BMPRIA 
(ALK3) 
BMPRIA 
(ALK3) 
ActRIB 
(ALK4) 
BMPRIA 
(ALK3) 
 ALK1 BMPRIB 
(ALK6) 
BMPRIB 
(ALK6) 
ALK7 BMPRIB 
(ALK6) 
 ALK2 ALK2 ALK2  ALK2 
 BMPRIA 
(ALK3) 
ALK1 ActRIB 
(ALK4) 
  
   ALK7   
   T-RI 
(ALK5) 
  
R-Smad SMAD2,3 SMAD1,5,8 SMAD1,5,8 SMAD2,3 SMAD1,5,8 
 SMAD1,5,8  SMAD2,3   
Co-Smad SMAD4 SMAD4 SMAD4 SMAD4 SMAD4 
I-Smad SMAD7 SMAD6,7 SMAD7 SMAD7 SMAD6,7 
Table 3. 1. TGF! superfamily signalling factors in human. Receptors are listed as 
type II (RII), and type I (RI). Ligands, type I receptors and R-Smads are color-coded: 
blue, BMP-like pathways; red, TGF/activin-like pathways. Modified from Moustakas 
and Heldin, 2009. 
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Figure 3. 1. Simplified schematic representation of the TGF!/BMP pathways. 
Upon ligand binding receptor activated Smad complexes (Smad2/3 or Smad1/5/8) 
become phosphorylated and associate with the common mediator Smad4, translocate to 
the nucleus and together with other transcription factors, regulate gene expression. 
Smad7 inhibits both branches of the pathway, while Smad6 selectively inhibits the 
BMP branch. 
1.1.3. Smad proteins 
Smad proteins are characterised by two highly conserved regions, the Mad-
homology 1 (MH1) domain at the N-terminus and the MH2 domain at the C-terminus, 
which are joined together by an intermediate linker domain (Ross and Hill, 2008; Yan et 
al., 2009). The MH1 domain carries NLSs and a DNA-binding domain and is important 
Smad7 - 128 
Irinna Papangeli 
for cytoplasmic anchoring, nuclear import and gene transcription regulation (Ross and 
Hill, 2008; Yan et al., 2009). The MH2 domain binds to type I receptors, can interact 
with other proteins, mediates Smad homo- and hetero-complex formation as well as 
cytoplasmic anchoring and transactivation of target genes (Ross and Hill, 2008; Yan et 
al., 2009). The linker domain is rich in prolines and phosphorylatable serines or 
threonines and interacts with prolyl-isomerases and ubiquitin ligases (Moustakas and 
Heldin, 2009). Both Smad6 and Smad7 have the conserved C-terminal MH2 domain, 
but not the N-terminal MH1 domain or the phosphorylation site by the type I receptors 
at the C-terminal tail (Figure 3.2) (Park, 2005; Yan et al., 2009). The two I-Smads are 
similar in only 36.7% of their N-terminus (Yan et al., 2009). Smad7 facilitates specific 
inhibition of the TGF-/activin signalling through both its N-terminus and MH2 domains 
(Yan et al., 2009).  
 
Figure 3. 2. Smad protein structure. Simplified structures of the mammalian Smad 
proteins divided into receptor-activated Smads (R-Smad), common-mediator Smad (Co-
Smad) and inhibitory Smads (I-Smad). The conserved N-terminal Mad-homology 1 
(MH1) (speckled shading) and C-terminal MH2 (angled-stripped box) domains are 
shown as well as the nuclear localisation signal (NLS, horizontal-striped box) and the 
nuclear export signal (NES, vertical-striped box). Co-Smad, common-mediator Smad; I-
Smad, inhibitory Smad; MH, mad homology; NLS, nuclear localisation signal; NES; 
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nuclear export signal; R-Smad, receptor-activated Smad. Drawn after Moustakas and 
Heldin, 2009. 
1.1.4. Cross-talk with other pathways 
Several elements of the TGF-/BMP pathways, and primarily the Smad proteins, 
make direct and dynamic contacts with numerous other proteins (Guo and Wang, 2009). 
Moreover, TGF- signalling has multiple targets, both transcriptional and non-
transcriptional, that all combined provide interconnections with other cellular signalling 
pathways (Guo and Wang, 2009). This cross-talk includes pathways such as the MAPK, 
P13/Akt, Wnt, SHH, Notch, IL, TNF- and IFN-. (Guo and Wang, 2009; Park, 2005). In 
that respect, I-Smads are also induced by other extracellular stimuli, apart from the 
TGF-/BMP regulation (Park, 2005).  
1.1.5. Smad7 interactors/regulators 
I-Smad expression and duration are essentially regulated at the transcriptional 
level or by post-translational degradation at the protein level in cells (Park, 2005). The 
TGF-/activin pathway controls Smad7 expression through direct binding of Smad3 and 
Smad4 to the Smad7 promoter (Nagarajan et al., 1999). Also, the Ski protein with co-
operation of Smad4 inhibits the Smad7 promoter basal activity (Park, 2005). 
Degradation of Smad7 by Arkadia, promotes TGF-/BMP signalling (Yan et al., 2009). 
Jab1/CSN5, a protein complex that is part of the COP9 signalosome complex, regulates 
the stability of Smad7 and thus effects TGF-/BMP signalling (Yan et al., 2009). Smad7 
binding partners like Hic-5/ARA55, Yes-associated protein (YAP65), the salt-inducible 
kinase (SIK), and Crk-associated substrate lymphocyte type (Cas-L) contribute in the 
regulation of the pathway (Yan et al., 2009). Smad7 can be acetylated by the coactivator 
protein p300 and deacetylated by histone deacetylases (HDACs) or SIRT1 (Yan et al., 
2009). Smad7 acetylation inhibits its ubiquitination and subsequent degradation, so 
Smad7 degradation is regulated by the balance between acetylation, deacetylation, and 
ubiquitination (Yan et al., 2009). Smad7 is also known to stabilise --catenin by 
protecting it from degradation by inhibiting its phosphorylation by Gsk3-- and by 
inhibiting recruitment of the ubiquitin ligase Smurf2, in vitro (Tang et al., 2008). A --
catenin/E-cadherin complex is thus favoured over a --catenin degradation in the 
cytoplasm, promoting cell adhesion (Tang et al., 2008). 
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1.2. TGF!/BMP/Smad gene mutations  
Members of the TGF! superfamily have been studied by means of gene knock-out 
or conditional mutagenesis in the mouse, which display a range of phenotypes including 
cardiovascular defects (Chen et al., 2004; Chen et al., 2009; Choudhary et al., 2006; 
Galvin et al., 2000; Gaussin et al., 2005; Gaussin et al., 2002; He et al., 2002; Jia et al., 
2007; Jiao et al., 2003; Kaartinen et al., 2004; Kim et al., 2001; Li et al., 2006; Liu et 
al., 2004; Ma et al., 2005; Molin et al., 2002; Nie et al., 2008; Sanford et al., 1997; 
Solloway and Robertson, 1999; Song et al., 2007; Stottmann et al., 2004; Tang et al., 
2010; Todorovic et al., 2007; Wang et al., 2006; Wurdak et al., 2005; Zhang and 
Bradley, 1996). The majority of the knock-outs are embryonic lethal and induce 
cardiovascular phenotypes including great vessel, valve and outflow tract defects, as 
well as cardiac hypertrophy and fibrosis (Chen et al., 2004; Chen et al., 2009; 
Choudhary et al., 2006; Galvin et al., 2000; Gaussin et al., 2005; Gaussin et al., 2002; 
He et al., 2002; Jia et al., 2007; Jiao et al., 2003; Kaartinen et al., 2004; Kim et al., 
2001; Li et al., 2006; Liu et al., 2004; Ma et al., 2005; Molin et al., 2002; Nie et al., 
2008; Sanford et al., 1997; Solloway and Robertson, 1999; Song et al., 2007; Stottmann 
et al., 2004; Tang et al., 2010; Todorovic et al., 2007; Wang et al., 2006; Wurdak et al., 
2005; Zhang and Bradley, 1996). TGF- signalling plays an important role in the 
development of tissue fibrosis, since stimulation of the pathway promotes the 
conversion of fibroblasts into myofibroblasts and enhances ECM protein synthesis 
whilst repressing ECM degradation (Bujak and Frangogiannis, 2007).  
1.2.1. TGF! mutants 
The different phenotypes of the Tgf!1, Tgf!2 and Tgf!3 knock-out models reflect 
the non-compensated functions of the three TGF- isoforms (Bujak and Frangogiannis, 
2007). The Tgf!1 null mutation is embryonic lethal with a penetrance of 50%, while all 
surviving mice eventually die within five weeks due to a wasting syndrome associated 
with multifocal inflammation and massive lymphocyte and macrophage infiltration in 
multiple organs (Bujak and Frangogiannis, 2007). Mice deficient for Tgf!2 exhibit 
perinatal mortality and a range of malformations including fourth arch artery, outflow 
tract and intracardiac septation defects (Bartram et al., 2001; Sanford et al., 1997). The 
fourth arch artery defect was further associated with a marked reduction in Smad2 
expression, confined in the specific vascular segment (Molin et al., 2004). Interestingly, 
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the mutants display craniofacial and ear defects too (Sanford et al., 1997), resembling 
the Tbx1 mutant phenotype (Jerome and Papaioannou, 2001). Tgf!3 nulls present with 
cleft palate and abnormal lung development due to defective EMT interactions (Bujak 
and Frangogiannis, 2007). It has also been suggested that TGF- signalling mediates 
processes of the inflammatory response in cardiac infarction, like monocyte recruitment 
at the wound site and promotion of granulation tissue formation (Bujak and 
Frangogiannis, 2007). 
Conditional deletion of T!RI (Alk5) in the neural crest led to abnormal pharyngeal 
arch artery remodelling and outflow tract septation, secondary to increased apoptosis of 
the crest cells (Wang et al., 2006). Neural crest ablation of T!RII produced craniofacial 
malformations, thymus and parathyroid gland hypo/aplasia, and cardiovascular defects, 
all reminiscent of the 22q11DS phenotype (Choudhary et al., 2006; Wurdak et al., 
2005). The phenotypes were attributed to loss of neural crest differentiation properties 
(Wurdak et al., 2005), or defective signalling to the surrounding tissues (Choudhary et 
al., 2006). Null mutants for Ltbp1 displayed pharyngeal arch artery, outflow tract and 
intracardiac septation defects (Todorovic et al., 2007). The absence of the AP septum 
was explained in this case too by functional defects of post migratory neural crest cells 
(Todorovic et al., 2007).  
1.2.2. BMP mutants 
Complete inactivation of Bmp2 resulted in delayed formation of the heart tube, 
which was found outside the amniotic cavity and eventually progressed into severe 
cardiac dysmorphogenesis (Zhang and Bradley, 1996). Conditional deletion of the gene 
in the AV myocardium led to early embryonic lethality and defects in AV cushion 
morphogenesis (Ma et al., 2005). Conditional deletion of Bmp4 in the cardiomyocyte 
lineage induced AV septation defects, although the endocardial cushion formation was 
normal (Jiao et al., 2003). Bmp4 conditional mutants in the branchial arch mesenchyme 
and outflow tract myocardium exhibited a range of cardiovascular defects including 
pharyngeal outflow tract and ventricular septation anomalies, due to abnormal 
differentiation into or recruitment of SMCs (Liu et al., 2004). Null mutation of Bmp10 
induced arrest of cardiogenesis at E9.0-E9.5 (Chen et al., 2004). The mutant embryos 
presented with hypoplastic ventricular walls and absence of ventricular trabeculae, 
while the endocardial cushion development arrested at the acellular stage (Chen et al., 
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2004). It was shown that Bmp10 deficient cardiomyocytes fail to proliferate and 
generate the ventricular trabeculae (Chen et al., 2004). Double knock-outs for Bmp6 and 
Bmp7 exhibited defective outflow tract cushion formation (Kim et al., 2001), while 
double knock-outs for Bmp5 and Bmp7 died by E10.5 from abnormal cardiogenesis 
(Solloway and Robertson, 1999). The phenotype was first noticed at the linear heart 
tube stage that progressed to disorganised cardiac morphology and absent endocardial 
cushions of the surviving embryos at E10.5 (Solloway and Robertson, 1999). Neural 
crest deletion of the BMP type I receptors Alk2 (Kaartinen et al., 2004) and Alk6 
(Stottmann et al., 2004) resulted in abnormal or absent AP septum, while cardiac-
specific deletion of Alk3 resulted in AV cushion, trabeculae and interventricular septum 
defects, but not outflow tract defects (Gaussin et al., 2002). It was also shown that Alk3 
is required in cardiomyocytes for Tgf!2 expression (Gaussin et al., 2002). Consistently, 
conditional deletion of Alk3 specifically in the AV cardiomyocyte lineage resulted in 
AV valve defects (Gaussin et al., 2005). Additionally, inactivation of Alk3 in the 
endocardium with a Tie2Cre driver resulted in failure of AV endocardial cushion 
formation with incomplete penetrance (Ma et al., 2005).  
1.2.3. Smad mutants 
Smad4 is the common mediator Smad, required by all branches of the pathway to 
promote Smad-dependent response (Bujak and Frangogiannis, 2007; Javelaud and 
Mauviel, 2004; Ikushima and Miyazono, 2010; Moustakas and Heldin, 2009; Park, 
2005; ten Dijke and Hill, 2004). Ablation of the gene in the neural crest led to outflow 
tract cushion hypoplasia and subsequent outflow tract septation defects (Jia et al., 2007; 
Nie et al., 2008), hypoplastic ventricular septa, thin ventricular wall and delayed 
remodelling of the pharyngeal arch arteries (Nie et al., 2008). The neural crest cells 
followed a normal migration pattern into the caudal arches (Jia et al., 2007; Nie et al., 
2008) but failed to invade the outflow tract (Jia et al., 2007). Abnormal apoptosis of 
neural crest cells within the arches (Jia et al., 2007; Nie et al., 2008) led to a diminished 
cardiac crest cell contribution into the outflow tract (Jia et al., 2007). Inactivation of the 
gene in the myocardium induced an initially incorrect alignment of the AV cushions, 
which did not however affect AV septation, while the myocardial walls exhibited 
reduced cellularity, suggested as the primary cause of embryonic lethality for these 
mutants (Song et al., 2007). Smad6, the only other I-Smad apart from Smad7, is also 
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involved in heart development and displays a restricted expression pattern in the 
cardiovasculature (Galvin et al., 2000). The standard knock-out exhibited cardiac valve 
hyperplasia and outflow tract septation defects (Galvin et al., 2000). Mutations of the 
rest of the Smad genes, apart from Smad7, produce early embryonic lethality and a 
spectrum of defects not directly associated with the cardiovasculature (from the MGI 
website, http://www.informatics.jax.org/). 
Smad7 is shown to be expressed in cardiac lineages throughout embryonic 
development (Liu et al., 2007; Luukko et al., 2001; Zwijsen et al., 2000) while a 
recently reported systemic conditional knock-out for Smad7 displayed perinatal lethality 
and a cardiovascular phenotype including VSD, thin ventricular wall, ventricular non-
compaction and malalignment of the pulmonary and aortic arteries (Chen et al., 2009). 
Interestingly, deletion of the first exon of the gene in mice had a mild effect on the B 
cells of the immune system but did not induce any other gross abnormalities (Li et al., 
2006). Furthermore, overexpression of Smad7 in the neural crest lineage that essentially 
abrogates TGF-/BMP signalling in this tissue resulted in impaired craniofacial, 
pharyngeal and cardiovascular development, including outflow tract and ventricular 
septation defects and retro-oesophageal localisation of the RSCA (Tang et al., 2010). 
Overexpression of the gene in epithelial tissues under a keratin K5 promoter that targets 
the epidermis, hair follicles, other stratified and squamous epithelia and the thymic 
epithelia, resulted in defects in multiple organs, including severe thymic hypoplasia (He 
et al., 2002). In the chick model, overexpression of SMAD7 induced vessel enlargement 
with compromised connectivity to the rest of the plexus, although this was independent 
to VSM cell recruitment (Vargesson and Laufer, 2001). 
The genetic mutations of components of the TGF-/BMP pathways described to 
date produce a similar group of cardiovascular phenotypes. It is apparent that neural 
crest is affected in the majority of the models, which directly associates with 
compromised cellular contribution into the outflow tract and deficient differentiation 
into SMCs (Choudhary et al., 2006; Jia et al., 2007; Kaartinen et al., 2004; Nie et al., 
2008; Stottmann et al., 2004; Todorovic et al., 2007; Wang et al., 2006; Wurdak et al., 
2005). Such aberrations lead to outflow tract and cardiac septation abnormalities, 
related with endocardial cushion formation defects or failure in the septation process 
itself (Bartram et al., 2001; Choudhary et al., 2006; Jia et al., 2007; Kaartinen et al., 
2004; Nie et al., 2008; Sanford et al., 1997; Stottmann et al., 2004; Todorovic et al., 
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2007; Wang et al., 2006; Wurdak et al., 2005). Nonetheless, mutations of TGF! 
superfamily genes also induce a different set of cardiovascular phenotypes that are 
related to defects in the pharyngeal arch artery remodelling or formation processes 
(Bartram et al., 2001; Choudhary et al., 2006; Nie et al., 2008; Todorovic et al., 2007; 
Wang et al., 2006; Wurdak et al., 2005). Often, these defects are described together with 
outflow tract or intracardiac defects, although their embryological origin is different 
(see introduction: 4.3, 7.4, 7.5). The first group of phenotypes, with regard to outflow 
tract and cardiac septation, along with the causative mechanisms have been more 
extensively studied than the great vessel defects. Of particular note is the fact that 
mutations targeting genes of the BMP pathway almost exclusively produce heart and/or 
outflow tract septation anomalies (Chen et al., 2004; Gaussin et al., 2005; Gaussin et al., 
2002; Jiao et al., 2003; Kaartinen et al., 2004; Kim et al., 2001; Liu et al., 2004; Ma et 
al., 2005; Solloway and Robertson, 1999; Stottmann et al., 2004) while TGF! gene 
mutations are additionally linked to great vessel malformations (Bartram et al., 2001; 
Choudhary et al., 2006; Todorovic et al., 2007; Wang et al., 2006; Wurdak et al., 2005). 
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2. Project overview 
Our microarray data that identified Smad7 as a putative Tbx1 target gene (van 
Bueren et al., 2010), the previously published Smad7 expression pattern in the 
cardiovasculature (Liu et al., 2007; Luukko et al., 2001; Zwijsen et al., 2000) and the 
extensive implication of the TGF-/BMP pathways in heart development, led us to 
further investigate this gene. Expression analysis was undertaken to establish the Smad7 
expression domains during early embryogenesis. Smad7 gene-trap heterozygous 
intercrosses provided embryos for the assessment of cardiovascular, thymic and 
secondary palate phenotypes, in the context of the Tbx1/22q11DS phenotype. Double 
heterozygous embryos for Tbx1 and Smad7 were used to examine a potential genetic 
interaction between the two genes in great vessel development. Biochemical assays 
were employed to investigate direct TBX1 binding onto the Smad7 promoter, assess the 
Smad7 actions on the two branches of the TGF-/BMP pathways and also examine any 
shear stress involvement in the cardiovascular phenotype of the Smad7 mutants through 
Klf factors. Finally, a model of Smad7 gene restoration in a time-controlled fashion 
during embryogenesis was standarised to the extent time allowed for this thesis. 
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3. Results 
3.1. Smad7 in Tbx1 mutant embryos 
Whole mount in situ hybridisation was used to show that Smad7 mRNA is 
downregulated in E9.5 Tbx1
lacZ/lacZ
 embryos in the pharyngeal endoderm and 
mesenchyme but not ectoderm, compared to littermate stage-matched wild type controls 
(Figure 3.3.C, C’, D, D’). This result corroborates the original microarray data (van 
Bueren et al., 2010) and supports the hypothesis that Smad7 could be a Tbx1 
downstream target. To overcome the problem of the physical malformation of the 
pharyngeal apparatus of the Tbx1
lacZ/lacZ
 embryos, hypomorphs were used to examine 
Smad7 mRNA levels. Tbx1
Neo2/Neo2
 embryos express 34% of the wild type Tbx1 mRNA 
dosage and lack the pharyngeal segmentation defect (Zhang and Baldini, 2008). By 
whole mount in situ hybridisation it was shown that Smad7 mRNA was not affected in 
the Tbx1
Neo2/Neo2
 embryos, compared to littermate stage-matched wild type controls 
(Figure 3.3E, E’, F, F’). 
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Figure 3. 3. Tbx1 and Smad7 mRNA expression detected by in situ hybridisation at 
E9.5. (A, A’) Wild type Tbx1 mRNA expression in whole mount (A) and parasagittal 
section (A’). (B, B’) Wild type Smad7 mRNA expression in whole mount (B) and 
parasagittal section (B’). (C, C’, D, D’) Smad7 mRNA expression in wild type control 
embryo in whole mount (C) and transverse section at the caudal pharyngeal level (C’) 
and in Tbx1
lacZ/lacZ
 embryo in whole mount (D) and transverse section at the caudal 
pharyngeal level (D’). (E, E’, F, F’) Smad7 mRNA expression in wild type control 
embryo in whole mount (E) and transverse section at the caudal pharyngeal level (E’) 
and in Tbx1
Neo2/Neo2
 embryo in whole mount (F) and transverse section at the caudal 
pharyngeal level (F’). Black arrow, pharyngeal mesenchyme; yellow arrowhead, 
pharyngeal ectoderm; blue arrowhead, core mesoderm; red arrowhead, SHF mesoderm; 
white arrowhead, pharyngeal endoderm; ov, otic vesicle; SHF, second heart field.
Smad7 - 138 
Irinna Papangeli 
3.2. Tbx1 binding onto the Smad7 promoter 
To test whether Smad7 is a Tbx1 target a bioinformatics approach was initially 
undertaken, to identify putative Tbx1 and other cardiac transcription factor binding 
elements, conserved throughout species, on the Smad7 regulatory region. MULtiple 
sequence Local Alignment and visualisation tool (http://mulan.dcode.org/) was used to 
align the genomic sequences of the different species and highlight the conserved 
domains. The T-half site TCACACCT (Conlon et al., 2001; Wilson and Conlon, 2002) 
was used as a putative Tbx1 binding site search term. In a genomic region including the 
Smad7 gene and 25 kb upstream and downstream sequence, several cardiac 
transcription factor binding sites were found conserved, across four species, human, 
mouse, rat and dog. There was a single putative Tbx1 binding site conserved, located 
approximately 13 kb upstream the 5‘UTR (Figure 3.4).  
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Figure 3. 4. Conserved TBEs on the Smad7 gene and upstream/downstream 
regulatory regions among human, mouse rat and dog genomes. A putative Tbx1 
binding site (A). Gata and Nkx factor binding sites (B).   
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To investigate this further, luciferase promoter assays were used to assess in vitro 
binding between TBX1 and Smad7, as previously described (Zweier et al., 2007). 
Around 2 kb of the upstream regulatory region of Smad7, relative to the transcription 
initiation site, was subdivided into overlapping sections of about 500 bp each. The 
putative Tbx1 binding site was not included since it was outside the 4.3 kb Smad7 
promoter that was shown to recapitulate gene-specific expression in the mouse embryo 
(Liu et al., 2007). Additionally, the conserved site was single and not in form of a 
palindrome, thought to be required for TBX1 binding (Sinha et al., 2000). The 
fragments were subcloned into the luciferase vector TKGL2 and transfected into cells 
together with either an empty vector or a TBX1C expressing construct. An empty 
TKGL2 vector was used as a negative control while the 2T-TKGL2 vector, which 
contains two palindromic T-box binding sites, was used as a positive control. A renilla 
luciferase or !-galactosidase expressing vector were used to assess the transfection 
efficiency and normalise the results within experiments. One of the four sequences 
tested, Smad7.4, showed a statistically significant increase in reporter expression 
(p<0.05, Mann-Whitney U test) (Figure 3.5.B), while Smad7.2 showed a marked 
decrease, statistically significant when using the dual luciferase method (p<0.05, Mann-
Whitney U test) (Figure 3.5.A). Although informative, these data do not provide 
conclusive results, as they need to be repeated for validation. Furthermore, the 
activation of the luciferase reporter measured from positive controls was much higher 
than the activation seen with the Smad7;luciferase plasmids. Also, despite the fact a 
proof reading Taq polymerase was used during the PCR amplification step, sequencing 
of all subcloned fragments is required to exclude the presence of randomly integrated 
mutations. 
The promoter cloning and luciferase assay experiments were carried out by a 
member of the lab, Jennifer Huang. These results were generated during her master’s 
course in which I helped to design the research project and supervised the experiments. 
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Figure 3. 5. Smad7 promoter activation by TBX1. Graphical representation of 
luciferase activation after TBX1C or pcDNA3 co-expression with Smad7.2;TKGL2 (A) 
or  Smad7.4;TKGL2 (B). The experiments are grouped based on the method used for 
normalisation within experiments; --galactosidase or renilla luciferase expression. exp, 
independent experiments. 
3.3. Smad7 gene-trap validation 
Smad7 gene-trap mice (hereafter Smad7
GT/GT
) were obtained from BayGenomics, 
University of California, San Francisco, USA. They derived from the YHCO53 
embryonic stem cell line in which the pGT0Lxf vector had integrated within intron 3 of 
Smad7, as verified by Bay Genomics. The vector consists of the first intron of the 
Engrailed 2 (En2) gene followed in succession by a splice acceptor, the !-galactosidase 
gene and an SV40 polyadenylation site. The splice acceptor is flanked by two lox sites 
(Figure 3.6.C) (http://baygenomics.ucsf.edu/). 
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Heterozygous mice and embryos were initially distinguished by PCR 
amplification of an En2 vector sequence. The embryo genotype was also verified by --
galactosidase expression through X-gal staining. To be able to identify the Smad7
GT/GT
 
from the Smad7
+/GT
 mutants it was necessary to locate the exact insertion site of the 
vector. Primers were designed in 500 bp intervals, corresponding to forward sequences 
of the Smad7 intron 3, and were used in combination with a reverse primer within the 
En2 intron sequence in the gene-trap vector to amplify and hence locate the insertion 
site. Wild type DNA (negative for the En2 intron PCR) was used as a negative control. 
The amplified products were sequenced, which resulted in the identification of the 
insertion site at +11,546 bp relative to the starting site of intron 3. Specific genotyping 
primers were subsequently designed (Figure 3.6.A). 
Efficient knock-down of the Smad7 gene by the gene-trap was verified using 
quantitative real time PCR comparing whole embryo RNA at E9.5 from Smad7
+/+
, 
Smad7
+/GT
 and Smad7
GT/GT 
embryos (Figure 3.6.B). Two different sets of primers were 
used, one spanning exons 3 and 4 and one within exon 4 of Smad7. One copy of the 
gene-trap vector resulted in less than half the dosage of the Smad7 gene, which was 
significantly different to the wild type levels when using Smad7 exons 3-4 primers 
(p<0.05, t-test). Two copies of the gene-trap vector completely inhibited Smad7 mRNA 
transcription, which was significantly different to the wild type levels with either primer 
pair (p<0.01, t-test, Smad7 exons 3-4 primers, p<0.05, t-test, Smad7 exon 4 primers) 
(Table 3.2). All efforts to measure the Smad7 protein levels in the different genotypes 
using the commercially available antibodies did not give a result, which has been a 
problem for other similar studies of Smad7 (Li et al., 2006; Tang et al., 2010). 
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Figure 3. 6. Smad7 gene-trap model characterisation. Genotyping PCR for the 
Smad7 gene-trap allele (A). Quantitative real time PCR for amplicons spanning Smad7 
exon 3-4 or within exon 4 in the different genotypes, in single embryos (B). Schematic 
representation of the gene-trap vector inserted into Smad7 intron 3, including the PCR 
primer site locations and lox sites (C). Ex, exon; Intr, intron; MUT, mutant; PA, 
polyadenylation; SA, splice acceptor; WT, wild type; --geo, --galactosidase/neomycin 
cassette. 
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Primer pair Genotype Average  SD  
 WT
 
1 - 
Smad7 ex4 Smad7
+/GT 
0.442 0.092 
 Smad7
GT/GT 
0.016 0.005 
 WT
 1 - 
Smad7 ex3-4 Smad7
+/GT 0.380 0.040 
 Smad7
GT/GT 0.002 0.001 
Table 3. 2. Smad7 gene-trap validation by quantitative real time PCR. Quantitative 
real time PCR results showing the average levels of Smad7 transcripts in the different 
genotypes normalised to the wild type. ex, exon; WT, wild type.  
Through heterozygous intercrosses it was observed that the gene-trap 
homozygous animals were underrepresented at P10 according to Mendelian rations, but 
the values did not reach statistical significance (p>0.05, Chi-square test) (Table 3.3). 
This partial embryonic lethality could be due to several different causes, including 
cardiovascular insufficiency.  
Genotype n observed n expected 
WT 11 9.5 
Smad7
+/GT 
22 19 
Smad7
GT/GT 
5 9.5 
Total 38  
p>0.05   
Table 3. 3. Frequency of P10 genotypes observed from Smad7
+/GT
 (x) Smad7
+/GT
 
matings. P value from Chi square test between the wild type and Smad7
GT/GT
 groups. 
WT, wild type. 
The gene-trap vector introduces a !-galactosidase gene that is essentially 
expressed instead of Smad7; therefore !-galactosidase expression should recapitulate 
the Smad7 expression pattern in a tissue-specific manner. Characterisation of the 
expression of the trapped vector was performed by X-gal staining and was compared to 
the Smad7 expression pattern as identified by whole mount in situ hybridisation. During 
the embryonic stages E7.5-E12.5 it was confirmed that the reporter expression matched 
the Smad7 mRNA pattern (Figure 3.7).  
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Figure 3. 7. Smad7 expression during embryogenesis. Smad7 expression detected by 
X-gal staining of Smad7
+/GT
 embryos (A-F) or whole mount in situ hybridisation on 
wild type embryos (A’-F’) from E7.5 to E12.5. 
3.4. Smad7 in the mouse embryo 
Smad7 mRNA transcripts were detected by whole mount in situ hybridisation in 
extraembryonic tissues at E7.5. A day later, at E8.5, weak expression was identified in 
the pharyngeal ectoderm and endocardial and myocardial lining of the primitive heart 
tube (Figure 3.8.A-A’’). During this stage strong staining was only observed in the 
distal part of the tail (Figure 3.8.B). At E9.0, the Smad7 expression domains included 
the pharyngeal mesenchyme, endoderm and predominantly ectoderm, while transcripts 
were also identified in the endocardial lining and the myocardial wall of the common 
ventricular chamber of the heart. Half a day later, at E9.5, Smad7 was strongly 
expressed in the pharyngeal ectoderm of the first arch, while weaker expression was 
detected in the pharyngeal endoderm and splanchnic mesenchyme (Figure 3.8.C-C’’). 
Smad7 mRNA transcripts were also detected in the endocardial and myocardial lining 
of the heart (Figure 3.8.C’’). At E10.5 Smad7 expression was maintained in the 
pharyngeal ectoderm throughout the apparatus, while it was detected strong in the 
endothelial lining of the anterior and posterior pairs of cardinal veins and in small 
clusters of cells scattered within the first two pairs of pharyngeal arches (Figure 3.8.D-
D’’). During the same stage expression in the outflow tract and AV cushions as well as 
in the endocardial and myocardial layers of the heart was observed (Figure 3.8.D’’). At 
E11.5, as identified by X-gal staining, Smad7 was expressed in the endothelium of the 
pharyngeal arteries, the outflow tract and AV cushions and the cardiac trabeculae. The 
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Smad7 expression profile in pharyngeal and cardiac tissues in the wild type embryo as 
identified through this thesis is summarised in Table 3.4. 
E8.5 E9.5 E10.5 E11.5* 
P ectoderm P ectoderm P ectoderm  
 P endoderm   
 P mesenchyme   
Heart tube endocardial 
lining 
Heart tube endocardial 
lining 
Heart tube endocardial 
lining 
 
Heart tube myocardial 
lining 
Heart tube myocardial 
lining 
Heart tube myocardial 
lining 
Heart trabeculae 
 OFT OFT cushions OFT septa 
  AV cushions AV septa 
  Cardinal vein endothelium P artery endothelium 
Table 3. 4. Smad7 expression in pharyngeal and cardiac structures. Expression of 
Smad7 in the mouse embryo from E8.5 to E11.5, as identified by X-gal and whole 
mount in situ hybridisation. AV, atrioventricular; OFT, outflow tract; P, pharyngeal. * 
by X-gal only. 
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Figure 3. 8. Smad7 expression in pharyngeal and cardiac structures. (A-D’) 
Consecutive transverse sections of wild type mouse embryos showing Smad7 mRNA 
expression after whole mount in situ hybridisation at E8.5 (A-A’’, B), E9.5 (C-C’’) and 
E10.5 (D-D’). Parasagittal section of a Smad7
+/GT
 embryo at E10.5 after X-gal staining 
(D’’). At E8.5, Smad7 mRNA expression was faint throughout the embryo body (A-
A’’) as compared to the strong tail staining (B). Black arrow, pharyngeal mesenchyme; 
white arrow, endocardial lining; red arrow, myocardial lining; yellow arrowhead, 
pharyngeal ectoderm; white arrowhead, pharyngeal endoderm. CaV, cardinal vein; 
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DAo, dorsal aorta; EC, ectoderm; HG, hindgut; PA, pharyngeal arch; PE, pharyngeal 
endoderm; PM, pharyngeal mesenchyme; R/L, right/left. 
3.5. The Smad7 mutant phenotype 
A recent study by Chen et al., associated Smad7 with cardiovascular development 
(Chen et al., 2009), however, the authors did not assess any 22q11DS-like phenotypic 
characteristics in the Smad7 mutants. Smad7
GT/GT
 embryos were examined as part of 
this project for the presence of thymic, palatal shelf, great vessel and intracardiac 
defects, in the context of the Tbx1 mutant phenotype. 
3.5.1. 22q11DS-like spectrum of defects 
By E15.5 in the mouse embryo the great vessels have assumed the final 
asymmetric left-sided configuration (Hiruma et al., 2002), the ventricular septum (Webb 
et al., 1998) and secondary palate (Gritli-Linde, 2007; Meng et al., 2009) have formed 
completely and the thymic lobes have descended above the heart and lie as a pair 
(Grevellec and Tucker, 2010). Table 3.5 presents the defects observed in E15.5-E18.5 
Smad7 mutants, highlighting a potential contribution of the gene in great vessel and 
thymus development. Twenty-five out of the thirty (83%) Smad7 gene-trap 
homozygous embryos had a thymic defect, including hypoplasia, aplasia, ectopic lobes 
or a single lobe (Figure 3.9.D’, D’’). Nine out of the thirty (30%) Smad7
GT/GT
 embryos 
also presented with a great vessel defect, which was, with one exception, either a 
cervical RSCA (Figure 3.10.F), a cervical aortic arch (Figure 3.10.I) or an RAA (Figure 
3.10.H). The single exception was a Smad7
GT/GT
 embryo with a missing LCC. In both 
categories of phenotypes the gene-trap homozygotes were statistically different to the 
wild types (p<0.01, Fisher’s exact test). There were also a few affected gene-trap 
heterozygotes, which exhibited a cervical RSCA (2%) or thymic hypoplasia (2%). Two 
Smad7
GT/GT
 embryos displayed a cleft palate (Figure 3.9.C) and three presented with a 
membranous VSD (Figure 3.9.G), one of which had an overriding aorta too. These 
values, however, do not reach statistical significance. One Smad7
GT/GT 
embryo exhibited 
subcutaneous oedema (Figure 3.9.E), while another presented with severe craniofacial 
malformation (Figure 3.9.A). No outflow tract defects were observed in any of the 
genotypes. 
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Genotype n 
Thymic 
hypo/aplasia 
Great vessel 
defects 
WT 37 0 0 
Smad7
+/GT 
82 2 (2%) 2 (2%) 
Smad7
GT/GT 
30 25* (83%) 9* (30%) 
Total 149   
* p<0.01    
Table 3. 5. Thymic and great vessel defects observed in the Smad7 gene-trap 
embryos at E15.5-E18.5. P value from Fisher’s exact test between the wild type and 
Smad7
GT/GT
 groups. WT, wild type. 
 
Figure 3. 9. 22q11DS-like spectrum of defects in Smad7 gene-trap embryos. 
Craniofacial malformation (arrow) in Smad7
GT/GT
 (A), compared to control embryo (B). 
Cleft palate in Smad7
GT/GT
 embryo (C). Smad7
GT/GT
 embryo thymic hypoplasia (D’) and 
a single thymic lobe (D’’) as compared to wild type (D). Subcutaneous oedema (arrows) 
in Smad7
GT/GT
 (E) compared to control embryo (F). Membranous VSD in Smad7
GT/GT
 
embryo (G). Asterisks denote missing segments. 
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3.5.2. Great vessel and arch artery phenotype 
Detailed analysis showed that the vast majority (7/9 affected) of the defects 
observed in E15.5-E18.5 Smad7
GT/GT
 embryos reflected a left fourth or a right fourth 
arch defect, aside from the one exception of the left third arch-derived defect and one 
embryo that had a combined left and right fourth arch defect. The results of this analysis 
are summarised in Table 3.6.  
E15.5-E18.5 WT Smad7
+/GT 
Smad7
GT/GT 
Total embryos 37 82 30 
Total normal 37 80 21 
Total abnormal 0 2 (2%) 9 (30%) 
L4th PAA - - 5 
R4th PAA - 2 2 
L4th and R4h PAA - - 1 
Other - - 1* 
*L3rd PAA    
Table 3. 6. Arch artery defects observed in the Smad7 gene-trap embryos at E15.5-
E18.5. L/R, left/right; PAA, pharyngeal arch artery; WT, wild type.  
Smad7 mutant embryos were subsequently examined at an earlier developmental 
stage, to establish whether the great vessel phenotype is due to a formation defect or 
aberrant remodelling of the arch arteries. Pharyngeal artery patterning was initially 
examined at E10.5, a stage by which all caudal arch arteries should be formed (Hiruma 
et al., 2002; Yanagisawa et al., 1998). Very few abnormalities were detected (Figure 
3.10.A-B’), which were scored in all the different genotypes (Table 3.7). The frequency 
of the defects between the wild types and the Smad7
GT/GT
 embryos was not statistically 
significant (p=0.50>0.05, Fisher’s exact test). A total of 105 embryos were collected at 
10.5 days post coitum, but the majority of them had to be excluded because they were 
actually of earlier developmental stages, most likely due to animal housekeeping 
problems. The fact that the wild type embryos had a small but yet noticeable number of 
defects combined with the staging issues, led to the change of the stage at which arch 
artery patterning was examined to E11.5. This is the stage of initiation of arch artery 
remodelling (Hiruma et al., 2002; Yanagisawa et al., 1998). In all genotypes examined 
at E11.5 all the caudal arch arteries had formed normally, while the first and second 
pairs had regressed. One Smad7
GT/GT
 embryo had an aplastic fourth arch artery, while in 
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a second embryo the right sixth arch artery was of equal size to the left counterpart, so it 
seemed that it was not regressing (Figure 3.10.C-D’, Table 3.8). By E11.5, in wild type, 
gene-trap heterozygous or unaffected gene-trap homozygous embryos the right sixth 
arch artery is observed narrower that the left, as described in the literature (Hiruma et 
al., 2002; Yanagisawa et al., 1998). However, at E11.5 too the defects in the Smad7
GT/GT
 
embryos were not statistically different to the wild types (p=0.20>0.05, Fisher’s exact 
test). Even by combining the populations of the two stages based on genotype, the 
differences between the wild type and the gene-trap homozygous mutant embryos still 
fail to reach statistical significance (p=0.20>0.05, Fisher’s exact test) (Table 3.9). This 
indicates that the Smad7 gene-trap mutation does not have a major effect on the 
formation of the pharyngeal arteries.  
E10.5 WT Smad7
+/GT 
Smad7
 GT/GT 
Total embryos 16 43 10 
Total normal 14 41 8 
Total abnormal 2 (12.5%) 2 (4.7%) 2 (20%) 
Persistent 1st &/or 2nd PAA - - - 
Hypo/aplastic 3rd PAA - - - 
Hypo/aplastic 4th PAA 1 (hypo), 1 (apl) 2 (hypo) 2 (hypo) 
Hypo/aplastic 6th PAA - - - 
Aberrant branching - - - 
Table 3. 7. Arch artery defects observed in the Smad7 gene-trap embryos at E10.5. 
apl, aplastic; hypo, hypoplastic; PAA, pharyngeal arch artery; WT, wild type. 
E11.5 WT Smad7
+/GT 
Smad7
 GT/GT 
Total embryos 17 24 14 
Total normal 17 24 12 
Total abnormal 0 0 2 (14.3%) 
Persistent 1st &/or 2nd PAA - - - 
Hypo/aplastic 3rd PAA - - - 
Hypo/aplastic 4th PAA - - 1 (apl) 
Hypo/aplastic 6th PAA - - 1 (not regr) 
Aberrant branching - - - 
Table 3. 8. Arch artery defects observed in the Smad7 gene-trap embryos at E11.5. 
apl, aplastic; not regr, not regressing; PAA, pharyngeal arch artery; WT, wild type.  
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E10.5-E11.5 WT Smad7
+/GT 
Smad7
 GT/GT 
Total embryos 33 67 24 
Total normal 31 65 20 
Total abnormal 2 (6%) 2 (3%) 4 (16.7%) 
Persistent 1st &/or 2nd PAA - - - 
Hypo/aplastic 3rd PAA - - - 
Hypo/aplastic 4th PAA 1 (hypo), 1 (apl) 2 (hypo) 2 (hypo), 1 (apl) 
Hypo/aplastic 6th PAA - - 1 (not regr) 
Aberrant branching - - - 
Table 3. 9. Arch artery defects observed in the Smad7 gene-trap embryos at E10.5-
E11.5. apl, aplastic; hypo, hypoplastic; not regr, not regressing; PAA, pharyngeal arch 
artery; WT, wild type. 
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Figure 3. 10. Arch artery and great vessel defects in Smad7 gene-trap embryos. 
Arch artery phenotype observed at E10.5 (A-B’) or E11.5 (C-D’) and great vessel 
defects observed at E15.5 (E-I). Right and left side of wild type embryos (A, A’ and C, 
C’), and Smad7
GT/GT
 embryos (B, B’ and D, D’). Thin left fourth (B’) and non 
regressing right sixth (D) arch arteries in Smad7
GT/GT
 embryos. Wild type configuration 
(E) and Smad7
GT/GT
 defects (F-I) at E15.5, cervical RSCA (F), cervical RSCA and IAA-
B (G), RAA (H) and cervical aortic arch (I). Asterisks denote missing segments. AoA, 
aortic arch; RCC/LCC, right/left common carotid artery; RSCA/LSCA, right/left 
subclavian artery. 
By comparing the defects observed in Smad7
GT/GT
 mutants between the two 
developmental stages, prior to and after arch artery remodelling (E11.5 and E15.5-
E18.5), statistical difference is not reached (p=0.20>0.05, Fisher’s exact test). A trend, 
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however, exists, shown by the increase of frequency of vessel defects at E15.5-E18.5. 
This supports a role for Smad7 in the remodelling of the great vessels. Furthermore, the 
gene-trap homozygous embryos at E11.5 are not different to the wild type controls 
considering the frequency of pharyngeal arch artery defects (p=0.20>0.05, Fisher’s 
exact test). In contrast, at E15.5-E18.5 statistically significant difference is observed in 
the great vessel defects scored between the Smad7
GT/GT
 and the wild type genotypes 
(p<0.01, Fisher’s exact test) (Figure 3.11). The sample size at E11.5 may be small to 
prove a difference in the Smad7
GT/GT
 populations between the two developmental 
stages. 
 
Figure 3. 11. Arch artery defects observed in Smad7 gene-trap embryos at E11.5 
and E15.5-E18.5. Before the remodelling stage, at E11.5, a small proportion of the 
Smad7
GT/GT
 embryos display arch artery defects. After complete remodelling of the 
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great vessels, at E15.5-E18.5, a greater population of the Smad7
GT/GT
 embryos exhibit 
great vessel defects. Difference/ no difference, according to Fisher’s exact test. L/R, 
left/right; PAA, pharyngeal arch artery; WT, wild type. 
3.5.3. Neural crest migration  
In several animal models arch artery development is affected by aberrant cardiac 
neural crest cell patterning that results in failed differentiation of post migratory crest 
(Liu et al., 2004) or reduced cellularisation of various structures (Kaartinen et al., 2004; 
Richarte et al., 2007). To investigate the underlying mechanisms of the Smad7
GT/GT
 arch 
artery phenotype, neural crest migration was examined at E10.5 embryos, compared to 
stage-matched wild type littermates. This was assessed by whole mount in situ 
hybridisation for Sox10, a known neural crest marker (Kuhlbrodt et al., 1998). No 
defects were seen, although this experiment needs to be repeated for validation (Figure 
3.12). Other neural crest markers can be used, like HNK-1 (Vincent et al., 1983), 
Crabp1 (Maden et al., 1991) or Ap2" (Mitchell et al., 1991). 
 
Figure 3. 12. Neural crest patterning in Smad7 gene-trap embryos at E10.5. As 
detected by whole mount in situ hybridisation for Sox10, there was no difference 
between the neural crest migration pattern of the wild type (A) and the Smad7
GT/GT
 
embryo (B). ov, otic vesicle. 
3.5.4. Shear stress related factors 
Since no significant aberration was seen in the formation of the pharyngeal arch 
arteries in Smad7
GT/GT
 embryos at E10.5/E11.5, it was hypothesised that lack of Smad7 
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affects the remodelling of the great vessels. Shear stress is important in angiogenesis 
(Ando and Yamamoto, 2009; Ando and Yamamoto, 2010). Smad7 was first 
characterised as a shear stress responsive gene in vitro (Topper et al., 1997). In 
beginning to understand whether response to flow might be dysregulated in embryos 
that lack Smad7, a number of shear stress related genes were studied in Smad7
GT/GT
 
embryos. Klf4 and Klf10 were downregulated in our original microarray screen (van 
Bueren et al., 2010) so these, along with Klf2 were evaluated in Smad7
GT/GT
 embryos by 
real time quantitative PCR. At E9.5 neither Klf4 nor Klf10 seemed to be affected. In 
addition, Klf10 only amplified at late cycles (Ct=30 out of 40 in total), resulting in 
differences among the triplicates. Conversely, Klf2 was found upregulated progressively 
in gene-trap heterozygotes and homozygotes compared to the wild type controls (Figure 
3.13). This implies a suppressive effect from Smad7 on Klf2. A day later, at E10.5, the 
reverse phenomenon was seen, where Klf2 was downregulated in the gene-trap 
heterozygous and homozygous embryos (Figure 3.13). Nonetheless, none of the values 
was statistically different to the respective wild type value in either stage.  
 
Figure 3. 13. Klf2 expression levels in Smad7 gene-trap embryos. Graphical 
representation of the relative expression levels of Klf2 by quantitative real time PCR in 
E9.5 and E10.5 Smad7 wild type, heterozygous and homozygous gene-trap embryos. 
WT, wild type. 
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3.5.5. TGF!/BMP pathway 
Smad7 is an inhibitor of both the TGF- and BMP pathways (Moustakas and 
Heldin, 2009; Park, 2005; Ross and Hill, 2008; Yan et al., 2009), so it is important to 
establish whether either or both branches are affected in the Smad7 gene-trap mutants. 
Whole embryo lysate from E9.5 wild type, gene-trap heterozygous and homozygous 
embryos was used for western blotting, to identify alterations in the levels of 
phosphorylated proteins representing activation of either branch of the pathway, namely 
the pSmad2/3 and pSmad1/5/8 complexes. Equal levels of pSmad2/3 were detected in 
all three genotypes (Figure 3.14), while a higher concentration of pSmad1/5/8 was 
observed in Smad7
GT/GT
 versus Smad7
+/GT
 embryos (Figure 3.14); no wild type controls 
were available for this experiment. This suggests that lack of Smad7 at E9.5 impacts on 
the BMP branch of the pathway. Dilution effects from the whole embryo lysates are 
likely to mask tissue-specific alterations in the phosphorylation of these complexes. 
Finer dissection or immunohistochemical methods can be employed to examine this 
further. 
 
Figure 3. 14. pSmad2/3 and pSmad1/5/8 levels in Smad7 gene-trap embryos. 
Western blots on Smad7
+/+
, Smad7
+/GT
 and Smad7
GT/GT
 whole embryo lysates with 
antibodies against pSmad2/3 and pSmad1/5/8 complexes at the 60 kDa band (black 
arrows) and Gapdh at the 37 kDa band (A). Graphical representation of the 
quantification of the pSmad2/3 and pSmad1/5/8 in the respective genotypes normalised 
to Gapdh (B). 
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3.6. Tbx1;Smad7 mutant phenotype 
Tbx1 mutation in heterozygosity or homozygosity produces fourth arch-derived 
great vessel defects or a single truncus arteriosus respectively (Jerome and 
Papaioannou, 2001; Merscher et al., 2001). Since the vast majority of the Smad7
GT/GT
 
abnormalities considered fourth arch-derived defects, the genetic interaction between 
Tbx1 and Smad7 was studied, by producing double heterozygous embryos for these 
genes. A general study of the 22q11DS-affected structures was undertaken, including 
intracardiac septation, thymus and secondary palate development, as well as a more 
detailed analysis of the great vessel anatomy of these animals. 
3.6.1. 22q11DS-like spectrum of defects 
Embryos were collected at E15.5 and the great vessel, cardiac, thymic and palate 
phenotypes were assessed. Table 3.10 presents the defects observed in E15.5 
Tbx1;Smad7 mutants, highlighting a possible interaction between the two genes in 
thymus and great vessel development. Six out of the nineteen (31.5%) double 
heterozygous embryos had a hypoplastic thymus. Thirteen out of the nineteen (68%) 
double heterozygotes presented with a great vessel defect, which was fourth arch-
derived in every case. The penetrance of the defects in the Tbx1;Smad7 double 
heterozygotes was significantly different to all the other genotypes, including the 
additive effect of the Tbx1 and Smad7 mutations (p<0.05 or p<0.01, detailed in Table 
3.10, Fisher’s exact test). The phenotypes ranged among cervical or retro-oesophageal 
RSCA and cervical aortic arch, defects caused by an early unilateral fourth arch artery 
defect, and IAA-B or cervical arch combined with a cervical RSCA, denoting an earlier 
bilateral fourth arch defect (Figure 3.15.H-I). The Tbx1 heterozygous embryos had the 
same spectrum of defects but always presented with unilateral fourth arch-derived 
defects (Figure 3.15.F-G). A detailed analysis of the arch artery defects observed in all 
genotypes at E15.5 is summarised in Table 3.11. An RAA, seen in almost half the 
Smad7 gene-trap homozygous embryos with a defect, was not scored in any genotype 
here. None of the double heterozygotes presented with a VSD while one had a small 
cleft on the secondary palate. No outflow tract defects were observed in any of the 
genotypes. 
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Genotype n 
Thymic 
hypo/aplasia 
Great vessel 
defects 
WT 37 0 0 
Tbx1
+/lacZ 
17 0 5 (29%) 
Smad7
+/GT 
82 0 1 (1%) 
Smad7
+/GT
;Tbx1
+/lacZ 
19 6 (31.5%) 13 (68%) 
Total 155   
Table 3. 10. Thymic and great vessel defects observed in the Tbx1;Smad7 double 
heterozygous embryos at E15.5-E18.5. P values from Fisher’s exact test between the 
following comparisons: Smad7
+/GT
;Tbx1
+/lacZ
 and wild type (!!,**), 
Smad7
+/GT
;Tbx1
+/lacZ
 and Tbx1
+/lacZ
 (!!,*), Smad7
+/GT
;Tbx1
+/lacZ
 and Smad7
+/GT
 (!!,**) 
and Smad7
+/GT
;Tbx1
+/lacZ
 and the additive effect of Tbx1
+/lacZ
 and Smad7
+/GT
 (!!,**) 
groups. ! p<0.05, !! p<0.01 for thymic defects; * p<0.05, ** p<0.01 for great vessel 
defects; WT, wild type. 
E15.5 WT Smad7
+/GT 
Tbx1
+/lacZ 
Smad7
+/GT
;Tbx1
+/lacZ 
Total embryos 37 82 17 19 
Total normal 37 81 12 6 
Total abnormal 0 1 (1%) 5 (29%) 13 (68%) 
L4th PAA - - 2 2 
R4th PAA - 1 3 8 
L4th and R4h PAA - - - 3 
Table 3. 11. Arch artery defects observed in the Tbx1;Smad7 double heterozygous 
embryos at E15.5. L/R, left/right; PAA, pharyngeal arch artery; WT, wild type.  
3.6.2. Great vessel and arch artery phenotype - genetic interaction 
The great vessel phenotype of the double heterozygous embryos for Tbx1 and 
Smad7 was subsequently examined at an earlier developmental stage, to assess if the 
genetic interaction between the two genes affects the formation of the pharyngeal 
arteries, or their remodelling. Embryos were collected at E11.0, and the pharyngeal 
patterning was assessed. At this stage, the double heterozygous embryos had 
comparable penetrance of fourth arch artery defects as the Tbx1 heterozygotes (Figure 
3.15.A-D’), (p=0.58>0.05, Fisher’s exact test), while they shared the same proportion of 
bilateral versus unilateral defects (Table 3.12). This indicates that there is no interaction 
between the two genes at E11.0. Consistent with the literature (Calmont et al., 2009; 
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Lindsay et al., 2001; Vitelli et al., 2002b Vitelli et al., 2006; Zhang and Baldini, 2008), 
Tbx1 heterozygotes produced here partially recovered from the fourth arch defects by 
E15.5. The penetrance of the great vessel defects observed in the Tbx1
+/lacZ
 embryos 
was reduced between E11.0 and E15.5 from 65% to 29%, which is statistically 
significant, with a p value of 0.042 (p<0.05, Fisher’s exact test). Conversely, the double 
heterozygous animals did not recover from the original Tbx1 haploinsufficiency-
induced defect, and presented with the same penetrance of defects at both stages, 67% 
at E11.0 as compared to 68% at E15.5. Hence, at E15.5, the Tbx1 heterozygotes are 
different to the double heterozygous population (p<0.05, Fisher’s exact test) (Figure 
3.16). This suggests that the Tbx1 mutation produces fourth arch artery defects during 
arch artery formation stages, but the concurrent presence of one gene-trap allele for 
Smad7 hinders the recovery of the Tbx1 haploinsufficient phenotype during the 
remodelling stages (Figure 3.17).  
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Figure 3. 15. Arch artery and great vessel defects in Tbx1;Smad7 double 
heterozygous embryos. Arch artery phenotype observed at E11.0 (A-D’) and great 
vessel defects observed at E15.5 (E-I). Right and left side of a wild type embryo (A, 
A’), Smad7
+/GT
;Tbx1
+/lacZ
 embryos (B, B’ and C, C’) and a Tbx1
+/lacZ
 embryo (D, D’). 
Bilaterally absent fourth (B, B’), bilaterally hypoplastic fourth (C, C’) and absent left 
fourth (D’) arch arteries. Wild type configuration (E), Tbx1
+/lacZ
 (F-G) and 
Smad7
+/GT
;Tbx1
+/lacZ
 phenotypes (H-I), absent RSCA (F), IAA-B (G), cervical RSCA 
and IAA-B (H) and cervical RSCA and cervical aortic arch (I). Asterisks denote 
missing segments. AoA, aortic arch; RCC/LCC, right/left common carotid artery; 
RSCA/LSCA, right/left subclavian artery. 
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E11.0 WT Smad7
+/GT 
Tbx1
+/lacZ 
Smad7
+/GT
;Tbx1
+/lacZ 
Total embryos 19 13 17 24 
Total normal 19 12 6 8 
Total abnormal 0 1 (8%) 11 (65%) 16 (67%) 
Persistent 1st &/or 2nd PAA - - - - 
Hypo/aplastic 3rd PAA - - - - 
Hypo/aplastic 4th PAA - 1 (apl) 7 (hypo), 4 (apl) 7 (hypo), 9 (apl) 
Hypo/aplastic 6th PAA - - - - 
Aberrant branching - - - - 
Unilateral/Bilateral  unilateral 5/11 bilateral 7/16 bilateral 
Table 3. 12. Arch artery defects observed in the Tbx1;Smad7 double heterozygous 
embryos at E11.0. apl, aplastic; hypo, hypoplastic; PAA, pharyngeal arch artery; WT, 
wild type. 
 
Figure 3. 16. Arch artery defects observed in Tbx1;Smad7 double heterozygous 
embryos at E11.0 and E15.5. Before the remodelling stage, at E11.0, the 
Smad7
+/GT
;Tbx1
+/lacZ 
embryos have comparable frequency of fourth arch artery defects 
to the Tbx1
+/lacZ
 embryos. After complete remodelling of the great vessels, at E15.5, 
although the Tbx1
+/lacZ
 embryos partially recover from the fourth arch related defects, 
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the Smad7
+/GT
;Tbx1
+/lacZ 
embryos fail to do so and present with the same frequency of 
defects between the earl and the late stage. Difference/ no difference, according to 
Fisher’s exact test. L/R, left/right; PAA, pharyngeal arch artery; WT, wild type. 
 
  
Figure 3. 17. Proportional representation of the fourth arch artery phenotype 
scored at E11.0 and E15.5 in Tbx1 heterozygous and Tbx1;Smad7 double 
heterozygous embryos. 
Smad7 - 164 
Irinna Papangeli 
3.6.3. Shear stress related factors 
Klf2 was observed to be downregulated in Smad7 gene-trap heterozygous and 
homozygous embryos at E10.5 (Figure 3.13). Although not consistently, it appeared to 
be downregulated in Tbx1 heterozygotes, and further decreased in Tbx1;Smad7 double 
heterozygous embryos (Figure 3.18). This may suggest a common pathway whereby 
Tbx1 is acting on Smad7, which subsequently reduces Klf2 levels. However, neither of 
the values was statistically different to the wild type value. 
  
Figure 3. 18. Klf2 expression levels in Tbx1 heterozygous and Tbx1;Smad7 double 
heterozygous embryos. Graphical representation of the relative expression levels of 
Klf2 by quantitative real time PCR in E10.5 wild type, Tbx1 heterozygous and 
Tbx1;Smad7 double heterozygous embryos. WT, wild type. 
3.7. Smad7 gene-trap time-dependent excision 
The Smad7 gene-trap model used for this study is designed with two lox sites to 
implement excision of the splice acceptor sequence and thus Cre-dependent restoration 
of normal gene transcription (Figure 3.6.C). The potential to restore Smad7 function to 
normal, combined with a time control element, is critical for the study of Smad7 in the 
arch artery remodelling process. A tamoxifen inducible model that ubiquitously 
expresses Cre recombinase under the Caggs promoter was used for this purpose. The 
tamoxifen administration time-point, method and concentration were standarised on the 
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basis of gene-trap recombination efficiency. This was assessed by quantitative real time 
PCR for Smad7 mRNA transcripts, compared to the wild type levels, in whole embryo 
lysates. The previously published optimal tamoxifen administration protocol for this 
line, for maximum recombination efficiency 24 hrs post administration, is IP injection 
of 3mg of tamoxifen per 40g body weight, equal to 75mg/ kg body weight (Hayashi and 
McMahon, 2002; Xu et al., 2005). Higher dosages are toxic and lead to embryonic 
lethality, while almost complete recombination is achieved 48 hrs post administration 
(Hayashi and McMahon, 2002).  
The aim of this experiment was to restore Smad7 mRNA transcripts in the 
Smad7
GT/GT
 embryos at E10.5 or E10.75, a time point by which all the pharyngeal arch 
arteries have formed and the remodelling of the vessels commences (Hiruma et al., 
2002; Yanagisawa et al., 1998). The embryos used were produced by intercrossing 
Smad7
+/GT
 to Smad7
+/GT
;CaggsCre animals and by treating the pregnant mothers with 
tamoxifen. Due to lack of animal availability, a second cross was used, Tbx1
+/lacZ
 to 
Smad7
+/GT
;CaggsCre. In this setting restoration of Smad7 was examined at the gene-
trap heterozygous level. A total of four different dosages or drug administration time 
points were tested using the free salt tamoxifen and one using the activated derivative 
(4OH), as summarised in Table 3.13. When administration was via the oral route, a final 
concentration of 4.8mg per 40g body weight, equal to 120mg/ kg body weight was 
given (Park et al., 2008).  
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TAMOXIFEN 
ADMINISTRATION 
CROSS 
method doses stage  
TAMOXIFEN 
CONCENTRATION 
(DURATION) 
RECOMBINATION 
AT E10.5  
or E10.75* 
IP 1 E9.5 75mg/kg bw (24hrs) 26% 
IP 
IP 1/2 
2 E9.0 
 
E10.0 
75mg/kg bw 
(24hrs) 
37.5mg/kg bw (6hrs) 
17% 
 
 
Smad7
+/GT
xSmad7
+/GT 
;CaggsCre 
OG 1 E10.0  120mg/kg bw 
(10hrs) 
0.5%* 
IP 1** E9.5 75mg/kg bw (24hrs) 12% 
 and X-gal staining 
IP 1 E9.0 75mg/kg bw (30hrs) 15% 
and X-gal staining 
 
 
Tbx1
+/lacZ
xSmad7
+/GT 
;CaggsCre 
    ** 4OH tamoxifen 
Table 3. 13. Tamoxifen administration and CaggsCre-dependent recombination 
efficiency of the Smad7 gene-trap vector. The different genetic crosses, tamoxifen 
administration protocols followed and the recombination efficiency of the Smad7 gene-
trap vector as assessed by quantitative real time PCR for the Smad7 mRNA levels in 
Smad7
GT/GT
;CaggsCre or Smad7
+/GT
;Tbx1
+/lacZ
;CaggsCre embryos are summarised here. 
IP, intraperitoneal; OG, oral gavage. 
Smad7 mRNA expression at E10.5, as detected by quantitative real time PCR in 
whole embryos, was around 40% in Smad7
+/GT
 embryos, between 40%-60% in 
Smad7
+/GT
;Tbx1
+/lacZ
 embryos and around 100% in Tbx1
+/lacZ
 embryos, relative to the 
wild type levels (Figure 3.19). The Smad7
+/GT
 embryos have not presented with 
significant phenotypic defects to date. Therefore, for safe interpretation of subsequent 
results, restored gene expression in Smad7
GT/GT
 mutants would be considered effective 
if it reached at least 40% of the wild type Smad7 mRNA levels. 
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Figure 3. 19. Smad7 expression levels in Tbx1 or Smad7 heterozygous and 
Tbx1;Smad7 double heterozygous embryos. Graphical representation of the relative 
expression levels of Smad7 by quantitative real time PCR in E10.5 wild type, Tbx1 
heterozygous, Smad7 heterozygous and Tbx1;Smad7 double heterozygous embryos. 
WT, wild type. 
As depicted on the graphs below, the best recombination efficiency at E10.5 or 
E10.75, achieved within 24 hours, was an increase to 26% of the wild type dosage of 
Smad7 mRNA in a Smad7
GT/GT
 embryo carrying the CaggsCre allele. It was induced 
after a single IP injection of free salt tamoxifen at E9.5. The levels of Smad7 expression 
in the Smad7
GT/GT
;CaggsCre embryo were statistically different to the wild type value 
(p=0.05, t-test). Prolonging the duration of the drug activity may induce greater 
recombination of the gene-trap vector and eliminate this difference between the 
Smad7
GT/GT
;CaggsCre and the wild type embryos. Free salt tamoxifen administered in a 
series of two IP injections, one full dosage at E9.0 and half the dosage at E10.0, induced 
at maximum expression of 17% of the wild type levels in E10.5 Smad7
GT/GT
;CaggsCre 
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embryos. The levels of Smad7 expression between the Smad7
GT/GT
;CaggsCre embryos 
and the wild type embryo were statistically different (p<0.01, t-test). Administration of 
free salt tamoxifen by OG at E10.0 induced no recombination (0.5% of the wild type 
levels) by E10.75. Smad7 mRNA expression in the Smad7
GT/GT
;CaggsCre embryo was 
statistically different to the wild type (p<0.01, t-test) (Figure 3.20).  
 
Figure 3. 20. Smad7 gene-trap vector recombination efficiency in 
Smad7
GT/GT
;CaggsCre embryos under different protocols of tamoxifen 
administration. Graphical representation of the relative expression levels of Smad7 by 
quantitative real time PCR in E10.5 wild type and Smad7
GT/GT
;CaggsCre embryos after 
tamoxifen induction with a single or double IP dosage, or OG (*p=0.05, **p<0.01). IP, 
intraperitoneal; OG, oral gavage; WT, wild type. 
The comparison in the second genetic setting was between the double 
heterozygote levels and the double heterozygote carrying the Cre allele, within 
littermates. IP injection of the activated derivative (4OH) tamoxifen at E9.5 resulted in 
an absolute difference of 12% of the Smad7 mRNA levels by E10.5 between a 
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Smad7
+/GT
;Tbx1
+/lacZ
;CaggsCre embryo and a Smad7
+/GT
;Tbx1
+/lacZ
 mutant. Relative to 
the wild type levels, the Smad7
+/GT
;Tbx1
+/lacZ
 embryo had 23% Smad7 transcripts and 
the Smad7
+/GT
;Tbx1
+/lacZ
;CaggsCre embryo had 35%. IP injection of free salt tamoxifen 
at E9.0 induced an absolute difference of 15% of the Smad7 mRNA levels by E10.5 in 
Smad7
+/GT
;Tbx1
+/lacZ
;CaggsCre embryos, compared to a Smad7
+/GT
;Tbx1
+/lacZ
 mutant. 
In this experiment the Smad7
+/GT
;Tbx1
+/lacZ
 embryo had 39% of the wild type Smad7 
mRNA and the Smad7
+/GT
;Tbx1
+/lacZ
;CaggsCre embryos had 54%. None of these values 
were statistically different to the wild type levels, so potentially both protocols can be 
used in future experiments (Figure 3.21). 
 
 
Figure 3. 21. Smad7 gene-trap vector recombination efficiency in 
Smad7
+/GT
;Tbx1
+/lacZ
;CaggsCre embryos under different protocols of tamoxifen 
administration. Graphical representation of the relative expression levels of Smad7 by 
quantitative real time PCR in E10.5 wild type, Tbx1
+/lacZ
;Smad7
+/GT
 and 
Smad7
+/GT
;Tbx1
+/lacZ
;CaggsCre embryos after induction with free salt tamoxifen or the 
activated derivative tamoxifen (4OH). WT, wild type. 
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To further validate the system’s efficiency, recombination was assessed through 
X-gal staining using a ROSA26 reporter line (Soriano, 1999), crossed to 
Smad7
+/GT
;CaggsCre animals. Two different drug administration protocols were used, 
IP injection of 4OH tamoxifen at E9.5 and IP injection of free salt tamoxifen at E9.0. 
Both showed minimal recombination, while the !-galactosidase gene driven from the 
Smad7 gene-trap was still highly expressed. Expression of the Cre gene was also tested 
by quantitative real time PCR and was found in abundance in all the expected 
genotypes. As shown in Figure 3.22, the levels of activated Cre are not sufficient for the 
level of recombination required. Changing the tamoxifen administration protocol to 
achieve prolonged activity of the drug, or a slightly higher dosage may produce better 
results. 
 
Figure 3. 22. Reporter expression indicating recombination efficiency in 
Smad
GT/GT
;CaggsCre embryos. X-gal staining for the --galactosidase reporter in E10.5 
ROSA26 embryos without the CaggsCre or the Smad7 gene-trap allele (WT, A), with a 
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Smad7 gene-trap allele (Smad7
+/GT
, B), with the CaggsCre allele (CaggsCre, C) and 
with both the CaggsCre and a Smad7 gene-trap alleles (Smad7
+/GT
;CaggsCre, D), after 
free salt tamoxifen induction for 30 hrs. White/ black arrows denote expression off the 
Smad7 gene-trap vector, indicating inefficient recombination of the vector in (D). WT, 
wild type. 
Genomic amplification and subsequent quantification of the wild type, gene-trap 
and recombined gene-trap locus showed similar levels of recombination to the 
quantitative real time PCR data (Figure 3.23). These results further support the notion 
that the current methods, including the type of tamoxifen, time of administration and 
administration method are not adequate. In conclusion, the lack of robust tamoxifen-
induced recombination achieved to date precluded the conditional “rescue” experiments 
originally envisaged. 
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Figure 3. 23. Genomic amplification of the gene-trap and recombined gene-trap 
vector in different genotypes. Proportional representation of the genomic 
amplification of Smad7 gene-trap (black) or recombined gene-trap alleles (grey) in 
E10.5 wild type, Tbx1;Smad7 double heterozygous and Smad7 gene-trap homozygous 
or Tbx1;Smad7 double heterozygous embryos carrying the Cre allele, for the different 
tamoxifen administration protocols. There is no amplification of either of the alleles in 
wild type or wild type embryos carrying the Cre allele. Amplification of only the gene-
trap allele is observed in Smad7
+/GT
;Tbx1
+/lacZ
 embryos, while amplification of both the 
gene-trap and the recombined alleles is observed in the Smad7
GT/GT
;CaggCre and 
Smad7
+/GT
;Tbx1
+/lacZ
;CaggsCre embryos. Note that there is no recombination when 
tamoxifen is administered by OG, confirming the quantitative real time PCR data and 
none detected by this method in the embryos treated with the activated derivative 
tamoxifen (4OH). IP, intraperitoneal; OG, oral gavage; WT, wild type. 
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4. Discussion - Future directions 
4.1. Smad7 as a Tbx1 target 
Smad7 was selected for this project as a putative Tbx1 downstream effector for a 
multitude of reasons. These included its expression profile during embryogenesis in 
heart and pharyngeal structures (Liu et al., 2007; Luukko et al., 2001; Zwijsen et al., 
2000) and its differential regulation in Tbx1-expressing heterozygous and null cells (van 
Bueren et al., 2010). Interestingly, Smad7 does not appear in two other array screens, 
one by us and one by an independent group that analysed the pharyngeal region of E9.5 
(Ivins et al., 2005) or the secondary heart field of E8.75, E9.75 or E10.75 (Liao et al., 
2008) mouse embryos respectively. This may reflect dilution effects, since both these 
arrays used entire embryonic segments that include non Tbx1-expressing cell 
populations. Also, as it was demonstrated in this thesis, a single null allele for Tbx1 or 
even 34% of its wild type dosage are not sufficient to affect Smad7 expression, when 
examined by whole mount in situ hybridisation. Stage, tissue and dosage-specific 
effects are probably characterising the Tbx1-Smad7 relationship. 
4.2. Direct or indirect target? 
Smad7 mRNA was reduced in pharyngeal and cardiac tissues of E9.5 Tbx1 null 
embryos, although not in heterozygotes or hypomorphs that express 34% of Tbx1. 
Limitations of the technique used here to identify changes in gene expression should not 
be disregarded. A more refined, quantitative approach can be followed, for example 
FACS sorting of Tbx1
Neo2/Neo2
 cells, to examine Smad7 levels on a cell autonomous 
setting and establish the Tbx1 dosage requirements for Smad7 expression. Nevertheless, 
these results indicate that Tbx1 is necessary for the expression of Smad7 in some 
embryonic domains, potentially in a dosage-dependent fashion.  
It was recently demonstrated that a 4.3 kb Smad7 promoter can recapitulate gene-
specific expression during mouse development (Liu et al., 2007). No putative Tbx1 
binding sites (Sinha, 2000) were found within this region and in vitro experiments 
within 2 kb upstream of the 5‘UTR of Smad7 did not conclusively show Tbx1 
dependent activation of these subregions of the Smad7 promoter. Putative Tbx1 binding 
elements have been identified in regulatory regions of the VEGFR3 (Chen et al., 2010), 
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Pitx2c (Nowotschin et al., 2006), Fgf8 (Hu et al., 2004) and Fgf10 (Xu et al., 2004) 
genes. Tbx1 activates reporter constructs harboring these elements. However, only 
VEGFR3 has been validated by ChIP (Chen et al., 2010) and Pitxc2 has been verified by 
an electromobility sift assay (EMSA) (Nowotschin et al., 2006). Tbx1 additionally 
required Nkx2.5 to activate the Pitx2c enhancer reporter construct (Nowotschin et al., 
2006). Ablating putative T-box binding elements from the Mef2c (Antonio Baldini, 
pers. comm.) or Pax9 (Rumiko Matsuoka, pers. comm.) promoters did not affect Tbx1 
activation at these promoters, indicating that elements other than canonical TBEs must 
be important for Tbx1 driven transcription. 
A recent study used ChIP with massively parallel sequencing (ChIP-Seq) to 
identify active tissue-specific enhancers that are bound by the ubiquitously expressed 
coactivator protein p300 (Blow et al., 2010). This assay was performed in E11.5 mouse 
heart tissue and yielded 3,597 regions that did not overlap with known promoters or 
with p300 peaks identified in E11.5 forelimb, midbrain and limb tissues (Blow et al., 
2010). An enhancer was detected 136 kb from Smad7, and in no closer proximity to any 
other known cardiac gene (Blow et al., 2010). This enhancer appeared to have activity 
in the outflow tract, as shown in vivo by transgene reporter expression (Blow et al., 
2010). The reporter expression resembles E11.5 Smad7 expression in the cardiac 
outflow tract but does not recapitulate all the Smad7 expression domains. The distance 
the site was identified at and the restricted expression pattern of the reporter denote that 
enhancer elements are not necessarily located close to the transcription initiation site of 
a gene and that different enhancers may regulate tissue-specific expression of a gene. 
Given the above, the presence or absence of putative Tbx1 binding sites in the 
immediate regulatory region of a gene does not conclusively indicate whether the gene 
of interest is directly regulated by Tbx1 or not. Smad7 may therefore be Tbx1 controlled 
through elements not yet identified or it may be an indirect Tbx1 target. The single 
putative Tbx1 binding site located approximately 13 kb upstream the 5’ UTR of Smad7 
could be examined in the future for in vitro Tbx1 binding. 
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4.3. Smad7 is expressed in heart and pharyngeal structures during 
development 
Smad7 expression was detected in multiple different cell types, structures and 
organs from E8.5 to E11.5. Whole mount in situ hybridisation and X-gal staining were 
used to confirm that the expression pattern of the --galactosidase reporter matched that 
of the Smad7 mRNA. Consistent with previous reports (Luukko et al., 2001; Zwijsen et 
al., 2000), Smad7 expression was detected by whole mount in situ hybridisation in 
extraembryonic tissues at E7.5, in the heart endocardium and myocardium from as early 
as E8.5, and in the outflow tract and AV cushions as well as in veins and arteries from 
E10.5-E11.5. Conversely to Luukko et al., however, expression in the cardinal veins 
identified here preceded DAo expression (Luukko et al., 2001). Zwijsen et al., have 
demonstrated strong Smad7 expression from as early as E8.0 in the lateral plate and 
cardiac mesoderm and weaker in the endoderm, neuroectoderm and paraxial and 
cephalic mesoderm (Zwijsen et al., 2000). These results were not reproduced here, 
although the same probe (Zwijsen et al., 2000) was used for whole mount in situ 
hybridisation. At E8.5, strong expression was only identified in the distal part of the tail 
and yolk sac tissues, while very faint expression was seen in the rest of the embryo 
proper, mainly in the myocardial and endocardial lining of the heart. This inconsistency 
with the previously published expression pattern may be attributed to the different 
methods used, chromophore versus radioactive labelling. Additionally, the myocardial 
and endocardial Smad7 staining detected here in all the embryonic stages examined is 
contradictory to the endocardial-specific reporter expression identified with the use of a 
Smad7Cre line (Snider et al., 2009). The particular line was established with the 4.3 kb 
Smad7 promoter (Liu et al., 2007). Nonetheless, the promoter itself has only been tested 
from E11.5 onwards (Liu et al., 2007); exclusion of earlier expression domains through 
different promoter elements cannot be ruled out. 
Tbx1 is expressed in the pharyngeal epithelia and mesoderm from as early as E7.5 
(Chapman et al., 1996; Huynh et al., 2007; Lindsay et al., 2001; Vitelli et al., 2002a) 
and hence partially overlaps with Smad7 between E8.5-E10.5. This supports the 
potential for an interaction between the two genes, while the Smad7 expression pattern 
in cardiac structures throughout embryogenesis suggests independent roles for Smad7 
during cardiovascular development. 
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4.4. Smad7 mutation produces aspects of the 22q11DS-like phenotype 
The gene-trap effectively introduces a null Smad7 mutation, at least at the mRNA 
level. Smad7
GT/GT
 embryos exhibit a cardiovascular phenotype that includes great vessel 
and intracardiac septation defects. This is in agreement with systemic Smad7 deletion 
under the Tie2Cre promoter in female carriers, or the EIIaCre promoter (Chen et al., 
2009). However, no valve defects were seen in any of the thirty gene-trap homozygotes 
examined in this thesis, while only three had a VSD, in contrast with the previous study 
(Chen et al., 2009). Genetic background modifiers or factors related to timing and/or 
efficiency of the recombination of the Smad7 locus in the work by Chen et al., may 
have resulted in these different phenotypes (Chen et al., 2009). The construct used to 
produce the conditional mouse model contains two loxP sites flanking exon 4 and the 
stop codon of the gene (Chen et al., 2009). Exon 4 harbors the entire MH2 domain 
located on the C-terminus of the protein (Chen et al., 2009), however, both the N-
terminus and MH2 domains participate in the Smad7-specific inhibition of 
TGF-/activin signalling (Yan et al., 2009). In that respect the truncated protein may still 
have limited functionality, causing inconsistencies between the phenotypes of the 
different mutants. 
Despite Smad7 expression in heart and outflow tract septation regions during 
embryogenesis, septation defects were not seen at all in the outflow tract, and with very 
reduced penetrance in the heart of the gene-trap homozygous mutants. This suggests 
that Smad7 is dispensable in these areas, and may be compensated for by Smad6, the 
other inhibitor of the TGF-/BMP pathways. The majority of the animal models with a 
mutation in a BMP factor display valve abnormalities, outflow tract and heart septation 
defects (Chen et al., 2004; Gaussin et al., 2005; Gaussin et al., 2002; Jiao et al., 2003; 
Kaartinen et al., 2004; Kim et al., 2001; Liu et al., 2004; Ma et al., 2005; Solloway and 
Robertson, 1999; Stottmann et al., 2004). TGF! gene mutations are additionally 
associated with great vessel malformations (Bartram et al., 2001; Choudhary et al., 
2006; Todorovic et al., 2007; Wang et al., 2006; Wurdak et al., 2005). Both Smad7 and 
Smad6 act on the BMP branch of the pathway (Moustakas and Heldin, 2009; Park, 
2005; Ross and Hill, 2008; Yan et al., 2009), and are strongly co-expressed in the 
cardiovasculature and mainly in the AV cushions, DAo and major arteries (Luukko et 
al., 2001). Therefore, if cardiac and outflow tract septation processes are primarily BMP 
Smad7 - 177 
Irinna Papangeli 
regulated, Smad6 may be compensating for the lack of Smad7. Additionally, no 
trabeculation abnormalities were observed in the Smad7 gene-trap homozygous mutants 
in spite of the myocardial and endocardial expression of the gene and in contrary with 
the previous systemic deletion of Smad7 (Chen et al., 2009). In this study the authors 
showed that Smad2/3 phosphorylation was increased in the ventricular endocardium of 
the Smad7 mutant mice, suggesting that the TGF-/activin pathway was affected in this 
process (Chen et al., 2009). Smad6 would not have a compensatory inhibiting role on 
this branch of the pathway, therefore genetic background modifiers or residual 
functionality of the proteins of either of the models may account for the differences in 
this phenotype. 
In the context of 22q11DS, Smad7
GT/GT
 embryos also display thymic and isolated 
palate malformations, partially phenocopying the Tbx1 mutation. These phenotypes 
have not been previously reported for Smad7. The thymic defects were identified in the 
majority of the gene-trap homozygous embryos, indicating that Smad7 is required for 
some or several of the steps of thymus formation and morphogenesis. At E9.5, when the 
thymic primordium evaginates into the underlying mesenchyme (Boehm, 2008; Gill et 
al., 2003; Hollander et al., 2006; Manley, 2000), the gene is expressed in the caudal 
pharyngeal endoderm, although no Smad7 expression was detected in this tissue from 
E10.5 onwards. Smad7 may participate in the early events of thymus development. 
Chicken-quail chimeras as well as in vitro studies have shown that the endoderm can 
induce non-pharyngeal mesenchyme to play a role in thymus organogenesis (Manley, 
2000). Smad7 may be modulating signalling originating from the gut endoderm at E9.5. 
Evidence shows that ectodermal signalling through Tbx1 participates in thymic 
development (Randall et al., 2009); therefore, the ectodermal expression of Smad7 
between E9.5-E10.5 may similarly be involved in this developmental process. Previous 
studies have shown that overexpression of SMAD7 in the thymic epithelia results in 
severe hypoplasia of the organ (He et al., 2002). This, however, does not indicate that 
Smad7 is important in thymic morphogenesis since this model effectively induces 
global inhibition of both TGF-/BMP pathways. Expression analysis of thymic markers 
on Smad7
GT/GT 
embryos could provide insight in the role of the gene in thymus 
development. The Smad7 requirements in thymic development were not investigated 
further in this thesis, due to time restraints. 
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4.4.1. The  Smad7 mutant great vessel and arch artery phenotype in detail 
The pharyngeal arch artery formation process completes by E10.5 in the mouse 
embryo (Hiruma et al., 2002; Yanagisawa et al., 1998), while by E15.5 the arch arteries 
have remodelled into the mature left-sided aortic arch configuration (Hiruma et al., 
2002). Smad7
GT/GT
 embryos have a very low penetrance of arch artery defects at E10.5-
E11.5, but a higher frequency of such defects at E15.5-E18.5. This great vessel 
phenotype is therefore more likely due to abnormalities during the remodelling rather 
than the formation of the pharyngeal arch arteries. In the current sample size there is no 
statistically significant difference between the arch artery defects scored at E10.5-E11.5 
versus E15.5-E18.5 in Smad7
GT/GT
 embryos. However, a trend exists, supporting a later 
contribution of Smad7 to the phenotype. The early stage (E10.5-E11.5) Smad7
GT/GT
 
embryos exhibit primarily hypoplastic fourth arches, or in a single case, non regressing 
right sixth artery. By the late stages (E15.5-E18.5) the defects observed in Smad7
GT/GT
 
mutants are mainly configurations that would have resulted from originally aplastic 
vascular segments and present with higher penetrance. Consequently, the type of the 
early stage defects does not sufficiently explain the late stage phenotype. 
4.4.2. Smad7 mutants display aberrant expression of Klf2, a shear stress related 
factor 
Vessel walls respond to mechanical forces like shear stress or pressure with 
functional and phenotypic changes, including calcium signalling, NO production and 
gene expression regulation (Ando and Yamamoto, 2009; Ando and Yamamoto, 2010). 
Endothelial cells are specifically sensitive to shear stress and can discriminate between 
that and stretch forces (Andersson et al., 2005). Smad7 was originally discovered as a 
shear stress responsive gene, induced by physiologic fluid mechanical stimulus in 
HUVECs (Topper et al., 1997). Additionally, Smad7 has an endothelial-specific 
expression pattern in human (Topper et al., 1997) and mouse (Zwijsen et al., 2000) 
tissues. Among others, Klf2 is a shear stress responsive gene (Poelmann et al., 2008). 
Interestingly, it was found to be upregulated in E9.5 Smad7 gene-trap homozygous and 
heterozygous embryos compared to wild type controls. This may be related to 
compromised vascular integrity and further to that, with the pharyngeal arch artery 
remodelling program, since blood flow influences vascular remodelling (Rudic et al., 
1998; Wang et al., 2009; Yashiro et al., 2007). A day later, at E10.5, Klf2 appeared 
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moderately downregulated in the Smad7 gene-trap homozygotes and heterozygotes. 
This transient differential Klf2 expression corresponds with the transient Smad7 
expression pattern in the pharyngeal tissues. At E8.5 and E10.5 Smad7 is detected 
weakly in the ectodermal covering alone, while in the intermediate stage, at E9.5, it is 
also found in the pharyngeal endoderm and mesenchyme. Maybe Klf2 is regulated by 
Smad7 at E9.5 and returns to normal expression levels in consequent stages. 
Nonetheless, it should be taken into account that these expression data were acquired 
from whole embryo lysates, and dilution effects are likely to mask tissue-specific 
changes, for example transcriptional alterations in the endothelial cell lineage. The 
examination of shear stress response genes on whole embryos was a prelude to 
investigating whether deficiency of Tbx1 and/or Smad7 impact upon this important 
aspect of remodelling, which will be assessed in more refined approaches in future 
work. 
4.4.3. Smad7 mutants appear to have unaffected neural crest patterning 
Several mouse models have been described to date displaying arch artery 
formation or remodelling defects. These defects are in many cases caused by defective 
neural crest cell patterning that results in failed differentiation of post migratory crest 
(Liu et al., 2004) or reduced cellularisation of various structures (Kaartinen et al., 2004; 
Richarte et al., 2007). The neural crest migration pattern appeared unaffected in the 
Smad7
GT/GT
 embryos by whole mount in situ hybridisation, although this experiment 
needs to be repeated, potentially with other crest markers too. The neural crest-derived 
VSM composition of the arch arteries has not yet been assessed in the mutant setting. 
All in all, solid conclusions regarding the role of the neural crest in the arch artery 
defects observed in Smad7
GT/GT
 embryos cannot be drawn as yet. 
Smad7 overexpression in the neural crest caused a spectrum of abnormalities, due 
to cell death in the pharyngeal arch arteries, craniofacial structures, and outflow tract 
cushions (Tang et al., 2010). Neural crest migration into the pharyngeal arches and 
subsequent differentiation in VSM cells was not affected (Tang et al., 2010). 
Nevertheless, this overexpression model does not provide insight into the roles of 
Smad7 in the neural crest cell lineage as it induces general knock-down of the 
TGF-/BMP pathways, so the resulting severe phenotype is hardly unexpected. 
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4.5. TGF!/BMP pathway inhibition by Smad7 
TGF- signalling is important for endocardial and outflow tract cushion formation 
through mechanisms well characterised for many of the pathway components following 
knock-out or conditional models and expression studies (Person et al., 2005). As 
discussed previously, the majority of the models that ablate expression of TGF! 
superfamily genes induce valve and/or septation defects and almost all of these genes 
are expressed in the embryonic heart (Person et al., 2005). BMP gene mutations 
predominantly produce septation anomalies (Chen et al., 2004; Gaussin et al., 2005; 
Gaussin et al., 2002; Jiao et al., 2003; Kaartinen et al., 2004; Kim et al., 2001; Liu et al., 
2004; Ma et al., 2005; Solloway and Robertson, 1999; Stottmann et al., 2004), however, 
a number of TGF! gene mutations induce great vessel malformations too (Bartram et 
al., 2001; Choudhary et al., 2006; Todorovic et al., 2007; Wang et al., 2006; Wurdak et 
al., 2005). Although Smad7 is an inhibitor of both pathways (Moustakas and Heldin, 
2009; Park, 2005; Ross and Hill, 2008; Yan et al., 2009), the gene-trap mutation used in 
this thesis resulted primarily in arch artery abnormalities in the homozygotes, and only 
very few intracardiac defects. So, Smad7 may be acting via a TGF-/activin route, 
towards the remodelling of the great vessels. Smad6 preferentially blocks the BMP 
branch (Moustakas and Heldin, 2009; Park, 2005; Ross and Hill, 2008; Yan et al., 
2009), therefore, there is more reason to expect compensatory effects in the BMP rather 
than the TGF- pathway, if there are any.  
To date it has not been possible to conclusively establish which pathway is 
affected in the Smad7 gene-trap mutants, by examining the levels of pSmad2/3 and 
pSmad1/5/8 in whole embryo lysates. An indication exists that in whole embryos, lack 
of Smad7 affects the BMP branch of the pathway, shown by a higher concentration of 
the pSmad1/5/8 complex in Smad7 gene-trap homozygous as compared to heterozygous 
embryos. Potentially, assessment of these phosphorylated complexes on a fine 
dissection of the pharyngeal apparatus and heart of Smad7
GT/GT
 embryos will address 
this more effectively. Moreover, Smad7 is probably involved in both pathways towards 
the development of different embryonic structures, so tissue-specific examination of the 
pSmad2/3 and pSmad1/5/8 readouts will further define the discrete pathway 
requirements for Smad7 in pharyngeal arch artery, cardiac, thymus and palatal shelf 
development. Immunohistochemical methods can be employed to that end. 
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TGF-/BMP signalling is involved in the EMT process during palatal shelf fusion 
(Nawshad and Hay, 2003). Cleft palate was scored in only two Smad7
GT/GT
 embryos, in 
combination with thymic, great vessel defects and in one of the two embryos with a 
VSD too. Consequently, Smad7 probably has a minor role in palate morphogenesis, as 
demonstrated by this low penetrant phenotype. This may be attributed to gene dosage 
effects and/or compensatory roles from other genes of the TGF-/BMP pathways. 
4.6. Double heterozygosity for Tbx1 and Smad7 induces thymic and 
cardiovascular anomalies 
At E15.5 Tbx1;Smad7 double heterozygotes present with a higher penetrance of 
some 22q11DS-related phenotypes, namely thymic hypoplasia and fourth arch-derived 
great vessel defects, than the single gene heterozygotes or the wild type littermates. The 
defects scored in the double heterozygotes were statistically different to all other 
genotypes including the additive phenotypic outcome of each single mutation, therefore, 
a synergistic interaction is more likely than an additive effect of the two genes. For the 
purposes of this thesis the thymic phenotype was not studied any further and the focus 
was turned to the cardiac phenotype.  
4.6.1. The great vessel and arch artery phenotype in detail 
In order to investigate the relationship between Tbx1 and Smad7 more deeply, the 
great vessel phenotype of the Smad7
+/GT
;Tbx1
+/lacZ
 embryos was examined in detail. 
During early stages, at E11.0, these embryos present with a frequency of fourth arch 
artery abnormalities comparable to the Tbx1 heterozygotes. There is no statistical 
difference between the Tbx1 and Tbx1;Smad7 heterozygotes at this stage and this 
reflects the sole contribution of Tbx1 to this phenotype. This is further supported by the 
fact that Smad7
+/GT
 embryos have normal arch artery formation. After arch artery 
remodelling has completed, at E15.5, the Tbx1 heterozygotes present with a reduced 
penetrance of fourth arch defects compared to the earlier stage, as reported in several 
previous studies (Calmont et al., 2009; Lindsay et al., 2001; Vitelli et al., 2002b Vitelli 
et al., 2006; Zhang and Baldini, 2008). The double heterozygotes however do not show 
similarly reduced penetrance in great vessel defects. This is indicated by the statistically 
significant difference in the frequency of abnormalities between the Tbx1
+/lacZ
 and 
Smad7
+/GT
;Tbx1
+/lacZ
 embryos of this stage. The great vessel defects observed in the 
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E15.5 double heterozygotes are exclusively fourth arch-derived, with similar frequency 
as scored at E11.0, prior to the remodelling process. No statistical difference exists in 
the double heterozygous populations between the two different time points. This 
suggests that recovery does not occur in the double heterozygotes and the defects 
initially caused by Tbx1 haploinsufficiency result in an abnormal phenotype due to 
diminished Smad7, which compromises the rescue.  
Similarly to what was observed in the Smad7
GT/GT
 embryos at E10.5, Klf2, a shear 
stress responsive gene appeared reduced at E10.5 in the Smad7
+/GT
;Tbx1
+/lacZ
 mutants, 
compared to both the wild type and Tbx1 heterozygous levels. Although this is 
insufficient evidence, it is supportive of a common pathway, further linking Smad7 with 
Tbx1. 
Another aspect that should be discussed here is the time-specific requirements for 
Tbx1 in the development of the different heart and pharyngeal structures. Xu et al., 
elucidated these requirements using a tamoxifen activatable model that induces 
ubiquitous deletion of Tbx1 within 24 hrs post drug administration (Xu et al., 2005). 
The haploinsufficient aortic arch phenotype was produced only with the earliest 
heterozygous deletion of Tbx1, by E8.5, and it was scored with a penetrance of 44% in 
term embryos (Xu et al., 2005). The penetrance of the phenotype was incomplete but 
did recapitulate the Tbx1
+/-
 phenotype expected (Calmont et al., 2009; Lindsay et al., 
2001; Vitelli et al., 2002b Vitelli et al., 2006; Zhang and Baldini, 2008) for the stage 
examined. These results indicated that Tbx1 is required before E8.5 for aortic arch 
patterning (Xu et al., 2005). Pharyngeal arch artery formation, prior to the remodelling 
process, was not assessed in these embryos (Xu et al., 2005). In summary, Tbx1 is 
probably required before E8.5 for pharyngeal arch artery formation, but does not appear 
to regulate the recovery of the fourth arch defects. 
4.6.2. Tbx1 genetically interacts with other genes towards fourth arch artery 
development 
4.6.2.1. Defining “genetic interaction” 
Addressing the functional relationships between genes can be a useful tool in 
understanding the basic principles of the underlying genetic networks (Wong et al., 
2004). A common approach includes intercrossing of single mutants with distinct 
Smad7 - 183 
Irinna Papangeli 
phenotypes and comparing these with the phenotype of the resulting double mutants 
(Perez-Perez et al., 2009). The phenotype of the double mutation is considered additive 
when it displays features present in the single mutants, or epistatic when it is 
reminiscent of the phenotype of one of the single mutants, but not the other. 
Alternatively, the double mutant phenotype can be regarded as suppressed when it is 
closer to the wild type condition than either of the single mutants (Perez-Perez et al., 
2009), or synergistic, when it is significantly different to the phenotype of either single 
mutations alone or the additive effects of the individual mutations (Perez-Perez et al., 
2009; Wong et al., 2004). Additivity is generally accepted as indication of absence of a 
functional relationship between the mutated genes under study (Perez-Perez et al., 
2009). Conversely, epistasis and suppression are considered as the phenotypic outcomes 
of genetic interaction (Perez-Perez et al., 2009). Interpreting synergistic interactions, 
however, is somewhat more controversial, mainly because of the difficulties in 
distinguishing synergy from additivity (Perez-Perez et al., 2009). Synergy can often be 
the result of functional redundancy between paralogous genes or haploinsufficiency 
effects, but it can also be observed when converging pathways are disrupted, or when a 
mutation enhances the sensitivity to the effects of another mutation (Perez-Perez et al., 
2009).  
The use of statistical methods that estimate the average deviation of combinations 
of alleles against the rest of the genotypes within a population has proved to be a safe 
tool for establishing the genetic interactions on a specific genetic context (Phillips, 
2008). Here, Fisher’s exact test was used to compare the populations of different 
genotypes or of different time points produced by intercrossing Tbx1
+/lacZ
 to Smad7
+/GT
 
animals. 
4.6.2.2. Pooling data from the literature 
Several studies to date have examined possible interactions between Tbx1 and 
other genes in pharyngeal arch artery formation or remodelling (Aggarwal et al., 2006; 
Calmont et al., 2009; Guris et al., 2006; Morishima et al., 2003; Randall et al., 2009; 
Vitelli et al., 2002b). Most commonly, the single and double heterozygous embryos are 
assessed for arch artery formation defects. In some cases, they are also examined at a 
later stage, after the completion of arch artery remodelling, for great vessel defects. For 
the purposes of this thesis, the results of such studies were pooled and where 
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possible/available fourth arch artery hypoplasia and aplasia were recorded (Table 3.14). 
A hypoplastic vessel was considered thin patent (Th-P) while an aplastic one was 
classified as non patent (NP). If we consider that a hypoplastic vessel has the capacity to 
revert its state through molecular signalling, mechanical forces or the combination of 
these and recover into a functional part of the mature configuration, then a number of 
genes would be involved in regulating these mechanisms. Conversely, an absent 
(aplastic) vessel would not have this potential, and in order for a viable system to be 
produced by the end of embryonic development, arterial rearrangements might occur to 
compensate for the lost segment, providing alternative routes for blood circulation. 
These rearrangements, however, would produce a distinguishable anatomical outcome, 
unrelated to whether the final configuration is viable or not. During the pooling of these 
studies, there was no discrimination between unilateral and bilateral defects if both sides 
presented the same type of anomaly, while the cases of bilateral abnormalities with one 
Th-P and one NP vessel were classified as NP, in the sense that they are predicted to 
produce an abnormal phenotype at the later stage, should the embryo survive. Fisher’s 
exact test was used on the data gathered from all the previously published studies, and 
the statistical result of this meta-analysis is denoted by a latin cross (!). 
4.6.2.3. Description and interpretation of the fourth arch artery phenotype in Tbx1 
heterozygotes 
All the studies addressing Tbx1 haploinsufficiency have to consider the fact that 
Tbx1 heterozygotes partially recover from the initial fourth arch artery defect in 
subsequent stages of development (Calmont et al., 2009; Lindsay et al., 2001; Vitelli et 
al., 2002b Vitelli et al., 2006; Zhang and Baldini, 2008). Whether or not this recovery is 
a Tbx1 controlled process has not been studied yet. Essentially, combining all these 
studies is useful in clarifying if Tbx1 plays an additional part in arch artery remodelling, 
aside from its known earlier role in arch artery formation (Jerome and Papaioannou, 
2001; Lindsay et al., 2001; Merscher et al., 2001). Such a role may be masked by the 
severity and penetrance of the earlier formation defect. From the data collected from the 
literature it is apparent that during early stages of development Tbx1 haploinsufficiency 
induces both hypoplastic and aplastic vascular segments. This difference may be due to 
genetic dosage, fine tuning in genetic networks, or purely the result of a set of stochastic 
events.  
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4.6.2.4. Reviewed gene interactions with Tbx1 in pharyngeal arch artery 
morphogenesis 
Morishima et al., only checked the early stage of arch artery formation in Tbx1 
and endothelin converting enzyme (Ece1) double heterozygous embryos (Morishima et 
al., 2003). At E10.5 80% of the Tbx1 heterozygotes had a hypoplastic fourth vessel with 
no statistically significant difference to the complete penetrance in hypoplastic fourth 
vessels of the double heterozygotes (Morishima et al., 2003). The Ece1 heterozygotes 
were normal with the exception of one displaying a persistent second arch artery 
(Morishima et al., 2003). No later developmental stages were examined and although it 
was a small sample size, the data indicate that Ece1 has no contribution in fourth arch 
artery formation. 
Tbx1 is shown to interact with Gbx2 in the formation of the fourth arch artery 
(Calmont et al., 2009). Although in this sample size the recovery of the fourth arch 
artery defect cannot be proven, the NP vessels alone at E10.5 (36% out of a total of 
45%) were sufficient to cause the fourth-related defects scored at E15.5 in 26% of the 
population (p=0.43>0.05, no difference !) (Calmont et al., 2009). The same was true in 
the double heterozygous setting, where 79% of the Gbx2
+/-
;Tbx1
+/lacZ 
embryos displayed 
NP fourth arches, and this was not different to the 59% of fourth arch related defects 
scored at E15.5 in the same genotype (p=0.20>0.05, no difference !) (Calmont et al., 
2009).  
Likewise, Tbx1 is shown to interact with Chd7 in the formation of the fourth arch 
arteries (Randall et al., 2009). In single gene heterozygosity on this background, Tbx1 
produced 21% of NP fourth arches at E10.5, correlating well with the 24% of fourth-
related defects scored at E15.5 (p=0.60>0.05, no difference !) (Randall et al., 2009). In 
the double heterozygous groups, 100% penetrance of non patency was comparable to 
100% penetrance of fourth arch related defects observed at the two stages respectively 
(Randall et al., 2009). 
Different studies have assessed the genetic interaction between Tbx1 and the FGF 
pathway. Aggarwal et al., examined Tbx1 heterozygosity in combination with Fgf8, 
Fgf10 or Fgf8 and Fgf10 heterozygosity (Aggarwal et al., 2006). Although in a very 
small sample size, a difference was observed between the Tbx1
+/-
 and Fgf8
+/-
;Fgf10
+/-
;Tbx1
+/-
 genotypes (p<0.05) (Aggarwal et al., 2006). In this study only the late 
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embryonic stage was studied, when the left-sided arch is fully formed (Aggarwal et al., 
2006). The triple heterozygotes had either a left or a right fourth arch artery related 
defect (Aggarwal et al., 2006). These results indicate a contribution of the FGF genes to 
the resulting phenotype, but there is not enough data to examine the fourth arch artery 
recovery processes in these mutants. Vitelli et al., showed that Fgf8 and Tbx1 
genetically interact in the formation of the fourth arch arteries by studying the severity 
of the defects scored in the different genotypes at E10.5 (Vitelli et al., 2002b). At this 
stage a total of 93% of Tbx1
+/lacZ
 embryos presented with a fourth arch defect but only 
50% exhibited an NP vessel. (Vitelli et al., 2002b) Similarly, 93% of the E10.5 Fgf8
+/-
;Tbx1
+/lacZ
 transheterozygotes displayed a fourth arch defect, while 86% had an NP 
vessel (Vitelli et al., 2002b). The authors added the individual NP defects in each group 
(i.e. 2 vessels per embryo so the number of defects is double the number of embryos) 
and concluded that Tbx1 and Fgf8 interact towards the formation of the fourth arch 
(p<0.01) (Vitelli et al., 2002b). By comparing the NP defects per embryo, disregarding 
the unilateral or bilateral nature as approached here in all the studies analysed, the two 
groups are barely significant (p=0.05, !) Also, in terms of total defect penetrance there 
is no difference between the Tbx1 heterozygous and the double heterozygous embryos 
(93% penetrance in both groups). Moreover, the great vessel defects scored in these two 
genotypes at E18.5, after complete remodelling of the arch arteries, indicate that both 
the Tbx1
+/lacZ
 and Fgf8
+/-
;Tbx1
+/lacZ
 embryos partially rescued the fourth arch defects 
(p=0.09>0.05, no difference !), as expected in Tbx1 heterozygosity. Therefore, it is 
probably not safe to say that Fgf8 interacts with Tbx1 towards fourth arch artery 
formation, at least not in the current sample size. Regardless of a formation role, 
however, Fgf8 does not appear to have any contribution to the arch artery remodelling 
process. 
The study relating most closely to the Tbx1-Smad7 interaction theory discussed in 
this thesis is the genetic interaction between Crkl and Tbx1 (Guris et al., 2006). Crkl 
heterozygotes did not display any early formation defect in the arch arteries while at the 
same stage the double heterozygotes exhibited only Tbx1-related defects and failed to 
recover from these in the course of development (Guris et al., 2006). A total of 87% 
Tbx1 heterozygotes displayed a fourth arch artery defect at E10.5-E11.0 but only 20% 
had one or both vessels NP, which correlates well with the 28% of the Tbx1
+/-
 embryos 
that displayed a fourth related defect after remodelling of the great vessels, at E16.5 
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(p=0.46>0.05, no difference !) (Guris et al., 2006). Similarly, out of the total of 100% 
of Crkl
+/-
;Tbx1
+/-
 transheterozygotes with an early fourth arch artery defect, 88% of 
those exhibited unilateral or bilateral non patency as compared to 100% of the same 
genotype at the later stage that displayed a fourth arch related defect (p=0.22>0.05, no 
difference !) (Guris, 2006). 
A similar pattern is observed in the progeny of Tbx1
+/lacZ
 (x) Smad7
+/GT
 crosses. 
At E11.0 Tbx1
+/lacZ
 embryos exhibited a fourth arch defect with a penetrance of 65% but 
only 24% displayed non patency of the vessels. At E15.5 the frequency of the fourth 
arch related defects was 29%, and although the two populations are statistically 
different in terms of total defects, they are the same if only the NP defects are compared 
to the later stage (p=0.5>0.05, no difference). However, in contrast to all previous 
studies, in the Smad7
+/GT
;Tbx1
+/lacZ
 embryos the 38% of NP vessels seen does not 
suffice to cause the 68% of fourth-related defects scored at E15.5 (p<0.05, difference). 
This implies that during normal development, Smad7 is part of a mechanism 
remodelling vessel architecture that can potentially sustain hypoplastic vessels and 
rescue a Th-P vessel phenotype. Therefore, Smad7 does not necessarily share a common 
pathway with Tbx1 in the remodelling process of the pharyngeal arteries, rather, lack of 
Smad7 in the Tbx1;Smad7 heterozygotes prevents them from rescuing the hypoplastic 
vessels formed aberrantly earlier, due to lack of Tbx1 (Figure 3.24).  
 
Figure 3. 24. Schematic representation of the presumptive requirement for Tbx1 
and Smad7 during vessel development. Tbx1 haploinsufficiency can result in normal, 
hypoplastic or aplastic vascular segments due to abnormalities in the formation process. 
During the remodelling process, a normal vessel or an aplastic one will produce a 
normal or a missing segment of the mature configuration respectively, regardless of the 
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Smad7 dosage. A hypoplastic vessel has the potential to recover, above a threshold of 
Smad7 expression, which does not occur in the Smad7 null setting. 
E10.5 E15.5-E18.5 
 WT Ece1
+/- 
Tbx1
+/lacZ 
Ece1
+/-
;Tbx1
+/lacZ 
WT Ece1
+/- 
Tbx1
+/lacZ 
Ece1
+/-
;Tbx1
+/lacZ 
Total embryos 7 8 5 9     
Total normal 7 7 1 0     
Total abnormal 0 1* (12.5%) 4 (80%) 9* (100%) NOT EXAMINED 
L4th PAA - -       
R4th PAA - -       
L4th and R4h PAA - -       
Th-P/NP vessels   4 Th-P 9 Th-P  * persistent 1st &/or 2nd PAA Morishima et al., 2003 
E10.5 E15.5 
 WT Gbx2
+/- 
Tbx1
+/lacZ 
Gbx2
+/-
;Tbx1
+/lacZ 
WT Gbx2
+/- 
Tbx1
+/lacZ 
Gbx2
+/-
;Tbx1
+/lacZ 
Total embryos 6 11 11 14 29 16 19 22 
Total normal 6 11 6 2 29 16 14 9 
Total abnormal 0 0 5 (45%) 12 (86%) 0 0 5 (26%) 13 (59%) 
L4th PAA - - 1 1 - - - 1 
R4th PAA - - 2 1 - - 2 5 
L4th and R4h PAA - - 2 10 - - 2 7 
Th-P/NP vessels   1 Th-P, 4 NP (36%) 1 Th-P, 11 NP (79%)    Calmont et al., 2009 
E10.5 E14.5 
 WT Chd7
+/- 
Tbx1
+/lacZ 
Chd7
+/-
;Tbx1
+/lacZ 
WT Chd7
+/- 
Tbx1
+/lacZ 
Chd7
+/-
;Tbx1
+/lacZ 
Total embryos  6 14 6  26 25 17 
Total normal  2 5 0  21 19 0 
Total abnormal  4 (67%) 9 (64%) 6 (100%)  5 (19%) 6 (24%) 17 (100%) 
L4th PAA  1 2 -  2 2 10 
R4th PAA  3 4 -  3 4 6 
L4th and R4h PAA  - 3 6  - - 1 
Th-P/NP vessels   3 NP (21%) 6 NP (100%)    Randall et al., 2009 
 E17.5 
 WT Tbx1
+/tm1Rak 
Fgf8
+/-
;Fgf10
+/- 
Fgf10
+/-
;Tbx1
+/tm1Rak 
Fgf8
+/-
;Tbx1
+/tm1Rak 
Fgf8
+/-
;Fgf10
+/-
;Tbx1
+/tm1Rak 
Total embryos 6 5 5 7 6 6 
Total normal 6 5 5 7 5 2 
Total abnormal 0 0 0 0 1 (17%) 4 (67%) 
L4th PAA - - - - - 2 
R4th PAA - - - - 1 2 
L4th and R4h PAA - - - - - - 
Th-P/NP vessels        Aggarwal et al., 2006 
E10.5 E18.5 
 WT Fgf8
+/- 
Tbx1
+/lacZ 
Fgf8
+/-
;Tbx1
+/lacZ 
WT Fgf8
+/- 
Tbx1
+/lacZ 
Fgf8
+/-
;Tbx1
+/lacZ 
Total embryos 18 10 14 14 30 30 35 36 
Total normal 18 10 1 1 30 30 24 18 
Total abnormal 0 0 13 (93%) 13 (93%) 0 0 11 (31%) 18 (50%) 
L4th PAA   - -   - - 
R4th PAA   5 1   6 6 
L4th and R4h PAA   8 12   5 12 
Th-P/NP vessels   6 Th-P, 7 NP (50%) 1 Th-P, 12 NP (86%)    Vitelli et al., 2002b 
E10.75-E11.0 E16.5-P2 
 WT Crkl
+/- 
Tbx1
+/tm1Pa 
Crkl
+/-
;Tbx1
+/tm1Pa 
WT Crkl
+/- 
Tbx1
+/tm1Pa 
Crkl
+/-
;Tbx1
+/tm1Pa 
Total embryos 24 10 15 25 21 15 18 16 
Total normal 23 10 2 0 21 15 13 0 
Total abnormal 1 (4%) 0 13 (87%) 25 (100%) 0 0 5 (28%) 16 (100%) 
L4th PAA - - 6 24 - - 1 - 
R4th PAA 1 - 11 23 - - 4 8 
L4th and R4h PAA - - 4 22 - - - 8 
Th-P/NP vessels Th-P  10 Th-P, 3 NP (20%) 3 Th-P, 22 NP (88%)    Guris et al., 2006 
E11.0 E15.5 
 WT Smad7
+/GT 
Tbx1
+/lacZ 
Smad7
+/GT
;Tbx1
+/lacZ 
WT Smad7
+/GT 
Tbx1
+/lacZ 
Smad7
+/GT
;Tbx1
+/lacZ 
Total embryos 19 13 17 24 37 82 17 19 
Total normal 19 12 6 8 37 81 12 6 
Total abnormal 0 1 (8%) 11 (65%) 16 (67%) 0 1 (1%) 5 (29%) 13 (68%) 
L4th PAA - - 2 6 - - 2 2 
R4th PAA - 1 4 3 - 1 3 8 
L4th and R4h PAA - - 5 7 - - - 3 
Th-P/NP vessels  NP (8%) 7 Th-P, 4 NP (24%) 7 Th-P, 9 NP (38%)    this thesis 
Table 3. 14. Arch artery defects observed in embryos with compound mutations for Tbx1 and other genes, at early or late developmental 
stages in the different studies. The Tbx1;Smad7 arch artery defects studied here were included for convenience purposes. L/R, left/right; NP, 
non patent; PAA, pharyngeal arch artery; Th-P, thin patent; WT, wild type. 
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The notion of prevention of recovery of the early fourth arch defect has been 
suggested for a different set of genetic mutations, Fgf8 and Crkl combined (Moon et al., 
2006). Fgf8 heterozygosity combined with a heterozygous or null Crkl mutation 
profoundly disrupts fourth arch artery formation (Moon et al., 2006). Fgf8 hypomorphs 
and conditional mutants were mildly affected while Crkl null mutants and Fgf8 
heterozygotes had normal arch arteries (Moon et al., 2006). During development Fgf8
+/-
;Crkl
-/-
 mutants did not recover and presented with complete penetrance of fourth arch 
related defects (Moon et al., 2006). Conversely, the Fgf8
+/-
;Crkl
+/-
 mutants had an 
incidence of 13% of defects at E15.5, as compared to 50% at E10.5 (Moon et al., 2006). 
The authors showed that there was compromised neural crest cell survival and 
population of the pharyngeal arches in the Crkl
-/-
 embryos, while Crkl bound activated 
Fgf receptors and was required for subsequent downstream signalling in vitro (Moon et 
al., 2006). 
4.6.3. Tbx1 is involved in pathways affecting pharyngeal arch artery remodelling 
To date, two independent pathways have been described specifically in 
pharyngeal arch artery remodelling. Huh et al., studied the canonical Wnt pathway (Huh 
and Ornitz, 2010), while Ryckebusch et al., examined the RA signalling (Ryckebusch et 
al., 2010) in the remodelling process. Both studies additionally assessed Tbx1 in their 
respective context, due to the well established Tbx1 role in arch artery development.  
4.6.3.1 Tbx1, Wnt signalling and arch artery remodelling 
By performing conditional deletion of !-catenin in the pharyngeal mesenchyme, 
effective in the entirety of the mesenchyme from E10.5 onwards, Huh et al., showed 
that lack of canonical Wnt signalling leads to cardiovascular defects, among other 
abnormalities (Huh and Ornitz, 2010). The mutant phenotype included A-RSCA, 
increased spacing between the right brachiocephalic and LCC arteries, lower 
positioning of the LSCA on the DAo as well as outflow tract and intracardiac septation 
defects, compared to wild type controls (Huh and Ornitz, 2010). The pharyngeal arch 
artery defects described in this study were right fourth arch (A-RSCA), aortic sac 
(brachiocephalic-LCC artery distance) or left seventh ISA (LSCA positioning) derived. 
The formation versus the remodelling of the arch arteries was examined, and it was 
concluded that the conditional mutant embryos had defects in the remodelling process, 
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dictated by failure of both carotid ducts to regress normally by E13.5 (Huh and Ornitz, 
2010). The conditional mutants did not display the normal pattern of cellular apoptosis 
in the mesenchyme surrounding the carotid ducts, explaining the persistence of these 
vascular segments (Huh and Ornitz, 2010). Further to describing the cardiovascular 
phenotype, the authors addressed the genetic mechanism underlying it, and 
demonstrated that lack of !-catenin is sufficient to increase Tbx1 expression and the 
Tbx1-related downstream FGF signalling in the embryonic pharynx at E9.5 (Huh and 
Ornitz, 2010). It should be noted that Cre recombinase was active only in the non neural 
crest mesenchyme at this stage in the conditional embryos, as shown by reporter 
expression (Huh and Ornitz, 2010). Reducing Fgf8 dosage in the conditional !-catenin 
ablated mutants partially rescued the carotid duct persistence phenotype (Huh and 
Ornitz, 2010). Constitutive or temporal activation of the Wnt-!-catenin signalling 
resulted in reduced expression of Tbx1 in the pharyngeal apparatus at E9.5 and E10.5 
and Fgf8 at E9.5 (Huh and Ornitz, 2010). The authors additionally showed that 
temporal activation of the Wnt-!-catenin signalling increased the penetrance of the 
Tbx1 haploinsufficient fourth arch phenotype at E10.5 (Huh and Ornitz, 2010). Through 
this study, the Wnt pathway, via !-catenin, has been associated with the arch artery 
remodelling process as well as with the Tbx1 pathway. This however does not 
necessarily link Tbx1 with the remodelling of the pharyngeal arch arteries, since the 
impact activated !-catenin had on the Tbx1 haploinsufficient phenotype considered 
formation rather than remodelling defects. 
These data indicate potential future directions on the Tbx1-Smad7 study. 
Functional interaction between Smad7 and !-catenin has been previously described 
(Edlund et al., 2005; Han et al., 2006; Tang et al., 2008). Tang et al., demonstrated that 
Smad7 stabilises cytoplasmic !-catenin in vitro, by inhibiting its phosphorylation by 
Gsk3-! (Tang et al., 2008). Huh et al., used LiCl injections to temporally inhibit Gsk3-! 
and activate !-catenin in vivo (Huh and Ornitz, 2010). In that respect it might be 
interesting to employ the same system and temporally activate !-catenin in Smad7
GT/GT
 
embryos and examine the potential rescue of the arch artery remodelling phenotype. 
Depending on the cell line used, Smad7 affected !-catenin related transcriptional 
activity (Edlund et al., 2005) or not (Tang et al., 2008). A potential role for Smad7 
upstream of Tbx1 through !-catenin can therefore be addressed too. Nevertheless, a 
linear pathway, whereby Tbx1 transcriptionally regulates Smad7, which in turn 
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modulates cytoplasmic !-catenin towards arch artery remodelling appears more 
plausible. In support of that, the Tbx1-Smad7 model discussed in this thesis involves 
aberrant remodelling of the fourth arch artery, solely inducing fourth arch related 
defects during development, rather than carotid duct persistence that leads to a range of 
defects observed in the !-catenin conditional mutants (Huh and Ornitz, 2010). 
4.6.3.2. Tbx1, retinoic acid signalling and arch artery remodelling 
RA signalling has also been recently discussed as an influencing factor in the arch 
artery remodelling process, although maybe without sufficient evidence. Raldh2 
homozygous mutants die at E10.5 and by then display a range of disfiguring phenotypes 
(Niederreither et al., 1999), so studying arch artery development in the null setting is not 
possible. Ryckebusch et al., generated double heterozygotes for the Raldh2 and Tbx1 
genes and scored the fourth arch artery defects at different developmental stages 
(Ryckebusch et al., 2010). The penetrance of the early fourth arch artery defects (E10.5) 
in Tbx1 heterozygotes is 45% (Jerome and Papaioannou, 2001), but varies depending on 
the genetic background, and for this study it was found to be 82% (Ryckebusch et al., 
2010). The frequency of the fourth arch defects was 8% in the Raldh2 heterozygotes 
and 85% in the Raldh2
+/-
;Tbx1
+/-
 mutants, suggesting that the single Raldh2 null allele 
has no contribution to the phenotype (Ryckebusch et al., 2010). The authors scored the 
arch artery defects at a later stage (E11.5) and established 57% penetrance for the Tbx1 
heterozygotes and 29% penetrance for the double heterozygotes (Ryckebusch et al., 
2010). The Tbx1 haploinsufficient fourth arch phenotype partially recovers during 
development (Calmont et al., 2009; Lindsay et al., 2001; Vitelli et al., 2002b Vitelli et 
al., 2006; Zhang and Baldini, 2008). Given the reduced penetrance of the defects in the 
Raldh2
+/-
;Tbx1
+/-
 embryos between E10.5 and E11.5 (85% compared with 29%) it was 
rationalised that the presence of one Raldh2 null allele accelerated the recovery of the 
double heterozygous phenotype (Ryckebusch et al., 2010). The aortic arch pattering 
defects scored at E14.5-E18.5 were 25% penetrant in the Tbx1
+/-
 embryos and 19% 
penetrant in the Raldh2
+/-
;Tbx1
+/-
 embryos (Ryckebusch et al., 2010). Statistical 
analysis shows no difference in the occurrence of great vessel defects between these two 
populations (p=0.39>0.05, Fisher’s exact test !). Essentially, the intermediate stage the 
authors chose to test for an RA signalling role in the recovery of the fourth arch defects 
was unnecessary, since judging by the other two stages (E10.5 and E14.5 onwards) 
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there is an expected pattern of occurrence of fourth arch artery defects. The difference 
that was nonetheless identified among the Raldh2
+/-
;Tbx1
+/-
 mutants between E10.5 and 
E11.5 probably reflects experimental errors in scoring of the phenotypes, changes in 
genetic background or other inconsistencies not related to a true mechanism. In general, 
recovery of an arch artery defect relates to either compensation of an absent vascular 
segment by another, resulting in an alternative configuration (see introduction: 4.3) or 
reversal of the regression fate of a vascular segment by signalling from the surrounding 
tissues, haemodynamic forces or the combination of both. The Tbx1 haploinsufficient 
fourth arch artery defect can be unilateral or bilateral hypoplasia or aplasia of the 
vessels (Lindsay et al., 2001). The Raldh2
+/-
;Tbx1
+/-
 embryos displayed all the expected 
types of fourth arch defects at both E10.5 and E11.5, but the notable difference was in 
the vessel aplasia frequencies between the two stages. The double heterozygotes 
examined at E10.5 exhibited NP vessels with a penetrance of 50% while the same 
genotype at E11.5 displayed 16% penetrance of NP fourth arch arteries. However, the 
formation of the caudal pharyngeal arches is completed by E10.5-E11.0 (Hiruma et al., 
2002; Yanagisawa et al., 1998) and there is not enough time for a vessel to collapse and 
recover between E10.5-E11.5, as the authors claim (Ryckebusch et al., 2010). The 
difference in the hypoplastic vessel frequencies between the two stages in Raldh2
+/-
;Tbx1
+/-
 embryos was more subtle, with a frequency of 35% at E10.5 as compared to 
25% at E11.5. In conclusion, even if RA signalling improves the VSM cellularisation of 
the fourth arch arteries and aids the recovery of hypoplastic fourth arches, as the authors 
support (Ryckebusch et al., 2010), there is still no sufficient explanation for the 
difference in the vessel aplasia frequencies in the double heterozygotes between E10.5 
and E11.5, rendering the current conclusions of this study open to doubt. 
Raldh2 homozygous mutants arrest developmentally at around E8.5 
(Niederreither et al., 1999) so it is impossible to assess the Smad7 levels in these 
embryos. The Raldh2 null phenotype suggests that the gene is required in the embryo 
before E8.5. However, the onset of Smad7 expression is at E8.5, which makes it 
unlikely for Raldh2 and Smad7 to be part of the same pathway at an early stage. A later 
interaction cannot be excluded, and can be assessed by examining Raldh2 expression in 
Smad7 gene-trap embryos and conversely, by examining Smad7 expression in Raldh2 
hypomorph embryos that survive to mid-gestation (Vermot et al., 2003). 
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4.6.4. Concluding remarks on Tbx1-Smad7 interaction in pharyngeal arch artery 
morphogenesis 
The genetic network regulating pharyngeal arch artery formation is likely to be 
distinct from that controlling arch artery remodelling. So far no links have been 
described between these two networks. Tbx1, a well known regulator of arch artery 
formation (Lindsay et al., 2001; Xu et al., 2005; Zhang and Baldini, 2008), appears to 
regulate the early expression of Smad7 or the survival/proliferation of a cell population 
that will express Smad7, a gene involved in the remodelling process of the arch arteries 
(Figure 3.25). Expression studies demonstrated that Smad7 transcripts are reduced in the 
absence of Tbx1 at E9.5, by microarray analysis, quantitative real time PCR (van 
Bueren et al., 2010) and whole mount in situ hybridisation (this thesis). It was also 
shown by quantitative real time PCR that at E10.5 Smad7 mRNA levels were 
comparable between Smad7 heterozygotes and Tbx1;Smad7 double heterozygotes, 
while remaining unaffected in Tbx1 heterozygotes. In that respect, Tbx1 
haploinsufficiency, acting at an earlier stage than E10.5, maybe an indirect regulator of 
arch artery remodelling through Smad7. This hypothesis has implications for the human 
disease of 22q11DS, caused by the hemizygous deletion of chromosome 22q11.2. 
Approximately 15% of the 22q11DS patients that have cardiovascular manifestations 
present with IAA-B, a fourth arch artery related defect (Yamagishi, 2002). There is a 
small proportion of patients that do not carry the typical or atypical deletions but only a 
subset of these carry point mutations in TBX1 (Paylor et al., 2006; Stoller and Epstein, 
2005a; Torres-Juan et al., 2007; Yagi et al., 2003; Zweier et al., 2007). The phenotype 
of TBX1 haploinsufficiency caused by the deletion may be modified by SMAD7 
mutations or sequence variants, resulting in the definite great vessel phenotype. To date, 
no SMAD7 mutations have been reported in human heart disease. 
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Figure 3. 25. Schematic representation of the presumptive modes of interaction 
between Tbx1 and Smad7 during development. The potential model and timing of 
interaction between Tbx1 and Smad7 (A). Tbx1 is required during early embryogenesis 
for multiple developmental processes. Tbx1 may regulate Smad7 or the 
survival/proliferation of a population that will express Smad7, at an early stage, prior to 
arch artery formation. Smad7 is subsequently required for arch artery remodelling. 
Possible types of interaction between Tbx1-Smad7 (1) direct (unlikely), (2) indirect, 
whereby Tbx1 regulates the differentiation of a progenitor population that will 
eventually express Smad7, or (3) indirect, whereby Tbx1 regulates the survival or 
proliferation of a progenitor population that will eventually express Smad7 (B). I-XI, 
pharyngeal arches; E, day of embryonic development. 
4.7. Smad7 gene-trap time-dependent rescue 
An elegant way of assessing if Smad7 is indeed required at E10.5-E11.5 onwards 
for the actual remodelling of the pharyngeal arteries is through a time-controlled 
inducible Cre/lox system. CaggsCre was used to provide ubiquitous recombination and 
excise the splice acceptor of the Smad7 gene-trap vector in a timely controlled fashion. 
This model, however, is still being standarised and currently cannot be used, since the 
published methods (Hayashi and McMahon, 2002; Xu et al., 2005) do not provide 
sufficient recombination efficiency, as examined here by DNA, RNA and protein 
assays. Hayashi and McMahon took advantage of the ROSA26 reporter line and 
assessed the recombination efficiency at the protein level (Hayashi and McMahon, 
2002). The authors concluded that 3mg per 40g body weight injected intraperitonealy 
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are sufficient to induce up to 75% ubiquitous recombination within 24 hrs, from as early 
as E8.5 (Hayashi and McMahon, 2002). A higher dosage of 9mg per 40g body weight 
induced quicker recombination but the embryos died around E13.5 and none survived to 
term (Hayashi and McMahon, 2002). Recombination varied among the different 
embryonic tissues and even with a high tamoxifen dosage a small percentage of cells in 
all tissues failed to undergo recombination within 24 hrs (Hayashi and McMahon, 
2002). Prolonged drug activity induced up to 95% recombination in the embryos 
injected with 3mg per 40g body weight (Hayashi and McMahon, 2002). Xu et al., 
addressed the recombination efficiency issue at the genomic, RNA and protein level 
(Xu et al., 2005). They showed that IP injection of 3mg per 40g body weight induced 
complete recombination within 24 hrs by estimating the levels of the recombined and 
non recombined genomic locus. Also, no mRNA transcripts of the gene were detectable, 
or at very low levels, at the same stage, examined by reverse transcriptase PCR (Xu et 
al., 2005). Ubiquitous recombination was demonstrated through reporter expression 
with the use of the ROSA26 line (Xu et al., 2005). 
A more refined method was used in this study to examine the recombination 
efficiency of the system, given that reconstitution of the gene is required here, rather 
than deletion. By quantitative real time PCR it was shown that the maximum efficiency 
achieved in our system was production of 26% of the wild type Smad7 mRNA levels in 
Smad7
GT/GT
;CaggsCre embryos, which is not considered sufficient. An arbitrary 
threshold of 40% of the wild type levels was set to achieve gene dosage greater than the 
Smad7 heterozygote, to safely interpret the results of this experiment. The Smad7 
heterozygotes have no phenotypic defects, so restoring gene dosage in the gene-trap 
homozygous embryos to a level greater than the heterozygote may be sufficient to 
rescue the gene-trap homozygous phenotype. The time control element of the system 
will help clarify the developmental stage at which Smad7 acts on arch artery 
remodelling. In combination with Tbx1 heterozygosity, this system can also ascertain 
whether Smad7 and Tbx1 are required in a linear pathway during the remodelling 
process.  
The discrepancy in the induction of the system among the different studies may be 
due to the different genetic backgrounds, inaccessibility of the Smad7 genomic locus or 
the methods used to test the recombination efficiency. Whichever the reasons, the 
system should be standarised in every new setting. A different approach in examining 
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the Smad7 role in arch artery remodelling is a Cre/lox system that conditionally deletes 
Smad7 in a timely controlled fashion, instead of the Smad7
GT
;CaggsCre model. 
4.8. Conclusion and future directions 
In this chapter I have shown that Smad7, a gene identified by a microarray screen 
as a potential Tbx1 target, is indeed related to Tbx1. The interaction between the two 
genes is more likely indirect. Smad7 expression depends upon tissue-specific Tbx1 
activation at an early developmental stage. Tbx1 is a major regulator of pharyngeal 
development (Zhang and Baldini, 2008). In that respect, it controls a great number of 
genes that will eventually play roles in different processes and at different time points. 
The developmental roles of Smad7 are apparent at a much later stage than its initial 
activation from Tbx1, during the remodelling of the great vessels. Therefore, a 
synergistic interaction between the two genes is proposed. 
To elucidate the role of Smad7 in the remodelling of the pharyngeal arteries, 
initially a neural crest patterning defect has to be conclusively ruled out, for example by 
Sox10, HNK-1, Ap2a or Crabp1 whole mount in situ hybridisation on Smad7 gene-trap 
homozygous versus wild type embryos. Next, the VSM population of the pharyngeal 
arch arteries has to be assessed, in case the neural crest cells migrate efficiently into the 
pharyngeal arches but fail to differentiate in situ and create this supportive lining. The 
mesodermally-derived arch artery endothelium should also be examined. 
Immunohistochemical methods can address both these issues. In vitro experiments can 
also be employed to assess for shear stress responsiveness of Smad7 deprived 
endothelium. HUVEC cultures can be used, where in a customised chamber differential 
stress forces and be applied, allowing for the measurement of the transcriptional 
response. Alternatively, FACS sorted endothelial cells from Smad7 gene-trap 
homozygous embryos can be examined for shear stress responsive or other 
haemodynamic related factors. Increasing the sample size of the E11.5 Smad7
GT/GT
 
embryos and scoring the arch artery defects will make a stronger argument towards a 
remodelling rather than a formation role of the gene. Interestingly, Tgf!2 mutants 
exhibit fourth arch artery remodelling defects too (Bartram et al., 2001; Molin et al., 
2002), associated with reduction in Smad2 expression in the fourth arch (Molin et al., 
2002). Future analysis of the Smad7 mutants at subsequent developmental stages during 
arch artery remodelling can address whether it acts via or dependent on Tgf!2, or if it is 
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part of a completely independent pathway. Tgf!2 null embryos have a 33% penetrance 
of aortic arch anomalies, which are hypoplasia of the ascending aorta and fourth arch-
related defects (Bartram et al., 2001), correlating well with the 30% penetrance of great 
vessel defects scored in Smad7 homozygotes, concerning almost exclusively fourth 
arch-related defects.  A possible interaction between Smad7 and the Wnt-!-catenin 
pathway can be addressed by temporally inhibiting Gsk3-! and activating !-catenin in 
Smad7
GT/GT
 embryos, to examine the potential rescue of the arch artery remodelling 
phenotype. The proliferation and apoptosis rates need to be scored in the developing 
vasculature of Smad7
GT/GT
 and Smad7
+/GT
;Tbx1
+/lacZ
 embryos, in order to investigate the 
precise mechanism by which Smad7 is part of the pharyngeal arch artery remodelling 
scheme. Finally, in terms of future work, a Cre/lox system can be employed to 
conditionally delete Smad7 in a timely controlled fashion, as a way of addressing its 
role in great vessel remodelling, instead of the Smad7
GT
;CaggsCre model. 
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1. Introduction – Literature review 
1.1. Notch pathway 
1.1.1. Biological functions 
Notch signalling is an evolutionary conserved pathway that influences cell fate 
specification, progenitor cell maintenance, boundary formation, cell proliferation and 
apoptosis and is involved in several developmental processes (Artavanis-Tsakonas et 
al., 1999; High and Epstein, 2008; High et al., 2007; Nemir and Pedrazzini, 2008). 
Dysregulation of the Notch pathway contributes to a number of human pathologies 
including congenital heart disease, cancer (Nemir and Pedrazzini, 2008), Alagille 
syndrome, Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy (CADASIL), and T-cell leukemia (Fischer and Gessler, 2007). 
1.1.2. Notch pathway genes  
Four type I transmembrane Notch receptors (Notch1-4) and five type I 
transmembrane Notch ligands (Jagged1-2 and Delta-like1,-3, and -4) have been 
identified in mammals (High et al., 2007; Jain et al., 2010; Niessen and Karsan, 2008). 
Both the receptors and ligands are expressed on the cell surface, promoting 
communication between two adjacent cells (High et al., 2007; Nemir and Pedrazzini, 
2008; Niessen and Karsan, 2008). Ligand binding induces two sequential cleavage 
events of the Notch receptor (Fischer and Gessler, 2007; Niessen and Karsan, 2008). 
The first cleavage occurs on the membrane and is mediated by the metalloprotease 
tumor necrosis factor-"-converting enzyme (TACE/ADAM17) (Nemir and Pedrazzini, 
2008; Niessen and Karsan, 2008). This is followed by proteolytic cleavage by a #-
secretase complex (High et al., 2007; Nemir and Pedrazzini, 2008; Niessen and Karsan, 
2008). The receptor eventually releases the intracellular domain of Notch (NICD), 
which translocates to the nucleus (Fischer and Gessler, 2007; High et al., 2007; 
Kageyama et al., 2005; Nemir and Pedrazzini, 2008; Niessen and Karsan, 2008). In the 
nucleus the NICD interacts with the DNA binding recombination signal binding protein 
for immunoglobulin kappa J region (RBP-Jkappa or RBP-J) and transcriptional co-
activators like the mastermind-like (MAML), promoting transcription of Notch target 
genes (Fischer and Gessler, 2007; High et al., 2007; Jain et al., 2010; Kageyama et al., 
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2005; Nemir and Pedrazzini, 2008; Niessen and Karsan, 2008). The most extensively 
studied target genes are those of the hairy and enhancer of split (HES) and HES-related 
(HRT or Hey) transcription factor families (Figure 4.1) (Fischer and Gessler, 2007; 
High et al., 2007; Jain et al., 2010; Kageyama et al., 2005; Nemir and Pedrazzini, 2008; 
Niessen and Karsan, 2008). 
 
Figure 4. 1. Simplified schematic representation of Notch signalling in two 
adjacent cells. (1) Notch is activated by Delta in a progenitor cell, (2) which leads to 
translocation of the intracellular domain of Notch (NICD) into the nucleus where it 
forms a complex with RBP-J, which in turn induces target gene transcription. (3) Hes 
proteins recruit Tle/Grg corepressors and inhibit transcription of activator-type bHLH 
genes by binding to their promoters. Differentiation genes are essentially not expressed. 
(4) In the absence of activated Notch in a differentiating cell, RBP-J promotes 
transcriptional repression of Hes genes, (5) while the activator-type bHLH genes are 
being expressed, subsequently inducing differentiation genes, (6) and Delta activation, 
promoting Notch signalling in neighboring cells. NICD, intracellular domain of Notch.  
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1.1.3. Notch target genes 
Generally, the Notch downstream effectors remain largely unknown (Nemir and 
Pedrazzini, 2008). The first Notch targets that were identified were genes encoding 
basic helix-loop-helix (bHLH) proteins of the Hes and Hey families, related to the 
Drosophila Hairy and Enhancer-of-Split (Nemir and Pedrazzini, 2008). Seven Hes 
genes (Hes1-7) have been described in mammals, of which only Hes1, 5 and 7 are 
activated by Notch (Fischer and Gessler, 2007; Kageyama et al., 2005; Nemir and 
Pedrazzini, 2008). All three members of the Hey family, Hey1, Hey2 and HeyL, are 
induced by Notch (Fischer and Gessler, 2007; Nemir and Pedrazzini, 2008). As 
effectors of Notch signalling, these genes are considered as central regulators of fate-
specific gene transcription (Nemir and Pedrazzini, 2008). Hes and Hey proteins form 
homo- or heterodimers, and generally act as transcriptional repressors, either actively, 
by direct association with E- and N-box DNA sequences on target gene promoters 
(Fischer and Gessler, 2007; Kageyama et al., 2005; Nemir and Pedrazzini, 2008; 
Pedrazzini, 2007) or passively, through interaction with other DNA-binding 
transcription factors, and transcription factor sequestration (Nemir and Pedrazzini, 
2008; Pedrazzini, 2007). Hes and Hey genes have a wide range of expression domains, 
indicative of their involvement in transcriptional regulation during development (Nemir 
and Pedrazzini, 2008). Until recently it was thought that, among the Notch effectors, 
only Hey genes were involved in cardiovascular development (Nemir and Pedrazzini, 
2008). However, we and others have shown that Hes1 deficiency induces aortic arch, 
outflow tract and intracardiac defects (Rochais et al., 2009b; van Bueren et al., 2010). 
1.1.3.1. Hes1 protein, interactors and biological functions 
Hes1 is a repressor bHLH protein involved in many developmental processes, 
such as regulation of binary cell decisions, T-cell development, (Kageyama et al., 
2000), maintenance and proliferation of neural stem cells, gliogenesis (Kageyama et al., 
2005) and boundary formation in the central nervous system (CNS) (Baek et al., 2006). 
It is expressed by almost all undifferentiated cells and it is required to maintain these 
cells in an undifferentiated state, while missexpression of Hes1 inhibits cell 
differentiation (Kageyama et al., 2000). Hes1 expression is activated by Notch through 
RBP-J (Jarriault et al., 1995; Nishimura et al., 1998). RBP-J can also act independently 
and repress Hes1 transcription by binding onto the Hes1 promoter (Kageyama et al., 
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2005). Of particular note is the fact that in the CNS Hes1 is expressed at the 
neuroepithelial stage, which precedes Notch and Delta expression, suggesting that 
Notch is not the sole regulator of Hes1 expression, at least in the neuronal cell lineage 
(Kageyama et al., 2005). 
Like the rest of the Hes proteins, Hes1 has an N-terminal domain used for 
dimerisation and DNA binding, a proline residue in the middle of the basic region 
producing high affinity to N-boxes (instead of E-boxes) and a less conserved Orange 
domain, involved in protein-protein interactions (Kageyama et al., 2005). Hes1 acts 
through promoter binding and transcriptional repression or by inactivating dimerisation 
with activator bHLH proteins, such as Mash1, a neuronal determination protein 
(Kageyama et al., 2005; Kageyama et al., 2000). Hes proteins additionally recruit 
Tle/Grg corepressors through their WRPW tetrapeptide, unlike the Hey proteins that 
lack this domain (Fischer and Gessler, 2007; Kageyama et al., 2005; Kageyama et al., 
2000).  
Hes1 has the ability of negatively regulating its own promoter (Takebayashi et al., 
1994) and thus functioning as a cellular oscillator both in vitro, in cultured cells, and in 
vivo, in the presomitic mesoderm during somitogenesis (Hirata et al., 2002). Hes1 
mRNA and protein have short half lives (~20 min) and oscillate in a 2-hour cycle in 
vitro (Hirata et al., 2002). Kobayashi et al., recently demonstrated that Hes1 exerts 
oscillatory roles in embryonic stem (ES) cells too, through a Notch independent 
pathway (Kobayashi et al., 2009).  
Hes genes are also suggested to modulate the timing of cell differentiation by 
repressing the premature onset of the activator bHLH genes (Kageyama et al., 2005). 
Hes1 together with Hes3 and Hes5 are expressed in neural stem cells and inhibit 
differentiation into neuronal fates, thereby maintaining the stem cell potential 
(Kageyama et al., 2005). Double mutation for Hes1 and Hes5 induces premature glial 
cell differentiation into neurons while triple knock-out for Hes1, Hes3 and Hes5 results 
in premature neuroepithelial cell differentiation into neurons, from as early as E8.5 
(Kageyama et al., 2005). Kobayashi et al., additionally studied Hes1 in ES cell 
differentiation (Kobayashi et al., 2009). ES cells expressing low levels of Hes1 
differentiated more efficiently into neural lineages, while ES cells expressing high 
levels of Hes1 tended to acquire mesodermal fates (Kobayashi et al., 2009). These 
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reflected different phases in ES cell differentiation and not different subpopulations, as 
both high and low Hes1-expressing populations returned to the original distribution of 
variable Hes1 expression levels within a day (Kobayashi et al., 2009). Inactivation of 
the gene in ES cells under neural differentiation conditions induced neural fates for 
almost all Hes1 null cells and at an earlier time point, compared to wild type ES cells 
(Kobayashi et al., 2009).  
1.1.4. Notch pathway in cardiovascular development 
Notch signalling functions via three distinct modes of action (Bray, 2006). First, 
through inductive signals between different cell populations Notch pathway promotes 
the formation of boundaries (Bray, 2006; Nemir and Pedrazzini, 2008; Pedrazzini, 
2007). Notch pathway is also involved in cell lineage determination by controlling 
asymmetric cell division, in which one cell divides to produce two daughter cells that 
adopt two different fates (Bray, 2006; Pedrazzini, 2007). Last, Notch acts through 
lateral inhibition between adjacent cells, whereby a cell assuming a particular fate 
inhibits its neighboring cells from adopting the same fate (Bray, 2006; Nemir and 
Pedrazzini, 2008; Pedrazzini, 2007).  
Several Notch receptors, ligands and targets are expressed in the developing 
cardiovasculature (Nemir and Pedrazzini, 2008). Notch1 and Notch2 are the 
predominant receptors expressed in the developing heart, whereas Notch3 is restricted 
to the smooth muscle and Notch4 to the endothelium of the vascular system (Nemir and 
Pedrazzini, 2008). The Notch ligand Jag1 is detected in the outflow tract, AVC and 
ventricular trabeculae, while Dll1 and Dll4 are expressed in the endocardium during 
different stages of development (Nemir and Pedrazzini, 2008). Dll4 is also observed in 
the cardiac crescent in early stages of cardiogenesis (Nemir and Pedrazzini, 2008). 
Notch target genes are also expressed in the developing cardiovasculature. Hey1 is 
initially expressed in the cardiac crescent, later in development it is detected in the 
endocardium and ultimately becomes restricted to the atrial myocardium and 
epicardium (Nemir and Pedrazzini, 2008). Hey2 is found in the presumptive ventricles 
at the heart tube stage and later it is limited to the compact myocardium (Nemir and 
Pedrazzini, 2008). Hey2 is also found highly expressed in the AV canal endocardium 
but not the mesenchyme at the onset of EMT (Nemir and Pedrazzini, 2008). HeyL is 
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expressed in the AV cushions between E9.5 and E12.5 and in an overlapping fashion 
with Notch1, Notch2, Jag1, Hey1 and Hey2 (Fischer et al., 2007).  
The spatiotemporal expression pattern of Notch receptors, ligands and targets in 
the embryonic heart, combined with the phenotype of animal mutants of components of 
the Notch pathway demonstrate the importance of Notch signalling during heart 
development (Nemir and Pedrazzini, 2008). Developmental processes the Notch 
pathway has been described in include cardiomyocyte differentiation, ventricular 
trabeculation, boundary formation of the AV canal, outflow tract remodelling and valve 
development (High and Epstein, 2008; Jain et al., 2010). Moreover, in the early stages 
of cardiogenesis, signalling through Notch1, Notch2 and Dll1 is essential for 
determination of the left-right embryonic axis and subsequently for normal looping of 
the heart tube (Niessen and Karsan, 2008). 
1.2. Notch gene mutations 
Inactivating mutations on factors of the Notch pathway or its targets have been 
associated with the etiology of cardiovascular anomalies (Cau et al., 2000; Fischer et al., 
2007; High et al., 2007; Hirata et al., 2004; Hirata et al., 2001; Nemir and Pedrazzini, 
2008; Rochais et al., 2009b; Stauber et al., 2009; van Bueren et al., 2010). 
1.2.1. Notch pathway gene mutations 
In humans, mutations in the NOTCH1 gene have been associated with T-cell acute 
lymphoblastic leukemia (Weng et al., 2004) and aortic valve disease (Garg et al., 2005) 
while mutations in the NOTCH3 gene have been identified in CADASIL patients 
(Shawber and Kitajewski, 2004). Moreover, Allagile syndrome has been linked to 
haploinsufficiency of the Notch ligand JAGGED1 (Shawber and Kitajewski, 2004; 
Warthen et al., 2006). Mutations in the DLL3 gene causes one form of autosomal 
recessive Spondylocostal Dysostosis (Gridley, 2003). 
In mice, interference with Notch signalling in the neural crest lineage through a 
dominant negative inhibitor induced cardiac outflow tract and aortic arch patterning 
defects (High et al., 2007). The neural crest cell migration was not affected in these 
mutants, however, localised downregulation of Notch target genes and diminished 
expression of SMC markers was observed (High et al., 2007). The authors concluded 
that Notch signalling has a cell-autonomous role in neural crest cell differentiation into 
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VSM (High et al., 2007). Other Notch gene mutants, including Notch1, RBP-J, Jag1, 
and Dll4, also display cardiovascular phenotypes, which are predominantly outflow 
tract, ventricular septation or trabeculation defects (Nemir and Pedrazzini, 2008). 
1.2.2. Notch target gene mutations 
Deficiency in Hey1 or HeyL does not result in heart anomalies, Hey2 deficient 
mice however display perinatal lethality and cardiovascular malformations, including 
ASDs and VSDs, enlargement of the atrial and ventricular cavities, thin ventricular 
walls, pulmonary stenosis and tricuspid atresia (Fischer et al., 2007). Double mutants 
for Hey1 and Hey2 die in utero due to severe cardiovascular insufficiency, reminiscent 
of the phenotype observed in Notch1 mutant mice (Fischer et al., 2007). Consistently, 
combined mutation for Hey1 and HeyL causes defects in the EMT processes of the 
AVC and results in congenital heart defects including chamber enlargement, 
membranous VSDs and dysplastic valves (Fischer et al., 2007). 
Null mutation of either the Hes3 (Hirata et al., 2001) or the Hes5 (Cau et al., 
2000) genes produces viable and fertile mice. Homozygosity for a targeted null 
mutation in Hes7 disrupts somite formation that leads to skeletal defects and neonatal 
death (Hirata et al., 2004; Stauber et al., 2009). Animal models for Hes2 or Hes6 
mutations have not been established yet, while for the purposes of this thesis, the 
phenotype of the Hes1 mutation will be discussed in greater detail here. 
During mouse embryogenesis Hes1 participates in neural tube (Ishibashi et al., 
1995), eye (Lee et al., 2005; Takatsuka et al., 2004; Tomita et al., 1996), thymus 
(Tomita et al., 1999), lung (Ito et al., 2000) and pancreas development (Jensen et al., 
2000), while homozygous knock-down of the gene results in a range of defects affecting 
these organs and is embryonic lethal (Ishibashi et al., 1995). We and others have shown 
that Hes1 null embryos additionally exhibit cardiovascular (Rochais et al., 2009b; van 
Bueren et al., 2010) and craniofacial anomalies (van Bueren et al., 2010). During early 
stages of development (E10.5), a proportion of the Hes1 homozygous embryos exhibit 
pharyngeal arch artery defects (van Bueren et al., 2010) (Table 4.1).  
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 WT Hes1
+/- 
Hes1
-/- 
Total embryos 77 80 40 
Total normal 76 67 27 
Total abnormal 1 (1%) 13* (16%) 13* (32.5%) 
Persistent 1st &/or 2nd PAA - 2 6 
Hypo/aplastic 3rd PAA - - 1 (apl) 
Hypo/aplastic 4th PAA 1 (hypo) 8 (hypo) 3 (hypo), 3 (apl) 
Hypo/aplastic 6th PAA - - 1 (hypo) 
Aberrant branching - 4 4 
*p<0.01    
Table 4. 1. Arch artery defects observed in Hes1 embryos at E10.5. P value from 
Fisher’s exact test against the wild type group. apl, aplastic; hypo, hypoplastic; PAA, 
pharyngeal arch artery; WT, wild type. Nb. Total WT embryos include additional WT 
non-littermates examined for the presence of arch artery defects (van Bueren et al., 
2010). 
At later stages of development (E14.5-E15.5), Hes1 null embryos present with 
high penetrance of thymic defects and moderate penetrance of secondary palate defects, 
depending on the genetic background (van Bueren et al., 2010). At the same stage and 
with variable penetrance the Hes1 mutants exhibit cardiovascular defects. These include 
great vessel defects, like RAA on an MF1;C57BL/6J background (van Bueren et al., 
2010) or isolated RSCA on an MF1 background (van Bueren et al., 2010) and outflow 
tract defects, like dextroposed aorta on a CD1 background (Rochais et al., 2009b) and 
DORV on an MF1 or MF1;C57BL/6J background (van Bueren et al., 2010). 
Intracardiac septation defects have also been reported in all genetic backgrounds 
examined (Table 4.2) (Rochais et al., 2009b; van Bueren et al., 2010).  
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Strain Genotype n Total CV 
defects 
Great 
vessel 
defect 
OFT 
defect 
Cleft 
Palate 
Thymic 
hypo/ 
aplasia 
MF1* WT 2 0 0 0 0 0 
 Hes1
+/- 
15 1
a
 (7%) 0 0 0 0 
 Hes1
-/- 
15 2 (13%) 1 1 9 (60%) 13 (87%) 
MF1;C57BL/6J* WT 7 0 0 0 0 0 
 Hes1
+/- 
21 0 0 0 1 (5%) 0 
  Hes1
-/- 
23 5 (22%) 4 1 9 (39%) 
23 
(100%) 
CDI** WT N/A N/A N/A N/A N/S N/S 
 Hes1
+/- 
N/A N/A N/A N/A N/S N/S 
 Hes1
-/- 21 8 (38%) 0 8 N/S N/S 
Table 4. 2. Thymic cardiovascular and palate defects observed in Hes1 embryos at 
E14.5-E15.5. OFT, outflow tract; CV, cardiovascular; N/A, not available; N/S, not 
studied; WT, wild type.
 a 
Dextroposition of the heart, * van Bueren et al., 2010, ** 
Rochais et al., 2009b.  
Although heterogeneity is observed in the cardiovascular phenotype among the 
different genetic backgrounds, Hes1 appears to participate in the development of both 
the great vessel and the outflow tract. Interestingly, the Hes1 null mutant is the first 
Notch effector mutant described with pharyngeal arch artery anomalies (van Bueren et 
al., 2010). Functional redundancy among related Notch pathway members may explain 
this inconsistency (van Bueren et al., 2010). 
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2. Project overview 
Hes1 was identified as a potential Tbx1 target through our microarray screen on 
Tbx1-expressing heterozygous and null cells, and validated by quantitative real time 
PCR (van Bueren et al., 2010). Preliminary experiments by a member of our lab 
demonstrated that Hes1 is expressed in an overlapping fashion with Tbx1 in E9.5 
pharyngeal tissues, while it was detected downregulated in all these tissues in E9.5 
Tbx1
lacZ/lacZ
 embryos, compared to stage matched wild type controls, by whole mount in 
situ hybridisation (van Bueren, 2008). Expression analysis was undertaken to further 
refine the Hes1 expression domains during early mouse embryogenesis, in relation to 
Tbx1 expression. Conditional knock-out embryos of Hes1 were generated for different 
tissues, using the Cre/loxP system, to establish the tissue-specific contributions of Hes1 
to the null phenotype. Neural crest cell patterning was assessed in Hes1 null and 
conditional embryos. Last, elements of the Notch and FGF pathways were also 
examined in the context of the phenotypes observed. 
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3. Results 
3.1. Hes1 in the mouse embryo 
Tbx1 is expressed in the pharyngeal epithelia and mesoderm from as early as E7.5 
(Chapman et al., 1996; Huynh et al., 2007; Lindsay et al., 2001; Vitelli et al., 2002a) 
while Tbx1 expression is required for fourth arch artery formation prior to its 
morphological appearance, before E9.5 (Xu et al., 2005). Immunohistochemistry was 
employed to study the localisation of Hes1 and Tbx1 proteins in the mouse embryo at 
E8.5. Both were found co-expressed in the pharyngeal ectoderm, endoderm and 
mesenchyme (Figure 4.2.E). Whole mount in situ hybridisation was used to demonstrate 
that at E9.5 Hes1 mRNA is also expressed in an overlapping fashion with Tbx1 in the 
pharyngeal endoderm, mesenchyme and ectoderm (Figure 4.2.A-B’). Furthermore, 
Hes1 expression was identified as downregulated by whole mount in situ hybridisation 
in E9.5 Tbx1
lacZ/lacZ
 embryos in the pharyngeal endoderm and mesenchyme but not 
ectoderm, compared to littermate stage matched wild type controls (Figure 4.2.C-D’). 
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Figure 4. 2. Tbx1 and Hes1 expression detected by immunofluorescence at E8.5 
and in situ hybridisation at E9.5. (A, A’) Wild type Tbx1 mRNA expression in whole 
mount (A) and transverse section at the caudal pharyngeal level at E9.5 (A’). (B, B’) 
Wild type Hes1 mRNA expression in whole mount (B) and transverse section at the 
caudal pharyngeal level at E9.5 (B’). (C, C’, D, D’)  E9.5 Hes1 mRNA expression in 
wild type control embryo in whole mount (C) and transverse section at the caudal 
pharyngeal level (C’) and in Tbx1
lacZ/lacZ
 embryo in whole mount (D) and transverse 
section at the caudal pharyngeal level (D’). Hes1 (green) and Tbx1 (red) protein 
expression in wild type embryo at E8.5 in transverse section at the caudal pharyngeal 
level (E). Black arrow, pharyngeal mesenchyme; yellow arrowhead, pharyngeal 
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ectoderm; red arrowhead, SHF mesoderm; white arrowhead, pharyngeal endoderm; 
SHF, second heart field; ov, otic vesicle. 
3.2. Tissue-specific contributions of Hes1 
The pharyngeal expression profile of the gene during early mouse embryogenesis 
led us to conditionally ablate Hes1 in the neural crest, ectoderm and neural crest, 
anterior heart field and finally endoderm and study the resulting phenotype. The gene 
was deleted in each tissue through a Cre/loxP model, on a Hes1 heterozygous 
background, by combining the Hes1 null and flox alleles with the respective Cre 
transgene. This induced complete inactivation of Hes1 in the tissue of interest and 
heterozygous inactivation of the gene in the rest of the embryo in the Hes1
Fl/-
;Cre 
genotypes. The fact that Hes1 heterozygous mutants have some pharyngeal arch artery 
defects at E10.5 but appear normal in subsequent stages of development (van Bueren et 
al., 2010) was considered when interpreting the results of the conditional deletions. 
Reporter expression through the ROSA26 line (Soriano, 1999) on a Hes1
Fl/+
 or Hes1
Fl/-
 
background was used as a proxy to assess the recombination efficiency of each Cre 
system. 
3.2.1. Hes1 in the neural crest 
The Wnt1Cre model (Danielian et al., 1998) was used to achieve conditional 
deletion of the gene in the neural crest. Timed matings of Hes1
Fl/Fl
 (C57BL/6J) to 
Hes1
+/-
;Wnt1Cre (MF1;C57BL/6J) mice were used to produce embryos to study the 
neural crest Hes1 contribution to the Hes1 null phenotype. This cross should ablate 
Hes1 in the Wnt1 expressing cells, which are predominantly neural crest cells, from 
E8.5 onwards (Figure 4.3.A-A’’) (Danielian et al., 1998; Echelard et al., 1994). 
3.2.1.1. Hes1 may have a minor role in the neural crest towards arch artery 
morphogenesis 
The pharyngeal arch artery phenotype of these mutants was assessed at two 
stages, the arch artery formation and the mature left-sided aortic arch stage. At E10.5, 
when all pairs of the caudal arch arteries have formed (Hiruma et al., 2002; Yanagisawa 
et al., 1998), two (10.5%) Hes1
Fl/+
;Wnt1Cre and two (12.7%) Hes1
Fl/-
;Wnt1Cre 
embryos (hereafter Wnt1Cre conditional mutants) presented with a defect, but this was 
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not statistically different to the wild type phenotype (p>0.05, Fisher’s exact test) (Table 
4.3).  
 Hes1
Fl/+
 (WT) Hes1
Fl/- 
Hes1
Fl/+
;Wnt1Cre
 
Hes1
Fl/-
;Wnt1Cre
 
Total embryos 23 21 19 16 
Total normal 23 21 17 14 
Total abnormal (%) 0 0 2 (10.5%) 2 (12.7%) 
Persistent 1st &/or 
2nd PAA - - 1 - 
Hypo/aplastic 3rd 
PAA 
- - 1 (apl) - 
Hypo/aplastic 4th 
PAA 
- - - 2 (hypo) 
Hypo/aplastic 6th 
PAA 
- - - - 
Table 4. 3. Arch artery defects observed in the Wnt1Cre conditional embryos at 
E10.5. apl, aplastic; hypo, hypoplastic; PAA, pharyngeal arch artery; WT, wild type. 
By E15.5 the pharyngeal arch arteries have completely remodelled into the mature 
left-sided configuration (Hiruma et al., 2002). At this stage three (11.5%) Wnt1Cre 
conditional mutants displayed cervical origin of the RSCA (Figure 4.3.C), which occurs 
after aberrant formation or remodelling of the right fourth arch artery. This however 
was not statistically different to the rest of the genotypes (p>0.05, Fisher’s exact test) 
(Table 4.4), suggesting that Hes1 in the neural crest is probably not required for great 
vessel development. No outflow tract defects were observed in any of the genotypes. 
Genotype n 
Thymic 
hypoplasia 
Great vessel 
defects Eye defects 
Hes1
Fl/+
 (WT) 17 0 0 0 
Hes1
Fl/- 
21 3 (14%) 0 0 
Hes1
Fl/+
;Wnt1Cre
 
31 2 (6%) 0 0 
Hes1
Fl/-
;Wnt1Cre
 26 10* (38%) 3 (11.5%) 0 
Total 95    
* p<0.05     
Table 4. 4. Thymic, great vessel and eye defects observed in the Wnt1Cre 
conditional embryos at E15.5. P value from Fisher’s exact test between the wild type 
and Hes1
Fl/-
;Wnt1Cre groups. WT, wild type. 
In summary, Wnt1Cre conditional deletion of Hes1 resulted in isolated fourth arch 
artery defects at both E10.5, after complete formation of the arch arteries, and E15.5, 
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after complete remodelling of the arch arteries. In that respect, Hes1 may have a minor 
contribution in fourth arch artery morphogenesis. 
3.2.1.2. Hes1 is required in the neural crest for thymus development 
Lack of Hes1 either at the heterozygous (Hes1
Fl/- 
or Hes1
Fl/+
;Wnt1Cre) or 
homozygous level (Hes1
Fl/-
;Wnt1Cre) in the neural crest induced thymic defects at 
E15.5, which ranged from a single thymic lobe to hypoplastic and/or ectopic lobes 
(Figure 4.3.D-F). By this stage the thymic lobes have normally descended above the 
heart and lie as a pair (Grevellec and Tucker, 2010). Ten out of twenty six (38%) 
Wnt1Cre conditional mutants exhibited thymic defects, in comparison to none out of 
seventeen wild type controls, which was significantly different (p<0.05, Fisher’s exact 
test). Defects were also seen in three out of twenty one (14%) of the Hes1
Fl/- 
and two out 
of thirty one (6%) of the Hes1
Fl/+
;Wnt1Cre
 
embryos, but these values did not reach 
statistical significance (Table 4.4). The thymic defects scored in these genotypes also 
included hypoplasia, single or ectopic lobes. 
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Figure 4. 3. Wnt1Cre conditional deletion. Reporter expression as detected by X-gal 
staining in Wnt1Cre;ROSA26 embryos indicating Cre activity in whole mount (A), 
parasagittal (A’) and transverse section at the caudal pharyngeal level (A’’). (B-C) 
Great vessel defects at E15.5. Wild type configuration (B) and Wnt1Cre conditional 
embryo displaying cervical RSCA (C). (D-F) Thymic defects at E15.5. Wild type 
thymus (D) and Wnt1Cre conditional embryos with hypoplastic thymus (E) or a single 
thymic lobe (F). Black arrow, recombination in the neural crest of the pharyngeal 
arches; white arrow, recombination in the neural crest at the SHF level; AoA, aortic 
arch; RCC/LCC, right/left common carotid artery; RSCA/LSCA, right/left subclavian 
artery; RV, right ventricle; SHF, second heart field. 
3.2.1.3. Hes1 may have a minor role in the neural crest towards secondary palate 
and ventricular septum development 
By E15.5 the ventricular septum (Webb et al., 1998) and secondary palate (Gritli-
Linde, 2007; Meng et al., 2009) have formed completely. A minor population of 
Hes1
Fl/+
;Wnt1Cre (one out of thirty one, 3%) and Hes1
Fl/-
;Wnt1Cre
 
(three out of twenty 
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six, 11.5%) embryos displayed intracardiac septation defects while none of the wild 
type embryos had the phenotype, but the values were not statistically significant. Also, 
one (3%) of the Hes1
Fl/+
;Wnt1Cre embryos had a cleft palate.  
3.2.1.3. Hes1 is not required in the neural crest for eye development 
No eye defects were scored in any of the genotypes, suggesting that Hes1 is not 
involved in eye development through the neural crest (Table 4.4). 
3.2.2. Hes1 in the ectoderm 
To assess the ectodermal role of Hes1, the Ap2"Cre model was used (Macatee et 
al., 2003). Conditional mutant embryos were obtained and analysed from Hes1
Fl/Fl
 
(C57BL/6J) to Hes1
+/-
;Ap2"Cre (MF1;C57BL/6J) timed matings. This cross should 
delete Hes1 in neural crest and ectodermal populations of the Hes1
Fl/+
;Ap2"Cre and 
Hes1
Fl/-
;Ap2"Cre
 
embryos (hereafter Ap2"Cre conditional mutants) (Figure 4.4.A-A’’). 
Ap2" driven expression of Cre recombinase should begin at E8.5 in the surface 
ectoderm and head mesenchyme and later in the neural crest lineages and the ectoderm 
of the pharyngeal region (Macatee et al., 2003; Mitchell et al., 1991). The already 
characterised phenotype of the Wnt1Cre conditional mutants was considered when 
discussing the Ap2"Cre conditional mutant phenotype. 
3.2.2.1. Hes1 is required in the neural crest and ectoderm towards arch artery 
morphogenesis 
The pharyngeal arch artery phenotype of the Ap2"Cre conditional mutants was 
also assessed at both stages, after arch artery formation and after arch artery 
remodelling. Conditional deletion of the gene in the neural crest and ectoderm induced 
persistent second arch arteries as well as hypoplasia or aplasia of the third arches in all 
the genotypes examined at E10.5. These, however, were isolated defects that did not 
reach statistical significance in any of the genotypes (p>0.05, between Ap2"Cre 
conditional mutants and wild types, Fisher’s exact test) (Table 4.5). 
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 Hes1
Fl/+
 (WT) Hes1
Fl/- 
Hes1
Fl/+
;Ap2!Cre
 
Hes1
Fl/-
;Ap2!Cre
 
Total embryos 14 9 12 16 
Total normal 13 8 11 14 
Total abnormal 
(%) 1 (7.1%) 1 (11%) 1 (8.3%) 2 (12.5%) 
Persistent 1st &/or 
2nd PAA - 1 1 1 
Hypo/aplastic 3rd 
PAA 
1 (hypo) - - 1 (apl) 
Hypo/aplastic 4th 
PAA 
- - - - 
Hypo/aplastic 6th 
PAA 
- - - - 
Table 4. 5. Arch artery defects observed in the Ap2!Cre conditional embryos at 
E10.5. apl, aplastic; hypo, hypoplastic; PAA, pharyngeal arch artery; WT, wild type. 
Deleting Hes1 in the neural crest and ectoderm produced great vessel defects in 
seven out of thirty two (22%) Ap2"Cre conditional mutants at E15.5 against none out of 
twenty seven wild type embryos, which is statistically significant (p<0.01, Fisher’s 
exact test) (Table 4.6). Five Ap2"Cre conditional embryos exhibited cervical RSCAs 
(Figure 4.4.E) and one had retro-oesophageal origin of the RSCA, which branched off 
the pulmonary artery instead of connecting to the RCC artery (Figure 4.4.D). These 
defects occur when there is aberrant formation or remodelling of the right fourth arch 
artery and are in agreement with the
 
Hes1
-/-
 phenotype (van Bueren et al., 2010). One 
Ap2"Cre conditional mutant presented with duplication of the RCC (Figure 4.4.C), 
potentially a right third arch artery defect, which has not been observed in the Hes1 null 
setting (van Bueren et al., 2010). No outflow tract defects were observed in any of the 
genotypes.   
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Genotype n 
Thymic 
hypo/aplasia 
Great vessel 
defects Eye defects 
Hes1
Fl/+
 (WT) 27 2 (7%) 0 0 
Hes1
Fl/- 
23 2 (8%) 0 0 
Hes1
Fl/+
;Ap2"Cre
 
20 0 0 0 
Hes1
Fl/-
;Ap2"Cre
 32 25** (78%) 7** (22%) 5* (16%) 
Total 102    
*p<0.05      
**p<0.01 
    
Table 4. 6. Thymic, great vessel and eye defects observed in the Ap2!Cre 
conditional embryos at E15.5. P value from Fisher’s exact test between the wild type 
and Hes1
Fl/-
;Ap2"Cre groups. WT, wild type. 
In summary, ablating Hes1 from both the ectodermal and neural crest lineages 
induced isolated second or third arch artery defects in the Ap2"Cre conditional mutants, 
but no fourth arch defects at E10.5. These abnormalities did not reach statistical 
significance compared to the wild type controls (p>0.05, Fisher’s exact test). At E15.5 
the Ap2"Cre conditional mutants exhibited fourth arch artery-derived and in one case 
third arch artery-derived great vessel defects, which were statistically different to the 
wild type controls (p<0.01, Fisher’s exact test). When comparing the Ap2"Cre 
conditional mutant defects between the two developmental stages there is no statistical 
difference (p>0.05, Fisher’s exact test), suggesting that the early formation defects are 
potentially sufficient to induce the late stage phenotype. Increasing the sample size of 
the E10.5 populations may provide safer conclusions. 
3.2.2.2. Hes1 is required in the neural crest and ectoderm for thymic development 
Thymic defects were observed in twenty five out of thirty two (78%) Ap2"Cre 
conditional mutants against two out of twenty seven (7%) wild type embryos at E15.5. 
The difference was statistically significant (p<0.01, Fisher’s exact test) (Table 4.6). The 
conditional mutant defects ranged from hypoplasia, single or ectopic lobes to complete 
aplasia (Figure 4.4.F-J). The two wild type embryos presented with a hypoplastic 
thymus. It should be noted that the great vessel defects were always accompanied by a 
thymic defect. Two out of twenty three (8%) Hes1
Fl/-
 embryos also displayed thymic 
hypoplasia, which was not however statistically significant. 
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Figure 4. 4. Ap2!Cre conditional deletion. Reporter expression as detected by X-gal 
staining in Ap2"Cre;ROSA26 embryos indicating Cre activity in whole mount (A), 
parasagittal (A’) and transverse section at the caudal pharyngeal level (A’’). Great 
vessel defects at E15.5. Wild type configuration (B) and Ap2"Cre conditional embryos 
displaying duplication of the RCC (C), retro-oesophageal RSCA (D) and cervical 
RSCA (E). (F-J) Thymic defects at E15.5. Wild type thymus (D, I) and Ap2"Cre 
conditional embryos with hypoplastic thymus (G), a single thymic lobe (H), or aplastic 
thymus (J). Asterisks denote abnormal vascular segments or missing thymic lobes in (J). 
Black arrow, recombination in the neural crest of the pharyngeal arches; white arrow, 
recombination in the ectoderm at the caudal pharyngeal level; AoA, aortic arch; OFT, 
outflow tract; RCC/LCC, right/left common carotid artery; RSCA/LSCA, right/left 
subclavian artery. 
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3.2.2.3. Hes1 may have a minor role in the neural crest and ectoderm during 
secondary palate and ventricular septum development 
One (3%) Ap2"Cre conditional mutant exhibited exencephaly, was overall 
delayed versus the gestational age and had a cleft lip/palate and VSD (Figure 4.5). It 
was also amongst the embryos with a cervical RSCA. There was also a second Ap2"Cre 
conditional mutant with unfused palatal shelves. 
 
Figure 4. 5. Craniofacial defects in the Ap2!Cre conditional embryos at E15.5. (A-
B) Whole mount views and (C-D) transverse histological sections. An Ap2"Cre 
conditional mutant displaying exencephaly (A), cleft lip (B, D), and cleft palate (C). 
Asterisks denote missing segments. Black arrow, cleft lip. 
3.2.2.4. Hes1 is required in the neural crest and ectoderm for eye development 
Five out of the thirty two (16%) Ap2"Cre conditional mutants presented with 
bilaterally missing eyes, which is statistically different to the wild type phenotype in the 
current sample size (Table 4.6). The eye defects previously reported for Hes1
-/-
 embryos 
range between reduced lenses with small optic cups and abnormal rosette-like structures 
in the retina to complete absence of the lens and an arrested optic cup (Lee et al., 2005; 
Takatsuka et al., 2004; Tomita et al., 1996). In all cases the Ap2"Cre conditional 
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mutants exhibited complete absence of the lens and disorganisation of the whole organ, 
the optic nerves and CNS structures like the optic chiasmata (Figure 4.6).  
 
Figure 4. 6. Eye defects in the Ap2!Cre conditional embryos at E15.5. (A, C) Whole 
mount views and (B, D) transverse histological sections. Normal eye development in 
wild type embryos (A, B) and undeveloped eye in Ap2"Cre conditional embryos 
displaying disorganisation of the organ without distinct cell layers (C, D). Black arrow, 
abnormal structures; C, cornea; G, ganglion cell layer; L, lens; V, ventricular zone. 
3.2.3. Hes1 in the anterior heart field 
The anterior heart field role of Hes1 was investigated through the Mef2c-AHF-Cre 
model (Verzi et al., 2005). Conditional mutant embryos from Hes1
Fl/Fl
 (C57BL/6J) to 
Hes1
+/-
; Mef2c-AHF-Cre (mixed background) timed matings were produced, to delete 
Hes1 in the anterior heart field of the Hes1
Fl/+
; Mef2c-AHF-Cre embryos (hereafter 
Mef2cCre conditional mutants) (Figure 4.7.A-A’’). The promoter and enhancer of the 
Mef2c gene that drive Cre recombinase expression in this model are active from the 
cardiac crescent stage, at E7.5 (Dodou et al., 2003; Verzi et al., 2005). During the linear 
heart tube stage Cre recombinase expression is detected in the pharyngeal mesoderm 
and arterial pole of the heart, and later it is identified in the outflow tract and RV of the 
heart (Dodou et al., 2003; Verzi et al., 2005). 
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3.2.3.1. Hes1 is not required in the anterior heart field for arch artery 
morphogenesis 
Similarly to the previous analyses, Mef2cCre conditional mutants were assessed 
after arch artery formation and after arch artery remodelling. Conditional deletion of the 
gene in the anterior heart field did not induce any pharyngeal arch artery defects at 
E10.5, apart from one case of a Hes1
Fl/+
; Mef2c-AHF-Cre embryo that displayed 
persistent second arch artery (Table 4.7). 
 Hes1
Fl/+
 (WT) Hes1
Fl/- 
Hes1
Fl/+
;Mef2c-
AHF-Cre
 
Hes1
Fl/-
;Mef2c-
AHF-Cre
 
Total embryos 1 1 16 20 
Total normal 1 1 15 20 
Total abnormal 
(%) 0 0 1 (6%) 0 
Persistent 1st &/or 
2nd PAA - - 1 - 
Hypo/aplastic 3rd 
PAA 
- - - - 
Hypo/aplastic 4th 
PAA 
- - - - 
Hypo/aplastic 6th 
PAA 
- - - - 
Table 4. 7. Arch artery defects observed in the Mef2cCre conditional embryos at 
E10.5. PAA, pharyngeal arch artery; WT, wild type. 
Conditional deletion of Hes1 in the anterior heart field did not result in any great 
vessel or outflow tract defects at E15.5-E19.5 either, although the Mef2cCre conditional 
mutant and wild type populations appeared underrepresented during these stages (Table 
4.8). One Hes1
Fl/+
;Mef2c-AHF-Cre embryo exhibited thinning of the arch on the left 
fourth-derived fragment, potentially by an aortic coarctation (Figure 4.7.C). Increasing 
the sample size may clarify whether the Mef2cCre conditional embryos die 
embryonically and if they display a cardiovascular phenotype. 
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Genotype n 
Thymic 
hypo/aplasia 
Great vessel 
defects Eye defects 
Hes1
Fl/+
 (WT) 7 0 0 0 
Hes1
Fl/- 
10 1 (10%) 0 0 
Hes1
Fl/+
;Mef2c-AHF-Cre
 
20 1 (5%) 1 (5%) 0 
Hes1
Fl/-
;Mef2c-AHF-Cre
 5 0 0 0 
Total 42    
Table 4. 8. Thymic, great vessel and eye defects observed in the Mef2cCre 
conditional embryos at E15.5-E19.5. WT, wild type. 
3.2.3.2. Hes1 is not required in the anterior heart field for thymus, palate or eye 
development 
Only isolated cases of thymic or secondary palate defects were scored in some of 
the genotypes of the Hes1
Fl/Fl
 (x) Hes1
+/-
;Mef2c-AHF-Cre cross. One Hes1
Fl/- 
and one 
Hes1
Fl/+
;Mef2c-AHF-Cre embryos displayed thymic hypoplasia. One Hes1
Fl/+
;Mef2c-
AHF-Cre embryo had cleft palate (Figure 4.7.D) and one Hes1
Fl/-
 embryo had 
exomphalos (Figure 4.7.E). No eye defects were scored in any of the genotypes (Table 
4.8). None of these values reached statistical significance.  
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Figure 4. 7. Mef2cCre conditional deletion. Reporter expression as detected by X-gal 
staining in Mef2c-AHF-Cre;ROSA26 embryos indicating Cre activity in whole mount 
(A), parasagittal (A’) and transverse section at the caudal pharyngeal level (A’’). (B-C) 
Great vessel defects. Control embryo normal configuration (B) and a Hes1
Fl/+
;Mef2c-
AHF-Cre embryo displaying thinning of the AoA (C). A Hes1
Fl/+
;Mef2c-AHF-Cre 
embryo had cleft palate (D) and a Hes1
Fl/-
 embryo had exomphalos (E). Asterisks 
denote missing segments. Black arrow, recombination in the ventricular myocardium; 
Hes1 - 228 
Irinna Papangeli 
white arrow, recombination in the mesoderm at the SHF level; AoA, aortic arch; 
RCC/LCC, right/left common carotid artery; RSCA/LSCA, right/left subclavian artery; 
SHF, second heart field. 
3.2.4. Hes1 in the endoderm 
Two different models were employed to conditionally delete Hes1 in the 
endoderm during embryogenesis. The Foxa2mcm (Park et al., 2008) and the Sox17-2A-
iCre (Engert et al., 2009) transgenic animals were used. Timed matings of Hes1
Fl/Fl
 
(C57BL/6J) to Hes1
+/-
;Foxa2mcm or Hes1
+/-
;Sox17-2A-iCre
 
(both MF1;C57BL/6J) 
mice were used to produce embryos to study the endodermal role of Hes1. Tamoxifen 
induction at E5.75 should induce Cre recombinase expression under the Foxa2 driver in 
the definitive endoderm and in a few anterior mesoderm cells at the 0 somite stage (Park 
et al., 2008). By E8.5 Cre recombinase expression should be detected in the foregut 
endoderm, notochord, floorplate and a few head mesenchyme and myocardial and 
endocardial cells (Park et al., 2008). At E9.5 pharyngeal and gut endoderm as well as 
liver bud, notochord and floorplate specific Cre expression should be induced (Park et 
al., 2008). The optimal tamoxifen administration protocol for this line is 120mg/ kg 
body weight by OG at E5.75 and E6.75 (Anne Moon, pers. comm.). Cre expression 
under the Sox17 promoter should be active in the extraembryonic visceral endoderm 
from E6.0, in the visceral and definitive endoderm from E7.5 and by E8.5 throughout 
the gut tube, the endocardial lining of the heart, the DAo, blood vessels in the head 
region and the allantois (Engert et al., 2009). From E9.5 onwards Cre recombinase 
should be expressed in the otic vesicle, the gut, the heart and all the blood vessels 
(Engert et al., 2009). 
The initial approach was deletion of Hes1 in the endoderm through the Foxa2mcm 
model. Although the optimal tamoxifen administration protocol for Cre recombinase 
induction was followed, the reporter expression showed that induction of the promoter 
was not reproducible (Figure 4.8). Unless the recombination efficiency can be assessed 
in each embryo, this model cannot be used to examine the endodermal requirements for 
Hes1 during embryogenesis. 
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Figure 4. 8. Foxa2mcm system induction at E9.5. Reporter expression as detected by 
X-gal staining in Foxa2mcm;ROSA26 embryos indicating maximal (A) and minimal (B) 
induction of the Foxa2mcm driver in two separate experiments following the same 
tamoxifen administration protocol. 
The Sox17-2A-iCre model was therefore used instead of the Foxa2mcm
 
model. 
This approach, however, was abandoned too, because the reporter expression indicated 
that a single Hes1 null allele, potentially in combination with background modifiers, 
interferes with the Sox17 promoter and induces ubiquitous recombination (Figure 4.9). 
Figure 4. 9. Sox17-2A-iCre system induction at E9.5. Reporter expression as detected 
by X-gal staining in Hes1
+/-
;Sox17-2A-iCre;ROSA26 (A, A’) or Hes1
+/+
;Sox17-2A-
iCre;ROSA26 (B, B’) embryos in whole mount (A, B) or transverse section at the caudal 
pharyngeal level (A’, B’) indicating ubiquitous activity of the Sox17-2A-iCre driver in 
the presence of one null Hes1 allele. 
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3.3. Hes1 in the neural crest lineage 
As demonstrated in this thesis, Hes1 is expressed in the pharyngeal mesenchyme 
at E9.5 and neural crest-specific deletion of the gene leads to thymic and isolated great 
vessel defects. Concurrent ectodermal and neural crest cell-specific ablation of the gene 
led to a more severe thymic phenotype and greater penetrance of cardiovascular 
anomalies. Abnormal neural crest patterning has been associated with pharyngeal arch 
artery defects (Kaartinen et al., 2004; Liu et al., 2004; Richarte et al., 2007) while 
conditional inhibition of the Notch pathway in the neural crest lineage induces outflow 
tract and arch artery defects and inhibits neural crest cell differentiation into VSM cells 
(High et al., 2007). Therefore, we sought to investigate potential cell-autonomous roles 
for Hes1 in the neural crest cell population. 
3.3.1. Hes1 in neural crest cell patterning 
Hes1, in co-operation with Hes3 and Hes5, maintains the undifferentiated state of 
neuronal lineages (Kageyama et al., 2005) while Hes1 alone is shown to participate in 
ES cell differentiation (Kobayashi et al., 2009). Combined Hes1 and Hes5 deficiency 
induces premature glial cell differentiation into neurons (Kageyama et al., 2005). 
Moreover, Kobayashi et al., showed that Hes1 binds to and regulates several neural 
crest genes in ES cells, through microarray and ChiP-on-chip assays (Kobayashi et al., 
2009). 
To test the hypothesis that Hes1 may be involved in maintaining cardiac neural 
crest cells in an undifferentiated state, thus allowing for migration into their target sites 
and subsequent in situ differentiation, neural crest cell patterning was examined at 
E10.5 in Hes1
-/-
, Hes1
Fl/-
;Wnt1Cre and Hes1
Fl/-
;Ap2"Cre embryos, compared to stage 
matched littermate controls. This was assessed by whole mount in situ hybridisation for 
Sox10, a known neural crest marker (Kuhlbrodt et al., 1998). A diminished population 
of neural crest cells was observed migrating through the post-otic streams in Hes1 null 
and Wnt1Cre conditional embryos, while diminished population and disrupted 
migratory pathways of the neural crest cells were detected in the Ap2"Cre conditional 
mutants (Figure 4.10). 
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Figure 4. 10. Neural crest patterning in Hes1 mutant embryos at E10.5. Whole 
mount in situ hybridisation for Sox10 on Hes1
Fl/+
 (WT) (A), Hes1
Fl/-
;Wnt1Cre (A’), 
Hes1
Fl/+
 (WT) (B), Hes1
Fl/-
;Ap2"Cre (B’), wild type (C) and Hes1
-/-
 (C’) embryos. 
White box, post otic neural crest streams; ov, otic vesicle; WT, wild type. 
A day earlier, at E9.5, the post-otic neural crest migration streams also appear 
disorganised in Hes1
-/-
 as compared to Hes1
+/-
 stage matched littermate control 
embryos. In Hes1
+/-
 embryos there are two distinct cardiac neural crest streams that will 
populate the third and fourth/sixth arches respectively. Conversely, the cardiac crest 
streams do not form discrete streams in the null embryos (Figure 4.11).  
 
Figure 4. 11. Neural crest patterning in Hes1 mutant embryos at E9.5. In situ 
hybridisation for Sox10 on wild type (A-A’’’) and Hes1
-/-
 (B-B’’’) embryos in whole 
mount (A, B) and coronal sections through the pharyngeal arches (A’-A’’’, B’-B’’’). 
White box, post otic neural crest streams in whole mount and non segregated streams in 
section; white arrow, segregation of neural crest streams; ov, otic vesicle; 1-6, neural 
crest migratory streams depending on target pharyngeal arch. 
3.3.2. Hes1 in post migratory neural crest 
To address whether neural crest cells become sequestered and fail to migrate into 
their target sites in Hes1 null mutants, members of the Hox family of genes, Hoxb4 and 
Hoxd4 that are expressed in the neural crest cells populating the fourth pharyngeal arch 
(Minoux et al., 2009) were examined in E10.5 Hes1
-/-
 versus stage matched littermate 
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control embryos by whole mount in situ hybridisation. Hoxb4 mRNA could not be 
detected with the probe used, and this was not further pursued. Consistently, no 
differences were seen between the Hes1 heterozygous and homozygous embryos in 
Hoxd4 expression at E10.5 (Figure 4.12), a stage by which all caudal pharyngeal arches 
have formed (Hiruma et al., 2002; Yanagisawa et al., 1998). This indicates that even if 
cardiac neural crest cells appear misspatterned at E9.5 and E10.5 by Sox10 labelling, 
neural crest cells eventually populate the fourth arch in the Hes1
-/- 
embryos. 
 
Figure 4. 12. Neural crest patterning in Hes1 mutant embryos at E10.5. Whole 
mount in situ hybridisation for Hoxd4 on control Hes1
+/-
 (A) and Hes1
-/-
 (B) embryos. 
White arrow, post migratory neural crest within the fourth; ov, otic vesicle. 
3.4. Hes1 and the Notch pathway during pharyngeal development 
Notch pathway genes that directly interact with Hes1, like Jag1 (Kobayashi et al., 
2009), which is also expressed in the pharyngeal apparatus during embryogenesis (Barsi 
et al., 2005) and the Hes1 upstream regulator RBP-J (Iso et al., 2003) and glial-specific 
genes, like Neuregulin (Meyer et al., 1997) were examined in E9.5 Hes1
-/- 
versus stage 
matched littermate control embryos by whole mount in situ hybridisation. The Hes1 
mutation induces higher frequency of cardiovascular defects on a C57BL/6J 
background (van Bueren et al., 2010). Therefore, the embryos used for these 
experiments derived from crosses between Hes1 heterozygous animals maintained on a 
C57BL/6J background for at least four generations. 
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Both Jag1 and RBP-J were differentially expressed in Hes1
-/-
 embryos at E9.5, 
compared to heterozygous controls. Jag1 was upregulated in the pharyngeal pouches in 
Hes1 null compared to control embryos, while the rest of the expression domains 
remained unaltered (Figure 4.13.A-B’). Conversely, RBP-J was detected downregulated 
in the pharyngeal ectoderm and mesenchyme in the Hes1 null embryos compared to the 
heterozygous controls (Figure 4.13.C-D’). 
 
Figure 4. 13. Pharyngeal expression of Notch genes in Hes1 mutant embryos at 
E9.5. In situ hybridisation for Jag1 on control Hes1
+/-
 (A, A’) and Hes1
-/-
 (B, B’) 
embryos and RBP-J on control Hes1
+/-
 (C, C’) and Hes1
-/-
 (D, D’) embryos in whole 
mount (A-D) and coronal sections through the pharyngeal arches (A’-D’). Black arrow, 
pharyngeal ectoderm; white arrow, pharyngeal endoderm; ov, otic vesicle. 
At E10.5, an attempt was made to assess cranial ganglia patterning through 
Neuregulin 1 (Nrg1), but the probe used did not detect Nrg1 transcripts, and this was 
not further pursued. 
Hes1 - 234 
Irinna Papangeli 
3.5. Hes1 and the FGF pathway during pharyngeal development 
Fgf8 has been associated with pharyngeal arch artery morphogenesis (Frank et al., 
2002) and has been shown to genetically interact with Tbx1 in great vessel development 
(Aggarwal et al., 2006; Vitelli et al., 2002b). Dominant negative inhibition of the Notch 
pathway in the SHF results in defective EMT in the outflow tract cushions, which can 
be rescued by Fgf8 in ex vivo culture (High et al., 2009). In that respect, differential 
regulation of Fgf8 may contribute to both the arch artery and outflow tract abnormalities 
observed in Hes1 nulls. Nonetheless, no alteration of Fgf8, or Etv4, a readout for FGF 
activity (Mao et al., 2009) was detected at E8.5 by whole mount in situ hybridisation, 
while Fgf8, Fgf10 and Etv4 appeared unaffected at E9.5 as well (Figure 4.14). No 
quantitative change was detected in Etv4 or Etv5 expression at both stages by 
quantitative real time PCR (Figure 4.14.K, K’). The embryos used for these experiments 
derived from crosses between Hes1 heterozygous animals maintained on an MF1 
background. 
Figure 4. 14. Expression of FGF genes in Hes1 mutant embryos at E8.5 and E9.5. 
In situ hybridisation for Fgf8 at E9.5 (A-B’) and E8.5 (C-D’) on wild type (A, A’, C, 
C’) and Hes1
-/-
 (B, B’, D, D’) embryos in whole mount (A, B, C, D) or transverse 
section at the caudal pharyngeal level (A’, B’, C’, D’). In situ hybridisation for Fgf10 at 
E9.5 (E-F’) on wild type (E, E’) and Hes1
-/-
 (F, F’) embryos in whole mount (E, F) or 
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transverse section at the caudal pharyngeal level (E’, F’). In situ hybridisation for Etv4 
at E9.0 (G-H’) and E9.5 (I-J’) on wild type (G, G’, I, I’) and Hes1
-/-
 (H, H’, J, J’) 
embryos in whole mount (G, H, I, J) or transverse section at the caudal pharyngeal level 
(G’, H’, I’, G’). Graphical representation of the relative expression levels of Etv4 (K) 
and Etv5 (K’) by quantitative real time PCR on E8.5 and E9.5 wild type and Hes1
-/-
 
embryos, in single embryos. Black arrow, pharyngeal mesenchyme; ov, otic vesicle; 
WT, wild type. 
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4. Discussion - Future directions 
4.1. Hes1 is expressed in overlapping domains with Tbx1 during early 
embryogenesis 
Hes1 was originally identified through a microarray screen as a putative Tbx1 
target (van Bueren et al., 2010). Preliminary data by a member of our lab suggested that 
Hes1 is expressed in an overlapping fashion with Tbx1 at E9.5 in pharyngeal tissues, 
while Hes1 transcripts appeared downregulated in these tissues in Tbx1
lacZ/lacZ
 embryos 
of the same stage, compared to stage matched wild type controls (van Bueren, 2008). 
Hes1 expression was therefore examined during embryogenesis in this thesis, to 
confirm and extend these results. At E8.5 Tbx1 and Hes1 proteins were found co-
expressed in the pharyngeal ectoderm, endoderm and mesenchyme. A day later, at E9.5 
Hes1 mRNA transcripts were also expressed in an overlapping fashion with Tbx1, in the 
pharyngeal endoderm, mesenchyme and ectoderm. Hes1 expression was additionally 
detected downregulated in E9.5 Tbx1
lacZ/lacZ
 embryos in the pharyngeal endoderm and 
mesenchyme but not ectoderm, compared to littermate stage matched wild type 
controls. These results support the potential for a Tbx1-Hes1 interaction in subsequent 
stages of development. 
Although it would be important to address the issue of a potential genetic 
interaction between Tbx1 and Hes1, to date there is no evidence supporting such a 
relationship in a mammalian system. Previous work by a member of our lab has 
examined the interaction between the two genes by intercrossing heterozygous mice for 
Tbx1 and Hes1. Double heterozygosity for the two genes did not have an effect on the 
Tbx1
 
haploinsufficient arch artery phenotype (van Bueren, 2008). Functional 
redundancy between Hes1 and other bHLH factors may partly explain these results. 
Hes5 compensates for loss of Hes1 expression in the CNS of Hes1 null embryos 
(Hatakeyama et al., 2004). Hey genes have overlapping expression domains with Hes1 
within pharyngeal tissues including the neural crest and pharyngeal endoderm (High et 
al., 2007). Moreover, redundancy between the Hey genes has been previously 
demonstrated, considering that the Hey2 mutation alone is sufficient to cause 
cardiovascular defects, but Hey1 and HeyL induce similar phenotypes only in double 
mutations (Fischer and Gessler, 2007).  
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4.2. Tissue-specific contributions of Hes1 to the null phenotype 
The tissue-specific contribution of Hes1 to the null phenotype previously reported 
was investigated through this work. The data collected (summarised in Table 4.9) 
indicate that Hes1 is involved in great vessel development through ectodermal lineages 
and in thymus development through the neural crest and ectoderm. Additionally, Hes1 
may be acting through the ectoderm towards eye development. 
Cardiovasculature  
Hes1 
deletion 
great 
vessels 
outflow 
tract 
ventricular 
septum 
 
Thymus 
 
Eye 
Neural 
crest  " - " " - 
Ectoderm/
Neural 
crest " - " " " 
Mesoderm - - - - - 
Endoderm could not assess 
Table 4. 9. Summary of the Hes1 conditional deletion phenotypes. ": statistically 
significant; ": potential minor contribution. 
The role of Hes1 via the endoderm has not been possible to be assessed with the 
models used in this thesis. The Foxa2mcm system is tamoxifen inducible and had 
variable activation, which was not consistent, while the Sox17-2A-iCre driver was 
ubiquitously activated in the presence of one null Hes1 allele. Hes1 is shown to repress 
Sox17 in the pharyngeal endoderm at E9.5, an interaction required for the patterning and 
morphogenetic segregation of the ventral foregut lineages (Spence et al., 2009). In that 
respect, earlier interactions between the two genes are possible, making the Sox17-2A-
iCre an inadequate model for Hes1 targeted deletion in the endoderm. 
4.2.1. Cardiovascular development 
All the embryonic germ layers participate in cardiovascular development during 
embryogenesis. The ectoderm is shown to be a distant regulator of fourth arch artery 
development, through Tbx1 (Calmont et al., 2009). The mesoderm provides the 
endothelial lining of the arch arteries (Graham, 2001; Graham, 2003; Graham, 2008; 
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Grevellec and Tucker, 2010) and through the SHF population contributes to the outflow 
tract, RV and parts of the LV and inflow region (Dunwoodie, 2007). The neural crest 
provides the VSM layer that supports the arch arteries (Hutson and Kirby, 2007; Scholl 
and Kirby, 2009) and a significant cellular contribution into the AP septum (Epstein et 
al., 2000; Nakamura et al., 2006), while the endoderm provides essential positional cues 
for the mesoderm and the invading neural crest of the arches (Graham, 2008). Deleting 
Hes1 from the neural crest lineage or the ectoderm and neural crest combined, but not 
the anterior heart field, induced cardiovascular phenotypes. 
Tissue-specific inactivation of Hes1 in neural crest and ectodermal tissues resulted 
in great vessel defects in the Ap2"Cre and in Wnt1Cre conditional mutants at E15.5, 
although with very reduced penetrance in the latter. The phenotype observed in both 
genetic settings included primarily right fourth arch artery related defects, with the 
exception of one Hes1
Fl/-
;Ap2"Cre
 
embryo that displayed duplication of the RCC, a 
right third arch artery-derived defect. These defects are consistent with the Hes1 null 
(MF1;C57BL/6J) great vessel phenotype at E14.5-E15.5 (p>0.05, no difference, 
Fisher’s exact test) (van Bueren et al., 2010). Since Hes1 ablation in the Wnt1 
expressing cells produced a weakly penetrant phenotype, Hes1 may have a minor role in 
great vessel development through the neural crest and a major contribution to the 
process through ectodermal expression. Hes1 may modulate signalling from the 
ectoderm to the neural crest or other mesenchymal lineages, acting non cell 
autonomously on great vessel development. Additive effects from both tissues cannot 
be excluded either. 
Homozygous knock-out of the Hes1 gene additionally induces outflow tract 
defects (Rochais et al., 2009b; van Bueren et al., 2010). However, no such defects were 
observed here, in any of the Hes1 conditional mutations. Two different phenotypes have 
been identified on the genetic backgrounds examined, DORV on MF1 or 
MF1;C57BL/6J backgrounds with very low penetrance (6% or 4% respectively, van 
Bueren et al., 2010) and dextroposed aorta on CD1 background with higher penetrance 
(38%, Rochais et al., 2009b). Additionally, the Hes1
-/-
 (CD1) embryos displayed 
shortening of the outflow tract and widening of the angle between the proximal and 
distal regions at E10.5, compared to littermate controls (Rochais et al., 2009b). Both the 
Ap2"Cre and Wnt1Cre Hes1 conditional mutants produced here were maintained on an 
MF1;C57BL/6J background, while the Mef2cCre conditional mutation was maintained 
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on a mixed background. The outflow tract anomalies may be difficult to demonstrate in 
the conditional deletions due to the fact that low penetrance (even in the constitutive 
nulls) is doubleed by genomic recombination at the Hes1
Fl
 allele, which may not be 
fully efficient. Genetic background modifiers may be responsible for rescuing the 
dextroposed aorta phenotype seen in Hes1
-/-
 CD1 embryos, in the Hes1 tissue-specific 
deletions studied here. It should be noted that during ink filling of the pharyngeal arch 
arteries via the outflow tract in E10.5 embryos, the impression was gained that the 
Wnt1Cre conditional mutants exhibited shorter outflow tracts. This was not observed in 
any of the other conditional or control embryos. It may be worth examining the outflow 
tract length and angulation in all conditional mutants, according to Rochais et al., to 
decisively answer whether Hes1 participates in outflow tract development through any 
of its expression domains (Rochais et al., 2009b).  
A small proportion of Hes1 null embryos display ventricular septation anomalies 
(Rochais et al., 2009b; van Bueren et al., 2010), which was recapitulated by Hes1 
deletion in the neural crest and in smaller frequency by Hes1 deletion in the ectoderm 
and neural crest lineages. Hes1 may hence participate in intracardiac septation through 
the ectoderm and neural crest, although none of these values reached statistical 
significance. 
Hes1 is expressed in the SHF as shown here by Tbx1-Hes1 protein overlap in the 
pharyngeal mesenchyme at E8.5 and the work by Rochais et al. (Rochais et al., 2009b). 
The anterior/secondary heart field is considered a subpopulation of the SHF (Perez-
Pomares et al., 2009). Deletion of Hes1 in the anterior heart field induced isolated arch 
artery defects in two Hes1
Fl/+
;Mef2c-AHF-Cre embryos, but no outflow tract defects or 
other gross anomalies in any of the other genotypes. Both the wild type and the Hes1
Fl/-
;Mef2c-AHF-Cre populations at E15.5-E19.5 appeared underrepresented compared to 
the other groups. Increasing the sample size may elucidate the role of Hes1 in the 
anterior heart field during development. Moreover, refined analysis of the Hes1 
expression domains in the splanchnic mesoderm will clarify if Hes1 is expressed in the 
anterior heart field or complementary domains of the SHF. A Cre allele active in early 
cardiogenic mesoderm, like the Mesp1Cre (Saga et al., 1999) may be more informative 
towards dissecting the Hes1 roles in the mesoderm. 
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4.2.2. Thymus development 
The thymus arises from endodermal cells of the anterior pharyngeal region that 
evaginate the underlying mesenchyme, controlled by signalling from both the neural 
crest-derived mesenchyme and the adjacent mesoderm (Boehm, 2008). The neural crest 
gives rise to the perivascular mesenchyme of the adult organ (Muller et al., 2008). 
Deleting Hes1 either in the neural crest lineage or in both the ectoderm and the neural 
crest populations induced thymic defects in the conditional mutants, highlighting the 
requirement of the gene’s expression for normal thymus development. The Wnt1Cre 
conditional mutants displayed thymic hypoplasia, single or ectopic lobes, partially 
recapitulating the Hes1
-/-
 phenotype characterised on MF1;C57BL/6J background 
(p<0.01, difference, Fisher’s exact test) (van Bueren et al., 2010). The Ap2"Cre 
conditional mutation induced more severe defects, ranging from thymic hypoplasia, 
single or ectopic lobes to thymic aplasia, which were also more penetrant. Hence, 
deletion of Hes1 in the neural crest and ectoderm fully recapitulated the Hes1 null 
thymic phenotype characterised on MF1 background (p>0.05, no difference, Fisher’s 
exact test) although not on the MF1;C57BL/6J background (p<0.05, difference, Fisher’s 
exact test) (van Bueren et al., 2010). No thymic abnormalities were detected in any of 
the Mef2c-AHF-Cre conditional mutants. These results suggest that Hes1 is required in 
the neural crest and ectoderm for thymus development.  
The mesenchyme surrounding the thymic primordium mediates cell proliferation 
and regulates morphogenesis of the thymic epithelium (Gill et al., 2003). Moreover, 
Kaneta et al. showed that in Hes1
-/-
 thymi the cells were reduced to half the number of 
the wild type control, ex vivo, while the ratio of different cell phenotypes was normal 
(Kaneta, 2000). Taken together, these findings propose non cell autonomous roles for 
Hes1 in thymus development, potentially as a mediator of the proliferative and 
morphogenetic actions of the mesenchyme surrounding the thymus. Since the 
perivascular mesenchyme of the adult thymus is of neural crest origin (Muller, 2008), 
Hes1 may be important through the neural crest for the maturity and maintenance of the 
organ, while lack of it may lead to thymic hypoplasia. 
4.2.3. Eye development 
The embryonic eye begins to develop at E8.5, when the anterior neural plate 
evaginates at both sides to form depressions, called optic grooves (Lamb et al., 2007; 
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Lee et al., 2005). These regions balloon outwards creating the optic vesicles that come 
in contact with the surface ectoderm (Lamb et al., 2007; Lee et al., 2005). Reciprocal 
signalling causes the optic vesicles to invaginate and form the optic cups, while the 
ectoderm forms the lens pit and the lens (Lamb et al., 2007; Lee et al., 2005). Retinal 
neurogenesis begins at E11.0 in the dorso-central optic cup (Lamb et al., 2007; Lee et 
al., 2005). Hes1 is required at several stages during eye morphogenesis (Lee et al., 
2005; Takatsuka et al., 2004; Tomita et al., 1996). Lee et al., have shown that Hes1 is 
expressed in the anterior neural plate at E8.5, while Hes1 protein is also detected in the 
surface ectoderm and later in the developing optic vesicle, cup, lens and pigmented 
epithelium (Lee et al., 2005). The same study showed that in Hes1
-/-
 embryos the optic 
vesicles fail to form a cup and the lens is smaller than normal or absent, suggesting that 
Hes1 is required for normal development of these structures (Lee et al., 2005). 
Furthermore, Hes1 is shown to regulate retinal morphogenesis by maintaining the 
precursor state of cells (Lee et al., 2005; Takatsuka et al., 2004). In the absence of Hes1, 
the precursors differentiate prematurely and scatter into the subretinal space, between 
neural retina and pigmented epithelium (Lee et al., 2005; Takatsuka et al., 2004). This 
may be the cause of the abnormal rosette-like structures seen in the Hes1
-/-
 retinas 
(Takatsuka et al., 2004; Tomita et al., 1996). The prematurely differentiated neurons 
cannot divide further, which accounts for the smaller than normal overall size of the 
organ (Takatsuka et al., 2004).  
Depending on the genetic background, the Hes1 null eye phenotype has variable 
expressivity (Lee et al., 2005; Takatsuka et al., 2004; Tomita et al., 1996). On both MF1 
and MF1;C57BL/6J backgrounds there is complete penetrance of absent eyes in Hes1 
null embryos (Kelly Lammerts van Bueren, pers. comm.). Eye defects were scored in 
Ap2"Cre conditional mutants, which also presented with complete loss of the organ. No 
organised structure was apparent, while there were abnormal tissue condensations. No 
eye defects were scored in any of the Wnt1Cre conditional mutants. These results 
highlight an ectodermal requirement for Hes1 in the development of the embryonic eye.  
The gene may mediate the signalling between the surface ectoderm and the optic 
vesicle, since Hes1 nulls present with absent lenses and an arrested optic vesicle (Lee et 
al., 2005; Tomita et al., 1996). From the previous studies it is apparent that Hes1 has 
multiple roles in eye formation and is important at different time points during 
development (Lee et al., 2005; Takatsuka et al., 2004; Tomita et al., 1996). Expression 
Hes1 - 242 
Irinna Papangeli 
in the ectoderm may regulate the development of the optic cup from the optic vesicle as 
well as the formation of the lens. It is plausible that the phenotypically normal eyes of 
the Wnt1Cre conditional mutants may have had a subtle defect in the retina, caused by 
loss of Hes1 in neural crest populations. This was not however examined. Generally, 
increased production of retinal ganglion cells, which is the Hes1 null (Lee et al., 2005; 
Takatsuka et al., 2004) and Shh conditional phenotype (Wang et al., 2002), results in 
micropthalmia, which was not observed in the Wnt1Cre conditionals. 
4.2.4. Neural tube closure 
The neural tube formation in mice commences at E7.5, when the neural folds 
elevate and approach each other medially (Copp, 2005). These start to fuse at E8.5 and 
the process is completed by E10 (Copp, 2005). Hes1 null embryos exhibit failure of 
closure of the cranial neural tube at E9.5 (Ishibashi et al., 1995). On ICR background, 
Hes1 null mice exhibit neurulation defects with 70% penetrance (Ishibashi et al., 1995). 
Work done in our lab has shown that Hes1
-/-
 embryos on MF1 background present with 
low frequency of neural tube defects (NTDs) while on mixed MF1;C57BL/6J 
background there are no neurulation defects (van Bueren et al., 2010). This suggests 
that modifiers within the C57BL/6J background may play a protective role against 
Hes1
-/-
 NTDs. The mixed background of the Ap2"Cre conditional mutants, which 
includes C57BL/6J, may account for the low frequency of NTDs observed. In the 
mouse models used, Cre recombinase begins to be expressed at E8.5, in the midbrain 
(Wnt1Cre) or the surface ectoderm and the head mesenchyme (Ap2"Cre), suggesting 
overlapping patterns of Hes1 deletion in the neural crest in both systems at this time 
point. However, no neurulation defects were observed in any of the Wnt1Cre 
conditional mutants, so Hes1 may have a minor role in neural tube formation through 
the ectoderm. Studying neural tube development in Hes1 conditional mutants 
maintained on an ICR background will probably provide greater insight in the tissue-
specific roles of Hes1 in this process. 
4.3. Genetic background considerations  
Within the genetic makeup of each strain there are different genetic modifiers that 
can affect the phenotype expressivity, penetrance and dominance of a gene of interest 
(Nadeau, 2001). In that respect, a mutation should be considered to induce a phenotype 
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in a specific
 
genomic context (Montagutelli, 2000). Consequently, great caution should 
be taken when comparing data between different experiments, as the background 
modifiers may profoundly influence the resulting phenotype of a mutation. 
The Hes1 mutation is highly background-dependent. A low penetrance great 
vessel phenotype is seen on an MF1 or MF1;C57BL/6J background (van Bueren et al., 
2010), while no great vessel defects are observed on a CD1 background (Rochais et al., 
2009b). Conversely, the outflow tract phenotype is weakly penetrant on an MF1 or 
MF1;C57BL/6J background (van Bueren et al., 2010), while it has greater penetrance 
on a CD1 background (Rochais et al., 2009b). Thymic abnormalities are observed with 
incomplete (MF1) or complete (MF1;C57BL/6J) penetrance, depending on the genetic 
background (van Bueren et al., 2010). The eye phenotype observed in Hes1 null 
embryos (Tomita et al., 1996) has variable expressivity on the different genetic 
backgrounds. On the original 129/Sv (x) ICR background Hes1
-/-
 embryos display 
disorganised lens, rosette-like structures dispersed in the ventricular zone and poor 
cornea development (Tomita et al., 1996). However, complete absence of the organs is 
observed in Hes1 nulls on both MF1 and MF1;C57BL/6J backgrounds (Kelly Lammerts 
van Bueren, pers. comm.). Moreover, approximately 70% of the Hes1
-/-
 embryos kept 
on the original 129/Sv (x) ICR background exhibit severe NTDs (Ishibashi et al., 1995), 
while some embryos of the same genotype present with NTDs when kept on an MF1 
background and none when kept on an MF1;C57BL/6J background (van Bueren, 2008). 
As it has become apparent from the literature and the results of this thesis, the 
different features of the Hes1 null phenotype have variable penetrance and expressivity 
on the different genetic backgrounds. Consideration is therefore required when 
discussing the results of different studies, while all comparisons should be made with 
reference to the respective genetic background. For this study, a mixed MF1;C57BL/6J 
background was used, so all comparisons between the Hes1 conditional mutants and the 
Hes1 knock-out phenotype are discussed based on this background, unless otherwise 
specified. 
4.4. Hes1 in the neural crest lineage 
The neuropilin receptors Npr1 and Npr2, together with their class 3 semaphorin 
ligands, direct cranial neural crest migration (Schwarz et al., 2008). Embryos carrying 
homozygous null mutations of Nrp1 or Nrp2 (Nrp1
-/-
 or Nrp2
-/-
) or Nrp2 null embryos 
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with reduced semaphorin signalling through neuropilins (Nrp1
sema3+/-
;Nrp2
-/-
)
 
present 
with ectopically patterned neural crest cells that subsequently give rise to ectopic 
neurons (Schwarz et al., 2008). Although cardiac neural crest cell patterning defects 
were identified in Hes1 null, Wnt1Cre and Ap2"Cre conditional mutants, no ectopic 
neural crest-derived structures were detected in consequent developmental stages. 
However, the main defect identified here was compromised cellular contribution from 
the neural crest to the pharyngeal arches, rather than additional ectopic migratory 
streams. Moreover, fourth arch neural crest cells appeared normally localised by Hoxd4 
expression in Hes1
-/-
 embryos compared to controls, suggesting normal population of 
cardiac crest cells within these arches. Potentially, the cardiac crest that reaches the 
pharyngeal arches is sufficient for subsequent arch artery and outflow tract 
development. The low penetrance of great vessel and outflow tract defects observed in 
Hes1 null (Rochais et al., 2009b; van Bueren et al., 2010) and Wnt1Cre and Ap2"Cre 
conditional mutants (this thesis, in van Bueren et al., 2010) may reflect stochastic events 
that additionally compromise neural crest contribution into the cardiovasculature, 
resulting in these defects. 
4.5. Hes1 and Notch pathway genes during pharyngeal development 
In beginning to identify a mechanism by which Hes1 is involved in cardiovascular 
and thymus morphogenesis, genes known to directly interact with Hes1, like Jag1 
(Kobayashi et al., 2009), also known to be expressed in pharyngeal structures during 
embryogenesis (Barsi et al., 2005) and the Hes1 upstream regulator RBP-J (Iso et al., 
2003) were examined in Hes1 null embryos. Differential regulation of both Jag1 and 
RBP-J was identified in the Hes1 null pharyngeal apparatus compared to controls at 
E9.5. Hes1 probably normally represses Jag1 and promotes RPB-J in the pharyngeal 
region of E9.5 mouse embryos. These results suggest that Hes1 may be acting through 
an auto-regulatory loop through the Notch pathway in exerting its roles in pharyngeal 
development. Nonetheless, conditional deletion of Jag1 in the anterior heart field, using 
the same Mef2c-AHF-Cre model implemented here, induced outflow tract and great 
vessel defects with high penetrance (High et al., 2009), conversely to the Mef2c-AHF-
Cre Hes1 conditional mutation.  
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4.6. Hes1 and the FGF pathway 
Fgf8 has been associated with pharyngeal arch artery morphogenesis (Frank et al., 
2002) and has been shown to genetically interact with Tbx1 in great vessel development 
(Aggarwal et al., 2006; Vitelli et al., 2002b). Recent evidence suggests that Notch 
functions via Jag1 in the SHF to regulate Fgf8, which in turn modulates downstream 
pathways affecting neural crest invasion and endocardial cushion development (High et 
al., 2009). However, no alteration in Fgf8 or elements of the FGF pathway were 
identified in Hes1 null compared to wild type control embryos, by both whole mount in 
situ hybridisation and quantitative real time PCR between E8.5-E9.5. Therefore, Hes1 
probably does not interact with the FGF pathway towards arch artery and outflow tract 
morphogenesis. 
4.7. Conclusion and future directions 
In this chapter I have addressed the tissue-specific requirements for Hes1 during 
embryogenesis and tried to study potential mechanisms of action. Non cell autonomous 
actions for Hes1 were revealed in the ectoderm, towards great vessel and eye 
development, while Hes1 is essential in both the ectodermal and neural crest lineages 
for thymus morphogenesis.  
To further understand the Hes1 requirements in mouse embryogenesis, the 
endodermal contribution of the gene has to be examined. This has not been possible 
through this thesis, so future work may implement a different endoderm-specific Cre 
line, like the Claudin-6Cre (Anderson et al., 2008) towards that end. Alternatively, both 
the standard knock-out and the conditional lines can be studied on the same 
background, to eliminate background specific modifiers. 
Potential Hes1 roles in the neural crest can be addressed further. During this 
project I have shown that Hes1 deficiency can cause aberrant neural crest patterning, 
although the final neural crest contribution to the fourth arches appears unaffected. 
Kobayashi et al., have demonstrated that lack of Hes1 affects multiple neural crest 
related genes in ES cells (Kobayashi et al., 2009). Neural crest explant assays can be 
implemented to examine the Hes1 role in differentiation and/or migration potential of 
this lineage. Last, Hes1 was originally identified as a putative Tbx1 target through a 
microarray screen and validated by quantitative real time PCR (van Bueren et al., 2010). 
Hes1 - 246 
Irinna Papangeli 
I demonstrated that Hes1 and Tbx1 proteins overlap in pharyngeal structures at E8.5, 
while a day later, at E9.5 both genes also shared common expression domains. 
Additionally, Hes1 was found downregulated in pharyngeal tissues in Tbx1 null 
embryos at E9.5. Although, to date, no evidence exists supporting a genetic interaction 
between Tbx1 and Hes1 (van Bueren, 2008), examination of a potential interaction 
during endocardial cushion and outflow tract development stages may be more 
informative. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V. SLIT2
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1. Introduction – Literature review 
1.1. The Slit/Robo pathway 
1.1.1. Biological functions 
Slit was originally described in Drosophila as a secreted protein expressed in the 
midline of the developing CNS (Andrews et al., 2007; Hohenester, 2008). By binding to 
its receptor, Roundabout (Robo), it acts as a repellent and regulates guidance, migration 
as well as outgrowth and branching of axons (Andrews et al., 2008). Slit/Robo 
interactions have been described in cortical, olfactory tract, optic chiasm and optic tract 
development as well as midline axonal crossing and motor axon path finding in the 
hindbrain (Andrews et al., 2007). In chicken embryos Slit/Robo signalling is important 
for the confinement of trunk neural crest cells to the ventral migratory pathway (Jia et 
al., 2005) and for the prevention of trunk crest cells from invading the gut (De Bellard 
et al., 2003). The Slit/Robo pathway is also involved in the development of other 
systems, including lung, kidney and mammary gland (Hohenester, 2008). Interestingly, 
Slit/Robo mediated signalling is required for the assembly of the heart tube in 
Drosophila, by regulation of the migration and adhesive interactions of cardiac 
precursor cells (MacMullin and Jacobs, 2006; Santiago-Martinez et al., 2006). 
Moreover, through repulsive interactions, Slit/Robo is also required for lumen 
formation of the Drosophila heart (Medioni et al., 2008; Santiago-Martinez et al., 
2008). 
1.1.2. Protein interactions 
There are at least three Slit homologs (Slit1-3) and four Robo homologs (Robo1-4) 
in mammals (Dickinson and Duncan, 2010). Slit proteins appear to lack hydrophobic 
sequences, which indicates transmembrane domains, and are predicted to be secreted 
proteins associated with the ECM (Dickinson and Duncan, 2010). The evolutionary 
conserved domains of the Slit proteins include four tandem leucine-rich repeats (D1-
D4) at the N-terminus, six EGF-like domains, a laminin G-like domain, three more 
EGF-like domains and a C-terminal cystine knot domain (Dickinson and Duncan, 2010; 
Hohenester, 2008). Among the Robo proteins, Robo1-3 share a common extracellular 
domain that is reminiscent of cell adhesion molecules (CAMs) (Dickinson and Duncan, 
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2010) and consists of five immunoglobulin (IG)-like domains and three fibronectin type 
3 (FN3) repeats (Andrews et al., 2007; Hohenester, 2008). Robo4, which unlike Robo1-
3 is expressed exclusively in endothelial cells and not the CNS, has two IG-like and two 
FN3 domains (Andrews et al., 2007; Hohenester, 2008). Robo proteins also have a 
transmembrane region and a cytoplasmic domain suggested to interact with downstream 
signalling molecules (Andrews et al., 2007). Slit binding has been confirmed 
biochemically for all Robos, except for Robo4 (Hohenester, 2008), and it has been 
suggested that Robo4 may not be a true Robo receptor (Dickinson and Duncan, 2010).  
Slit binding onto the Robo receptors leads to modifications in the cytoplasmic 
domain of the receptors and reorganisation of the actin cytoskeleton (Dickinson and 
Duncan, 2010). The Robo cytosolic domains do not have catalytic activity (Hohenester, 
2008). It is believed that several catalytically inactive adaptors are bound to the Robo 
cytosolic domain and respond to Slit binding, subsequently promoting downstream 
signalling (Hohenester, 2008).  
1.1.2.1. Slit2 
Slit2 is expressed in the pharyngeal clefts from E8.5 while it is detected 
prominently in CNS structures throughout development (Yuan et al., 1999). It is 
involved in retinal axon growth and guidance (Plump et al., 2002) as well as ureteric 
bud formation (Grieshammer et al., 2004). In the developing kidney Slit2 associates 
with the receptor Robo2 to promote intracellular signalling (Grieshammer et al., 2004).  
1.2. Slit/Robo gene mutations 
Slit1 or Slit2 targeted mutations lead to nervous system defects ((Plump et al., 
2002). Slit2 null embryos additionally exhibit defects in the renal/urinary system and 
display prenatal or perinatal lethality (Grieshammer et al., 2004). Slit3 mutants exhibit 
right ventricular hypertrophy, diaphragm and kidney defects (Liu et al., 2003; Yuan et 
al., 2003). Targeting genes of the Robo family affects the nervous system and causes 
prenatal or perinatal lethality in all cases (Andrews et al., 2008; Andrews et al., 2006; 
Long et al., 2004; Sabatier et al., 2004), while systems like the respiratory, renal/urinary 
and vasculature are also affected in Robo1 (Xian et al., 2001), Robo2 (Grieshammer et 
al., 2004; Lu et al., 2007) and Robo4 (Jones et al., 2008) mutants respectively.   
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2. Project overview 
The initial indication that Slit2 may be a Tbx1 regulated gene resulted from our 
microarray screen and subsequent quantitative real time PCR validation (van Bueren et 
al., 2010). Further study in our lab demonstrated that during early embryogenesis Slit2 
is expressed in an overlapping fashion with Tbx1 in the surface ectoderm, while the 
receptor Robo1 is expressed in the migrating neural crest (Calmont et al., 2009). Slit2 
was also found downregulated in pharyngeal tissues of Tbx1 null embryos (Calmont et 
al., 2009). Previous studies have shown that the Slit/Robo pathway is involved in trunk 
neural crest migration in the chicken (De Bellard et al., 2003; Jia et al., 2005). 
Collectively, these data highlight a potential involvement of the Slit/Robo pathway in 
cardiac neural crest migration, potentially regulated by Tbx1, which motivated us to 
further study Slit2. As part of this thesis, the expression profiles of both Slit1 and Slit2 
were examined at E9.5. Moreover, the Slit2 null and double Slit1;Slit2 null phenotypes 
were assessed in terms of cardiovascular and other 22q11DS-like defects. Finally, the 
potential Tbx1-Slit2 genetic interaction was studied to establish whether the two genes 
act through a common pathway. 
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3. Results 
3.1. Slit1 and Slit2 in the mouse embryo 
3.1.1. Expression domains 
At E9.5 both Slit1 and Slit2 are expressed in the pharyngeal apparatus, as 
identified by whole mount in situ hybridisation. Slit1 is detected in the pharyngeal 
mesenchyme, potentially the core mesoderm (Figure 5.1.B, B’), while Slit2 is found in 
the pharyngeal ectoderm and endoderm (Figure 5.1.C, C’). Hence, both genes share 
expression domains with Tbx1.   
 
Figure 5. 1. Tbx1, Slit1 and Slit2 mRNA expression detected by in situ 
hybridisation at E9.5. (A, A’) Tbx1 mRNA expression in whole mount (A) and 
coronal section through the pharyngeal arches (Ivins et al., 2005) (A’). (B, B’) Slit1 
mRNA expression in whole mount (B) and coronal section through the pharyngeal 
arches (B’). (C, C’) Slit2 mRNA expression in whole mount (C) and coronal section 
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through the pharyngeal arches (C’). Yellow arrowhead, pharyngeal ectoderm; blue 
arrowhead, core mesoderm; white arrowhead, pharyngeal endoderm; ov, otic vesicle. 
3.1.2. Slit2 mutant phenotype
1
 
By E15.5 in the mouse embryo the great vessels (Hiruma et al., 2002) and the 
ventricular septum (Webb et al., 1998) have formed completely, while the thymic lobes 
have descended above the heart and lie as a pair (Grevellec and Tucker, 2010). Slit2 
mutant embryos were examined between E15.5-E18.5 but none exhibited any great 
vessel or thymic defects, whereas one out of the seventeen (6%) Slit2
-/-
 embryos 
assessed had a VSD (Table 5.1). This however is not statistically significant. No 
outflow tract defects were observed in any of the genotypes. 
Genotype n 
Thymic 
hypo/aplasia 
Great vessel 
defects 
Intracardiac 
septation 
WT 17 0 0 N/S 
Slit2
+/- 
21 0 0 N/S 
Slit2
-/- 
17 0 0 1 (6%) 
Total 55    
Table 5. 1. Thymic, great vessel and intracardiac defects observed in the Slit2 
embryos at E15.5-E18.5. N/S, not studied; WT, wild type. 
3.1.3. Slit1;Slit2 mutant phenotype
1
 
Slit1 and Slit2 act synergistically in the developing CNS regulating retinal axon 
guidance (Plump et al., 2002). In an effort to overcome any functional redundancy that 
might occur between the two genes in cardiovascular and thymic development, 
transheterozygous Slit1
+/-
;Slit2
+/-
 animals were intercrossed and embryos were analysed 
between E14.5-E18.5 for thymic and great vessel defects. The E14.5 embryos were 
examined for great vessel and outflow tract defects only, since the mature left-sided 
configuration is fully remodelled by E13.5 (Hiruma et al., 2002). No defects were 
scored in any of the genotypes (Table 5.2). Consistently, no thymic, great vessel or 
outflow tract abnormalities were observed in any of the genotypes at E18.5 (Table 5.3).   
                                                
1
 All the Slit2 and Slit1;Slit2 embryos analysed in this study were kindly provided by our collaborator, 
William Andrews, Department of Anatomy and Developmental Biology, University College London, 
London, UK. Therefore, there was limitation in the available embryonic stages, while the embryonic 
heads had been used for his own studies. 
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Genotype n 
Great vessel 
defects 
WT 1 0 
Slit1
+/- 
6 0 
Slit2
+/- 
0 0 
Slit1
-/- 
1 0 
Slit2
-/- 
0 0 
Slit1
+/-
;Slit2
+/- 
0 0 
Slit1
-/-
;Slit2
+/- 
6 0 
Slit1
+/-
;Slit2
-/- 
1 0 
Slit1
-/-
;Slit2
-/- 
1 0 
Total 16  
Table 5. 2. Great vessel defects observed in the Slit1;Slit2 double mutant embryos 
at E14.5. WT, wild type. 
Genotype n 
Thymic 
hypo/aplasia 
Great vessel 
defects 
WT 0 0 0 
Slit1
+/- 
4 0 0 
Slit2
+/- 
1 0 0 
Slit1
-/- 
2 0 0 
Slit2
-/- 
0 0 0 
Slit1
+/-
;Slit2
+/- 
6 0 0 
Slit1
-/-
;Slit2
+/- 
12 0 0 
Slit1
+/-
;Slit2
-/- 
1 0 0 
Slit1
-/-
;Slit2
-/- 
4 0 0 
Total 30   
Table 5. 3. Thymic and great vessel defects observed in the Slit1;Slit2 double 
mutant embryos at E18.5. WT, wild type. 
3.2. Tbx1-Slit2 genetic interaction 
Slit2 was originally identified as a potential Tbx1 downstream effector (van 
Bueren et al., 2010). Moreover, the Slit2 expression pattern has overlapping domains 
with Tbx1 in the pharyngeal apparatus at E9.5 (Calmont et al., 2009; this thesis), and 
Slit2 is detected downregulated in these tissues in Tbx1 null embryos (Calmont et al., 
2009). The potential genetic interaction between Tbx1 and Slit2 was therefore examined 
as part of this thesis. Two different Tbx1 null alleles (Lindsay et al., 2001; Xu et al., 
2004) were used for this purpose, due to lack of available animals. 
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3.2.1. Tbx1 and Slit2 double heterozygosity 
Double heterozygous animals were generated for Tbx1 and Slit2 and were 
examined for 22q11DS-like features. The embryos were assessed at E15.5, a stage by 
which the great vessels (Hiruma et al., 2002), ventricular septum (Webb et al., 1998) 
and secondary palate (Gritli-Linde, 2007; Meng et al., 2009) have formed completely 
and the thymic lobes have assumed their final position as a pair above the heart 
(Grevellec and Tucker, 2010). One out of five (20%) Slit2
+/-
;Tbx1
+/lacZ 
embryos 
exhibited cervical origin of the RSCA (Figure 5.2.B) as compared to one out of seven 
(14%) Tbx1
+/lacZ 
embryos that displayed the same phenotype. Four out of five (80%) 
Slit2
+/-
;Tbx1
+/lacZ  
embryos had a cleft palate (Figure 5.2.C), against three out of three 
(100%) of the Slit2
+/-
 embryos and four out of seven (57%) of the Tbx1
+/lacZ 
embryos. 
Moreover, two out of five (40%) Tbx1;Slit2 double heterozygotes had a VSD (Figure 
5.2.D), which was in one case accompanied by an overriding aorta (Figure 5.2.E). Two 
out of seven (29%) Tbx1
+/lacZ 
embryos also displayed a VSD. None of these phenotypes 
were scored in any of the three wild type controls. Although a trend of increased 
frequency in all the Slit2
+/-
;Tbx1
+/lacZ
 phenotypes is apparent, in the current sample size 
none of these values reaches statistical significance (Table 5.4). No outflow tract defects 
were observed in any of the genotypes. 
Genotype n 
Thymic 
hypo/aplasia 
Great vessel 
defects 
Palatal 
defects 
Intracardiac 
septation 
WT 3 0 0 0 0 
Tbx1
+/lacZ 
7 1 (14%) 1 (14%) 4 (57%) 2 (29%) 
Slit2
+/- 
3 0 0 3 (100%) 0 
Slit2
+/-
;Tbx1
+/lacZ 
5 0 1 (20%) 4 (80%) 2 (40%) 
Total 18     
Table 5. 4. Thymic cardiovascular and palate defects observed in the Tbx1;Slit2 
double heterozygous embryos at E15.5. WT, wild type. 
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Figure 5. 2. Great vessel, palate and intracardiac defects observed in the Tbx1;Slit2 
double heterozygous embryos at E15.5. (A-B) Great vessel defects. Wild type 
configuration (A) and a Slit2
+/-
;Tbx1
+/lacZ
 embryo displaying cervical RSCA (B). Cleft 
palate (C), VSD (D) and VSD with OA (E) observed in Slit2
+/-
;Tbx1
+/lacZ
 embryos. 
Asterisks denote missing segments. AoA, aortic arch; RCC/LCC, right/left common 
carotid artery; RSCA/LSCA, right/left subclavian artery. 
3.2.2. Tbx1 heterozygosity on a Slit2 null background 
To examine whether complete lack of Slit2 might influence the Tbx1 
haploinsufficient phenotype, double heterozygous animals for Tbx1 and Slit2 were 
intercrossed with Slit2 heterozygotes, and the progeny was assessed at E15.5 for 
22q11DS-like phenotypes. One out of six (17%) Slit2
-/-
;Tbx1
+/mcm 
embryos displayed 
thymic hypoplasia (Figure 5.3.D), while two out of seven (29%) Slit2
+/-
;Tbx1
+/mcm 
embryos (Figure 5.3.C) and two out of six (33%) Tbx1
+/mcm 
embryos (Figure 5.3.B) 
exhibited the same phenotype. In terms of great vessel defects, four out of six (67%) 
Slit2
-/-
;Tbx1
+/mcm 
embryos (Figure 5.3.D’), three out of seven (43%) Slit2
+/-
;Tbx1
+/mcm 
embryos (Figure 5.3.C’), three out of six (50%) Tbx1
+/mcm 
embryos (Figure 5.3.B’) and 
one out of eight (13%) Slit2
+/- 
embryos displayed a phenotype. The great vessel 
phenotype ranged from cervical or retro-oesophageal RSCA to IAA-B in all affected 
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groups, denoting fourth arch artery-derived defects. None of these values reached 
statistical significance in the current sample size (Table 5.5). No outflow tract defects 
were observed in any of the genotypes. 
Genotype n 
Thymic 
hypoplasia 
Great vessel 
defects 
WT 2 0 0 
Tbx1
+/mcm 
6 2 (33%) 3 (50%) 
Slit2
+/- 
8 0 1 (13%) 
Slit2
-/- 
3 0 0 
Slit2
+/-
;Tbx1
+/mcm 
7 2 (29%) 3 (43%) 
Slit2
-/-
;Tbx1
+/mcm 
6 1 (17%) 4 (67%) 
Total 32   
Table 5. 5. Thymic and great vessel defects observed in the Tbx1;Slit2 double 
mutant embryos at E15.5. WT, wild type. 
Figure 5. 3. Thymic and great vessel defects observed in the Tbx1;Slit2 double 
mutant embryos at E15.5. (A-D) Thymic defects. Wild type thymus (A) and 
hypoplastic phenotypes in Tbx1
+/mcm
 (B), Slit2
+/-
;Tbx1
+/mcm
 (C) and Slit2
-/-
;Tbx1
+/mcm
 (D) 
embryos. (A’-D’) Great vessel defects. Wild type configuration (A’) and IAA-B (B’), 
retro-oesophageal RSCA (C’) and IAA-B (D’) in Tbx1
+/mcm
 (B), Slit2
+/-
;Tbx1
+/mcm
 (C) 
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and Slit2
-/-
;Tbx1
+/mcm
 (D) embryos. Asterisks denote missing segments. Black arrow, 
abnormal structure; AoA, aortic arch; RCC/LCC, right/left common carotid artery; 
RSCA/LSCA, right/left subclavian artery. 
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4. Discussion - Future directions 
4.1. Slit1 and Slit2 share expression domains with Tbx1 
Slit2 was originally identified as a putative Tbx1 downstream effector in our 
microarray screen comparing Tbx1-expressing heterozygous and null cells at E9.5 (van 
Bueren et al., 2010). Further work conducted in our lab demonstrated that Slit2 is 
expressed in an overlapping fashion with Tbx1 in the surface ectoderm at E8.75, while 
the receptor Robo1 is expressed in the migrating neural crest at E9.0 (Calmont et al., 
2009). Both genes appeared downregulated or misspatterned in Tbx1 null embryos 
(Calmont et al., 2009). Previous studies have shown that the Slit/Robo pathway is 
involved in trunk neural crest migration in chicken embryos (De Bellard et al., 2003; Jia 
et al., 2005). These data combined support a role for Slit/Robo signalling in cardiac 
crest migration, potentially regulated by Tbx1.  
The Slit genes are expressed in similar patterns in the mouse pharyngeal apparatus 
(Yuan et al., 1999), and may therefore display functional redundancy. Moreover, 
synergistic actions between Slit1 and Slit2 have been proven in the developing CNS in 
retinal axon guidance (Plump et al., 2002). The expression pattern of both Slit1 and 
Slit2 was studied in this thesis. Slit3 is shown to share expression domains with Slit2 
during early embryogenesis (Yuan et al., 1999) but it was not studied due to probe 
unavailability. Through this thesis, and verifying the previous studies, both Slit1 and 
Slit2 were found expressed in pharyngeal tissues at E9.5, in an overlapping fashion with 
Tbx1 but not between them. Although this is further evidence that Slit2 might be 
regulated by Tbx1, compensatory roles between Slit1-Slit2 are rather unlikely, while a 
Slit2-Slit3 compensation appears more possible. 
4.2. Slit2 or Slit1;Slit2 deficiency does not induce cardiovascular 
defects 
The expression pattern of Slit1 and Slit2, as described in this thesis, leads to some 
predictions as to what might have been expected, if these genes had a role in 
cardiovascular development. Slit1, similarly to Tbx1 (Zhang et al., 2006), via 
mesodermal expression could have been required in the developing outflow tract. By 
contrast, Slit2 would be expected to regulate the pharyngeal arch arteries through 
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ectodermal signalling, like Tbx1 (Calmont et al., 2009). Moreover, targeted mutation for 
Slit2 induces prenatal or perinatal lethality (Plump et al., 2002), which has not been 
justified to date, leaving cardiovascular deficiency as a possible explanation. However, 
none of the Slit2 null embryos examined displayed any cardiovascular defects, apart 
from one embryo that had VSD. Since there is potential redundancy among the Slit 
family genes, double homozygous mutants for Slit1 and Slit2 were assessed for 
cardiovascular defects. Lack of both copies of Slit1 and Slit2 did not induce a heart 
phenotype either. This is also in accordance with the fact that Slit1 null animals are 
viable and fertile (Plump et al., 2002). Taken together, these results do not suggest any 
redundant actions between Slit1 and Slit2 or any involvement of either of the genes in 
heart development, at least in the current sample size. 
4.3. Slit2 or Slit1;Slit2 deficiency does not induce thymic defects 
Following the original hypothesis, that Slit2 might be a Tbx1 downstream effector 
and hence may be mediating some of its actions, the thymic phenotype was also 
examined in Slit2 null and Slit1;Slit2 null embryos. However, neither the Slit2 null 
mutation nor the combined Slit1;Slit2 null mutation induced any thymic defects. 
Therefore, these genes are more likely not involved in thymic development. 
4.4. Tbx1 and Slit2 probably do not genetically interact 
To further investigate a potential relationship between Tbx1 and Slit2, the genetic 
interaction between the two genes was examined by studying the phenotype of Slit2
+/-
;Tbx1
+/- 
or Slit2
-/-
;Tbx1
+/-
 embryos at E15.5. Due to lack of available animals, two 
different Tbx1 null alleles (Lindsay et al., 2001; Xu et al., 2004) were used. Combined 
heterozygosity for Slit2 and Tbx1 when using the Tbx1
lacZ
 allele (Lindsay et al., 2001), 
showed a trend towards greater frequency in the defects scored. However, the sample 
size is too small to deduce safe conclusions. In contrast, combined heterozygosity for 
Slit2 and Tbx1 with the use of the Tbx1
mcm
 allele (Xu et al., 2004) produced defect 
frequencies similar to that induced by single heterozygosity for Tbx1. Moreover, the 
Slit2
-/-
;Tbx1
+/- 
embryos did not differ significantly in terms of great vessel or thymic 
defects with the Tbx1 heterozygotes. These results suggest that, in the current sample 
size, Tbx1 does not interact with Slit2 towards cardiovascular or thymic development.  
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It should be noted that the initial cross, between Tbx1
+/lacZ
 and Slit2
+/- 
animals did 
not produce the expected frequency of great vessel defects for Tbx1 heterozygosity in 
the Tbx1
+/lacZ 
progeny (Calmont et al., 2009; Lindsay et al., 2001; Vitelli et al., 2002b 
Vitelli et al., 2006; Zhang and Baldini, 2008). The Tbx1
+/mcm 
embryos examined from 
the second cross, however, which was between Slit2
+/-
;Tbx1
+/mcm
 and Slit2
+/-
 animals, 
displayed the expected frequency of great vessel defects for Tbx1 haploinsufficiency. 
This difference is probably due to the small sample size of the first cross. Nonetheless, 
allele-specific or background-specific modifiers potentially influencing the phenotype 
between the two different experiments cannot be excluded. Therefore, the results 
between the experiments cannot be combined, but should rather be discussed 
independently. 
One other aspect that should be discussed here is the cleft palate phenotype 
identified in the Slit2
+/-
 and Slit2
+/-
;Tbx1
+/lacZ 
embryos. Tbx1 is required for palatal shelf 
elongation and elevation (Goudy et al., 2010). Palatal clefting has been reported in Tbx1 
null mutants but not heterozygous embryos (Hu et al., 2004; Jerome and Papaioannou, 
2001). Although a proportion of the Tbx1 heterozygotes examined here displayed cleft 
palate, both Slit2
+/-
 and Slit2
+/-
;Tbx1
+/lacZ
 groups displayed higher frequency of palatal 
defects, as compared to the wild type controls or the Tbx1 heterozygotes. The facial 
primordia consist of a mesenchymal core that is predominantly of cranial neural crest 
origin, and of an outer epithelial covering deriving from the embryonic ectoderm 
(Gritli-Linde, 2007). Overall these results may be an indication of a Tbx1-Slit2 pathway 
involved in cranial neural crest patterning towards the morphogenesis of craniofacial 
structures.  
4.5. Conclusion and future directions 
Through this last chapter, I examined the phenotype caused by Slit2 or Slit1;Slit2 
deficiency, but found no evidence of a role for either of this genes in the development of 
structures affected in 22q11DS. Moreover, I addressed the possible genetic interaction 
between Tbx1 and Slit2 and also found no evidence of such a relationship. The sample 
size is small, so an interaction between the two genes cannot be excluded either. 
Increasing the sample size and using the same Tbx1 allele consistently may elucidate 
this. Additionally, it might be worth examining the Slit2;Slit3 mutation for a 
cardiovascular phenotype and further to that, in combination with Tbx1. Slit3 mutants 
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display right ventricular hypertrophy (Liu et al., 2003), which is not a Tbx1 related 
phenotype. However, Slit2 and Slit3 have similar expression patterns during 
embryogenesis (Yuan et al., 1999) and compensatory actions between them may be 
masking a Tbx1 regulatory role on Slit2. Multiple gene mutations, for example triple 
mutants for the Robo1-3 receptors or the Slit1-3 ligands are probably the way forward 
due to the redundancy in the system. Alternatively dominant negative constructs for 
elements of the pathway can be used on avian models, according to Shiau et al. (Shiau 
and Bronner-Fraser, 2009). In light of the palatal shelf defects identified in Slit2
+/-
 and 
Slit2
+/-
;Tbx1
+/lacZ 
embryos, further study can involve examining cranial neural crest 
patterning in Slit2 and/or Tbx1;Slit2 deficient embryos. Moreover, phenotyping of Slit2
-
/-
 animals can address whether palatal clefting contributes to the perinatal lethality 
observed, since it is a severe defect, incompatible with life in rodents (Gu et al., 2008).  
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1. Conclusions 
1.1. General overview: “From disease to gene and back” 
Three decades have passed since subcloning of mammalian genes into prokaryotic 
plasmids first became possible (Flotte, 2007). This opened the way for gene 
engineering, while further technical progress, the sequencing of the human genome and 
the characterisation of animal models contributed to the identification of a multitude of 
genes in human disease. Currently, over 12,000 genes are linked to at least one 
mendelian human disease (OMIM website, http://www.ncbi.nlm.nih.gov/omim). The 
research questions, however, have not changed over the years, and still centre around 
understanding and modifying the pathogenesis of human disease.  
The discovery of the cystic fibrosis gene (Kerem et al., 1989; Riordan et al., 1989) 
was considered the first successful linkage mapping (Botstein and Risch, 2003). 
Nevertheless, and despite all the scientific and technical progress since, cystic fibrosis 
remains one of the most common life-threatening inherited diseases (World Health 
Organization website, http://www.who.int/en/). This is just one example of how the 
illusion of single gene disorder simplicity has come and gone. Monogenic diseases are 
now considered extremely complex syndromes, often involving many different genes 
together with equally numerous poorly understood effects of the environment 
(Weatherall, 2000). Variable expressivity, environmental influences, genetic 
interactions, pleiotropy and genotypic and phenotypic heterogeneity are phenomena that 
lead to lack of one to one correspondence between genotype and phenotype 
(Merikangas et al., 2006), which render polygenic disorders even more complex. The 
environmental contribution is increasingly gaining substantial research interest, as it has 
been cleverly summarised by the phrase “nature versus nurture” (McClearn, 2004).  
It has therefore become apparent that linking one gene to a disease is no longer 
sufficient. The challenge of our time is now the effort to link the events occurring at a 
molecular level with the clinical findings of human disorders (Weatherall, 2000). 
Establishing genetic networks, rather than genes, in the context of but not limited to a 
human disease can aid the understanding of disease mechanisms, complications and 
possibly prognosis. From a clinical point of view, identifying such networks can also 
improve genetic screening, predictive genetic tests as well as genetic counseling. 
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1.2. Dealing with Tbx1 targets and complex interactions 
Cardiovascular disease is the most common cause of mortality worldwide (World 
Health Organization website, http://www.who.int/en/), while 22q11DS, the most 
frequent microdeletion syndrome in humans (Emanuel, 2008; Wurdak et al., 2006; Yagi 
et al., 2003), affects the cardiovasculature in 70% of the cases (Shprintzen, 2008; 
Wurdak et al., 2006). To date, 22q11DS has a sole major determinant gene, the T-box 
transcription factor TBX1 (Paylor et al., 2006; Stoller and Epstein, 2005a; Torres-Juan et 
al., 2007; Yagi et al., 2003; Zweier et al., 2007). 
Since its discovery, TBX1 has been shown to be an important regulator in the 
development of several embryonic structures (Arnold et al., 2006; Lindsay et al., 2001; 
Merscher et al., 2001; Xu et al., 2004; Zhang et al., 2005). During mouse development 
Tbx1 is required in a tissue-specific, time and dosage-dependent fashion (Arnold et al., 
2006; Vitelli et al., 2009; Xu et al., 2004; Xu et al., 2005; Zhang and Baldini, 2008; 
Zhang et al., 2005; Zhang et al., 2006). Nevertheless, and although it has been the focus 
of research for over a decade, the genetic pathways Tbx1 is involved in as well as its 
downstream effectors are poorly characterised. Several studies have discussed potential 
Tbx1 interactors, including Fgf8 (Vitelli and Baldini, 2003; Vitelli et al., 2010; Vitelli et 
al., 2006), Raldh2 (Ivins et al., 2005; Ryckebusch et al., 2010), Chordin (Choi and 
Klingensmith, 2009), Prdm1 (Vincent et al., 2010), Wnt-!-catenin signalling (Huh and 
Ornitz, 2010), Vegf (Chen et al., 2010; Stalmans et al., 2003) and Sprouty 1a and 2 
(Albert Basson, pers. comm.). Each of these appears to interact with Tbx1 in discrete 
pathways towards the development of different embryonic structures. Direct interaction 
between Tbx1 and target promoter sequences has also been proved difficult to identify. 
Although multiple interactors have been proposed, to date, the only confirmed 
interactions are between TBX1 and VEGFR3 (Chen et al., 2010) or Pitxc2 (Nowotschin 
et al., 2006). The number of studies as well as the number of different genes suggested 
to act downstream of Tbx1 indicate the complexity of the Tbx1 related networks and the 
multitude of its downstream effectors. In that respect, Tbx1 may act as a global modifier 
gene in mammalian organisms. Systematic mapping of genetic interactions in 
Saccharomyces cerevisiae (Tong et al., 2001; Segre et al., 2005), Caenorhabditis 
elegans (Lehner et al., 2006) and Arabidopsis thaliana (Perez-Perez et al., 2009) has 
identified genes that have wide patterns of interaction across multiple pathways, the so 
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called “hub” genes (Hartman et al., 2001; Lehner et al., 2006). These can buffer the 
effects of genetic variation in many functionally diverse loci (Lehner et al., 2006), so 
that their inactivation can enhance the phenotypic outcome of mutations in functionally 
unrelated genes and in otherwise unlinked pathways (Lehner et al., 2006). Tbx1 may, 
likewise, function as a mammalian hub gene, required to buffer pharyngeal and 
cardiovascular development. Consequently, dissecting the Tbx1 networks is not a 
straightforward process and requires refined approaches. 
1.2.1. Microarray screens, outcomes and limitations 
Microarray chips became a breakthrough by providing the opportunity of 
simultaneous expression analysis of tens of thousands of genes (Eszlinger et al., 2007), 
leading many laboratories to follow this transcriptomics approach. The power of such 
studies relies on both the experimental design and the statistical analysis of the data 
produced (Eszlinger et al., 2007). In that respect, limitations exist, which should be 
considered when discussing the outcomes of microarray screens. Decreased sensitivity 
in the detection of genes with low expression levels and tissue/cell heterogeneity that 
may influence the microarray sensitivity by masking changes in gene expression 
(dilution effects) are some of these limitations (Bunney et al., 2003). The real weakness 
in microarray studies, however, lies in the statistical treatment of the results. Multiple 
tests are performed in each array allowing for several incorrect inferences by chance 
alone, since for each statistical test performed there is some probability that an incorrect 
assumption will be made (Pounds, 2006). In microarray studies the error rate is 
commonly measured with the false discovery rate (FDR) that describes the expected 
proportion of significant findings that are false positives (Pounds, 2006).  
Undoubtedly, microarray techniques provide great insight into the transcriptomic 
regulation of tissues, cells, organs or even organisms, allowing for the comparison 
between normal and disease, treated and untreated groups or other types of experimental 
designs. Nevertheless, further in vitro and in vivo validation is required to prove 
functional changes in gene expression, while subsequent analysis can determine the 
biological significance of the initial findings. 
We recently undertook a refined microarray approach towards identifying Tbx1 
target genes on a cell autonomous setting (van Bueren et al., 2010). Following statistical 
analysis, quantitative real time PCR validation (van Bueren et al., 2010) and literature 
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review, Smad7, Hes1 and Slit2 were selected for further study. Their potential 
developmental roles, interaction with Tbx1 and relation with the 22q11DS-like 
phenotypes were the project of this thesis. The aims were to characterise the putative 
Tbx1 downstream effectors and to associate the genetic networks with the pathogenesis 
of the different 22q11DS-like phenotypes. Different approaches were followed to that 
end. 
1.2.2. Characterisation of mutant phenotypes - an invaluable tool for linking genes 
to developmental processes 
Genetically engineered animal models have revolutionised biomedical research 
(Eisener-Dorman et al., 2009). Mice in particular, by providing an in vivo, mammalian 
system that is easy to handle, can be used effectively for understanding the genetic 
elements of human disease (Gama Sosa et al., 2010; Claij and Peters, 2006). A plethora 
of systems are available, including transgenics, standard knock-outs, inducibles, tissue-
specifics, multiple gene knock-outs and other, more elaborate designs (Castrop, 2010; 
Gama Sosa et al., 2010). More commonly a gene’s role in a process is studied through 
its absence, through null mutations of the gene being studied. Without disregarding the 
genetic background contribution, in many cases an observed phenotype is indeed the 
result of ablation of a single gene (Eisener-Dorman et al., 2009), which can reveal 
important information about gene functions (Claij and Peters, 2006). 
Throughout this project, I used a gene-trap model to establish the Smad7 
requirements during embryogenesis. I have shown that the Smad7 gene-trap mutation 
induces a range of 22q11DS-like phenotypes, including, cardiovascular, thymic and 
with low penetrance, VSD and secondary palate defects. I also discussed the potential 
roles for Smad7 in pharyngeal arch artery remodelling. By contrast, when I examined 
the phenotype caused by Slit2 or Slit1;Slit2 deficiency I found no evidence of a role for 
either of the genes in the development of structures affected in 22q11DS, although there 
was an indication that Slit2 may be involved in palatogenesis. 
1.2.3. Conditional deletion - a tool for dissecting tissue and/or time-specific gene 
requirements 
More complex systems, like the Cre/lox, provide the opportunity of controlled 
gene inactivation, allowing for the study of gene functions in restricted tissues, organs 
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or at defined time points (Claij and Peters, 2006). Analysis of the effects of such gene 
ablation strategies can provide useful information about a gene’s roles through distinct 
expression domains (Claij and Peters, 2006). 
Using a conditional mutagenesis approach I demonstrated that Hes1 functions non 
cell autonomously in the ectoderm affecting great vessel and eye development, while it 
is essential in both the ectodermal and neural crest lineages for thymus morphogenesis.  
1.2.4. Genetic interaction - a tool for dissecting genetic pathways 
Given the complexity of biological systems the focus of research has lately turned 
from individual genes to the interactions between genes (Hartman et al., 2001; Wang et 
al., 2010). Different types of genetic interactions exist, which are usually identified by 
the discrepancy between mendelian segregation ratios based on the action of individual 
genes and the actual outcome of a dihybrid cross (Phillips, 2008). Synergy between 
mutations is assumed when the phenotype of a double mutation is significantly different 
to the phenotype of either single mutation alone or the additive effects of the individual 
mutations (Perez-Perez et al., 2009; Wong et al., 2004). Synergy can be the result of 
redundant actions among paralogous genes but can also be observed when converging 
pathways are disrupted, or when a mutation enhances the sensitivity to the effects of 
another mutation (Perez-Perez et al., 2009). Other types of genetic interaction exist, like 
epistasis, when the phenotype of the double mutation is reminiscent of the phenotype of 
one of the single mutants, but not the other, or suppression, when the double mutant 
phenotype is closer to the wild type condition than either of the single mutants (Perez-
Perez et al., 2009). Assessing such functional relationships can be a useful tool in 
understanding the basic principles of the underlying genetic networks (Wong et al., 
2004). Genetic interactions are involved in many complex phenotypes and are the 
defining basis of human multigenic genetic disease (Wong et al., 2004).  
In that respect, the possible interactions between Tbx1 and the putative 
downstream effector genes were assessed as part of this thesis. I demonstrated that 
Smad7 acts synergistically with Tbx1 in the development of the great vessels. The 
mechanism probably requires tissue-specific Tbx1-dependent activation of Smad7 at an 
early developmental stage, whilst affecting great vessel remodelling at a much later 
stage. In addition, I addressed the possible genetic interaction between Tbx1 and Slit2 
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but found no evidence of such a relationship. However, the sample size was small, so an 
interaction between the two genes cannot be completely excluded. 
1.2.5. Bioinformatics - probably a weak tool in establishing direct interactions  
Computational approaches have been widely employed to identify TBEs on 
regulatory regions of genes being studied. Nevertheless, although most human genes 
have been successfully annotated, the regulatory elements controlling these genes in 
different cell types, at various time points and under different environmental influences 
are largely unknown (Narlikar and Ovcharenko, 2009). This is due to the fact that in 
eukaryotic organisms a single transcription factor - DNA binding event rarely controls 
the transcription of the target genes (Narlikar and Ovcharenko, 2009). Rather, different 
combinations of cell type-specific factors act in co-operation, so that transcriptional 
regulation requires a complex set of protein-DNA and protein-protein interactions 
(Narlikar and Ovcharenko, 2009). Apart from the DNA-binding proteins, other trans 
regulatory factors are non-DNA-binding proteins (co-factors), while the transcription 
factors utilise cis regulatory elements like promoters, enhancers, silencers, insulators or 
other elements to promote gene transcription (Narlikar and Ovcharenko, 2009). A 
common approach in identifying cis regulatory elements is to feed the binding sequence 
of a protein into a bioinformatics software and examine the conservation of the site 
among species (phylogenetic footprinting, Hannenhalli, 2008). If the binding sequence 
of the protein is not known, binding sequences of other family members, or putative 
sites suggested from the literature can be used instead. Predictions based solely on 
sequence conservation have been shown to achieve remarkable success (Narlikar and 
Ovcharenko, 2009). A different approach employs the search for clusters of 
transcription factor sites, which are more likely to regulate transcription in co-operation 
(Hannenhalli, 2008; Narlikar and Ovcharenko, 2009). 
To date no binding site has been established for Tbx1, so different studies have 
used either the Tbx5 binding sequence (Ng et al., 2002), or the putative T-half site 
(Conlon et al., 2001; Wilson and Conlon, 2002), known to be recognised by T-box 
family members, including TBX1 (Sinha et al., 2000). Putative Tbx1 binding elements 
have been identified in regulatory regions of the VEGFR3 (Chen et al., 2010), Pitx2c 
(Nowotschin, 2006), Fgf8 (Hu et al., 2004) and Fgf10 (Xu et al., 2004) genes, but only 
the VEGFR3 (Chen et al., 2010) and Pitxc2 (Nowotschin et al., 2006) elements have 
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been verified. Ablating putative T-box binding elements from the Mef2c (Antonio 
Baldini, pers. comm.) or Pax9 (Rumiko Matsuoka, pers. comm.) promoters did not 
affect Tbx1 activation at these promoters. This is an indication that elements other than 
canonical TBEs must be important for Tbx1 driven transcription. Moreover, a recent 
study identified by ChIP-Seq active tissue-specific enhancers in the mouse genome, 
recognised by the ubiquitously expressed coactivator protein p300 (Blow et al., 2010). 
An enhancer was detected 136 kb from Smad7, and in no closer proximity to any other 
known cardiac gene (Blow et al., 2010). Reporter gene expression of this enhancer 
appeared reminiscent of Smad7 expression in the cardiac outflow tract but did not 
recapitulate all the Smad7 expression domains. The distance the site was identified at 
and the restricted expression pattern of the reporter denote that enhancer elements are 
not necessarily located close to the transcription initiation site of a gene and that 
different enhancers may regulate tissue-specific expression of a gene. Collectively, 
these data suggest that the presence or absence of putative binding elements in the 
immediate regulatory region of a gene does not conclusively answer whether there is 
direct interaction between the genes of interest. Bioinformatic approaches are 
essentially indicative but not necessarily conclusive, in terms of establishing direct 
relationships, unless accompanied by high throughput analyses like ChIP assays (in 
vitro), or reporter gene assays (in vivo) (Narlikar and Ovcharenko, 2009). 
Through this project I undertook a similar approach and examined T-half site 
conservation in the Smad7 regulatory region, among four mammalian species, but found 
no conclusive evidence of the presence of such an element. In vitro binding assays were 
performed by a member of our lab, which also provided no definitive positive evidence 
of Tbx1 binding onto the Smad7 regulatory region. In light of the above, Smad7 may be 
controlled by Tbx1 through elements not yet identified or it may be an indirect Tbx1 
target.  
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2. Thesis summary 
In the course of this thesis I have employed different means of evaluating in vivo 
and in vitro potential Tbx1 downstream effectors, as these were established by 
microarray screens. I showed that Smad7 is a Tbx1 target, although more likely indirect, 
acting synergistically with Tbx1 in great vessel development. To date there is no 
evidence supporting a Hes1-Tbx1 interaction in a mammalian system; however, I 
demonstrated that Hes1 plays important roles in great vessel and thymus development 
through ectodermal and neural crest expression. Finally, by examining Slit2, I 
concluded that it does not appear to be regulated by Tbx1 or have a contribution to the 
development of structures affected in 22q11DS. Nevertheless, it is part of a redundant 
system, therefore, complex interactions and compensatory roles from other members of 
the Slit family cannot be excluded.  
At the conclusion of this work, it remains to be decided which studies will be 
carried forward and in what direction. Smad7 presents an important regulator of 
vascular remodelling. Addressing the molecular mechanisms Smad7 is involved in by 
means of in vivo or in vitro examination of endothelial and/or VSM cell behaviours in 
different Smad7 genetic settings could be an initial approach. Identifying the 
TGF!/BMP pathway branch Smad7 acts on and possible Smad7 interactors are also 
future directions. Furthermore, a Cre/lox system can be employed to study the tissue 
and time-specific requirements for Smad7 during embryogenesis. Smad7 deletion in the 
Tbx1 expression domains can decisively answer the genetic synergy hypothesis.  
Overall, this thesis has described a novel Tbx1 regulated pathway in pharyngeal 
arch artery remodelling, as characterised in an in vivo mammalian system, which has the 
potential to be further dissected into its fine elements in future work. 
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Stock solutions and Antibodies 
1. Stock Solutions 
10mM dNTP 10mM dATP, 10mM dCTP, 10mM dGTP, 10mM dTTP 
20X SSC 3M NaCl, 0.3M Sodium Citrate pH 7.0 
BM Purple staining 
solution 
BM Purple (Roche, UK), 1X Levamisole (Sigma Aldrich), 
0.1% Tween-20 
Bone and cartilage 
staining solution 
1/20 0.3% alcian blue in 70% EtOH, 1/20 0.1% alizarin red in 
95% EtOH, 1/20 acetic acid, 17/20 70% EtOH 
DNA ladder 50 ng/µl DNA ladder in 1 X loading buffer 
Hybridisation buffer 50% formamide, 5X SSC, 1% SDS, 50µg/ml yeast RNA, 
50µg/ml heparin, 0.1% Tween-20, in DEPC H2O 
Laemmli buffer (6X) 125mM Tris-HCl pH 6.8, 6% SDS, 20% glycerol, 0.1% 
bromophenol blue - 10% 2-mercaptoethanol, added prior to 
use 
LB agar 2% Bactoagar, 1% Bactotryptone, 0.5% Bactoyeast, 1% NaCl
  
LB broth 1% Bactotryptone, 0.5% Bactoyeast, 1% NaCl 
Loading buffer (6X) 10mM Tris-HCl pH 7.5, 50mM EDTA pH 8.0, 10% Ficoll-
400, 0.4% Orange G 
MAB 100mM maleic acid, 150mM NaCl, 0.001% Tween-20, NaOH 
pellets 
NTMT  100mM Tris-HCl pH 9.5, 100mM NaCl, 50mM MgCl2, 0.1% 
Tween-20 in DEPC H2O 
PBS (10X) pH 7.4 80g NaCl, 2.0g KCl, 14.4g Na2HPO4, 2.4g KH2PO in 1L 
water, pH 7.4 
RIPA buffer 150mM NaCl, 1% NP-40 or Triton-X, 50mM Tris-HCl pH 8.0 
Running buffer 25mM Tris-base, 192 mM Glycine, 0.1% SDS 
Solution I 50% formamide, 5X SSC pH 5.0, 1% SDS, in DEPC H2O 
Solution II 50% formamide, 2X SSC pH 5.0, 0.2% SDS, 0.1% Tween-20, 
in DEPC H2O 
TAE buffer (10X) 0.4M Tris-acetate, 10mM EDTA pH 8.0 
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Tail lysis buffer 100mM Tris-HCl pH 8.5, 5mM EDTA pH 8.0, 0.2%, SDS, 
200mM NaCl, 100 µg/ml proteinase K (added immediately 
prior to use) 
TE pH 8.0 10mM Tris-HCl pH 8.0, 1mM EDTA pH8.0 
TBST (10X) 25ml Tris-HCl pH 7.5, 8g NaCl, 0.2g KCl, 11ml Tween-20 in 
100ml water 
Transfer buffer 0.5X Running buffer, 20% MeOH 
X-gal buffer 20mM K3Fe(CN)6, 20mM K4Fe(CN)6-3H2O, 5mM EGTA, 
2mM MgCl2, 0.02% NP40, 0.01% Deoxycholate, in PBS - 
1mg/ml X-gal, added prior to use 
Table AI. 1. Stock solutions. 
 
2. Antibodies 
Antigen Source Application Acquired from 
Tbx1 rabbit IF Zymed, Invitrogen 
Hes1 guinea pig IF Ryoichiro Kageyama 
pSmad2/3 
rabbit WB 
Cell Signaling 
Technology 
pSmad1/5/8 
rabbit WB 
Cell Signaling 
Technology 
Gapdh mouse WB Millipore 
Table AI. 2. Antibodies. IF, immunofluorescence; WB, western blotting. 
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Primer Sequences and Cycling conditions 
 
1. Genotyping primer sequences 
Reference Forward Reverse Alleles Tm 
AGTCTGGGGACTCTGGAAGG AAGGCAGATCCTGCTACACC wt 65 
0
C 
Tbx1
lacZ 
 TCGACTAGAGCTTGCGGAAC mutant 65 
0
C 
Tbx1
mcm 
GCTCCACTTCAGCACATTCC CATAAGCCAGAGAAGGGTCG - 60 
0
C 
Tbx1
Neo2 
GCCAGAGGCCACTTGTGTAG AGGCTGGGATTCCAAAAGAC - 60 
0
C 
GCTCCAGATGTTCAGTTGC CTCCTTTAGAAAGAGTGGTGCC wt 60 
0
C 
Smad7 
 
 
CATACAGTCCTCTTCACATCCAT
GCTG 
mutant 60 
0
C 
CCCCTTTGCAGTCATCAAAG GCATTGCTCACTTACATCTTTC wt 60 
0
C 
Hes1 
GGGAGGATTGGGAAGACAAT GGCGGAAGTCTGGAAGAAAT mutant 60 
0
C 
Hes1
Flox CAGCCAGTGTCAACACGACACCG
GACAAAC 
TGCCCTTCGCCTCTTCTCCATGA
TA 
- 62 
0
C 
Cre GTTCGCAAGAACCTGATGGACA CTAGAGCCTGTTTTGCACGTTC - 60 
0
C 
GTGTATAAGCCCGAGATGG CTCAACTGTTCAAGTGGCAG wt 60 
0
C 
Sox17-iCre 
 GATCTATGGTGCCAAGGATGAC mutant 60 
0
C 
AAGATGCCTCCTCTGACTTC ACCCTTAGCTTCTACCAACC wt 55 
0
C 
Slit1 
TCTCCTTTGATCTGAGACCG  AGGTTTCTCGAGCGTCATAG mutant 55 
0
C 
AAGACCTGTCGCTTCTGTCAG AAACAGGTTTCTACCGCACG wt 55 
0
C 
Slit2 
AAGACCTGTCGCTTCTGTCAG AAGTCTAGTAGAGTCGAGCG mutant 55 
0
C 
AAAGTCGCTCTGAGTTGTTAT GGAGCGGGAGAAATGGATATG wt 60 
0
C 
R26R/R 
 GCGAAGAGTTTGTCCTCAACC mutant 60 
0
C 
En2  AACAAACTTGGCCTCACCAG GCCAAGGCCATACAAGTGTT - 60 
0
C 
pGT0lxf-SA GATGCCAGAGACTCAGTGAA GTTGTAAAACGACGGGATCCTC - 60 
0
C 
Table AII. 1. Genotyping PCR primer sequences.  
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2. Quantitative real time PCR primer sequences 
Reference Forward Reverse Tm 
Smad7 exon 3-4 GAAACCGGGGGAACGAATTAT CGCGAGTCTTCTCCTCCCA 60 
0
C 
Smad7 exon 4 TCTACTGTGTCCAAGAGCCCT GCGGTTGTAAACCCACACG  60 
0
C 
Klf2 GGACCTAAACAACGTGTTGGA CTCCGGGTAGTAGAAGGCAG 60 
0
C 
Klf4 TGATGGTGCTTGGTGAGTTG  TTGCACATCTGAAACCACAG  60 
0
C 
Klf10 TTCTCTCCAGCAAGCTTCGGA  TCACTCTGCTCAGCTTTGTCCC  60 
0
C 
Etv4 CCCACCACCAGGATCAAGAAG TGTCTGGAGTAAAGGCACTGC 60 
0
C 
Etv5 TCAGTCTGATAACTTGGTGCTTC GGCTTCCTATCGTAGGCACAA 60 
0
C 
GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 60 
0
C 
Table AII. 2. Quantitative real time PCR primer sequences. 
 
3. Smad7 luciferase construct primer sequences 
Reference Forward Reverse Tm 
Smad7.1 CCCCAGCTCTTCCGATTT GACGAAGAGAGTCTCCGAGG 60 
0
C 
Smad7.2 GGGATAGCTTTCTCTGGTACC GGAGGAGGTACCTGTCTGTT 60 
0
C 
Smad7.3 GGTACCAGGCAGTCCTAGAA CAGTTGGTACCACCCTCTCC 60 
0
C 
Smad7.4 GAAGGGGAATGGTACCAGA GGTACCTGCTTAGGGTCAGA 60 
0
C 
Table AII. 3. Smad7 luciferase construct PCR primer sequences. 
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4. Cycling conditions 
Reference PCR Cycling conditions 
General genotyping 
94 °C - 2 minutes  
     94 °C - 30 seconds 
     60 °C - 30 seconds (30x cycles) 
     72 °C - 30 seconds 
72 °C - 10 minutes 
Tbx1
lacZ 
genotyping 
95 °C - 30 seconds  
     95 °C - 30 seconds 
     65 °C - 20 seconds (33x cycles) 
     72 °C - 20 seconds 
Hes1
Flox 
genotyping 
95 °C - 2 minutes  
     95 °C - 10 seconds 
     62 °C - 30 seconds (33x cycles) 
     72 °C - 1 minute 
72 °C - 5 minutes 
Sox17-iCre  genotyping 
95 °C - 5 minutes  
     95 °C - 30 seconds 
     60 °C - 30 seconds (35x cycles) 
     72 °C - 1 minute 
72 °C - 10 minutes 
Slit1, Slit2 genotyping 
95 °C - 5 minutes  
     95 °C - 30 seconds 
     60 °C - 30 seconds (30x cycles) 
     72 °C - 30 seconds 
General quantitative 
94 °C - 15 minutes  
     94 °C - 15 seconds 
     60 °C - 30 seconds (40x cycles) 
     72 °C - 30 seconds 
dissociation stage 
Table AII. 4. PCR cycling conditions. 
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Plasmid constructs 
 
1. Whole mount in situ hybridisation probe plasmids 
Reference A/S S Vector Acquired from 
Tbx1 XhoI, T7 ClaI, T3 pBSKII(-) Albert Basson 
Smad7 EcoRI, T3 NotI, T7 pBSKII Christine Mummery 
Sox10 NcoI, T7 N/A N/A Christiana Ruhrberg 
Hes1 EcoRI, T7 BamHI, T3 pBSKII(+) Francois Guillemot 
Jag1 EcoRI, T3 NotI, T7 pYX-Asc imaGenes 
RBP-J SalI, T7 NotI, Sp6 pCMV-SPORT6 imaGenes 
HOXD4 PmeI, T7 NotI, T3 pCR4-TOPO 
Geneservice 
Limited 
Fgf8 SmaI or XhoI, T7 N/A pBSK Gail Martin 
Fgf10 BamHI, T3 PstI, T7 pBSKII(+) Albert Basson 
Etv4 ApaI or XbaI, Sp6 BamHI, T7 N/A N/A 
Slit1 BamHI, T7 XhoI, T3 pBSK 
Marc Tessier-
Lavigne 
Slit2 NcoI, Sp6 SpeI, T7 pGEM-T David Ornitz 
Table AIII. 1. Whole mount in situ hybridisation probe plasmids. Restriction digests 
and RNA polymerases for anti-sense (A/S) or sense (S) orientation, and vector 
backbone information. N/A, not available. 
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2. Expression and luciferase constructs 
Reference Vector Description Acquired from 
Smad7.1;TKGL2 pTKGL2 firefly luciferase in house 
Smad7.2;TKGL2 pTKGL2 firefly luciferase in house 
Smad7.3;TKGL2 pTKGL2 firefly luciferase in house 
Smad7.4;TKGL2 pTKGL2 firefly luciferase in house 
pTKGL2 pTKGL2 firefly luciferase Anita Rauch 
p2T-TKGL2 pTKGL2 firefly luciferase Anita Rauch 
TBX1C CMV human TBX1 expression Anita Rauch 
!-galactosidase pcDNA3 !-galactosidase expression in house 
pRLSV40 SV40 renilla luciferase Bruno Ferraz de Souza 
pcDNA3 pcDNA3 - Promega 
Table AIII. 2. Expression and luciferase constructs. 
 
